fluorouracil has been researched along with irinotecan in 2374 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 83 (3.50) | 18.2507 |
| 2000's | 929 (39.13) | 29.6817 |
| 2010's | 953 (40.14) | 24.3611 |
| 2020's | 409 (17.23) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Ding, J; Gao, H; Li, C; Lu, W; Pang, T; Shen, H; Sun, J; Xu, C; Zhang, X | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Chao, SH; Chen, CH; Kakadiya, R; Lee, TC; Lin, YW; Ou, TH; Su, TL; Suman, S; Tala, KS; Tala, SD; Tsai, TH; Wu, MH | 1 |
| Fischer, C; Hetterling, G; Kliem, M; Micikas, RJ; Plauth, A; Rousseau, M; Sauer, S; Schroeder, FC; Siems, K; Weidner, C; Wowro, SJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jiang, Z; Li, ZR; Sha, MQ; Shen, JJ; Wang, Z; Wu, LT; Xue, ST; Yi, H; Zhan, YC | 1 |
| Jiang, J; Muhammad, Y; Rashid, HU; Wang, L; Xu, Y | 1 |
| Gao, F; Wang, T; Xiao, J; Zhang, X | 1 |
| Maltais, R; Perreault, M; Poirier, D; Roy, J | 1 |
| Abrantes, AM; Botelho, MF; Costa, SC; Gomes, AR; Gonçalves, AC; Pires, AS; Roleira, FMF; Silva, ET; Varela, CL | 1 |
| Guo, K; Li, J; Ma, X; Wu, L; Zhang, C | 1 |
| Kurjata, J; Piorecka, K; Stanczyk, WA | 1 |
| Ohtsu, A; Ono, K; Saijo, N; Sasaki, Y; Shimada, Y | 1 |
| Fujita, F; Fujita, M; Sakamoto, Y | 1 |
| Bleiberg, H | 1 |
| Aiba, K | 2 |
| Drengler, R; Eckardt, J; Eckhardt, G; Villalona-Calero, M; Von Hoff, D | 1 |
| Sakata, Y; Suzuki, H; Takemori, H | 1 |
| Berkery, R; Dietz, A; Eng, M; Kanowitz, J; Kelsen, DP; Kemeny, NE; Locker, P; Saltz, LB; Schaaf, L; Spriggs, D; Staton, BA; Steger, C | 1 |
| Khayat, D; Saltz, L; Shimada, Y | 1 |
| Adenis, A; Becouarn, Y; Bonneterre, J; Brunet, P; Bugat, R; Burki, F; Conroy, T; Culine, S; Douillard, JY; Extra, JM; Ganem, G; Herait, P; Mahjoubi, M; Marty, M; Merrouche, Y; Mousseau, M; Namer, M; Negrier, S; Rougier, P; Seitz, JF; Suc, E; Ychou, M | 1 |
| Furue, H | 1 |
| Ghosh, C; Goldberg, RM; Kirschling, RJ; Knost, JA; Levitt, R; Mailliard, JA; O'Connell, MJ; Pitot, HC; Rubin, J; Schroeder, G; Wender, DB; Windschitl, HE | 1 |
| O'Reilly, S; Rowinsky, EK | 1 |
| Courtney, A; Cox, J; Meyer, W; Mues, G; Nemunaitis, J | 1 |
| Sasaki, T | 1 |
| Fujimura, M; Fushiki, H; Hidaka, T; Hori, S; Izumi, R; Yamakawa, Y | 1 |
| Fujita, A; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Bugat, R; Canal, P; Cussac, D; Guichard, S; Hennebelle, I | 1 |
| Sakata, Y; Tsushima, K | 1 |
| Bugat, R; Canal, P; Guichard, S; Hennebelle, I | 1 |
| Araki, S; Asakura, R; Hojo, K; Itoh, A; Kawahara, M; Konishi, T; Nouchi, T; Takeda, Y; Teruya, M | 1 |
| Bierling, P; Bozec, L; Cvitkovic, E; Debat, P; Fromont, P; Lévi, F; Misset, JL | 1 |
| Rowinsky, EK; Siu, LL | 1 |
| Bulusu, VR | 1 |
| McCann, J | 1 |
| Punt, CJ | 3 |
| Bours, V; Fillet, G; Jerusalem, G | 1 |
| Pazdur, R | 2 |
| Pitot, HC | 1 |
| Erlichman, C; Goldberg, RM | 1 |
| Antoine, EC; Bastian, G; Benhammouda, A; Coeffic, D; Gil-Delgado, M; Grapin, JP; Khayat, D | 1 |
| Michael, M; Moore, MJ | 1 |
| Benson, AB; Catalano, R; Engelking, C; Field, M; Kornblau, SM; Mitchell, E; Rubin, J; Trotta, P; Vokes, E; Wadler, S | 1 |
| Kobayashi, A; Yamaguchi, M | 1 |
| Erlichman, C; Kaufmann, SH; Mullany, S; Svingen, PA | 1 |
| Meyer, W; Nemunaitis, J; Ognoskie, N; Singh, A; Tong, A | 1 |
| Goldberg, RM | 4 |
| Henderson, CA | 1 |
| Berg, D | 1 |
| Danenberg, K; Danenberg, PV; Groshen, S; Leichman, CG; Leichman, L; Lenz, HJ; Metzger, R; Salonga, D; Schwartz, EL; Wadler, S | 1 |
| Awad, L; Bajetta, E; Bleiberg, H; Herait, P; Jacques, C; Labianca, R; Morant, R; Navarro, M; Niederle, N; Possinger, K; Rougier, P; Van Cutsem, E; Wils, J | 1 |
| Awad, L; Cunningham, D; Heikkila, R; Herait, P; Hickish, TF; Jacques, C; James, RD; Johannesen, TB; Punt, CJ; Pyrhönen, S; Starkhammar, H; Topham, CA | 1 |
| Cheshire, PJ; Hallman, JD; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L | 1 |
| Etienne, MC; Fischel, JL; Formento, JL; Formento, P; Francoual, M; Milano, G; Pavillard, V; Rostagno, P | 1 |
| Ajani, JA | 1 |
| Barone, C; Cognetti, F; Cote, C; Dirix, L; Filez, L; Garufi, C; Gruia, G; Humblet, Y; Pozzo, C; Starkhammar, H; Terzoli, E; Van Cutsem, E | 1 |
| Armand, JP; Boige, V; Raymond, E | 1 |
| Peeters, M; Van Cutsem, E | 1 |
| Ducreux, M; Mitry, E; Rougier, P | 1 |
| André, T; de Gramond, A; Ducreux, M; Gil-Delgado, M; Khayat, D; Ychou, M | 1 |
| Hashimoto, A; Matsuura, T; Murakami, K; Saiki, I; Sakukawa, R; Sano, M; Yamada, Y; Yonekura, K | 1 |
| Taguchi, T | 2 |
| Britten, CD; Eckhardt, SG; Hilsenbeck, SG; MacDonald, JR; Mangold, G; Marty, J; Rowinsky, EK; Von Hoff, DD; Weitman, S | 1 |
| Achterrath, W; Harstrick, A; Köhne, CH; Rustum, YM; Seeber, S; Vanhoefer, U; Wilke, H | 1 |
| Cox, JV; DeVore, RF; Elfring, GL; Geyer, CE; Hainsworth, JD; Macdonald, JS; Miller, LL; Mohrland, JS; Pazdur, R; Rivkin, SE; Rothenberg, ML; Sandbach, J; Von Hoff, DD; Wolf, DL | 1 |
| Fukuda, S; Kume, S; Nagamoto, N; Okamura, K; Sakaguchi, T; Tanabe, D | 1 |
| Alexopoulos, CG; Blanc, C; Bleiberg, H; Blijham, GH; Cholet, P; Cote, C; Cunningham, D; Dirix, L; Fillet, G; Hérait, P; Levi, F; Panagos, G; Punt, CJ; Symann, M; Ten Bokkel Huinink, WW; Unger, C; Van Cutsem, E; Van Groeningen, C; Vannetzel, JM; Wils, J | 1 |
| Cunningham, D | 1 |
| Cunningham, D; Glimelius, B | 1 |
| Blijham, GH; Van Cutsem, E | 1 |
| Wilke, HJ | 1 |
| Ogawa, M | 1 |
| Miller, M | 1 |
| Allegrini, G; Antonuzzo, A; Brunetti, I; Cianci, C; Conte, P; Falcone, A; Galli, C; Lencioni, M; Masi, G; Pfanner, E | 1 |
| Dörr, T; Kemmeries, G; Petrasch, S | 1 |
| Avallone, A; Casaretti, R; Catalano, G; Comella, G; Comella, P; Comis, S; De Vita, F; Faranda, A; Gravina, A; Orditura, M; Petrillo, A | 1 |
| Angerstein, C; Becker, H; Becker, W; Béhé, M; Behr, TM; Blumenthal, RD; Fayyazi, A; Goldenberg, DM; Hiddemann, W; Liersch, T; Ringe, B; Salib, AL; Sharkey, RM; Wörmann, B | 1 |
| Ebuchi, M; Irie, T; Kure, M; Maruyama, M; Nagahama, T; Yoshida, T | 1 |
| Armand, JP; Bexon, A; Bonnay, M; Ducreux, M; Mahjoubi, M; Méry-Mignard, D; Rougier, P; Seitz, JF; Ychou, M | 1 |
| Droege, CM; Hausamen, TU; Lenfers, BH; Loeffler, TM | 1 |
| Bekradda, M; Cvitkovic, E | 1 |
| Armand, JP; Cunningham, D; Kohne, CH; Misset, JL; van Cutsem, E | 1 |
| Androulakis, N; Aravantinos, G; Bafaloukos, D; Florou, S; Fountzilas, G; Georgoulias, V; Kosmidis, P; Sgouros, I; Skarlos, DV | 1 |
| Van Cutsem, E | 1 |
| Ford, HE; Jackman, AL; Kimbell, R | 1 |
| Adenis, A; Conroy, T; Paillot, B | 1 |
| André, T; Carola, E; Couteau, C; de Gramont, A; Gilles-Amar, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F | 1 |
| Boisdron-Celle, M; Boulanger, N; Gamelin, E | 1 |
| Hickish, T; Iveson, TJ; Schmitt, C; Van Cutsem, E | 1 |
| Grivicich, I; Mans, DR; Peters, GJ; Schwartsmann, G | 2 |
| Handa, T; Kai, S; Kazami, A; Koizumi, K; Maruyama, M; Takemoto, N; Yamao, T | 1 |
| Hasegawa, S; Ishikawa, H; Kamma, H; Ohtomo, M; Ohtsuka, M; Satoh, H | 1 |
| Kobayashi, T; Maeda, Y; Okamoto, R; Omuro, Y; Sasaki, T; Takeda, N | 1 |
| Alakl, M; Awad, L; Carmichael, J; Cunningham, D; Douillard, JY; Gruia, G; Iveson, T; James, RD; Jandik, P; Karasek, P; Navarro, M; Roth, AD; Rougier, P | 1 |
| Bellanger, A; Durand-Zaleski, I; Juhel, H; Levy-Piedbois, C; Piedbois, P; Schmitt, C | 1 |
| Hara, N; Nakanishi, Y; Osaki, S; Pei, XH; Takayama, K; Ueno, H | 1 |
| Adenis, A; Burki, F; Douillard, JY; Dufour, P; Marty, M; Mignard, D; Mousseau, M; Rougier, P; Wendling, JL; Ychou, M | 1 |
| Schallhorn, A | 1 |
| Arimoto, J; Bessho, T; Furukawa, T; Hirai, I; Maebeya, S; Matsuyama, K; Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tanino, H; Yano, T; Yoshimasu, T | 1 |
| Blijham, G; Jolain, B; Rougier, P; Schmitt, C; Van Cutsem, E | 1 |
| Furuhata, T; Hata, F; Hirata, K; Kawasaki, H; Matsunaga, T; Nakagawa, N; Sasaki, K; Shibata, K; Takasaka, H; Yabana, T; Yasojima, T | 1 |
| Azoulay, D; Goldwasser, F; Gornet, JM; Lévi, F; Misset, JL; Yovine, A | 1 |
| Cao, S; Rustum, YM | 1 |
| Baba, H; Endo, K; Ikeda, Y; Kohnoe, S; Nakashima, H; Okamura, T; Toh, Y | 1 |
| Awad, L; Bleiberg, H; Bugat, R; Culine, S; Droz, JP; Freyer, G; Herait, P; Marty, M; Mignard, D; Rougier, P; Trillet-Lenoir, V | 1 |
| Hisano, C; Ishikawa, T; Kaji, Y; Maruyama, T; Masumoto, N; Nakamura, M; Nakano, S; Niho, Y; Ohkuma, K | 1 |
| Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB | 1 |
| Mayer, RJ | 1 |
| Graeven, U; Schmiegel, W | 1 |
| Kitagata, S; Mai, M; Takahashi, Y | 1 |
| Borsellino, N; Cigolari, S; Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Paoletti, G; Pedicini, T | 1 |
| Hoff, PM; Pazdur, R; Royce, ME | 2 |
| Mitry, E; Rougier, P | 2 |
| Cunningham, D; Sumpter, K | 1 |
| Kajiyama, Y; Tsurumaru, M | 1 |
| Brodowicz, T; Hejna, M; Köstler, WJ; Raderer, M; Scheithauer, W; Tomek, S; Wiltschke, C; Zielinski, CC | 1 |
| Ohtsu, A; Tahara, M | 1 |
| Avallone, A; Biglietto, M; Cartenì, G; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lena, M; De Lucia, L; De Vita, F; Farris, A; Ianniello, GP; Leo, SS; Lorusso, V; Mancarella, S | 1 |
| Innocenti, F; Iyer, L; Ratain, MJ | 1 |
| Saltz, LB | 2 |
| Cunningham, D; Waters, J | 1 |
| Maeda, Y; Sasaki, T | 1 |
| Cvitkovic, E; Di Palma, M; Goldwasser, F; Gross-Goupil, M; Marceau-Suissa, J; Misset, JL; Tigaud, JM; Wasserman, E; Yovine, A | 1 |
| Jirajarus, M; Ratanatharathorn, V; Sirachainan, E; Sirilerttrakul, S | 1 |
| Heinemann, V | 3 |
| Alakl, M; Awad, L; Douillard, JY; Elfring, GL; Gruia, G; Locker, PK; Miller, LL; Pirotta, N; Saltz, LB | 1 |
| Flieger, D; Hoff, AS; Sauerbruch, T; Schmidt-Wolf, IG | 1 |
| Iqbal, S; Lenz, HJ | 1 |
| Pelley, RJ | 1 |
| Messori, A; Trippoli, S; Vaiani, M | 1 |
| Erlichman, C; Goldberg, RM; O'Connell, MJ | 1 |
| Pestalozzi, BC | 1 |
| Ducreux, M; Pignon, JP | 1 |
| Köhne, CH; Wilke, HJ; Wils, JA | 1 |
| Enzinger, PC; Ilson, DH | 1 |
| Dwivedy, S; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, ME; Zukowski, TH | 1 |
| Saltz, L | 2 |
| Douillard, JY | 2 |
| Mitchell, EP | 1 |
| Berlin, J | 1 |
| Bregman, D; Manalo, J; Mani, S | 1 |
| Rothenberg, ML | 2 |
| Dubreuil, A; Etienne, MC; Fischel, JL; Formento, P; Milano, G; Rostagno, P | 1 |
| Boushey, RP; Drucker, DJ; Yusta, B | 1 |
| Achterrath, W; Cao, S; Harstrick, A; Rustum, YM; Seeber, S; Vanhoefer, U | 1 |
| Adam, R; Bismuth, H; Castaing, D; Coeffic, D; Durrani, AK; Gil-Delgado, MA; Guinet, F; Khayat, D | 1 |
| Aschelter, AM; Comis, S; D'Attino, RM; Dogliotti, L; Garufi, C; Nisticó, C; Perrone, M; Pugliese, P; Tampellini, M; Terzoli, E | 1 |
| Avallone, A; Biglietto, M; Casaretti, R; Comella, G; Comella, P; De Cataldis, G; De Lucia, L; Di Lullo, L; Maiorino, L; Rivellini, F | 1 |
| Astrow, AB; Macdonald, JS | 1 |
| O'Connell, MJ | 1 |
| Cunningham, D; James, RD | 1 |
| Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, A; Koukourakis, M; Kouroussis, C; Mavroudis, D; Romanos, J; Souglakos, J; Vardakis, N | 1 |
| Antoine, EC; Bastian, G; Gil-Delgado, M; Khayat, D; Nizri, D | 1 |
| Delitheos, A; Miligkos, V; Papamichael, K; Tiligada, E; Ypsilantis, E | 1 |
| Akiyama, Y; Nishio, K; Saijo, N; Shimizu, M; Tamura, T; Yamada, Y | 1 |
| Hiratsuka, N; Sato, A; Tadokoro, K; Takebuchi, K; Ushio, J; Yamamoto, W | 1 |
| Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Schuell, B; Ulrich-Pur, H | 1 |
| Bokemeyer, C; Honecker, F; Kolb, G; Wedding, U | 1 |
| Krieger, G | 1 |
| Louvet, C | 1 |
| Traynor, K | 1 |
| Niedzwiecki, D; O'Connell, MJ; Sargent, DJ; Schilsky, RL | 1 |
| Ledermann, JA; Leonard, P; Seymour, M | 1 |
| Bruckner, HW; Evans, A; Kozuch, P; Petryk, M | 1 |
| Allegrini, G; Comis, S; Conte, P; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Lencioni, M; Masi, G; Pfanner, E | 1 |
| Meropol, NJ; Poplin, EA; Rothenberg, ML; Van Cutsem, E; Wadler, S | 1 |
| Baz, DV; Bofill, JS; Nogueira, JA | 1 |
| Guillou, PJ; Guthrie, JA; O'Riordain, DS; Ride, E; Sarela, AI; Seymour, MT | 1 |
| Law, S; Wong, J | 1 |
| Cunningham, D; Maroun, J; Van Cutsem, E; Vanhoefer, U | 1 |
| Saitoh, S; Sakata, Y | 1 |
| Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Pidlich, J; Raderer, M; Scheithauer, W; Ulrich-Pur, H | 1 |
| Boyer, J; Ferguson, PR; Harkin, DP; Johnston, PG; Latif, T; Longley, DB; Lynch, M; Maxwell, P | 1 |
| Furukawa, J; Inoue, M; Ishikawa, H; Katsumoto, Y; Nakayama, T; Oshima, S; Sue, F; Yukawa, M | 1 |
| Amaya, K; Miwa, K; Nishijima, K; Nishimura, G; Sasaki, S; Shimizu, K; Tani, T; Terada, I | 1 |
| Fukumoto, S; Habara, K; Iwasaki, T; Kamigaki, T; Ku, Y; Kunimoto, Y; Kuroda, Y; Nakamura, T; Nakamura, Y; Tamura, T | 1 |
| Bécouarn, Y; Bekradda, M; Coudert, B; Gamelin, E; Germa, C; Krisch, C; Mignard, D; Mousseau, M; Négrier, S; Pierga, JY; Provençal, J; Raoul, JL; Rixe, O | 1 |
| Reimer, P; Rückle-Lanz, H | 1 |
| Araneo, M; Barzdins, A; Bruckner, HW; DeGregorio, P; Frager, D; Grossbard, ML; Homel, P; Kozuch, P; Marino, J; Robin, A | 1 |
| Abrams, SI; Bergmann-Leitner, ES | 1 |
| Blumenthal, RD; Goldenberg, DM; Lew, W; Modrak, DE; Rodriguez, MD | 1 |
| Adler, G; Lutz, MP | 1 |
| Douillard, JY; Köhne, CH; Van Cutsem, E | 1 |
| Benson, AB; Berlin, J; Blanke, CD; Haller, DG; Hsieh, YC; Miller, LL; Mori, M; Rothenberg, ML | 1 |
| Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kandilis, K; Kouroussis, C; Mavroudis, D; Sarra, E; Souglakos, J; Vamvakas, L; Ziras, N | 1 |
| Wilke, H | 1 |
| Bleiberg, H; Di Leo, A | 1 |
| Boige, V; Ducreux, M; Taïeb, J | 1 |
| Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M | 1 |
| Cohen, Y; Lavrenkov, K; Man, S; Mermershtain, W | 1 |
| Adlard, JW; Quirke, P; Richman, SD; Seymour, MT | 1 |
| Holen, KD; Saltz, LB | 1 |
| Cerna, C; Davidson, KK; Heise, C; Izbicka, E; Kirn, D; Lawrence, RA; Petit, T; Von Hoff, DD | 1 |
| Chang, W; Kondo, Y; Kosaka, H; Maeda, S; Matsusaka, S; Okada, T; Oriyama, T | 1 |
| Fietkau, R; Klautke, G | 2 |
| Giacchetti, S | 1 |
| Hara, H; Hiramatsu, M; Sako, S; Shinohara, H; Tanigawa, N; Toyoda, M | 1 |
| Ando, N; Shih, CH | 1 |
| Benchalal, M; Fingerhut, A; Fouere, S; Yahchouchy-Chouillard, E | 1 |
| Dimitrakopoulos, A; Gennatas, K; Giannopoulos, A; Kosmas, Ch; Koufos, Ch; Macheras, A; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Tsavaris, NB; Tsipras, H; Vadiaka, M | 1 |
| Kerr, DJ | 1 |
| Agelaki, S; Androulakis, N; Athanasiadis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, Ch; Mavroudis, D; Samonis, G; Souglakos, J; Tsetis, D; Vardakis, N | 1 |
| Bruckner, HW; Kozuch, P; Petryk, M | 1 |
| Manzione, L; Reggiardo, G; Rosati, G; Rossi, A | 1 |
| Avallone, A; Casaretti, R; Catalano, G; Comella, G; Comella, P; Crucitta, E; De Lucia, L; De Vita, F; Del Prete, S; Lorusso, V; Orditura, M; Palmeri, S | 1 |
| Cunningham, D; Falk, S; Jackson, D | 1 |
| Fujita, M; Kawasaki, M; Shibata, J; Tani, T | 1 |
| Minsky, BD | 2 |
| Descos, L; Freyer, G; Kraft, D; Ligneau, B; Trillet-Lenoir, V | 1 |
| Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Louvet, C; Raymond, E; Tournigand, C | 1 |
| Buzzi, F; Comella, P; Crucitta, E; De Cataldis, G; De Lucia, L; De Vita, F; Del Gaizo, F; Farris, A; Lannelli, A; Maiorino, L; Mancarella, S; Palmeri, S; Tafuto, S | 1 |
| Aparicio, J; de las Peñas, R; Farrés, J; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM; Yuste, AL | 1 |
| Berlin, JD | 1 |
| Höffken, K; Kliche, KO; Kubsch, K; Masri-Zada, R; Raida, M | 1 |
| Allegrini, G; Brunetti, IM; Conte, P; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G; Pfanner, E | 1 |
| Goto, S; Ihara, Y; Kamada, K; Kondo, T; Soh, Y | 1 |
| Bennouna, J; Ducreux, M; Hua, A; Lepille, D; Marre, A; Méry-Mignard, D; Mignot, L; Rougier, P | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Kaufmann, SH; Miller, LL; Pitot, HC; Rubin, J; Sloan, JA | 1 |
| Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE | 1 |
| Hylander, BL; Naka, T; Repasky, EA; Rustum, YM; Sugamura, K; Widmer, MB | 1 |
| Baker, C; Chun, HG; Fehn, K; Goel, S; Hoffman, A; Hopkins, U; Jhawer, M; Landau, L; Makower, D; Mani, S; Rajdev, L; Wadler, S | 1 |
| Azuma, T; Hatada, T; Inoue, Y; Kusunoki, M; Miki, C; Mohri, T; Ojima, E | 1 |
| Schmoll, HJ | 1 |
| Emig, M; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, R; Pilz, L; Queisser, W; Samel, S; Willeke, F | 1 |
| Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT | 1 |
| Budman, DR | 1 |
| Fisher, MD | 3 |
| D'Orazio, AI; Gambill, BD | 1 |
| Fishman, AD; Wadler, S | 1 |
| Bilchik, AJ; Chawla, SP; Chung, MH; Foshag, LJ; Ramming, KP; Rose, DM; Stern, SS; Wood, TF | 1 |
| André, T; Artru, P; Louvet, C | 1 |
| Erlichman, C; Hobday, TJ | 1 |
| Feld, R; Fields, A; Goel, R; Hedley, D; Jolivet, J; Lee, IM; Maroun, J; Michael, M; Moore, MJ; Oza, A; Pintilie, M | 1 |
| Danesi, R; Di Paolo, A | 1 |
| Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; García-Foncillas, J; Martín-Algarra, S; Martínez-Monge, R; Rebollo, J; Rodríguez, J | 1 |
| Chico, IM; Pazdur, R | 1 |
| Chu, E | 2 |
| Blackstock, AW; McMullen, KP | 1 |
| Boussard, B; Frödin, JE; Glimelius, B; Kjaer, M; Linné, T; Oulid-Aïssa, D; Pfeiffer, P; Pyrhönen, S; Ristamäki, R; Skovsgaard, T; Tveit, KM | 1 |
| Avallone, A; Casaretti, R; Comella, G; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Lapenta, L | 1 |
| Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Saguchi, T; Suzuki, T; Yamamoto, T; Yasuda, S | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Panopoulos, C; Papadouris, S; Sarra, E; Souglakos, J; Vardakis, N | 1 |
| Chu, E; Copur, S; DeGrendele, HC; Jain, VK; Lee, D; Maung, K; Schilsky, R | 1 |
| Goldberg, RM; Hobday, TJ | 1 |
| Calvo, E | 1 |
| Azzariti, A; Church, SW; Colucci, G; Johnston, PG; Lacalamita, R; Paradiso, A; Tommasi, S; Xu, JM | 1 |
| Ebisui, C; Fujimoto, T; Fukuchi, N; Izawa, H; Kanai, T; Kouro, T; Sakita, I; Souma, I; Yoshida, T | 1 |
| Hata, Y; Itoh, T; Maeda, Y; Matsuoka, S; Nakajima, N; Osada, T; Sano, F | 1 |
| Bastidas, JA; Cho, C; Dunphy, EP; Fisher, G; Ford, JM; Jambalos, C; Koong, A; Lin, A; Mehta, VK; Poen, J; Young, H | 1 |
| Agrawal, S; Wang, H; Yu, D; Zhang, R | 1 |
| Kerr, D | 1 |
| Gotoh, M; Katsu, K; Kawabe, S; Ohta, S; Takiuchi, H | 1 |
| Akbulut, H; Akbulut, KG; Altuntas, F; Cindoruk, M; Icli, F; Ozturk, G; Unal, E | 1 |
| Adami, B; Baldus, M; Burg, H; Ehscheid, P; Galle, PR; Heike, M; Hoffmann, T; Hohl, H; Klein, O; Moehler, M; Schroeder, M; Schwindt, P; Zanke, C | 1 |
| Galle, PR; Heike, M; Hildner, K; Hoffmann, T; Moehler, M; Siebler, J | 1 |
| Evans, JF; Kargman, S; Kelly, CR; Kwong, E; Lam, EC; Luk, P; Wolfe, MM; Yao, M; Zheng, Y | 1 |
| Bonetti, A | 1 |
| Conroy, T; Gourgou, S; Hua, A; Kramar, A; Mery-Mignard, D; Seitz, JF; Ychou, M | 1 |
| Boku, N; Hyodo, I; Nakamura, A; Ohtsu, A; Saitoh, S; Shimada, Y; Shirao, K; Yamamichi, N; Yamamoto, S; Yoshida, S; Yoshioka, T | 1 |
| McLeod, HL; Watters, JW | 1 |
| Farrell, MP; Kummar, S | 1 |
| Braun, MS; Button, CJ; Cheeseman, SL; Chester, JD; Davis, T; Hall, GD; Joel, SP; Perry, J; Seymour, MT | 1 |
| Comte, S; Lebrun, T; Selke, B | 1 |
| Akasu, T; Fujita, S; Hosokawa, A; Matsumura, Y; Moriya, Y; Muro, K; Shimada, Y; Shirao, K; Yamada, Y | 1 |
| Chen, PM; Chen, WS; Chiou, TJ; Lin, JK; Liu, JH; Tai, CJ; Wang, WS; Yen, CC | 1 |
| Anné, PR; Fry, RD; Goldstein, SD; Isenberg, GA; Mahmoud, NN; Mitchell, E; Rose, DG; Stein, DE | 1 |
| Alimonti, A; Burattini, E; Pavese, I; Satta, F; Vecchione, A; Zoffoli, V | 1 |
| Glimelius, B | 2 |
| Lièvre, A; Mitry, E | 1 |
| Alvarez, E; Buesa, JM; Carrasco, J; Esteban, E; Fra, J; Jiménez Lacave, A; Muñiz, I; Sala, M; Viéitez, JM | 1 |
| Blackburn, A; Cunningham, C; Freeman, S; Gibson, B; Nemunaitis, J; Netto, G; Paulson, AS; Post, L; Randlev, B; Rich, D; Sands, B; Tong, A | 1 |
| Chiba, H; Hirayama, Y; Iyama, S; Niitsu, Y; Oku, T; Sagawa, T; Sakamaki, S; Sato, Y; Takahashi, M; Takayama, T; Takayanagi, N; Tsuji, Y | 1 |
| Berlin, JD; Bigelow, RH; Burger, BG; Garay, CA; Gupta, S; Haller, DG; Hart, LL; Le Bail, N; Marshall, JL; Oza, AM; Ramanathan, RK; Rothenberg, ML | 1 |
| Ambo, T; Arai, Y; Denda, T; Hyodo, I; Ohtsu, A; Shirao, K; Yamada, Y | 1 |
| Kikuchi, R; Noguchi, T; Oka, Y; Okada, S; Shibata, T; Toyoda, H; Uchida, Y | 1 |
| André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M | 1 |
| Friedman, HS; Gilbert, M; Powell, JB; Reardon, DA; Yung, WK | 1 |
| Benson, AB; Goldberg, RM | 1 |
| Carnaghi, C; Comella, P; Díaz-Rubio, E; Douillard, JY; Santoro, A; Sobrero, A; Van Cutsem, E | 1 |
| Ducreux, M; Köhne, CH; Schwartz, GK; Vanhoefer, U | 1 |
| Cascinu, S; Georgoulias, V; Kerr, D; Labianca, R; Maughan, T; Ychou, M | 1 |
| Bugat, R | 1 |
| Van Cutsem, E; Wilke, HJ | 1 |
| Boku, N; Ikeda, H; Ishikura, S; Ito, Y; Nihei, K; Ogino, T; Ohtsu, A | 1 |
| Gemici, C; Uygur-Bayramiçli, O | 1 |
| Haller, DG | 2 |
| Sawabu, N | 1 |
| Artru, P; De Gramont, A; Krulik, M; Louvet, C; Nahon, P; Tournigand, C | 1 |
| Aparicio, J; Borrega, P; de la Puente, CG; Lorenzo, A; Moreno-Nogueira, JA; Pica, JM; Reina, JJ; Rueda, A; Salvador, J | 1 |
| Boussard, B; Bouzid, K; Khalfallah, S; Padrik, P; Piko, B; Plate, S; Pshevloutsky, EM; Purkalne, G; Serafy, M; Tujakowski, J | 1 |
| Aparicio, J; Bosch, C; Busquier, I; Díaz, R; Fernández-Martos, C; Galán, A; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM | 1 |
| Bamias, A; Papamichael, D; Pavlidis, N; Syrigos, K | 1 |
| Cohen, Y; Geffen, DB; Gluzman, A; Lavrenkov, K; Man, S | 1 |
| Lenz, HJ; Park, DJ; Stoehlmacher, J | 1 |
| Fujimoto, T; Hashimoto, M; Ishibashi, K; Iwasaki, K; Kato, H; Ogawa, K; Umehara, A; Yokomizo, H; Yoshida, K; Yoshimatsu, K | 1 |
| Barceló, R; Ferreiro, J; López-Vivanco, G; Mañé, JM; Muñoz, A; Rubio, I | 1 |
| Akiyama, N; Arai, F; Funakoshi, K; Inayoshi, J; Kato, T; Kozakai, I; Motoyama, H; Ohta, T; Saito, Y; Takii, Y | 1 |
| Fukuda, K; Kimura, F; Kokufu, I; Tanei, T; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T | 1 |
| de Gramont, A; Louvet, C | 1 |
| Levin, M | 1 |
| Achterrath, W; Frings, S; Harstrick, A; Rustum, YM; Schleucher, N; Seeber, S; Tewes, M; Vanhoefer, U; Wilke, HJ | 1 |
| Alfonso, R; Díaz-Rubio, E; Flores, L; Macías, JA; Manrique, I; Sastre, J | 1 |
| Adjei, AA; Ames, MM; Atherton, P; Erlichman, C; Galanis, E; Goetz, MP; Goldberg, RM; Pitot, H; Reid, JM; Rubin, J; Sloan, JA; Windebank, AJ | 1 |
| Buzzi, F; Comella, P; De Lucia, L; De Vita, F; Farris, A; Gambardella, A; Lorusso, V; Maiorino, L; Mancarella, S; Palmeri, S | 1 |
| Galle, PR; Haas, U; Heike, M; Hertkorn, C; Hoehler, T; Moehler, M; Schimanski, C; Siebler, J | 1 |
| Auroux, J; Aziza, T; Braud, AC; Bugat, R; Buyse, M; Cherqui, D; Dupuis, O; Fagniez, PL; Ganem, G; Guimbaud, R; Haddad, E; Kobeiter, H; Piedbois, P; Piolot, A; Tayar, C; Valleur, P; Zelek, L | 1 |
| Dimitrakopoulos, A; Giannakakis, T; Gouveris, P; Karadima, D; Kosmas, C; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Rokana, S; Tsavaris, N; Tsipras, H; Vadiaka, M; Ziras, N | 1 |
| Fuchs, CS | 1 |
| Diasio, R | 1 |
| Venook, AP | 1 |
| Gill, S; Goldberg, RM; Thomas, RR | 1 |
| Azuma, M; Higuchi, K; Kitamura, T; Koizumi, W; Nagaba, S; Nakayama, N; Saigenji, K; Sasaki, T; Tanabe, S | 1 |
| Sato, A; Shimada, K; Taguchi, S | 1 |
| de Gramont, A; Kuebler, JP | 1 |
| Atalay, G; Bleiberg, H; Cardoso, F; Goldberg, RM; Paesmans, M | 1 |
| Bittorf, B; Brueckl, V; Brueckl, WM; Hahn, EG; Hegewald, J; Hohenberger, W; Jüngert, B; Männlein, G; Mühldorfer, S; Schirner, I; Stickel, F; Wein, A | 1 |
| Aparicio, T; Artru, P; Belloc, J; Desramé, J; Dominguez, S; Etienney, I; Ezenfis, J; Lecomte, T; Locher, C; Mabro, M; Mitry, E; Montembault, S; Vayre, L | 1 |
| Iwai, T; Ohtsukasa, S; Okabe, S; Sugihara, K; Yamashita, H | 1 |
| Ajani, JA; Faust, J; Komaki, R; Putnam, JB; Rice, D; Roth, J; Smythe, R; Stevens, C; Swisher, S; Vaporciyan, A; Walsh, G; Yao, J | 1 |
| Eisenberg, SG; Hwang, JJ; Marshall, JL | 1 |
| Hazama, S; Hinoda, Y; Oka, M | 1 |
| Maeda, Y; Sasaki, E; Sasaki, T | 1 |
| Nagao, M; Nakajima, Y | 1 |
| Hirata, K; Nishikawa, N; Sasaki, K; Takasaka, H; Yoshikawa, T | 1 |
| Kataoka, M; Kondo, K; Shimoyama, S | 1 |
| Motomura, S | 1 |
| Doi, T; Ohtsu, A | 1 |
| Shirao, K; Ura, T | 1 |
| Fukuda, H | 1 |
| Akazawa, S; Murakami, T; Nakazima, T; Sakurai, T; Yamashina, T | 1 |
| Brasiūnas, V; Brasiūniene, B; Inciūra, A; Juozaityte, E | 1 |
| Omura, K | 1 |
| O'Neil, BH | 1 |
| Willett, CG; Zhu, AX | 2 |
| Bria, E; Garufi, C; Sperduti, I; Terzoli, E; Vanni, B; Zappalà, AM | 1 |
| Furukawa, J; Ishigami, H; Katsumoto, Y; Kinuta, M; Maruyama, KT; Maruyama, N; Nagai, K; Nakaguchi, K; Tanaka, J; Yokouchi, H | 1 |
| Handa, R; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Naoi, Y; Oshima, S; Tsujie, M; Yamamoto, H | 1 |
| Hasuike, Y; Kashiwazaki, M; Mishima, H; Nishisyo, I; Takeda, Y; Tsujinaka, T | 1 |
| Furukawa, H; Imamura, H; Inoue, Y; Ishida, H; Kishi, K; Kitamura, S; Masutani, S; Nakayama, T; Saeki, N; Shimizu, J; Takamura, M; Tatsuta, M; Tomotsu, K; Yura, M | 1 |
| Handa, R; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Naoi, Y; Ohshima, S; Tsujie, M; Yamamoto, H | 1 |
| Arai, K; Horiguchi, S; Iwasaki, Y; Katayanagi, S; Matsumoto, H; Miyamoto, H; Nishioka, K; Takahashi, K; Yamaguchi, T | 1 |
| Anderson, SE; Bains, M; Ilson, DH; Kelsen, DP; Minsky, BD | 1 |
| Enomoto, M; Higuchi, T; Sugihara, K; Uetake, H | 1 |
| Goto, M; Hiraide, Y; Matsumoto, T; Saito, E; Takada, T | 1 |
| Akiyama, T; Doi, T; Hirata, K; Homma, H; Iyama, S; Kida, M; Kogawa, K; Mezawa, S; Murakami, K; Murase, K | 1 |
| Achille, E; André, T; Buyse, M; Colin, P; Couteau, C; de Gramont, A; Flesh, M; Ganem, G; Landi, B; Lledo, G; Louvet, C; Mery-Mignard, D; Quinaux, E; Tournigand, C | 1 |
| Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J | 1 |
| Curley, SA; Ellis, LM; Gentner, B; Parikh, AA; Vauthey, JN; Wu, TT | 1 |
| Han, JY; Ju, SY; Kim, EA; Kim, HY; Lee, DH; Lee, JJ; Lee, JS; Shin, EH | 1 |
| Assersohn, L; Brown, G; Cunningham, D; Hill, ME; Norman, AR; Oates, J; Ward, C; Waters, JS | 1 |
| Arciero, C; Peoples, GE; Shriver, CD | 1 |
| Viele, CS | 1 |
| Lewis, NL; Meropol, NJ | 1 |
| Arizcun, A; Cruz, JJ; de la Torre, A; Diz, P; Duarte, I; España, P; García López, MJ; García-Girón, C; Martínez del Prado, P; Méndez, M; Navalon, M; Pujol, E; Salut, A | 1 |
| Comella, P | 1 |
| Altundag, K; Barista, I; Celik, I; Engin, H; Guler, N; Gullu, I; Kars, A; Oksuzoglu, B; Ozisik, Y; Tekuzman, G; Turker, A; Yalcin, S | 1 |
| Artale, S; Bajetta, E; Beretta, E; Biasco, G; Bonaglia, L; Bonetti, A; Buzzoni, R; Carreca, I; Cassata, A; Cortinovis, D; Di Bartolomeo, M; Ferrario, E; Frustaci, S; Iannelli, A; Lambiase, A; Mariani, L; Marini, G; Pinotti, G | 1 |
| Gill, S; Goldberg, RM | 2 |
| Bafaloukos, D; Bamias, A; Economopulos, T; Fountzilas, G; Janinis, J; Kalofonos, HP; Kouvatseas, G; Papakostas, P; Skarlos, D; Stavropoulos, M; Timotheadou, E | 1 |
| Davis, ID; Green, M; Jefford, M; McClure, B; Michael, M; Rosenthal, MA; Smith, J; Waite, B; Zalcberg, J | 1 |
| Folprecht, G; Köhne, CH | 5 |
| Berger, MR; Leible, M; Saenger, J; Seelig, MH | 1 |
| Cats, A | 1 |
| Cohen, MH; Griebel, DJ; Hirschfeld, S; Ibrahim, A; Pazdur, R; Williams, GA | 1 |
| Fakih, M | 1 |
| Cammia, C; Croci, V; De Nicolao, G; Germani, M; Magni, P; Pesenti, E; Poggesi, I; Rocchetti, M; Simeoni, M | 1 |
| Azrak, RG; Cao, S; Durrani, FA; McLeod, HL; Pendyala, L; Rustum, YM; Slocum, HK; Tóth, K; Yin, MB; Zhang, W | 1 |
| Sasako, M; Ushijima, T | 1 |
| Barni, S; Cazzaniga, M; Cremonesi, M; Ferretti, G; Ghilardi, M; Mandalà, M; Mary, C; Rezzani, C | 1 |
| Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G | 1 |
| Dietrich, M; Grossbard, ML; Kozuch, P; Malamud, S; Mathew, S; Rachamalla, R | 1 |
| Algars, A; Bendardaf, R; Collan, Y; Lamlum, H; Pyrhönen, S; Ristamäki, R | 1 |
| Bleiberg, H; Buyse, M; Di Leo, A | 1 |
| Abad, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Gómez, MA; Marcuello, E; Masutti, B; Pronk, L; Ribera, F; Sastre, J | 1 |
| Aroori, S; Boyer, J; Carey, PD; Johnston, PG; Longley, DB; McCulla, A; McLean, EG; Wilson, P | 1 |
| Fujii, M; Kasakura, Y; Kobayashi, M; Kochi, M; Morishita, Y; Sato, K; Takayama, T | 1 |
| Aihara, T; Fukuhara, A; Kouno, T; Murayama, M; Nakagawa, K; Nakamura, E; Niida, M; Nishimoto, Y; Nozaki, H; Syouda, S; Watanabe, Y; Yagyu, T; Yasuoka, H | 1 |
| Goldberg, RM; Grothey, A; Sargent, D; Schmoll, HJ | 1 |
| Belmar, N; Buelow, R; Fong, T; Huang, L; Zhao, J | 1 |
| Baba, E; Fujishima, H; Harada, M; Kikuchi, I; Mitsugi, K; Miyanaga, O; Nakano, S; Ueda, A | 1 |
| Bajetta, E; Beretta, E; Buzzoni, R; Cortinovis, D; Di Bartolomeo, M; Dognini, G; Ferrario, E; Toffolatti, L | 1 |
| Chen, VM; Flower, RL; Jackson, D; Morel-Kopp, MC; Thrift, KM; Ward, CM | 1 |
| Ajani, JA; Cohen, DS; Faust, J; Komaki, R; Lynch, PM; Morris, J; Nivers, R; Putnam, JB; Roth, JA; Smythe, R; Swisher, SG; Vaporciyan, A; Walsh, G; Wu, TT | 1 |
| Abad, A; Antón, A; Carrato, A; Diaz-Rubio, E; Gallego, J; Manzano, JL; Marfa, X; Massutí, B; Yuste, AL | 1 |
| Batran, SA; Bokemeyer, C; Büchele, T; Haag, C; Hartmann, JT; Hofheinz, RD; Jäger, E; Kanz, L; Niederle, N; Oechsle, K; Pflüger, KH; Reis, HE; Wilke, HJ | 1 |
| Adam, R; Bastian, G; Bismuth, H; Castaing, D; Gil-Delgado, MA; Guinet, F; Khayat, D; Rocher, MA; Spano, JP; Taillibert, S; Urien, S | 1 |
| Aozasa, S; Fujino, K; Hase, K; Ito, H; Okada, K; Shikina, A; Suganuma, T; Tanaka, M; Terauchi, R; Tsuda, T; Utsunomiya, K | 1 |
| Baron, A; Berlin, J; Cartwright, T; Fehrenbacher, L; Ferrara, N; Fyfe, G; Griffing, S; Hainsworth, J; Heim, W; Holmgren, E; Hurwitz, H; Kabbinavar, F; Novotny, W; Rogers, B; Ross, R | 1 |
| Bajetta, E; Biasco, G; Brandi, G; Calabrese, C; Di Battista, M; Pantaleo, MA; Poggi, R | 1 |
| Kullmann, F; Schölmerich, J; Schultz, M | 1 |
| Fox, R; Melisko, ME; Venook, A | 1 |
| Punt, CJ; van Laarhoven, HW | 1 |
| Chiriatti, A; Colucci, G; Giuliani, F; Maiello, E; Mangia, A; Montemurro, S; Paradiso, A; Simone, G; Xu, J; Zito, A | 1 |
| Awad, L; Cunningham, D; Douillard, JY; Magherini, E; Mery-Mignard, D; Mitry, E; Rougier, P; Van Cutsem, E | 1 |
| Bereder, JM; Bernardini, D; Cals, L; Deplanque, G; Favre, R; François, E; Herait, P; Juin, P; Laadem, A; Merad, L; Rixe, O | 1 |
| Bertagnolio, MF; De Marco, S; Squilloni, E; Sternberg, CN; Vigna, L | 1 |
| Agarwal, R; Ardalan, B; Patel, M | 1 |
| Liu, WM; Propper, DJ; Scott, KA; Shahin, S | 1 |
| Grothey, A; Jordan, K; Kegel, T; Kellner, O; Schmoll, HJ | 1 |
| King, CR; Marsh, S; McLeod, HL | 1 |
| Hoff, PM; Pazdur, R | 1 |
| Goldberg, RM; Penland, SK | 1 |
| Hidaka, K; Matsukura, S; Samejima, R; Tanaka, M | 1 |
| Gürkan, A; Kaçar, S; Kahya, M; Karaca, C; Uslu, A; Varilsüha, C | 1 |
| Bathe, OF; Bigam, D; Butts, C; Dixon, E; Dowden, S; Ernst, S; Ruether, D; Sutherland, F; Walley, B | 1 |
| Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J | 1 |
| Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C | 1 |
| Goetz, MP; Grothey, A | 1 |
| Brank, A; Camp, ER; Hochwald, SN; Li, J; MacKay, SL; Minnich, DJ; Moldawer, LL | 1 |
| Jahnke, K; Keilholz, U; Schmittel, A; Thiel, E | 1 |
| Carlo, WF; Fong, Y; Gonen, M; Hummer, AJ; Jarnagin, W; Kemeny, N; Schwartz, L; Sullivan, D | 1 |
| Abad, A; Martinez-Balibrea, E; Plasencia, C; Taron, M | 1 |
| Boisdron-Celle, M; Dumont, A; Gamelin, E; Guérin, O; Morel, A; Rouits, E | 1 |
| Ajani, JA; Andrassy, RJ; Blakely, ML; Harting, MT; Herzog, CE; Lally, KP | 1 |
| Baek, JH; Bang, SM; Cho, EK; Im, SA; Lee, JH; Oh, JH; Park, SH; Park, YS; Shin, DB | 1 |
| Colarusso, D; Manzione, L; Pizza, C; Reggiardo, G; Rinaldi, A; Rosati, G; Tucci, A | 1 |
| Harada, O; Kobayashi, M; Sasamoto, M; Shimaya, S | 1 |
| Beppu, T; Doi, K; Egami, H; Ishiko, T; Morinaga, H; Nakagawa, M; Sugiyama, S; Tanaka, H; Yamane, T | 1 |
| Fenske, A; Hribaschek, A; Krüger, S; Lippert, H; Meyer, F; Pross, M; Ridwelski, K | 1 |
| Chau, I; Cunningham, D; Hill, M; Katopodis, R; Middleton, G; Norman, AR; Oates, JR; Ross, PJ; Stewart, G; Topham, C; Waters, JS | 1 |
| Liu, JH | 1 |
| Damjanovic, D; Findlay, MP; Thompson, P | 1 |
| Hayashi, T; Ishiwatari, H; Kato, J; Kogawa, T; Miyanishi, K; Niitsu, Y; Oku, T; Takada, K; Takahashi, M; Takanashi, K; Takayama, T | 1 |
| Fukuhara, A; Kikuchi, S; Murayama, M; Nakamura, E; Nishimoto, Y; Nozaki, H; Shouda, S; Watanabe, Y; Yagyu, T | 1 |
| Scheithauer, W | 1 |
| Balcells, M; Benavides, M; Carabantes, F; Cobo, M; García-Alfonso, P; Gil-Calle, S; Graupera, J; Muñoz-Martín, A; Pérez-Manga, G; Villar, E | 1 |
| Acusa, A; Antón, I; Batiste-Alentorn, E; Campos, JM; Guasch, I; Losa, F; Manzano, H; Saigi, E; Salut, A; Vélez de Mendizabal, E | 1 |
| Ajani, JA; Bresalier, R; Correa, AM; Erasmus, JJ; Komaki, R; Macapinlac, H; Maish, M; Munden, RF; Putnam, JB; Rice, D; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL; Wu, TT | 1 |
| Cesta, A; Lalli, A; Lullo, LD; Nuzzo, A; Rea, S; Recchia, F; Saggio, G | 1 |
| Boothman, DA; Hwang, A; Meyers, M; Wagner, MW | 1 |
| Delaunoit, T; Findlay, BP; Fuchs, CS; Goldberg, RM; Green, E; Mailliard, JA; Morton, RF; Salim, M; Sargent, DJ; Schaefer, PL; Stella, PJ; Thomas, SP | 1 |
| Donehower, RC; Grouleff, P; Hidalgo, M; Kelley, SK; Laheru, DA; Lum, BL; Messersmith, WA; Ramies, DA; Rogers, T; Senzer, NN | 1 |
| Sharieff, W | 1 |
| Arsène, D; Bedenne, L; Bonnetain, F; Bouché, O; Buecher, B; Etienne, PL; Giovannini, M; Guérin-Meyer, V; Kaminsky, MC; Lledo, G; Milan, C; Mitry, E; Paitel, JF; Raoul, JL; Rougier, P; Seitz, JF | 1 |
| Hejna, M; Raderer, M; Wöhrer, SS | 1 |
| Hiro, J; Inoue, Y; Kobayashi, M; Kusunoki, M; Miki, C; Mori, K; Shirane, M; Tanaka, K; Yanagi, H | 1 |
| Arai, T; Goto, A; Hamaguchi, T; Hosokawa, A; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y | 1 |
| Allegrini, G; Andreuccetti, M; Brunetti, I; Cerri, E; Cupini, S; Falcone, A; Fontana, E; Marcucci, L; Masi, G; Ricci, S | 1 |
| Doi, K; Hashimoto, D; Ishimoto, T; Kikuchi, N; Muranaka, T; Ochiai, T; Ogata, K; Ogawa, M; Ohchi, T | 1 |
| Hazama, S; Mori, N; Oka, M; Tamesa, T; Tangoku, A; Watanabe, Y; Yamamoto, S; Yoshimura, K | 1 |
| Reddy, GK | 1 |
| Geffen, DB; Gluzman, A; Idelevich, E; Lavrenkov, K; Man, S; Shani, A | 1 |
| Akbulut, H; Deisseroth, A; Maynard, J; Pizzorno, G; Tang, Y; Zhang, L | 1 |
| Adam, R; Azoulay, D; Bismuth, H; Castaing, D; Delvart, V; Levi, F; Pascal, G; Paule, B | 1 |
| Iishi, H; Narahara, H; Sugimoto, N; Tatsuta, M | 1 |
| Doggrell, SA | 1 |
| Azrak, R; Bhattacharya, A; Cao, S; Durrani, FA; Mazurchuk, R; Pendyala, L; Rustum, YM; Slocum, HK; Spernyak, JA; Tóth, K | 1 |
| Blumenthal, RD; Goldenberg, DM; Hansen, HJ; Hayes, MK; Horak, ID; Osorio, L | 1 |
| Andre, N; Graeven, U; Schmiegel, W | 1 |
| Babic, DR; Grbic, B; Jelic, SB; Matijasevic, MM; Popov, IP | 1 |
| Gnad-Vogt, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Pilz, L; Saussele, S; Wein, A | 1 |
| Carvalho, LP; Fleshman, JW; Glasgow, SC; McLeod, HL; Shannon, WD; Yu, J | 1 |
| Hitre, E; Láng, I | 1 |
| Cao, S; Durrani, FA; Rustum, YM | 1 |
| Bocci, G; Danesi, R; Di Paolo, A | 1 |
| Bernhard, J; Borner, MM; Brauchli, P; Dietrich, D; Herrmann, R; Honegger, H; Koeberle, D; Lanz, D; Popescu, R; Rauch, D; Roth, AD; Saletti, P; Wernli, M | 1 |
| Enomoto, M; Higuchi, T; Iida, S; Sugihara, K; Tsunozaki, H; Uetake, H; Yasuno, M | 1 |
| Assadourian, S; deJonge, MJ; Dumez, H; Eskens, FA; Sanderink, GJ; Selleslach, J; Semiond, D; Soepenberg, O; Sparreboom, A; ter Steeg, J; van Oosterom, AT; Verweij, J | 1 |
| Gnad, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kraus-Tiefenbacher, U; Müldner, A; Post, S; von Gerstenberg-Helldorf, B; Wenz, F; Willeke, F | 1 |
| Hwang, JJ | 1 |
| Gallagher, M; Giantonio, B; Haller, D; Metz, J; O'Dwyer, P; Sun, W; Whittington, R | 1 |
| Becerra, CR | 1 |
| Cecchin, E; Toffoli, G | 1 |
| Mayer, RJ; Meyerhardt, JA | 1 |
| Brown, JL; Charlton, PA; Freathy, C; Harris, SM; Mistry, P | 1 |
| Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H | 1 |
| Tejpar, S; Van Cutsem, E; Verslype, C | 1 |
| Haller, DG; Sun, W | 1 |
| McLeod, HL; Tan, BR | 1 |
| Grem, JL | 1 |
| Lentz, F; Pons, G; Rey, E; Tran, A; Tréluyer, JM | 1 |
| Li, YS | 1 |
| Hamm, JT; Hecht, JR; Kabbinavar, FF; Mass, R; McCleod, M; Nelson, B; Novotny, WF; Patel, T; Perrou, B; Schulz, J | 1 |
| Albert, A; Chang, AJ; Liu, TC; Sangha, S; Wolfe, MM; Yao, M; Zhou, W | 1 |
| Alajati, A; Ganslmayer, M; Hahn, EG; Herold, C; Lüders, M; Neureiter, D; Ocker, M; Schuppan, D; Zopf, S | 1 |
| Bertheault-Cvitkovic, F; Bugat, R; Canal, P; Chatelut, E; Cornen, X; Delord, JP; Dieras, V; Guimbaud, R; Lochon, I; Lokiec, F; Mery-Mignard, D; Mouri, Z; Pierga, JY; Turpin, FL | 1 |
| Bleiberg, H; Borner, M; Dirix, L; Gonzalez Baron, M; Gruia, G; Joosens, E; Morant, R; Roth, A; Sibaud, D; Van Belle, S; Van Cutsem, E; Van Laethem, JL | 1 |
| Artandi, M; Borner, M; Boussard, B; Carlsson, G; Espana, P; Graeven, U; Ridwelski, K; Rosales, AM; Schmiegel, W; Schölmerich, J | 1 |
| Vega-Stromberg, T | 1 |
| Susman, E | 1 |
| Feyerherd, P; Fietkau, R; Foitzik, T; Klautke, G; Ludwig, K; Prall, F | 1 |
| Arnold, CN; Blum, HE | 1 |
| Allal, A; Bauer, J; Gervaz, P; Mentha, G; Morant, R; Philippe, M; Roth, AD; Ruhstaller, T; Seium, Y; Stupp, R; Trembleau, C | 1 |
| Alfonso, R; Carcas, A; Cortés-Funes, H; Díaz-Rubio, E; Frías, J; Grávalos, C; Guerra, P; Paz-Ares, L; Pronk, L; Sastre, J | 1 |
| Venook, A | 1 |
| Asaka, M; Furukawa, S; Fuse, N; Kato, M; Kato, T; Komatsu, Y; Takeda, H; Takei, M; Yuki, S | 1 |
| Poston, GJ | 1 |
| Im, YH; Ji, SH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, SH; Lim, DH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS | 1 |
| Hurwitz, H | 1 |
| Aravantinos, G; Bacoyiannis, C; Bamias, A; Basdanis, G; Chalkidou, S; Dimopoulos, M; Economopoulos, T; Fountzilas, G; Kalfarentzos, F; Kalofonos, HP; Karina, M; Kosmidis, P; Koutras, A; Papakostas, P; Pectasides, D; Samantas, E; Samelis, GF; Skarlos, D | 1 |
| Bauer, I; Freund, M; Köhne, CH; Schuff-Werner, P; Seule, M; Steiner, B; Steiner, M | 1 |
| Kallinowski, B | 1 |
| Galle, PR; Moehler, M; Teufel, A | 1 |
| Cordon-Cardo, C; Drobnjak, M; Gonen, M; Hummer, A; Kemeny, N; Motwani, M; Schwartz, GK; Shah, MA | 1 |
| Im, YH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, ST; Kim, WS; Lee, J; Lee, SH; Park, JO; Park, K; Park, KW; Park, YS | 1 |
| Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML | 1 |
| Brener, J; Chaitchik, S; Czerniak, A; Hayat, H; Schachter, P; Shimonov, M | 1 |
| Alves, PA; da Rocha, AB; Grass, LB; Grivicich, I; Henriques, JA; Kayser, GB; Regner, A; Schunemann, DP; Schwartsmann, G | 1 |
| Silberman, H | 1 |
| Chen, LB; Dai, M; Owen, DA; Tai, IT | 1 |
| Jäger, D; Knuth, A; Pestalozzi, BC | 1 |
| Boige, V; Elias, D; Estphan, G; Laplanche, A; Malka, D; Pocard, M; Raynard, B | 1 |
| Abad, A; Antón, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Gil, S; Maestu, I; Marcuello, E; Masutti, B; Maurel, J; Navarro, M; Sastre, J; Valladares, M; Vicent, JM | 1 |
| Asama, T; Ashida, T; Ayabe, T; Chisato, N; Ebisawa, Y; Kamiya, K; Kasai, S; Kohgo, Y; Kono, T; Tomita, I | 1 |
| Fernandez, FG; Goodwin, JW; Hawkins, WG; Linehan, DC; Ritter, J; Strasberg, SM | 1 |
| Di Costanzo, F; Doni, L | 1 |
| Asmar, L; Boehm, KA; Cartwright, T; Encarnacion, C; Lopez, T; Vukelja, SJ | 1 |
| Fioravanti, S; Grem, JL; Guo, X; Harold, N; Hopkins, JL; Leguizamo, JP; Leonard, GD; Lin, P; Monahan, BP; Morrison, G; Nguyen, D; Pang, J; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Wright, MA | 1 |
| Bang, SM; Cho, EK; Choi, EY; Chung, M; Ki Lee, W; Lee, JH; Park, SH; Shin, DB | 1 |
| Wu, WQ; Yu, BM | 1 |
| David, A; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N | 1 |
| Bakker, JM; Falk, S; Groenewegen, G; Kerr, DJ; Maughan, T; Nortier, JW; Punt, CJ; Rea, DW; Richel, DJ; Semiond, D; Smit, JM; Steven, N; Ten Bokkel Huinink, WW | 1 |
| Anak, O; Bokemeyer, C; El-Serafi, M; Frickhofen, N; Fuchs, R; Genicot, B; Köhne, CH; Langenbuch, T; Lorenz, M; Lutz, MP; Mergenthaler, HG; Müller, L; Nordlinger, B; Reichardt, P; Rougier, P; Rückle-Lanz, H; van Cutsem, E; Vanhoefer, U; Voigtmann, R; Wils, J | 1 |
| Eimermacher, A; Flieger, D; Galle, PR; Geer, T; Gracien, E; Heike, M; Höhler, T; Junginger, T; Menges, M; Moehler, M; Siebler, J; Wein, A | 1 |
| Aggarwal, S; Chu, E | 1 |
| Berdzik, J; Creaven, PJ; Hoffman, JL; Intengan, ME; Javle, MM; Khushalani, N; Litwin, AM; Pendyala, L; Ramnath, N; Rustum, YM; Slocum, HK; Smith, PF; Stewart, CC; Toth, K | 1 |
| Arnold, D; Schmoll, HJ | 1 |
| Achiwa, H; Bessho, Y; Maeda, H; Muramatsu, H; Niimi, T; Oguri, T; Sato, S; Ueda, R | 1 |
| Colucci, G; Giuliani, F; Maiello, E; Mangia, A; Montemurro, S; Paradiso, A; Simone, G; Xu, JM; Zhu, BD | 1 |
| Allen, WL; Johnston, PG | 2 |
| Blumgart, L; D'Angelica, M; DeMatteo, R; Fong, Y; Gönen, M; Jarnagin, W; Kemeny, N; Leonard, G; Morse, M; Paty, P; Schwartz, L | 1 |
| André, T; Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Kornprobst, M; Larsen, AK; Louvet, C; Raymond, E; Tournigand, C | 1 |
| Barni, S; Berardi, R; Beretta, GD; Cascinu, S; Catalano, V; Gasparini, G; Graziano, F; Labianca, R; Scartozzi, M; Sobrero, A; Zaniboni, A | 1 |
| Lopes, G; Rocha Lima, CM | 1 |
| Philip, PA | 1 |
| Bubis, JA; Dragnev, KH; Rigas, JR | 1 |
| Cree, IA; Di Nicolantonio, F; Di Palma, S; Fernando, A; Gabriel, FG; Glaysher, S; Gulliford, T; Higgins, B; Hurren, J; Johnson, P; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Somers, SS; Toh, S; Whitehouse, PA; Yiangou, C | 1 |
| Baek, JH; Bang, SM; Cho, EK; Han, SH; Lee, JH; Oh, JH; Park, SH; Shin, DB; Sung, JY | 1 |
| Leong, LA; Rosales, J | 1 |
| Hanyu, F; Harada, N; Hayashi, T; Suzuki, M; Suzuki, S; Takeo, Y; Tanaka, S | 1 |
| Ahn, JS; Chang, HM; Kang, WK; Kang, YK; Kim, HK; Kim, SR; Kim, TW; Lee, KH; Park, JO; Ryoo, BY; Zang, DY | 1 |
| Almerud, A; Gubanski, M; Lideståhl, A; Lind, PA; Naucler, G | 1 |
| El-Salhy, M; Hilding, L; Royson, H; Tjomsland, V | 1 |
| Bendardaf, R; Elzagheid, A; Lamlum, H; Pyrhönen, S; Ristamäki, R | 1 |
| Caricato, M; Coppola, R; Di Seri, M; La Cesa, A; Rocci, L; Santini, D; Schiavon, G; Spalletta, B; Tonini, G; Vincenzi, B | 1 |
| Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J | 1 |
| Chong, G; Cunningham, D; Dickson, JL; Hill, ME; Norman, AR; Oates, J; Price, TJ; Rao, S; Tebbutt, N | 1 |
| Tyagi, P | 1 |
| Advani, RH; Cho, CD; Fisher, GA; Ford, JM; Halsey, J; Kuo, T; Sikic, BI; Wakelee, HA | 1 |
| Chan, AT; Ho, WM; King, A; Koh, J; Lai, P; Leow, CK; Lim, R; Ma, B; Mok, T; Wong, YY; Yeo, W | 1 |
| Anderson, KS; Ansén, S; Bohlen, H; Diehl, V; Geisen, C; Gracien, E; Jurkiewicz, E; Nadler, LM; Schmidt, M; Weihrauch, MR; Wittig, B; Wolf, J; Xia, Z | 1 |
| Aiba, M; Kamoshita, N; Makita, F; Morishita, Y; Nagashima, T; Ohwada, S; Takeyoshi, I; Tokiniwa, H | 1 |
| Adróver Cebrián, E; Alonso López, C; Alvarez Gallego, J; Arroyo Yustos, M; Barceló Galíndez, R; García Palomo, A; García-Girón, C; León Carbonero, A; Méndez Ureña, M | 1 |
| Jones, DH; Lynch, H; Silberstein, PT; Ternet, C | 1 |
| Abbruzzese, JL; Eng, C | 1 |
| Brahmandam, M; Cantor, M; Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kinsella, K; Kulke, MH; Loda, M; Meyerhardt, JA; Michelini, AL; Namgyal, C; Ogino, S; Ryan, DP | 1 |
| Ko, AH; Tempero, MA | 1 |
| Akasaka, Y; Hata, Y; Honda, S; Ito, T; Matsuoka, S; Nakajima, N; Ohmori, K; Sano, F; Yokoyama, R | 1 |
| Mitsugi, K; Nakano, S; Tanaka, R; Ueki, T; Umeno, M | 1 |
| Carrato-Mena, A; Guillén-Ponce, C; Maciá-Escalante, S; Molina-Garrido, MJ | 1 |
| Buzzi, F; Comella, P; De Cataldis, G; De Lucia, L; Farris, A; Filippelli, G; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Natale, D; Palmeri, S; Roselli, M; Tafuto, S | 1 |
| Biason, P; Buonadonna, A; Cattarossi, G; Cecchin, E; Colussi, A; Corona, G; Frustaci, S; Masier, S; Toffoli, G | 1 |
| Allen, W; Galligan, L; Johnston, PG; Longley, DB; McDermott, U; Wilson, T | 1 |
| Chmura, SJ; Haraf, DJ; Kao, J; Milano, MT; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Fujii, Y; Kobayashi, T; Kuga, T; Matsuoka, T; Morikage, N; Nakayama, T | 1 |
| Laurent-Puig, P; Lièvre, A | 1 |
| Fung, A; Viale, PH; Zitella, L | 1 |
| Ajani, JA; Cox, JD; Komaki, R; Liao, Z; Liu, H; Swisher, S; Tucker, SL; Vaporciyan, AA; Wang, SL; Wei, X | 1 |
| Akiyama, T; Hirabayashi, Y; Hirai, T; Ikeda, M; Iki, K; Kubozoe, T; Matsumoto, H; Sadahira, Y; Tsunoda, T; Urakami, A; Yamamura, M; Yamashita, K | 1 |
| Gamucci, T; Gasparini, G; Gattuso, D; Longo, R; Mariani, L; Morabito, A; Sarmiento, R; Torino, F; Vitale, S | 1 |
| Dercksen, W; Giaccone, G; Noordhuis, P; Peters, GJ; Pinedo, HM; Smid, K; Smorenburg, CH; van Groeningen, CJ; van Riel, AM | 1 |
| El-Deiry, WS; Finnberg, N; Furth, EE; Grimberg, A; Kim, SH; Liu, JJ; Piccoli, DA; Russo, P | 1 |
| Jensen, BV; Pfeiffer, P | 1 |
| Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L | 1 |
| Isomura, M; Miki, Y | 1 |
| Fujio, N; Fukuda, Y; Ihara, T; Koyama, I; Osugi, H; Takatori, H; Tsukazaki, T; Tsukazaki, Y | 1 |
| Lokiec, F; Rezaí, K; Urien, S | 1 |
| Baltesgard, L; Ehrsson, H; Fokstuen, T; Glimelius, B; Mortensen, JP; Pfeiffer, P; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, KM; Wallin, I; Øgreid, D | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Lee, SY; Park, CG | 1 |
| Byun, JH; Chang, SK; Choi, MG; Choi, SI; Hong, YS; Kang, JH; Lee, DS; Lee, KS; Lee, MA; Oh, ST; Shim, BY; Woo, IS | 1 |
| Hurwitz, H; Kabbinavar, F | 1 |
| Folprecht, G; Köhne, CH; Lutz, MP; Nolting, A; Pollert, P; Schöffski, P; Seufferlein, T | 1 |
| Amano, M; Fujita, M; Hayashida, H; Higaki, N; Itani, Y; Nakagawa, S; Niinobu, T; Nishikawa, Y; Sakon, M | 1 |
| Kitamura, M; Noda, K; Shiba, Y; Umekita, N | 1 |
| Berry, S; Billingsley, K; Croitoru, M; Gallinger, S; Krishnamurthi, S; Mackay, HJ; Pond, GR; Siu, LL; Smith, A; Swanson, PE; Yeung, R | 1 |
| Dimou, E; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Xynotroulas, JP | 1 |
| Alonso, M; Balcells, M; Barceló, R; Castañón, C; Centelles, M; GarcíaGirón, C; López Vivanco, G; Navalón, M; Ramos, M; Rivera, F | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Milaki, G; Pallis, A; Souglakos, J; Xenidis, N | 1 |
| Grothey, A; Kim, GP | 1 |
| Dong, QM; He, YJ; Li, YH | 1 |
| Ishiguro, A; Munakata, M; Saitoh, S; Sakata, Y; Shitara, K | 1 |
| Becker, K; Hochster, H; Hong, S; John, W; Kettner, E; Kroning, H; Lordick, F; Macdonald, J; Ramanathan, RK; Schmoll, HJ | 1 |
| Gill, S; Ho, C; Ng, K; O'Reilly, S | 1 |
| Grothey, A; Sargent, D | 1 |
| Chaudhury, PK; Horton, PJ; Martinie, JB; Metrakos, P; Rochon, C; Tzimas, GN; Znajda, TL | 1 |
| Abderrahim, AG; Astre, C; Bressolle, F; Duffour, J; Pinguet, F; Poujol, S; Ychou, M | 1 |
| Abdalla, EK; Vauthey, JN | 1 |
| Allegrini, G; Brunetti, IM; Cerri, E; Cupini, S; Falcone, A; Filipponi, F; Goletti, O; Loupakis, F; Marcucci, L; Masi, G; Pfanner, E; Viti, M | 1 |
| Bhatnagar, P; Levine, E; Saunders, MP; Swindell, R; Valle, JW; Young, E | 1 |
| Beck, S; Bourquin, C; Endres, S; Hartmann, G; Schreiber, S | 1 |
| Leichman, CG | 1 |
| Eguchi, T; Hiro, J; Inoue, Y; Kusunoki, M; Miki, C; Tanaka, K; Toiyama, Y; Yoshiyama, S | 2 |
| Hoff, PM; Varadhachary, GR | 1 |
| Marshall, J | 1 |
| Aggarwal, BB; Ajani, JA; Chao, KS; Ensor, J; Hittelman, WN; Izzo, JG; Lee, JH; Liao, Z; Luthra, R; Malhotra, U; Swisher, SG; Wu, TT | 1 |
| Hanna, N; Hayostek, C; Mitchell, E; Mohiuddin, M; Nichols, C; Shane, R; Willett, C; Winter, K; Yuen, A | 1 |
| Bas, C; Bella, S; Chacon, M; Coppola, F; Escobar, E; Hidalgo, J; Korbenfeld, E; Martin, C; Martinez, J; Reale, M; Richardet, E; Senna, S; Smilovich, AM; Wasserman, E | 1 |
| Goyle, S; Maraveyas, A | 1 |
| de Gramont, A; Tournigand, C | 1 |
| Alves, PA; da Rocha, AB; Grass, LB; Grivicich, I; Henriques, JA; Kayser, GB; Regner, A; Schwartsmann, G | 1 |
| Arveux, P; Bedenne, L; Bonnetain, F; Bouché, O; Conroy, T; Etienne, PL; Giovannini, M; Girault, C; Mitry, E; Raoul, JL; Rougier, P; Seitz, JF | 1 |
| Bogdanow, M; Gorschlüter, M; Lamberti, C; Lundin, S; Sauerbruch, T; Schmidt-Wolf, IG | 1 |
| Bai, T; Tanaka, T; Umesaki, N; Yukawa, K | 1 |
| Biasco, G; Brandi, G; Derenzini, E; Ercolani, G; Grazi, G; Pantaleo, MA; Ravaioli, M | 1 |
| Chua, YJ; Cunningham, D | 1 |
| Fietkau, R; Foitzik, T; Klar, E; Klautke, G; Küchenmeister, U; Ludwig, K; Prall, F | 1 |
| Cannita, K; Cianci, G; De Galitiis, F; De Tursi, M; Di Rocco, ZC; Ficorella, C; Iacobelli, S; Marchetti, P; Morelli, MF; Morese, R; Porzio, G; Ricevuto, E; Tinari, N | 1 |
| Berlin, JD; Cropp, GF; Donnelly, E; Fleischer, AC; Hande, KR; Hannah, AL; Lockhart, AC; Rothenberg, ML; Schaaf, LJ; Schumaker, RD | 1 |
| András, C; Farczádi, E; Szántó, J | 1 |
| André, T; Artru, P; de Gramont, A; Flesch, M; Landi, B; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Plantade, A | 1 |
| Anthoney, DA; Burge, ME; Halstead, F; Jackson, DP; Seymour, MT; Smith, D; Topham, C | 1 |
| Alvarez, JV; Arcediano, A; Cassinello, J; Castro, IG; Colmenarejo, A; Filipovich, E; López, MJ; Marcos, F; Pujol, E; Segovia, F | 1 |
| Büchler, P; Ganten, TM; Haas, TL; Koschny, R; Schader, MB; Schulze-Bergkamen, H; Stremmel, W; Sykora, J; Untergasser, A; Walczak, H | 1 |
| Crews, KR | 1 |
| Baek, JH; Chae, YS; Cho, GJ; Choi, YJ; Chung, JS; Jeon, SB; Jung, HY; Kim, DH; Kim, JG; Lee, KB; Shin, HJ; Sohn, SK; Yu, W | 1 |
| Barten, M; Fietkau, R; Klautke, G; Prall, F; Schiffmann, L; Wöhlke, M | 1 |
| Boukovinas, I; Christofillakis, C; Georgoulias, V; Potamianou, A; Syrigos, K; Tselepatiotis, E; Tsousis, S; Varthalitis, I; Ziras, N | 1 |
| Baudin, E; Boige, V; de Baere, T; Dromain, C; Ducreux, MP; Duvillard, P; Elias, D; Kergoat, P; Lasser, P; Leboulleux, S; Malka, D; Sabourin, JC; Schlumberger, M | 1 |
| Akazai, Y; Kimura, H; Nitta, Y | 1 |
| Beaven, AW; Goldberg, RM | 1 |
| Allen, WL; Coyle, VM; Johnston, PG | 1 |
| Colucci, G; Di Renzo, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Mallamaci, R; Pezzella, G; Romito, S | 1 |
| Chen, JZ; Liao, WJ; Luo, RC; Zheng, H | 1 |
| Allegrini, G; Andreuccetti, M; Barbara, C; Brunetti, IM; Bursi, S; Cerri, E; Cupini, S; Falcone, A; Loupakis, F; Marcucci, L; Masi, G; Murr, R; Ricci, S | 1 |
| Lenz, HJ; Park, DJ | 1 |
| Assenat, E; Duffour, J; Ychou, M | 1 |
| Konietzny, P; Schmassmann, A; Schmassmann-Suhijar, D; Yoon, S; Zuber, M | 1 |
| Eng, C; Shalan, N | 1 |
| Biason, P; Boccalon, M; Bonura, S; Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Pangher, V; Errante, D; Frustaci, S; Gaion, F; Galligioni, E; Giusto, M; Medici, M; Pasetto, LM; Pessa, S; Russo, A; Sandri, P; Toffoli, G | 1 |
| Aranda, E; Cervantes, A; Dotor, E; Gallén, M; García, JL; Navarro, M; Rivera, F; Sánchez-Rovira, P; Vega-Villegas, ME | 1 |
| Goto, A | 1 |
| Meropol, NJ | 2 |
| Alberts, S; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK | 1 |
| Aranda, E; Bandres, E; De la Haba, J; Garcia, F; García-Foncillas, J; Gómez, A; Huarriz, M; Morales, R; Romero, RZ | 1 |
| Hirakawa, K; Ren, J; Yashiro, M; Zhang, X | 1 |
| Afchain, P; André, T; de Gramont, A; Segura, C | 1 |
| Akkermans-Vogelaar, JM; Antonini, NF; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Punt, CJ; Rodenburg, CJ; Vreugdenhil, G; Wals, J | 1 |
| Benson, AB; Catalano, PJ; Giantonio, BJ; Levy, DE; Meropol, NJ; O'dwyer, PJ | 1 |
| Alacacioglu, A; Oztop, I; Somali, I; Tarhan, O; Yaren, A; Yilmaz, U | 1 |
| Eguchi, T; Shirao, K | 1 |
| Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasada, T; Yamada, Y; Yamamitsu, S | 1 |
| Caciagli, B; Capaccioli, S; Donnini, M; Landini, I; Lapucci, A; Lulli, M; Mazzei, T; Mini, E; Morganti, M; Nobili, S; Papucci, L; Perna, F; Schiavone, N; Sobrero, A; Tempestini, A; Witort, E | 1 |
| Casaretti, R; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Massidda, B; Palmeri, S; Putzu, C; Sandomenico, C | 1 |
| Andria, M; Dhami, M; Diasio, RB; Godfrey, T; Gold, PJ; Kovatich, AJ; Lund, KA; Meropol, NJ; Mitchell, E; Schwarting, R | 1 |
| Andre, T; Bleiberg, H; de Gramont, A; Goldberg, RM; Green, E; Rothenberg, ML; Sargent, DJ; Tabah-Fisch, I; Tournigand, C | 1 |
| Deguchi, Y; Kaneko, I; Kii, E; Murata, T; Sonoda, K; Tsubono, M; Yasuda, K | 1 |
| Fujiwara, T; Gouchi, A; Kagawa, S; Matsuoka, J; Nishizaki, M; Tanaka, N; Teraishi, F; Tokunaga, N; Uno, F | 1 |
| Han, MJ; Kang, WK; Kim, HJ; Kwon, JM; Lee, HR; Lee, J; Lim, HY; Oh, SY; Park, BB; Park, JO; Park, YS | 1 |
| Dinter, D; Grobholz, R; Heeger, S; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kraus-Tiefenbacher, U; Post, S; Wenz, F; Willeke, F; Woernle, C | 1 |
| Hiro, J; Inoue, Y; Kusunoki, M; Miki, C; Nakatani, K; Nobori, T; Ojima, E; Toiyama, Y; Watanabe, H | 1 |
| Beale, PJ; Childs, A; Clarke, SJ; Read, JA; Smith, N; Volker, DH | 1 |
| Kaneko, H; Koshino, H; Kurihara, A; Otsuka, Y; Takita, W; Tamura, A; Teramoto, T; Tsuchiya, M; Watanabe, M; Yamazaki, K | 1 |
| Andres, A; Audard, V; Brezault, C; Chaussade, S; Dousset, B; Giostra, E; Majno, PE; Mentha, G; Roth, AD; Rubbia-Brandt, L; Sartoretti, P; Soubrane, O; Terris, B | 1 |
| Cattral, MS; Chan, EK; Dixon, E; Gallinger, S; Grant, DR; Greig, PD; Sahajpal, A; Taylor, BR; Vollmer, CM; Wei, A | 1 |
| Fukada, T; Hasegawa, A; Hashimoto, R; Hayashi, T; Kametaka, H; Kawano, H; Koyama, T; Seike, K; Tanaka, H; Yasuno, K | 1 |
| Sekine, N; Terada, K | 1 |
| Bressole, F; Chalbos, P; Debrigode, C; Desseigne, F; Duffour, J; Gourgou, S; Mineur, L; Pinguet, F; Poujol, S; Ychou, M | 1 |
| Andreadis, C; Gennatas, C; Michalaki, V; Mouratidou, D; Pafiti, A; Papaxoinis, G; Tsavaris, N | 1 |
| Wang, JW; Zhou, ZT | 1 |
| Aparicio, T; Artru, P; Asnacios, A; Desrame, J; Fallik, D; Landi, B; Lecomte, T; Lledo, G; Mansourbakht, T; Spano, JP; Taïeb, J | 1 |
| Barone, C; Basso, M; Cassano, A; D'Argento, E; Di Leonardo, G; Landriscina, M; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N | 1 |
| Baker, S; Bulgaru, A; Camacho, F; Chaudhary, I; Desai, K; Einstein, M; Goel, S; Goldberg, G; Gollamudi, R; Karri, S; Kaubisch, A; Mani, S | 1 |
| Ikami, I; Ishiguro, A; Kasai, M; Kudo, T; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Sakuraba, H; Shitara, K | 1 |
| Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J | 1 |
| Aphinives, P; Bhudhisawasdi, V; Sae-seow, O; Uttaravichien, T | 1 |
| Fujiwara, T; Gochi, A; Kagawa, S; Tanaka, N; Teraishi, F; Uno, F | 1 |
| Iwazawa, T; Kanoh, T; Kimura, Y; Monden, T; Nakano, Y; Ohnishi, T; Shiozaki, K; Takemoto, H; Tono, T; Yano, H | 1 |
| Gyôrffy, B; Tegze, B; Tulassay, Z | 1 |
| Fujino, K; Ishikubo, T; Shimamura, T; Tada, M; Yamaguchi, K | 1 |
| Falk, S; Glynne-Jones, R; Maughan, TS; Meadows, HM; Sebag-Montefiore, D | 1 |
| Dietrich, M; Goel, A; Grossbard, ML; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Rodriguez, T | 1 |
| Abad, A; Catot, S; Cirauqui, B; Manzano, JL; Martinez-Balibrea, E; Martinez-Cardus, A; Moran, T; Taron, M | 1 |
| Guan, ZZ | 1 |
| Yoshida, S | 1 |
| Kitajima, M; Kubota, T; Wada, N | 1 |
| Matsukawa, M; Sato, A | 1 |
| Adena, M; Damianovich, D; Tebbutt, NC | 1 |
| Hiro, J; Inoue, Y; Kusunoki, M; Miki, C; Ojima, E; Toiyama, Y; Watanabe, H; Yanagi, H | 1 |
| Cao, S; Creaven, PJ; Durrani, FA; Iyer, RV; Javle, MM; Lawrence, DD; Noel, DC; Pendyala, L; Rustum, YM; Smith, PF | 1 |
| Honda, K; Kondo, H; Ohura, K; Sumiyoshi, T; Takahari, D; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N | 1 |
| Dranitsaris, G; Shah, A; Spirovski, B; Vincent, M | 1 |
| Grobholz, R; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kraus-Tiefenbacher, U; Leitner, A; Post, S; Wenz, F; Willeke, F; Willer, A | 1 |
| Bareil, C; Bascoul-Mollevi, C; Bibeau, F; Chalbos, P; Conseiller, E; Copois, V; Del Rio, M; Fraslon, C; Granci, V; Kramar, A; Leblanc, B; Martineau, P; Molina, F; Pau, B; Salvetat, N; Ychou, M | 1 |
| Kuboki, Y; Mizunuma, N | 1 |
| Kabeya, K; Kamoshita, N; Kobayashi, M; Makita, F; Matsuzaki, Y | 1 |
| Billard, V; Blot, F; Elias, D; Goere, D; Kohneh-Shahri, N; Pocard, M; Raynard, B | 1 |
| Hyodo, I | 1 |
| Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kulke, MH; Loda, M; Meyerhardt, JA; Ogino, S; Ryan, DP; Wolpin, BM | 1 |
| Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ | 1 |
| López-Brea, MF; Rivera, F; Vega-Villegas, ME | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Pallis, A; Souglakos, J; Vardakis, N | 1 |
| Arnold, D; Graeven, U; Heuer, T; Nusch, A; Porschen, R; Reinacher-Schick, A; Schmiegel, W | 1 |
| El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM | 1 |
| Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S | 1 |
| Wils, J | 1 |
| André, T; de Gramont, A; Larsen, AK; Louvet, C; Tournigand, C | 1 |
| Iinuma, N; Ishizone, S; Koide, N; Maruta, F; Miyagawa, S; Nakayama, J; Yanagisawa, Y | 1 |
| Allegrini, G; Andreuccetti, M; Barbara, C; Benedetti, G; Brunetti, I; Chiara, S; Cortesi, E; Crinò, L; Evangelista, W; Falcone, A; Fanchini, L; Fioretto, L; Granetto, C; Masi, G; Orlandini, C; Pfanner, E; Picone, V; Porcile, G; Ricci, S; Vitello, S | 1 |
| Choi, IK; Chun, HJ; Jeen, YT; Kim, JS; Kim, YH; Mok, YJ; Oh, SC; Park, SS; Seo, JH; Shin, SW; Sung, HJ; Sur, HY | 1 |
| Caron, P; Liu, D; Patel, S; Seiter, K | 1 |
| Benson, AB; Mulcahy, MF; Wisinski, KB | 1 |
| Adoniou, E; Bacoyiannis, C; Felekouras, E; Gryniatsos, J; Kosmas, C; Papadoniou, N; Papalambros, E; Papastratis, G; Polyzos, A; Sigala, F; Skopelitis, H; Tsavaris, N; Zacharakis, M; Zografos, G | 1 |
| Komatsu, Y | 1 |
| Rödel, C; Sauer, R | 1 |
| Amado, RG; Berlin, J; Chan, D; Hecht, JR; Hu, E; Malik, I; Posey, J; Tchekmedyian, S; Yang, L | 1 |
| Fakih, MG; Gupta, B; LeVea, C; Litwin, A | 1 |
| Hashimoto, H; Hirabayashi, T; Ishikawa, H; Ohi, S; Sugiyama, K; Tachibana, T; Takahashi, N; Yanaga, K | 1 |
| Alessandroni, P; Andreoni, F; Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Ficarelli, R; Fontana, A; Giustini, L; Graziano, F; Lippe, P; Loupakis, F; Magnani, M; Maltese, P; Mari, D; Menichetti, ET; Pizzagalli, F; Ruzzo, A; Santini, D; Schiavon, G; Testa, E; Tonini, G | 1 |
| Caca, K; Feisthammel, J; Mössner, J; Schoppmeyer, K; Schulze, M; Wiedmann, M | 1 |
| Ames, MM; Erlichman, C; Goetz, MP; Krook, JE; McWilliams, RR; Morlan, BW; Rowland, KM; Salim, M | 1 |
| Iversen, A; Jensen, BV; Nielsen, D; Pfeiffer, P; Vejlø, C; Yilmaz, M | 1 |
| Fujii, M; Kaiga, T; Kanamori, N; Kochi, M; Takahashi, T; Takayama, T | 1 |
| Doi, K; Kudo, K; Matsuo, A; Ogata, K; Ohchi, T; Ootao, R | 1 |
| Glimelius, B; Graf, W; Grundmark, B; Larsson, R; Mahteme, H; Nygren, P; Påhlman, L; Tholander, B; von Heideman, A | 1 |
| Benson, A; Wisinski, K | 1 |
| Gemma, A; Kawakami, A; Kudoh, S; Li, C; Matsuda, K; Minegishi, Y; Noro, R; Ogawa, N; Seike, Y; Shionoya, A | 1 |
| Sargent, D; Schmoll, HJ | 1 |
| Antonini, NF; Creemers, GM; Dalesio, O; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Loosveld, OJ; Mol, L; Punt, CJ; Rodenburg, CJ; Sinnige, HA; Slee, PHTJ; Tesselaar, ME; van Bochove, A; Vreugdenhil, G; Wals, J; Werter, MJ | 1 |
| Ferry, DR; Griffiths, GO; Gwyther, SJ; James, R; Ledermann, JA; Maraveyas, A; Maughan, TS; Meade, AM; Parmar, MK; Seymour, MT; Shepherd, S; Smith, DB; Stephens, RJ; Thompson, L; Topham, C | 1 |
| Deutsch, E; Ducreux, M; Ezra, P; Mangoni, M | 1 |
| Folprecht, G; Köhne, CH; Lutz, MP | 1 |
| Berglund, A; Brünner, N; Byström, P; Christensen, IJ; Glimelius, B; Nielsen, HJ; Sørensen, NM | 1 |
| Ae, T; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Nakatani, K; Saigenji, K; Sasaki, T; Tanabe, S | 1 |
| Edelstein, E; Gutman, M; Klein, B; Paran, H | 1 |
| Gu, J; Yao, YF | 1 |
| Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ | 1 |
| Abrahantes, JC; André, T; Burzykowski, T; Buyse, M; Carola, E; Cervantes, A; Chirivella, I; de Gramont, A; Etienne, PL; Figer, A; Flesch, M; Lledo, G; Louvet, C; Mineur, L; Perez-Staub, N; Quinaux, E; Rivera, F; Tabah-Fisch, I; Tournigand, C | 1 |
| Lagarde, C; Lebrun-Ly, V; Peyronnet, P; Saint-Marcoux, F; Tubiana-Mathieu, N; Vénat-Bouvet, L | 1 |
| Sharma, SP | 1 |
| Klek, S; Kulig, J; Popiela, T; Richter, P | 1 |
| Alberts, SR; Delaunoit, T; Dy, GK; Findlay, BP; Fuchs, CS; Goldberg, RM; Green, EM; Krook, JE; Morton, RF; Pitot, HC; Pockaj, BA; Ramanathan, RK; Sargent, DJ; Sticca, RP; Williamson, SK | 1 |
| Boku, N; Yamazaki, K; Yoshino, T | 1 |
| He, YJ; Jiang, WQ; Li, YH; Luo, HY; Shi, YX; Wang, F; Xu, RH; Zhang, L | 1 |
| Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, A; Prezerakos, P | 1 |
| Bendardaf, R; Korkeila, E; Lamlum, H; Pyrhönen, S; Ristamäki, R; Syrjänen, K | 2 |
| Bexon, A; Diamandidis, D; Eckhardt, SG; Javle, M; Justice, GR; Keiser, W; Lee, FC; Liebmann, JE; Lin, E; Patt, YZ; Salvatore, JR | 1 |
| Adenis, A; Bécouarn, Y; Boucher, E; Cany, L; Cvitkovic, F; Jacob, JH; Montoto-Grillot, C; Senesse, P; Thézenas, S; Ychou, M | 1 |
| Bajetta, E; Bajetta, R; Celio, L; Colombo, A; Denaro, A; Di Bartolomeo, M; Dotti, K; Ferrario, E; Mancin, M; Pusceddu, S | 1 |
| Eigenbrod, T; Klebl, F; Kullmann, F | 1 |
| Ishizu, K; Makuuchi, H; Sadahiro, S; Sunose, N; Tsuruo, T; Yamazaki, K; Yamori, T | 1 |
| Choi, CH; Han, HK; Han, SI; Jung, GR; Kim, KJ; Lee, TB; Lim, SC | 1 |
| Flaherty, KT; Fleming, RA; Kerr, DJ; Koch, KM; Middleton, MR; Midgley, RS; O'Dwyer, PJ; Pratap, SE; Smith, DA; Stevenson, JP; Versola, M; Ward, C | 1 |
| Czaykowski, PM | 1 |
| Astone, A; Barone, C; Basso, M; Cassano, A; D'Argento, E; Giuliante, F; Nuzzo, G; Pozzo, C; Schinzari, G; Trigila, N | 1 |
| Delpero, JR; Desseigne, F; Guimbaud, R; Kramar, A; Mitry, E; Nordlinger, B; Portier, G; Quénet, F; Rivoire, M; Viret, F; Ychou, M | 1 |
| Allal, AS; Andres, A; Gervaz, P; Giostra, E; Majno, PE; Mentha, G; Morel, P; Roth, AD; Rubbia-Brandt, L; Terraz, S | 1 |
| Carroll, C; Jones, R; Paisley, S; Tappenden, P | 1 |
| Berglund, A; Dahl, O; Glimelius, B; Ogreid, D; Sørbye, H; Tveit, KM; Wanderås, EH; Wentzel-Larsen, T | 1 |
| Chang, HM; Kang, YK; Kim, MK; Kim, TW; Koo, DH; Lee, JL; Lee, JS; Lee, SS; Ryu, MH; Sym, SJ | 1 |
| Brandsma, D; De Jong, FA; Hamberg, P; Sleijfer, S; Verweij, J | 1 |
| Chen, TC; Hofman, FM; Lee, AS; Pyrko, P; Schönthal, AH | 1 |
| Bendell, JC; Czito, BG; Willett, CG | 1 |
| Akiyama, S; Gotoh, H; Gotoh, Y; Nakayama, H; Takami, H | 1 |
| Abad, A; Alonso, V; Antón, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Manzano, JL; Marcuello, E; Martinez-Villacampa, M; Massuti, B; Rivera, F; Tabernero, J; Vega, ME; Yuste, AL | 1 |
| Meric, JB | 1 |
| Abderrahim, AG; Bressolle, FM; Duffour, J; Pinguet, F; Poujol, S; Ychou, M | 1 |
| Arnold, D; Lordick, F | 1 |
| Audisio, RA; Bruce, C; Köhne, CH | 1 |
| Fujisawa, M; Ishibiki, Y; Ishiyama, S; Kitabatake, T; Kojima, K; Machida, M; Nakayama, Y; Nitta, S; Ono, S; Shinjou, K; Urao, M | 1 |
| Fietkau, R; Foitzik, T; Klar, E; Klautke, G; Küchenmeister, U; Ludwig, K; Prall, F; Semrau, S | 1 |
| Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Sukthomya, V; Tonusin, A | 1 |
| Carroll, MW; Chikoti, P; Drury, N; Griffiths, R; Harrop, R; Hawkins, RE; Kingsman, SM; Naylor, S; Redchenko, I; Shingler, W; Steven, N | 1 |
| Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ | 1 |
| Ando, M; Hirayama, Y; Kohda, K; Konuma, Y; Nakamura, Y; Obata, M; Seki, R; Wada, Y; Yoshida, M | 1 |
| Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY | 1 |
| Alami, N; Belanger, S; Grieshaber, CK; Juste, S; Leyland-Jones, B; Paterson, J | 1 |
| Amadio, P; Caputo, G; Condorelli, S; Cordio, S; Germano, D; Manzione, L; Mattina, M; Reggiardo, G; Rosati, G | 1 |
| Nakano, T; Tomimatsu, H | 1 |
| Hasegawa, H; Kanekiyo, S; Kubo, H; Tada, K; Watanabe, Y | 1 |
| Cho, EK; Chung, M; Lee, JH; Lee, SI; Lee, WK; Nam, E; Park, J; Park, SH; Shin, DB | 1 |
| Mohile, SG; Petrylak, DP; Schleicher, L | 1 |
| Hentrich, M; Hoffmann, U; Lutz, L; Reitmeier, M; Scheidt, B; Schiel, X | 1 |
| Au, GK; Chan, RT; Choi, CK; Ho, JW; Law, WL; Lui, L; Siu, S; Tung, SY | 1 |
| Bramhall, SR; Buckels, JA; Coldham, CA; Hubscher, SG; Mayer, AD; Mehta, NN; Mirza, DF; Ravikumar, R; Wigmore, SJ | 1 |
| Abbas, R; Andreu, J; Baselga, J; Casado, E; Cortes-Funes, H; Folprecht, G; Köhne, CH; Lejeune, C; Marimón, I; Paz-Ares, L; Quinn, S; Rojo, F; Salazar, R; Tabernero, J; Ubbelohde, U; Zacharchuk, C | 1 |
| Goldberg, RM; Grothey, A; Hedrick, EE; Hurwitz, HI; Mass, RD; Ramanathan, RK; Sargent, DJ; Sarkar, S; Suzuki, S | 1 |
| Endlicher, E; Golder, S; Grossmann, J; Herfarth, H; Herold, T; Kullmann, A; Kullmann, F; Schlottmann, K; Troppmann, M | 1 |
| Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Siriwittayakorn, P; Somwangprasert, A; Sukthomya, V; Tharavichitkul, E | 1 |
| Hamaguchi, T; Kano, Y; Kato, K; Koizumi, F; Matsumura, Y; Nakajima, TE; Shimada, Y; Shirao, K; Yamada, Y; Yasunaga, M | 1 |
| Balteskard, L; Braendengen, M; Sørbye, H | 1 |
| Albertsson, M; Balteskard, L; Berglund, A; Byström, P; Garmo, H; Glimelius, B; Heikkilä, R; Keldsen, N; Pfeiffer, P; Starkhammar, H; Sørbye, H; Tveit, K | 1 |
| Ide, Y; Kinuta, M; Maruyama, K; Murata, K; Ohta, H; Okada, K; Yasumoto, T; Yokouchi, H | 1 |
| Chrysanthopoulos, C; Gerolymos, MK; Iconomou, G; Kalofonos, HP; Kontogeorgou, E; Koutras, AK; Makatsoris, T; Tsiata, E; Vourli, G | 1 |
| Ariad, S; Gluzman, A; Lavrenkov, K; Man, S; Mermershtain, W; Rubinov, K | 1 |
| Barrueco, J; Fuchs, CS; Marshall, J | 1 |
| Allegrini, G; Bursi, S; Falcone, A; Fontana, A; Loupakis, F; Masi, G; Petrini, I; Ricci, S; Vasile, E | 1 |
| Bergsland, E; Berlin, JD; Lockhart, AC; Rosen, L; Rothenberg, M; Venook, A | 1 |
| Bjerregaard, J; Jensen, B; Nielsen, D; Pfeiffer, P; Qvortrup, C; Yilmaz, M | 1 |
| Balteskard, L; Berglund, A; Fokstuen, T; Ogreid, D; Pfeiffer, P; Ploen, J; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, K; Yilmaz, M | 1 |
| Barone, C; Kemeny, NE; Pozzo, C | 1 |
| Cordoba-Rodriguez, R; Fuchs, C; Giusti, RM; Hughes, M; Keegan, P; Koti, K; Men, AY; Pazdur, R; Pilaro, AM; Rothmann, M; Shastri, K; Weiss, KD; Zhao, H | 1 |
| Bazin, IS; Biakhov, MY; Blatter, J; Goldstein, D; Gorbounova, VA; Granov, DA; Hossain, AM; Kaiser, C; Ma, D; Underhill, C | 1 |
| Andreoni, F; Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Floriani, I; Fontana, A; Giustini, L; Graziano, F; Humar, B; Loupakis, F; Magnani, M; Maltese, P; Masi, G; Rulli, E; Ruzzo, A; Santini, D; Schiavon, G; Tonini, G; Torresi, U | 1 |
| Douillard, JY; Folprecht, G; Hecker, H; Köhne, CH; Maughan, TS; Mitry, E; Rougier, P; Saltz, L; Schubert, U; Seymour, MT; Stephens, RJ; Van Cutsem, E | 1 |
| Biswas, A; Gollins, S; Haylock, B; Iles, S; Levine, E; Myint, S; Susnerwala, S; Swindell, R | 1 |
| Bowen, JM; Gibson, RJ; Keefe, DM; Logan, RM; Sonis, ST; Stringer, AM | 2 |
| Hashimoto, K; Igishi, T; Matsumoto, S; Morita, M; Shigeoka, Y; Shimizu, E; Sumikawa, T; Suyama, H; Takeda, K; Ueda, Y; Yamasaki, A | 1 |
| Chu, E; Lee, JJ | 1 |
| Cohen, DJ; Hochster, HS | 1 |
| Barutca, S; Bolaman, Z; Kadikoylu, G; Meydan, N; Yavasoglu, I | 1 |
| Bonnet, S; Boulet, T; Di Pietrantonio, D; Elias, D; Goere, D; Honore, C; Kohneh-Shahri, N; Raynard, B | 1 |
| Chang, HM; Kang, YK; Kim, TW; Lee, JL; Lee, JS; Lee, SS; Ryu, MH; Sym, SJ | 1 |
| Barbet, N; Falandry, C; Freyer, G; Glehen, O; Heudel, P; Romestaing, P; You, B | 1 |
| Brell, JM; Cooney, MM; Dowlati, A; Egorin, MJ; Gibbons, J; Hoppel, CL; Ingalls, ST; Ivy, SP; Krishnamurthi, SS; Li, X; Overmoyer, BA; Remick, SC; Schluchter, MD; Weaver, KC; Zuhowski, EG | 1 |
| Bueter, M; Fein, M; Gasser, M; Illert, B; Meyer, D; Reimer, P; Thalheimer, A; Thiede, A; Waaga-Gasser, AM | 1 |
| Fricker, J | 1 |
| Folprecht, G; Goldberg, RM; Köhne, CH; Mitry, E; Rougier, P | 1 |
| D'Angelica, MI; Fong, Y; Jarnagin, WR; Kemeny, NE; Munoz, JA; Raggio, G; Schwartz, LH; White, RR | 1 |
| Eggington, S; Hind, D; Ryan, A; Sutcliffe, P; Tappenden, P; Tumur, I | 1 |
| Asaka, M; Doi, T; Fuse, N; Hamamoto, Y; Minashi, K; Muto, M; Ohtsu, A; Tahara, M; Yano, T; Yoshida, S | 1 |
| Mayer, RJ; Wolpin, BM | 1 |
| Argon, A; Aykan, NF; Basaran, M; Gumus, M; Guney, N; Saglam, S; Sakar, B; Tenekeci, AN; Ustaoglu, MA; Ustuner, Z | 1 |
| Bao, HY; Jiao, SC; Li, F; Li, J; Shen, L; Song, ST; Wang, JW; Wang, Y; Xu, JM; Xu, N; Yang, L; Zhang, JS | 1 |
| Hayashi, S; Karaki, H; Sugano, I; Sugimoto, K; Suzuki, H; Takayanagi, H; Yamamori, H; Yamamoto, K | 1 |
| Bokemeyer, C; Hartmann, JT; Höhler, T; Holtmann, M; Kröning, H; Pintoffl, JP | 1 |
| Chang, HM; Kang, BW; Kang, YK; Kim, JC; Kim, JH; Kim, TW; Lee, JL; Lee, JS; Ryu, MH; Yu, CS | 1 |
| Heinemann, V; Moosmann, N | 1 |
| Duffy, A; Fong, Y; Huitzil-Melendez, FD; O'Reilly, EM; Shia, J | 1 |
| Adlard, JW; Barrett, JH; Braun, MS; Daly, C; Elliott, F; Meade, AM; Parmar, MK; Quirke, P; Richman, SD; Selby, P; Seymour, MT; Stephens, RJ | 1 |
| Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS | 1 |
| Pantano, F; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B | 1 |
| Amarantidis, K; Ardavanis, A; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Polyzos, A; Souglakos, J; Tsousis, S; Vamvakas, L; Vardakis, N; Varthalitis, I; Ziras, N | 1 |
| Bang, YJ; Butts, C; Cox, JV; Cunningham, D; Goel, R; Gollins, S; Laguerre, S; Navarro, M; Rothenberg, ML; Siu, LL | 1 |
| Barone, C; Bugat, R; Cisar, L; Dank, M; Goker, E; Peschel, C; Valvere, V; Wang, K; Wenczl, M; Yalcin, S; Zaluski, J | 1 |
| Alvarez Z, M; González D, R; Jarufe C, N; Martínez C, J | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Punt, CJ; Van der Straaten, T | 1 |
| Bearz, A; Berretta, M; Berretta, S; Fisichella, R; Lleshi, A; Nasti, G; Simonelli, C; Tirelli, U; Zanet, E | 1 |
| Bolognese, A; Caputo, M; Di Cello, P; Izzo, L; Izzo, P; Meloni, P; Pietrasanta, D | 1 |
| Berger, MR; Ehrenberg, R; Galle, PR; Heeger, S; Hickmann, L; Moehler, M; Schad, A; Schimanski, CC; Schulze-Bergkamen, H; Urbanik, T; Vick, B; Weber, A | 1 |
| Cunningham, D; Ghaneh, P; Neoptolemos, JP; Smith, CT; Starling, N; Sultana, A | 1 |
| Barone, C; Pozzo, C | 1 |
| Fakih, MG; Patel, A; Puthillath, A; Yang, G | 1 |
| Duhoux, F; Mano, MS | 1 |
| Sharma, RI; Smith, TA | 1 |
| Fukazawa, A; Hayashi, T; Konno, H; Kurachi, K; Nakajima, A; Nakamura, K; Nakamura, T; Suzuki, S | 2 |
| Bafaloukos, D; Bamias, A; Basdanis, G; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Karanikiotis, C; Kardamakis, D; Karina, M; Koutras, A; Misailidou, D; Papadimitriou, C; Papakostas, P; Pectasides, D; Pentheroudakis, G; Pisanidis, N; Samantas, E; Skarlos, DV; Stavropoulos, M; Vourli, G | 1 |
| Healey-Bird, BR; Kemeny, NE; Power, DG | 1 |
| Brell, JM; Dowlati, A; Ivy, SP; Javle, M; Kantharaj, BN; Krishnamurthi, SS; Pelley, R; Rath, L; Remick, SC; Saltzman, J; Schluchter, MD; Wollner, I | 1 |
| Benson, AB; Berinstein, NL; Caterini, J; Conry, RM; Cripps, C; Dalfen, R; Debenedette, M; Elias, I; Garett, C; Heim, WJ; Kaufman, HL; Kim-Schulze, S; Lenz, HJ; Marshall, J; Moore, M; Salha, D; Singh, D; Urba, WJ; Vogel, T; von Mehren, M; Yu, M | 1 |
| Abe, K; Fujiwara, J; Hayashi, I; Ishida, H; Kawauchi, A; Miki, T; Mizuno, M; Mizutani, Y; Nakanishi, H; Okada, K; Toiyama, D; Yamamoto, K; Yoshida, J | 1 |
| Aranda, E; Benavides, M; Cámara, JC; Carrato, A; Constenla, M; Díaz-Rubio, E; Dueñas, R; Gomez, A; Marcuello, E; Martinez-Villacampa, M; Massutti, B; Navarro, M; Reboredo, M; Valladares, M | 1 |
| Bai, Y; Chu, YP; Jin, ML; Li, J; Liu, DQ; Shen, L; Wang, YH; Xu, JM; Zhang, XD | 1 |
| Bang, YJ; Im, SA; Kim, DY; Kim, JH; Kim, TY; Lee, JS; Lee, KW; Lim, JH; Oh, DY; Seo, MD; Yi, HG | 1 |
| Eberhardt, S; Lee, F; Lee, SJ; Lu, H; Maestas, A; Rabinowitz, I; Royce, M; Sayar, H; Shen, Z; Smith, H; Verschraegen, C | 1 |
| Cella, D; Holmgren, E; Hurwitz, HI; Kabbinavar, FF; Wallace, JF; Yi, J; Yost, KJ | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Koopman, M; Kweekel, DM; Nortier, JW; Punt, CJ; Van der Straaten, T | 1 |
| Bodoky, G; Garay, C; Habboubi, N; Haller, DG; Koralewski, PM; Miller, WH; Olivatto, LO; Rothenberg, ML; Wong, AO | 1 |
| Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E | 1 |
| Berardi, R; Cascinu, S; Chiorrini, S; Galizia, E; Giampieri, R; Pierantoni, C; Scartozzi, M | 1 |
| Asaka, M; Boku, N; Fukutomi, A; Hironaka, S; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Hurwitz, H; Irl, C; Kabbinavar, F; Zurlo, A | 1 |
| Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J | 1 |
| Ayuso, JR; Castells, A; Conill, C; de Lacy, A; Delgado, S; Gallego, R; Ginés, A; Maurel, J; Miquel, R; Tosca, M; Ugidos, L | 1 |
| Bekaii-Saab, T; Haghighat, P | 1 |
| Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P | 1 |
| Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Matsunaga, M; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W; Yamashita, K | 1 |
| Campbell, ML; Landry, CS; Martin, RC; McMasters, KM; Scoggins, CR; Slomiany, BA; Woodall, CE | 1 |
| Lam, MG; Nijsen, JF; van den Bosch, MA; van der Tweel, I; van Het Schip, AD; Vente, MA; Wondergem, M; Zonnenberg, BA | 1 |
| Boige, V; Ducreux, M; Laurent-Puig, P; Malka, D | 1 |
| Ducreux, M; Laurent-Puig, P; Lièvre, A; Loriot, MA | 1 |
| Adam, MJ; Anantha, M; Baker, JH; Bally, MB; Co, SJ; Dragowska, WH; Kozlowski, P; Kyle, AH; Lam, J; Minchinton, AI; Ng, SS; Oliver, T; Ramsay, E; Ruth, TJ; Sy, J; Yapp, DT; Yung, A | 1 |
| Aoki, K; Hoshikawa, K; Nitta, H; Noda, H; Oyama, K; Wakabayashi, G | 1 |
| Chin, K; Hatake, K; Matsusaka, S; Mizunuma, N; Muto, T; Oya, M; Shinozaki, E; Shouji, D; Suenaga, M; Yamaguchi, T | 1 |
| Auman, JT; McLeod, HL; Yen-Revollo, JL | 1 |
| Checcacci, D; Del Buono, S; Filippelli, F; Mazzei, T; Mazzocchi, V; Mini, E; Nobili, S | 1 |
| Asmar, L; Berger, M; Boehm, KA; Cartwright, T; Cohn, A; Hyman, W; Kuefler, P; Nugent, JE; Richards, D; Ruxer, RL; Vukelja, S | 1 |
| Brown, TJ; Cinc, E; Fox, RM; Gibbs, P; Jennens, R; Michael, M; Ng, R; Pho, M | 1 |
| Hurwitz, HI; Kabbinavar, FF; Rosen, O; Sarkar, S; Yi, J | 1 |
| Ariche, A; Baruch, NB; Brenner, B; Dinerman, M; Greif, F; Idelevich, E; Kashtan, H; Mavor, E; Miller, R; Shani, A; Susmalian, S | 1 |
| Khan, AZ; Makuuchi, M; Morris-Stiff, G | 1 |
| Mitry, E | 1 |
| Inoue, N; Ishibashi, K; Ishida, H; Ishiguro, T; Matsuki, M; Mitsuhashi, T; Miyazaki, T; Okada, N; Okita, T; Sano, M; Yokoyama, M | 1 |
| Barreto-Miranda, M; Dinter, D; Erben, P; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kienle, P; Mai, S; Post, S; Ströbel, P; Treschl, A; Wenz, F; Willeke, F; Woernle, C | 1 |
| Chin, K; Hatake, K; Konishi, F; Matsusaka, S; Mizunuma, N; Muto, T; Oya, M; Shinozaki, E; Suenaga, M; Ueno, M; Yamaguchi, T | 1 |
| Davies, JM; Goldberg, RM | 1 |
| Hurwitz, HI; Ince, W; Novotny, WF; Rosen, O; Yi, J | 1 |
| Gennatas, C; Gennatas, S; Michalaki, V | 1 |
| Buffart, TE; Carvalho, B; Eijk, PP; Koopman, M; Meijer, GA; Peters, GJ; Postma, C; Punt, CJ; van Krieken, JH; Ylstra, B | 1 |
| André, T; Bengrine-Lefevre, L; Bidard, FC; Cervantes, A; de Gramont, A; Figer, A; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C | 1 |
| Antonini, NF; Hoogerbrugge, N; Koopman, M; Kortman, GA; Ligtenberg, MJ; Mekenkamp, L; Punt, CJ; van Krieken, JH | 1 |
| Ahn, JB; Byun, JH; Hong, YS; Im, SA; Jung, KH; Kang, WK; Kim, TW; Lee, J; Lee, N; Lim, HY; Oh, DY; Park, JO; Park, SH; Park, YS; Shin, DB; Shin, SJ | 1 |
| Becouarn, Y; Bedenne, L; Bouché, O; Bugat, R; Conroy, T; Douillard, JY; Ducreux, M; Gamelin, E; Gourgou-Bourgade, S; Kramar, A; Mineur, L; Raoul, JL; Seitz, JF; Viret, F; Ychou, M | 1 |
| Ahn, KD; Cho, YB; Choi, SH; Chun, HK; Kim, HC; Lee, JM; Lee, WY; Shin, HJ; Song, SY; Yun, SH | 1 |
| Cannone, M; Casaretti, R; Comella, P; Franco, L; Greco, E; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Palmeri, S; Putzu, C; Roselli, M; Sandomenico, C; Vessia, G | 1 |
| Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M | 1 |
| Bhushan, S; McLeod, H; Walko, CM | 1 |
| Berglund, A; Byström, P; Frödin, JE; Glimelius, B; Johansson, B; Letocha, H; Nygren, P; Pedersen, D | 1 |
| Ambrosi, A; Calise, S; Costantino, E; Esposito, F; Fersini, A; Landriscina, M; Maddalena, F; Neri, V; Piscazzi, A; Tirino, V | 1 |
| Ilson, DH; Kelsen, DP; Ku, GY; Maki, RG; O'Reilly, EM; Saltz, LB; Schrag, D | 1 |
| Milicević, M; Popov, I; Radosević-Jelić, Lj | 1 |
| Baracos, VE; Dieleman, LA; Field, CJ; Le Roy, S; Sawyer, MB; Xue, H | 1 |
| Koopman, M; Punt, CJ; Seymour, MT | 1 |
| Bertagnolli, MM; Compton, CC; Damas, B; Goldberg, RM; Hahn, HP; Hall, M; Jewell, SD; Mayer, RJ; Niedzwiecki, D; Redston, M; Saltz, LB; Warren, RS | 1 |
| Cohen, MH; Giusti, RM; Keegan, P; Pazdur, R | 1 |
| Nadai, M; Palù, G; Palumbo, M; Richter, SN | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Ono, A; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Dugan, U; Heimbrook, D; Higgins, B; Kolinsky, K; Packman, K; Zhang, YE | 1 |
| Castillo, C; Cendoya, I; Fernández, E; Fernández, JL; Gil, A; Gómez Martínez de Lecea, C; Gómez Portilla, A; Guede, N; Kvadatze, M; Larrabide, I; Lirola, A; Magrach, L; Martín, E; Martínez de Lecea, C; Moraza, N; Muriel, J; Olabarría, I; Romero, E; Rua, O; Ruiz de Alegría, N; Ulibarrena, MA; Valdovinos, M | 1 |
| Asanuma, F; Atsuda, K; Hiraku, O; Inoue, G; Morimoto, Y; Sasaki, K; Suzuki, Y; Takeuchi, O; Takizawa, A; Yamada, Y; Yoshizawa, J | 1 |
| Italiano, A; Sablin, MP; Spano, JP | 1 |
| Chang, MH; Ji, SH; Jun, HJ; Kang, WK; Kim, HS; Kim, KH; Lee, J; Lim, DH; Lim, HY; Park, JO; Park, MJ; Park, SH; Park, YS; Uhm, JE; Yi, SY | 1 |
| Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL | 1 |
| Bonfill Cosp, X; López, JJ; Martin-Richard, M; Roqué I Figuls, M; Solà, I | 1 |
| Alberts, SR; Fitch, TR; Goldberg, RM; Kim, GP; Mahoney, MR; Mathews, AP; Mitchell, E; Philip, PA; Pitot, HC; Rowland, KM; Sargent, DJ | 1 |
| Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X | 1 |
| Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E | 1 |
| Sobrero, A | 1 |
| Drolet, P; Dubé, P; Leblanc, G; Leclerc, YE; Mitchell, A; Sideris, L | 1 |
| Berg, DJ; Bernaards, C; Blanchard, R; Denlinger, CS; Dorr, A; Hambleton, J; Holden, S; Kearns, A; Kenkare-Mitra, S; Litwin, S; Lum, B; McLaughlin, S; Meropol, NJ; O'Dwyer, PJ; Redlinger, M; Spittle, C; Xu, L | 1 |
| Hamada, A; Saito, H; Sasaki, Y; Tazoe, K; Yokoo, K | 1 |
| Amoroso, D; Andreuccetti, M; Antonuzzo, A; Brunetti, IM; Bursi, S; Chiara, S; Cupini, S; Di Donato, S; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Petrini, I; Ricci, S; Vasile, E | 1 |
| Korbakis, D; Scorilas, A | 1 |
| André, T; Aranda, E; Barone, C; Bodoky, G; Bokemeyer, C; Cisar, L; Collette, L; Cunningham, D; Di Costanzo, F; Greil, R; Khayat, D; Labianca, R; Mini, E; Nordlinger, B; Roth, AD; Sobrero, AF; Tabernero, J; Topham, C; Van Cutsem, E; Zhang, X | 1 |
| Polansky, M; Ross, AC | 1 |
| Bathe, OF; Bigam, D; Butts, C; Dixon, E; Dowden, S; Ernst, S; Holland, D; Koppel, J; Porter, GA; Sutherland, FR | 1 |
| Koopman, M; Ligtenberg, MJ; Nagtegaal, I; Punt, CJ; Van Krieken, JH; van Tinteren, H; Venderbosch, S | 1 |
| Bando, Y; Kenzaki, K; Kondo, K; Miyoshi, T; Ohnishi, Y; Sawada, N; Seike, J; Takizawa, H; Tangoku, A; Yamai, H; Yoshida, T | 1 |
| Koopman, M; Nagtegaal, ID; Punt, CJ; van Krieken, JH; Venderbosch, S | 1 |
| Kannerup, AS; Knudsen, AR; Mortensen, FV; Nielsen, DT | 1 |
| Arce-Lara, C; Bekaii-Saab, T; Cataland, S; Kraut, E; Ntukidem, N; Otterson, GA | 1 |
| Kocák, I; Kocáková, I; Nemecek, R; Rehák, Z; Standara, M; Svoboda, M | 1 |
| Bozkurt, MT; Cirak, Y; Degirmenci, M; Demir Piskin, G; Durusoy, R; Gorumlu, G; Karabulut, B; Karaca, B; Sanli, UA; Tunali, D; Uslu, R | 1 |
| Matono, K; Ogata, Y; Shirouzu, K; Torigoe, S | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Nortier, JW; Punt, CJ | 1 |
| Johnstone, E; Kerr, D; Midgley, R; Swanton, C; Tomlinson, I; Walther, A | 1 |
| Hamaguchi, T; Hirashima, Y; Horita, Y; Kato, K; Nakajima, T; Shimada, Y; Yamada, Y | 1 |
| Bokemeyer, C; Hohenberger, W; Kwok-Keung Choi, C; Maurel, J; Navarro, M; Rivera, F; Santoro, A; Shacham-Shmueli, E; Thezenas, S; Ychou, M | 1 |
| Barone, C; Bugat, R; Curran, D; Dank, M; Goker, E; Peschel, C; Pozzo, C; Valvere, V; Wenczl, M; Yalcin, S; Zaluski, J | 1 |
| Landherr, L; Nagykálnai, T | 2 |
| Li, J; Saif, MW | 1 |
| Chang, HJ; Hong, YS; Jeong, SY; Jung, KH; Park, JG; Shin, YK; Yoo, BC | 1 |
| Gunderson, HD; Leung, N; Shaikh, A; Wiisanen, ME | 1 |
| Chen, B; Chen, JZ; Cui, F; Luo, RC; Wan, C; Zheng, H | 1 |
| Daum, S; Ebert, MP; Flieger, D; Galle, PR; Geissler, M; Hoehler, T; Kanzler, S; Moehler, M; Raedle, J; Seufferlein, T | 1 |
| Fukuoka, T; Hatano, N; Imamura, Y; Morita, Y; Usui, H; Yokoyama, S | 1 |
| Gon, H; Hamabe, Y; Inui, K; Ishida, T; Kanemitsu, K; Nakajima, T; Tanaka, K; Toyokawa, A; Tsukamoto, T; Yamashita, H | 1 |
| Bai, CM; Chen, SC; Cheng, YJ; Jia, N; Shao, YJ; Zhou, JF | 1 |
| Saltz, LB; Segal, NH | 1 |
| Koopman, M; Mol, L; Ottevanger, PB; Punt, CJA | 1 |
| Fukumitsu, H; Hirakawa, H; Hoshikawa, T; Makuuchi, H; Mukai, M; Ogoshi, K; Okada, K; Tajima, T; Yazawa, N | 1 |
| Cunningham, D; Okines, A | 1 |
| Chahine, GY; Farhat, FS; Ghosn, MG; Kattan, J; Mroue, RM; Nasr, FL; Younes, FC | 1 |
| Kuebler, JP | 1 |
| Bower, GD; Briggs, GM; George, J; Goldstein, D; Olver, IN; Pavlakis, N; Price, D; Rossleigh, MA; Tapner, MJ; Taylor, DJ; van Hazel, GA | 1 |
| Huang, YT; Liao, WJ; Luo, W; Ma, L; Shi, M; Wang, XN; Wen, Q | 1 |
| Del Monte, G; Formica, V; Guadagni, F; Ludovici, G; Palmirotta, R; Roselli, M; Savonarola, A | 1 |
| Bosman, FT; Dietrich, D; Fiocca, R; Kennedy, RD; Roth, A; Tejpar, S; Van Cutsem, E; Yan, P | 1 |
| Gollins, SW; Haylock, B; Levine, E; Mason, L; Morris, J; Myint, S; Samuel, L; Susnerwala, S; Swindell, R; Topham, C; Wise, M | 1 |
| Bodnar, L; Stec, R; Szczylik, C | 1 |
| Alì, G; Allegrini, G; Bocci, G; Canu, B; Danesi, R; Del Tacca, M; Di Desidero, T; Emmenegger, U; Falcone, A; Fioravanti, A; Fontanini, G; Orlandi, P | 1 |
| Saif, MW | 1 |
| Al-Kasspooles, MF; Broward, M; Cohen, MS; Henry, D; Roby, KF; Williamson, SK | 1 |
| Ehrnrooth, E; Frederiksen, KS; Skak, K; Søndergaard, H | 1 |
| Bordonaro, R; Caputo, G; Cordio, S; Manzione, L; Novello, G; Reggiardo, G; Rosati, G | 1 |
| Goldberg, RM; O'Neil, BH | 1 |
| Kim, R; Lee, C; Wesolowski, R | 1 |
| Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xu, RH; Zhang, DS; Zhang, L | 1 |
| An, X; Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH | 1 |
| Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Watanabe, M; Yasuda, N | 1 |
| Kemeny, NE; Power, DG | 1 |
| de Gramont, A; Hebbar, M; Pruvot, FR; Romano, O; Triboulet, JP | 1 |
| Garcia-Alfonso, P; Gonzalez-Flores, E; Mendez-Ureña, M; Muñoz-Martin, A; Perez-Manga, G; Quiben-Pereira, R | 1 |
| Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S | 1 |
| Jang, JS; Kim, BG; Kim, DK; Kim, HJ; Kim, MC; Kim, SG; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY | 1 |
| Cai, J; Ji, X; Li, Q; Tucker, S; Wan, F; Wang, D; Zhao, R; Zhong, B; Zhu, J | 1 |
| Koopman, M; Punt, CJ | 1 |
| Cunningham, D; Yim, KL | 1 |
| Hang, M; Hang, X; Li, M; Mao, W; Sun, Q; Xu, W; Zhang, J | 1 |
| Teng, KY; Xu, RH | 1 |
| Alqaisi, M; Bernal, P; Bush, D; Byrd, J; Garberoglio, C; Hussein, F; Malik, I | 1 |
| Boku, N; Doi, T; Fukuda, H; Koizumi, W; Nasu, J; Ohtsu, A; Saito, H; Sawaki, A; Shirao, K; Takiuchi, H; Yamaguchi, K; Yamamoto, S | 1 |
| Han, DJ; Hwang, JY; Kim, JE; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, JS; Lee, SK; Lee, SS; Park, DH; Seo, DW; Yoo, C | 1 |
| Heymanns, J; Kleboth, K; Köppler, H; Thomalla, J; Weide, R | 1 |
| Adlard, JW; Allan, JM; Braun, MS; Daly, CL; Meade, AM; Parmar, MK; Quirke, P; Richman, SD; Seymour, MT; Thompson, L | 1 |
| Nishida, T | 1 |
| Barrett, JH; Chambers, P; Daly, CL; Elliott, F; Meade, AM; Quirke, P; Richman, SD; Seymour, MT; Taylor, G | 1 |
| Garita, R; Michelin, OC; Okoshi, K; Paiva, BS; Paiva, CE | 1 |
| Baselga, J; Cervantes, A; Ciardiello, F; Kisker, O; Liebscher, S; Macarulla, T; Martinelli, E; Ramos, FJ; Rivera, F; Rodriguez-Braun, E; Roselló, S; Tabernero, J; Vega-Villegas, ME | 1 |
| Abbruzzese, JL; Adinin, R; Ellis, LM; Eng, C; Glover, KY; Heymach, JV; Hoff, PM; Kopetz, S; Lieu, C; Morris, JS; Overman, MJ; Tran, HT; Valero, V; Wen, S; Wolff, RA; Yan, S | 1 |
| Hara, T; Hiramatsu, K; Hosoya, J; Kato, K; Kimura, A; Kojima, T; Machiki, Y; Otsuji, H; Sakuragawa, T; Tanaka, H; Tsuchiya, T; Yoshida, K | 1 |
| Baba, N; Ishigami, S; Kitaguchi, K; Nakauchi, M; Nakayama, Y; Ohe, H; Sakikubo, M; Taira, K; Tamura, J; Ura, K; Yoshikawa, A | 1 |
| Prewett, M; Steiner, P; Surguladze, D; Tonra, JR | 1 |
| Akabane, H; Hanamoto, T; Kita, K; Kuji, M; Miyagi, H; Nakano, S; Oikawa, F; Shomura, H; Takahashi, M; Takaoka, M; Yanagida, N; Yoneya, R | 1 |
| Iida, A; Kaneko, T; Mishima, T; Miyazaki, M; Muto, T; Shimizu, K; Yoshidome, H | 1 |
| Inoue, S; Nasu, K; Noda, K; Umekita, N | 1 |
| Akabane, H; Hanamoto, T; Kita, K; Kuji, M; Miyagi, H; Nakano, S; Oikawa, F; Shomura, H; Takahashi, M; Yanagida, N | 1 |
| Azzarello, G; Basso, U; Buonadonna, A; Cecchin, E; D'Andrea, M; De Mattia, E; De Paoli, P; Gasparini, G; Innocenti, F; Lo Re, G; Mini, E; Nobili, S; Pessa, S; Toffoli, G | 1 |
| Cho, SH; Go, SI; Kang, JH; Kim, HG; Kim, HJ; Kim, SH; Lee, GW | 1 |
| Choi, SH; Chun, HK; Lee, WS; Lee, WY | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Onozawa, Y; Sakamoto, T; Shimoyama, R; Taku, K; Todaka, A; Tomita, H; Tsushima, T; Yamazaki, K; Yasui, H | 1 |
| Adam, R; Azoulay, D; Castaing, D; de Haas, RJ; Ducreux, M; Flores, E; Lemoine, A; Lévi, F; Paule, B; Wicherts, DA | 1 |
| Gerhardt, T; Heller, J; Höblinger, A; Rings, D; Sauerbruch, T; Schepke, M | 1 |
| Abe, T; Fujii, K; Goto, A; Hasegawa, Y; Nishimura, S; Shinomura, Y; Sukawa, Y; Suzuki, K; Yonezawa, K | 1 |
| Baba, K; Ishigami, S; Kitazono, M; Matsushita, D; Natsugoe, S; Ogawa, H; Shinchi, H; Ueno, S | 1 |
| Kubo, N; Matuoka, T; Nobuhara, Y; Yo, T | 1 |
| Fukunaga, M; Furukawa, H; Imamura, H; Kishimoto, T; Miyazaki, Y; Ohta, K; Ohzato, H; Shimizu, H; Tatsuta, M | 1 |
| Arcara, C; Borsellino, N; Colucci, G; Gebbia, V; Giuliani, F; Maiello, E | 1 |
| Chang, PY; Cheng, MF; Hsieh, CB; Lee, HS; Yao, NS | 1 |
| Berglund, A; Berglund, M; Byström, P; Fredriksson, LA; Garmo, H; Glimelius, B; Kohnke, H; Sørbye, H; Wadelius, M | 1 |
| Glynne-Jones, R; Harrison, M; Mawdsley, S | 1 |
| Blair, EA; Haraf, DJ; Pederson, AW; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Brighenti, M; Buti, S; Dalla Chiesa, M; Donati, G; Lazzarelli, S; Passalacqua, R; Rovere, RK; Tomasello, G | 1 |
| Bandres, E; Bitarte, N; Chopitea, A; Gacía-Foncillas, J; Patiño-Garcia, A; Ponz-Sarvise, M; Ramirez, N; Rodríguez, J; Viudez, A; Zarate, R | 1 |
| Afchain, P; Aparicio, T; Bonnetain, F; Costes, L; Gauthier, M; Gornet, JM; Lecomte, T; Locher, C; Malka, D; Mitry, E; Moulin, V; Sobhani, I; Taïeb, J; Tougeron, D; Zaanan, A | 1 |
| Brendel, E; Laferriere, N; Langenberg, MH; Mergui-Roelvink, M; Roodhart, JM; Schellens, JH; van der Sar, J; Verheul, HM; Voest, EE; Witteveen, PO | 1 |
| Allegrini, G; Andreuccetti, M; Cascinu, S; Cortesi, E; Falcone, A; Fontana, E; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Mentuccia, L; Merlano, M; Salvatore, L; Vasile, E | 1 |
| Fleig, WE; Grothe, W; Grothey, A; Haerting, J; Kleber, G; Unverzagt, S; Wagner, AD | 1 |
| Asaka, M; Iwanaga, I; Kawamoto, Y; Komatsu, Y; Miyazaki, T; Nakatsumi, H; Sasaki, T; Sogabe, S; Takagi, T; Takano, H; Uehata, Y; Yuki, S | 1 |
| Falcone, A; Loupakis, F | 1 |
| Mehta, SP | 1 |
| Boehm, KA; Cartwright, T; McCollum, D | 1 |
| Barrois, M; Beaune, P; Boige, V; Bouché, O; Castaing, M; Ducreux, M; Laurent-Puig, P; Le Corre, D; Loriot, MA; Malka, D; Mendiboure, J; Miran, I; Mulot, C; Pignon, JP; Trégouët, DA | 1 |
| Abbruzzese, A; Arcuri, FP; Caraglia, M; Carducci, A; Correale, P; Del Vecchio, MT; Loiacono, L; Marra, M; Migali, C; Misso, G; Remondo, C; Tagliaferri, P; Tassone, P | 1 |
| Adam, R; Bouchahda, M; Giacchetti, S; Gorden, L; Guettier, C; Hauteville, D; Innominato, PF; Karaboué, A; Lévi, F; Saffroy, R | 1 |
| Andres, A; Gervaz, P; Majno, P; Mentha, G; Morel, P; Roth, A; Rubbia-Brandt, L | 1 |
| Liao, WJ; Luo, RC; Shen, P; Shi, M; Wu, Wy | 1 |
| Hashimoto, T; Inoue, K; Kokudo, N; Makuuchi, M; Maruyama, Y; Ogata, S; Sano, K; Takamoto, T; Takemura, T | 1 |
| Bruera, G; Calista, F; Cannita, K; De Galitiis, F; Ficorella, C; Gebbia, N; Guglielmi, F; Iacobelli, S; Lanfiuti Baldi, P; Mancini, M; Marchetti, P; Martella, F; Morelli, MF; Pelliccione, M; Porzio, G; Ricevuto, E; Russo, A; Santomaggio, A; Tudini, M | 1 |
| Dasanu, CA; Trikudanathan, G | 1 |
| Matsumoto, H; Mori, T; Takahashi, K; Yamaguchi, T; Yasutome, M | 1 |
| Gallagher, M; Giantonio, B; Haller, DG; Metz, JM; O'Dwyer, PJ; Sun, W; Whittington, R | 1 |
| Gallagher, DJ; Kemeny, N | 1 |
| Cathomas, R; Köberle, D; Lanz, D; Popescu, R; Roth, A; Ruhstaller, T; Simcock, M; Uhlmann, C; von Moos, R; Widmer, L | 1 |
| Bai, J; Chen, J; Duanmu, Z; Gong, Y; Huang, H; Tang, C; Yang, J; Zhou, B; Zhuang, L | 1 |
| Alonso-Varona, A; Caramés, M; García-Alonso, I; Palomares, T | 1 |
| Muro, K | 1 |
| Endo, T; Hasegawa, H; Ishii, Y; Kitagawa, Y; Moritani, K; Ochiai, H; Okabayashi, K; Watanabe, M | 1 |
| Chau, GY; Chen, WS; Hsieh, YY; Hsu, YN; King, KL; Lin, JK; Lin, TC; Liu, JH; Teng, HW; Tzeng, CH | 1 |
| Aranda, E; Bandrés, E; Boni, V; Garcia-Foncillas, J; Gomez, MA; Maiello, E; Villa, JC; Zarate, R | 1 |
| Chang, HJ; Choi, HS; Hong, YS; Jeong, JY; Jeong, SY; Jung, KH; Kim, DH; Kim, DY; Lim, SB; Park, JG; Sohn, DK | 1 |
| Abad, A; Aranda, E; Benavides, M; Carrato, A; Ginés, A; Layos, L; Manzano, JL; Marcuello, E; Martinez-Balibrea, E; Martínez-Cardús, A; Massutí, B; Moreno, V; Navarro, M; Valladares, M | 1 |
| Astier, A | 1 |
| Elliott, RA; Newman, WG; Payne, K; Shabaruddin, FH; Valle, JW | 1 |
| Goldberg, RM; McLeod, H; Sargent, DJ | 1 |
| Amoroso, D; Andreuccetti, M; Ciarlo, A; Cortesi, E; Cremolini, C; Cupini, S; Del Monte, F; Falcone, A; Fontanini, G; Fornaro, L; Granetto, C; Loupakis, F; Lupi, C; Masi, G; Salvatore, L; Sensi, E | 1 |
| Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K | 1 |
| Díaz-Rubio, E; García-Foncillas, J | 1 |
| Charles, KA; Chua, W; Clarke, SJ; Kho, PS; Moore, MM | 1 |
| Armakolas, A; Batzios, S; Batziou, C; Koutantos, J; Legakis, J; Stathopoulos, GP; Stathopoulos, J; Trafalis, D | 1 |
| Fukushima, M; Nakagawa, F; Ohshimo, H; Sakamoto, K; Taguchi, T | 1 |
| Lee, SY; McLeod, HL | 1 |
| Baxevanis, CN; Gritzapis, AD; Kosmas, C; Tsavaris, N; Voutsas, IF | 1 |
| Berglund, A; Fernebro, E; Flygare, P; Glimelius, B; Gubanski, M; Johnsson, A; Kadar, L; Karlberg, I; Lind, PA | 1 |
| Jaitner, S; Jung, A; Kirchner, T; Schäffauer, AJ | 1 |
| Hosono, S; Ito, H; Ito, S; Kawai, H; Kawase, T; Matsuo, K; Muro, K; Sawaki, A; Shibata, T; Shitara, K; Tajima, K; Takahari, D; Tanaka, H; Ura, T; Watanabe, M; Yatabe, Y; Yokota, T | 1 |
| Bruns, H; Büchler, MW; Hoffmann, K; Longerich, T; Mikalauskas, S; Mikalauskiene, L; Nickkholgh, A; Schemmer, P; Strupas, K | 1 |
| Benner, RJ; Benson, AB; Berlin, JD; Denis, LJ; Goff, LW; LoRusso, PM; Rothenberg, ML; Tan, AR; Yin, D | 1 |
| Khattak, A; Price, TJ; Townsend, AR | 1 |
| Chang, HJ; Choi, HS; Hong, YS; Im, SA; Jeong, SY; Jung, KH; Kim, DY; Kim, JH; Kim, SY; Kim, TW; Lee, KS; Lim, SB; Yun, T | 1 |
| Aliberti, C; Chiriatti, A; Fiorentini, G; Licitra, S; Montagnani, F | 1 |
| Fan, J; Ling, W; Ma, Y; Wang, H | 1 |
| Bohn, B; Erben, P; Hanfstein, B; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kienle, P; Popa, J; Post, S; Ströbel, P; Wenz, F | 1 |
| Cane, LM; Carvajal, RD; Dials, HJ; Dickson, MA; Gonen, M; Lefkowitz, RA; Rathkopf, D; Schwartz, GK; Shah, MA; Tse, A; Wu, N | 1 |
| Akiyama, Y; Ando, Y; Araki, K; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Saji, S; Sasaki, Y; Sunakawa, Y; Yamamoto, W; Yamashita, K | 1 |
| Antonucci, A; Baldi, PL; Bruera, G; Cannita, K; De Galitiis, F; Ficorella, C; Mancini, M; Marchetti, P; Ricevuto, E; Santomaggio, A; Tudini, M | 1 |
| Campanella, C; Cognetti, F; Ettorre, GM; Garufi, C; Mottolese, M; Sperduti, I; Torsello, A; Tumolo, S; Vennarecci, G; Zeuli, M | 1 |
| Akiyama, Y; Ando, M; Ando, Y; Endo, H; Fujita, K; Kawara, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Yamamoto, W; Yamashita, K | 1 |
| Bosse, D; Fischer von Weikersthal, L; Giessen, C; Goebeler, M; Grundeis, M; Heinemann, V; Lambertz, H; Maubach, PA; Mittermüller, J; Oruzio, D; Quietzsch, D; Schalhorn, A; Schlag, R; Schulze, M; Stauch, M; Szukics, B; Truckenbrodt, J; Vehling-Kaiser, U; Weigang-Köhler, K; Zwingers, T | 1 |
| Adam, R; Azoulay, D; Castaing, D; Ciacio, O; de Haas, RJ; Giacchetti, S; Guettier, C; Lévi, F; Paule, B; Sebagh, M; Wicherts, DA | 1 |
| Alvarez-Suarez, S; García-Alfonso, P; Jerez-Gilarranz, Y; Khosravi, P; Martin, M; Muñoz-Martin, AJ; Riesco-Martinez, M | 1 |
| Aravantinos, G; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Linardou, H; Makatsoris, T; Papadimitriou, C; Papakostas, P; Papamichael, D; Pectasides, D; Pentheroudakis, G; Samelis, G; Skondra, M; Stavropoulos, M; Syrigos, KN; Varthalitis, I; Vourli, G; Xanthakis, I; Xiros, N | 1 |
| Cho, DH; Hong, YS; Jin, DH; Jung, KA; Kim, JC; Kim, SM; Kim, TW; Lee, JS; Na, YS; Ro, S; Ryu, MH; Yang, SJ | 1 |
| Berglund, A; Byström, P; Einarsson, R; Glimelius, B; Johansson, B; Larsson, A; Nygren, P; Wernroth, L | 1 |
| Kim, R | 1 |
| Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S; Vincent, J | 1 |
| Aglietta, M; Barni, S; Beretta, GD; Corsi, D; Cortesi, E; Dapretto, E; Floriani, I; Fornarini, G; Isa, L; Labianca, R; Lonardi, S; Nicolella, D; Sobrero, A; Turci, D; Zaniboni, A | 1 |
| Furukawa, K; Kanazawa, Y; Mamada, Y; Uchida, E; Yamada, T; Yokoi, K | 1 |
| Heinemann, V; Hoff, PM | 1 |
| Dong, CM; Kang, MF; Liu, Y; Luo, MQ | 1 |
| Goubely, Y; Kirscher, S; Mineur, L; Molinari, N; Plat, F; Sabatier, R | 1 |
| Balzano, G; Belli, C; Brioschi, M; Cereda, S; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E | 1 |
| Galle, PR; Geißler, M; Kanzler, S; Kubicka, S; Lordick, F; Moehler, M; Mueller, A; Schwarz, S; Seufferlein, T; Trarbach, T | 1 |
| Ababneh, Y; Fahlke, J; Galle, PR; Maintz, C; Moehler, M; Musch, R; Schimanski, CC; Schmidt, B; Siebler, J; Soeling, U; Verpoort, K | 1 |
| Azzariti, A; Cinieri, S; Colucci, G; De Vita, F; Lorusso, V; Maiello, E; Millaku, A; Numico, G; Petriella, D; Pisconti, S; Russo, A; Santini, D; Silvestris, N; Tommasi, S | 1 |
| Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW | 1 |
| Gmeiner, WH; Pommier, Y; Reinhold, WC | 1 |
| Ait-Arsa, I; Askari, N; Bibeau, F; Boissière, F; Causse, A; Cortijo, C; Del Rio, M; Denis, V; Denouel, A; Gongora, C; Martineau, P; Marzi, L; Mollevi, C; Paillas, S; Pourquier, P; Vezzio-Vié, N | 1 |
| Ge, FJ; Li, SS; Li, ZQ; Lin, L; Liu, JZ; Liu, LJ; Wang, Y; Xu, JM; Zhao, CH | 1 |
| Hou, SH; Li, YP; Liang, XB; Wang, LC; Yang, J; Zhang, X | 1 |
| Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S | 1 |
| Chua, TC; Doerfer, J; Esquivel, J; Germer, CT; Kerscher, AG; Maeder, U; Morris, DL; Pelz, JO; Stojadinovic, A | 1 |
| De Marchis, ML; Del Monte, G; Formica, V; Grenga, I; Guadagni, F; Ludovici, G; Palmirotta, R; Roselli, M; Savonarola, A; Schirru, M | 1 |
| Ahn, JB; Chung, HC; Hong, YS; Kim, C; Kim, DH; Kim, HR; Kim, TW; Lee, YJ; Park, KS; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Faybik, P; Fleischmann, E; Gruenberger, T; Herberger, B; Krieger, PM; Maresch, J; Tamandl, D | 1 |
| Aritake, N; Endoh, A; Katsumoto, Y | 1 |
| Fujimoto, T; Itagaki, H; Matsumoto, A; Ogawa, K; Osawa, G; Otani, T; Umehara, A; Yano, Y; Yokomizo, H; Yoshimatsu, K | 1 |
| Doki, Y; Hirose, H; Ikeda, M; Ishii, H; Kim, HM; Miyoshi, N; Mizushima, T; Mori, M; Okano, M; Sekimoto, M; Takemasa, I; Uemura, M; Yamamoto, H; Yamashita, S | 1 |
| Doki, Y; Hirose, H; Ikeda, M; Kim, HM; Miyoshi, N; Mizushima, T; Mori, M; Okano, M; Sekimoto, M; Takemasa, I; Yamamoto, H; Yamashita, S | 1 |
| Aoyagi, H; Hamada, S; Hasegawa, K; Isogai, J; Kaneko, J; Katsuta, E; Maejima, S; Saguchi, M; Someno, Y; Takahata, T | 1 |
| Gotoh, K; Ishikawa, O; Kano, S; Kishi, K; Miyashiro, I; Motoori, M; Noura, S; Ohigashi, H; Ohue, M; Shingai, T; Takahashi, H; Yamada, T; Yano, M | 1 |
| Ng, S; O'bichere, A; Platell, C; Tebbutt, N | 1 |
| Huang, YT; Liao, WJ; Luo, W; Ma, L; Shi, M; Wen, Q; Zhang, Y; Zhou, MQ | 1 |
| Hori, S; Seki, A | 1 |
| Endo, I; Kumamoto, T; Nojiri, K; Takeda, K; Tanaka, K | 1 |
| Aravantinos, G; Bafaloukos, D; Bamias, A; Basdanis, G; Dimopoulos, MA; Economopoulos, T; Efstratiou, I; Fountzilas, G; Kafiri, G; Kalofonos, HP; Karanikiotis, C; Karina, M; Klouvas, G; Korantzis, I; Makatsoris, T; Malettou, L; Matsiakou, F; Miliaras, D; Papadimitriou, CA; Papakostas, P; Papaspirou, I; Pectasides, D; Pentheroudakis, G; Pisanidis, N; Samantas, E; Xiros, N | 1 |
| Chang, HJ; Choi, HS; Kim, DY; Kim, SY; Kim, TH; Oh, JH; Park, JW; Sohn, DK; Yeo, SG | 1 |
| Abenhardt, W; Decker, T; Dietzfelbinger, H; Haberl, C; Hass, HG; Heinemann, V; Jung, A; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schalhorn, A; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF; Zellmann, K | 1 |
| Fujikawa, K; Hazama, S; Kato, T; Kimura, H; Kobayashi, M; Mishima, H; Nagata, N; Nozawa, H; Oba, K; Okuyama, Y; Sakamoto, J; Takahashi, K | 1 |
| Asaka, M; Hatanaka, K; Hosokawa, A; Iwanaga, I; Kato, T; Komatsu, Y; Kusumi, T; Miyagishima, T; Nakamura, M; Sakata, Y; Sogabe, S; Yuki, S | 1 |
| Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW | 1 |
| Ito, S; Kawai, H; Kondo, C; Matsuo, K; Mizota, A; Muro, K; Nomura, M; Sawaki, A; Shitara, K; Tajika, M; Takahari, D; Ura, T; Yokota, T | 1 |
| Ito, S; Kawai, H; Muro, K; Sawaki, A; Shitara, K; Tajika, M; Takahari, D; Ura, T; Yokota, T | 1 |
| Kang, SP; Saif, MW | 1 |
| Abdalla, EK; Andreou, A; Brouquet, A; Cooper, A; Curley, SA; Garrett, CR; Kopetz, S; Loyer, EM; Maru, DM; Overman, MJ; Vauthey, JN | 1 |
| Arai, Y; Boku, N; Denda, T; Fujii, H; Hamaguchi, T; Hyodo, I; Iwase, H; Koizumi, W; Ohtsu, A; Saito, H; Shirao, K; Takiuchi, H; Yoshida, M | 1 |
| Dzurenkova, A; Kadasi, L; Minarik, G; Mladosievicova, B; Soltysova, A; Sufliarska, S; Turna, J | 1 |
| Albrecht, H; Boxberger, F; Busse, D; Golcher, H; Hahn, EG; Hohenberger, W; Janka, R; Konturek, PC; Koucky, K; Männlein, G; Neurath, MF; Ostermeier, N; Reulbach, U; Schildberg, C; Siebler, J; Wein, A; Wolff, K | 1 |
| Begnami, MD; Cezana, L; Costa, LA; Dettino, AL; Fanelli, MF; Mello, CA; Oliveira, TB; Pinto, CA | 1 |
| Van Loon, K; Venook, AP | 2 |
| Adenis, A; Assenat, E; Bachet, JB; Bécouarn, Y; Bennouna, J; Bouché, O; Chauffert, B; Conroy, T; de la Fouchardière, C; Delbaldo, C; Desseigne, F; Ducreux, M; Gourgou-Bourgade, S; Guimbaud, R; Khemissa-Akouz, F; Michel, P; Montoto-Grillot, C; Péré-Vergé, D; Raoul, JL; Ychou, M | 1 |
| Chen, DY; Qi, Q; Zhao, WY | 1 |
| Arimochi, H; Itoh, M; Kashiwagi, M; Morita, K; Nishibori, N | 1 |
| Chang, HJ; Kim, BC; Kim, DY; Kim, MJ; Kim, SY; Kim, TH; Oh, JH; Park, JW; Sohn, DK; Yeo, SG | 1 |
| Ahn, JB; Hong, YS; Kim, SH; Kim, SY; Kim, TW; Lee, KH; Lee, SH; Park, SH; Park, YS; Shin, SJ | 1 |
| Bubenzer, J; do O, N; Fuchs, R; Luedde, T; Roderburg, C; Spannbauer, M; Tischendorf, JJ; Trautwein, C | 1 |
| Barbato, E; Barberis, G; Comella, P; Condemi, G; Filippelli, G; Ionta, MT; Massidda, B; Natale, D; Palmeri, S; Putzu, C; Sandomenico, C; Tafuto, S; Vessia, G | 1 |
| Boc, M; Ocvirk, J; Rebersek, M | 1 |
| Branda, ME; Goldberg, RM; Grothey, A; Heun, JM; Sargent, DJ | 1 |
| Abbas, F; Adenis, A; Afchain, P; Aparicio, T; Bécouarn, Y; Bouché, O; Desseigne, F; Dorval, E; Edeline, J; Guimbaud, R; Kramar, A; Mitry, E; Romano, O; Samalin, E; Thézenas, S; Ychou, M | 1 |
| Allen, JE; Brown, JM; Daniel, CJ; Dicker, DT; Dolloff, NG; Dorsey, JF; El-Deiry, WS; Furth, EE; Hart, LS; Jee, DI; Klein, PS; Kuribayashi, K; Liu, JJ; Liu, YY; Mayes, PA; Sears, RC | 1 |
| Blanke, CD; Bleyer, A; Bot, BM; de Gramont, A; Goldberg, RM; Kohne, CH; Sargent, DJ; Seymour, MT; Thomas, DM | 1 |
| Baiget, M; del Rio, E; Marcuello, E; Páez, D; Paré, L; Salazar, J; Sebio, A | 1 |
| Boland, A; Brown, C; Buck, M; Clarke, SJ; Gebski, V; Goldstein, D; Jeffrey, GM; Lowenthal, RM; Ransom, DT; Simes, RJ; Tebbutt, NC; van Hazel, GA; Yip, S; Zalcberg, J | 1 |
| Kabbinavar, F; Kozloff, M | 1 |
| Boisen, MK; Jensen, BV; Johansen, JS; Larsen, O | 1 |
| Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W | 1 |
| Chabot, J; Saif, MW | 1 |
| Ankerst, DP; Giessen, C; Heinemann, V; Laubender, RP; Modest, DP; Moosmann, N; Schalhorn, A; Schulz, C; Stintzing, S; von Weikersthal, LF | 1 |
| Chen, Y; Hotta, K; Ichihara, E; Kiura, K; Ochi, N; Tabata, M; Takigawa, N; Tanimoto, M; Tanimoto, Y; Zhang, D | 1 |
| Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K | 1 |
| Holt, K | 1 |
| Rocha, JA | 1 |
| Aprile, G; Avallone, A; Bordonaro, R; Butera, A; Cordio, S; De Pauli, F; Di Lucca, G; Parra, HS; Reggiardo, G; Rosati, G | 1 |
| Matsueda, S; Sasaki, H; Tokunaga, Y | 1 |
| Dumont, F; Elias, D; Goéré, D; Hessissen, M; Mehta, SS; Quenet, F; Roca, L; Saint-Aubert, B | 1 |
| Anne, PR; Erickson, BA; Haddock, M; Kachnic, L; Lee, RJ; Meropol, NJ; Mitchell, E; Pollock, J; Rashid, A; Watson, JC; Willett, CG; Winter, K; Wong, SJ | 1 |
| Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M | 1 |
| Gamo, M; Kambe, M; Kanamaru, R; Kikuchi, H; Ohashi, Y; Yoshioka, T | 1 |
| Bosset, JF; Créhange, G; Maingon, P | 1 |
| Bennouna, J; Borg, C; Bouché, O; Delord, JP; Douillard, JY; Faroux, R; François, E; Goldwasser, F; Husseini, F; Kraemer, S; Senellart, H; Trillet-Lenoir, V; Ychou, M | 1 |
| Derleyn, VA; Koopman, M; Mol, L; Muller, EW; Punt, CJ; Simkens, LH; Teerenstra, S; Ten Bokkel Huinink, D; Veldhuis, GJ | 1 |
| Korovina, IaV; Nasyrov, AR; Pirtskhalava, TL | 1 |
| Adenis, A; Boige, V; Boucher, E; Chauffert, B; Conroy, T; Cvitkovic, F; Ducreux, M; Farace, F; François, E; Galais, MP; Guichard, P; Jacques, N; Malka, D; Pierga, JY; Vimond, N | 1 |
| Asaka, M; Fukushima, H; Iwanaga, I; Kawamoto, Y; Kobayashi, Y; Komatsu, Y; Nakatsumi, H; Sasaki, T; Sogabe, S; Takano, H; Uehata, Y; Yuki, S | 1 |
| Hanna, N; Hsiao, FY; Mullins, CD; Onukwugha, E; Pandya, N | 1 |
| Berglund, Å; Blomqvist, L; Byström, P; Glimelius, B; Jacobsson, H; Nygren, P; Sundin, A; Suzuki, C | 1 |
| Bohn, B; Erben, P; Gencer, D; Hofheinz, RD; Hofmann, WK; Horisberger, K; Kähler, G; Kienle, P; Post, S; Schwaab, J; Ströbel, P; Wenz, F | 1 |
| Cohn, AL; Khandelwal, P; Mehta, N; Neubauer, MA; Richards, D; Shumaker, GC; Smith, DA; Watkins, DL; Yassine, MR; Zhang, K | 1 |
| Agarwal, A; Ferrarotto, R; Hoff, PM; Kopetz, S; Maru, D; Overman, M; Pathak, P | 1 |
| Critchfield, GC; Hamilton, SA; Kaldate, RR; Roa, BB; Saam, J; Wenstrup, RJ | 1 |
| Brenckman, W; Cheng, YC; Chu, E; Copur, MS; Jiang, Z; Kummar, S; Liu, SH; O'Rourke, M; Rose, M; Stephenson, J; Su, T; Tilton, R; Wadler, S | 1 |
| André, T; Artru, P; Bengrine-Lefevre, L; Bonnetain, F; Chibaudel, B; de Gramont, A; Desramé, J; Larsen, AK; Louvet, C; Teixeira, L; Tournigand, C | 1 |
| Farma, JM; Matteotti, RS; Nitzkorski, JR; Sigurdson, ER; Siripurapu, V; Watson, JC; Zhu, F | 1 |
| Aubele, P; Bangerter, M; Denzlinger, C; Freiberg-Richter, J; Giessen, C; Heinemann, V; Hinke, A; Kullmann, F; Mayerle, J; Modest, DP; Moosmann, N; Schulz, C; Sieber, M; Stintzing, S; Teschendorf, C; Vehling-Kaiser, U; von Weikersthal, LF | 1 |
| Milella, M; Sperduti, I; Vaccaro, V | 1 |
| Ikeda, R; Iseki, K; Iwashita, Y; Kondo, T; Osada, T; Shibayama, Y; Sugawara, M; Takeda, Y; Yamada, K; Yoshikawa, Y | 1 |
| Di Fiore, F; Michel, P | 1 |
| Angelopoulos, S; Despoudi, K; Kanellos, D; Koliakos, G; Lazaridis, C; Mantzoros, I; Pramateftakis, MG; Raptis, D; Zaraboukas, T | 1 |
| Bhattacharyya, M; Mutsvangwa, K; Oliver, T; Powles, T; Shamash, J; Wilson, P | 1 |
| Efrusy, MB; Göke, B; Goldberg, RM; Kirchner, T; Santas, CC; Vijayaraghavan, A | 1 |
| Peeters, M; Price, T | 1 |
| Ko, AH | 1 |
| Kamiyama, H; Kato, T; Koizumi, K; Konishi, F; Maeda, T; Miyaki, Y; Saito, M; Shibata, K; Shiya, N; Suzuki, K | 1 |
| Abbas, M; Auby, D; Azzedine, A; Bedenne, L; Bouché, O; Castaing, M; Denis, B; Ducreux, M; Etienne, PL; Gargot, D; Gasmi, M; Geoffroy, P; Lombard-Bohas, C; Malka, D; Mendiboure, J; Michel, P; Pignon, JP; Rougier, P; Texereau, P | 1 |
| Allegrini, G; Baldi, GG; Brunetti, IM; Cortesi, E; Cremolini, C; Cupini, S; Falcone, A; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Ricci, S; Salvatore, L; Tuzi, A; Vasile, E | 1 |
| Fayad, W; Felth, J; Fryknäs, M; Glimelius, B; Graf, W; Gullbo, J; Hassan, S; Larsson, R; Laryea, D; Linder, S; Mahteme, H; Nygren, P; Påhlman, L; Rickardson, L | 1 |
| Kageyama, S; Katayama, N; Mizuno, T; Nomura, H; Oda, H; Saito, K; Tamaru, S; Yamashita, Y | 1 |
| Crea, F; Cremolini, C; Danesi, R; Falcone, A; Farrar, WL; Fornaro, L; Frumento, P; Graziano, F; Loupakis, F; Masi, G; Paolicchi, E; Ricci, V; Ronzoni, M; Salvatore, L; Schirripa, M | 1 |
| Capussotti, L; Mellano, A; Muratore, A; Ribero, D; Viganò, L; Zimmitti, G | 1 |
| Crea, F; Danesi, R; Landini, I; Mini, E; Napoli, C; Nobili, S; Paolicchi, E; Perrone, G | 1 |
| Ba, Y; Feng, FY; Guan, ZZ; He, J; Liang, J; Luo, RC; Qi, C; Qin, SK; Shen, L; Wang, D; Wang, JJ; Wang, LW; Xu, JM; Xu, RH; Yu, SY | 1 |
| Chang, CY; Cho, YB; Choi, DH; Chun, HK; Kim, HC; Lee, WY; Park, HC; Park, JO; Park, YS; Yun, SH | 1 |
| Iannotti, N; Lacouture, ME; Mitchell, EP; Pillai, MV; Piperdi, B; Shearer, H; Xu, F; Yassine, M | 1 |
| Assenat, E; Bibeau, F; Bleuse, JP; Crapez-Lopez, E; Desseigne, F; Kramar, A; Mineur, L; Portales, F; Samalin, E; Thezenas, S; Viret, F; Ychou, M | 1 |
| Hanna, N; Hsiao, FY; Mullins, CD; Onukwugha, E; Pandya, NB | 1 |
| Allen, WL; Carson, G; Coyle, VM; Gordon, MA; Jithesh, PV; Johnston, PG; Lenz, HJ; Longley, DB; Proutski, I; Stevenson, L; Van Schaeybroeck, S | 1 |
| Assenat, E; Bleuse, JP; Mazard, T; Pinguet, F; Portales, F; Poujol, S; Samalin, E; Thezenas, S; Thirion, A; Ychou, M | 1 |
| Alyasiri, A; Dvorak, A; Fleshman, JW; Hoskins, JM; McLeod, HL; Motsinger-Reif, AA; Myerson, RJ; Roy, S; Tan, BR; Thomas, F | 1 |
| Chen, MX; Fan, L; Hu, XZ; Jiang, HY; Li, CY; Liang, XB; Ma, JJ; Yan, D | 1 |
| He, YJ; Li, YH; Luo, HY; Qiu, MZ; Ruan, DY; Teng, KY; Wang, FH; Wang, ZQ; Xu, RH | 1 |
| Baba, H; Beppu, T; Hayashi, N; Sawayama, H; Takamori, H; Watanabe, M | 1 |
| El-Hadaad, HA; Roshdy, S; Wahba, HA | 1 |
| Benson, AB; Bertagnolli, MM; Fuchs, CS; Goldberg, RM; Hantel, A; Hollis, D; Mayer, RJ; McCleary, NJ; Meyerhardt, JA; Ng, K; Ogino, S; Saltz, LB; Schaefer, P; Shima, K; Spiegelman, D; Whittom, R | 1 |
| Alberts, SR; Franko, J; Goldberg, RM; Goldman, CD; Grothey, A; Nelson, GD; Pitot, HC; Pockaj, BA; Sargent, DJ; Shi, Q | 1 |
| Bollag, G; Bradley, WD; Heimbrook, D; Higgins, B; Kolinsky, K; Kopetz, S; Lee, RJ; Lestini, B; Packman, K; Schostack, K; Simcox, ME; Su, F; Yang, H | 1 |
| Brünner, N; Jensen, NF; Nielsen, KV; Nygård, SB; Rømer, MU; Smith, DH | 1 |
| Benhaim, L; Labonte, MJ; Lenz, HJ | 1 |
| Ciccolini, J; Dahan, L; Evrard, A; Iliadis, A; Lacarelle, B; Mbatchi, L; Mercier, C; Norguet, E; Ouafik, L; Ries, P; Seitz, JF; Tibbitts, J | 1 |
| Bellot, GL; Koh, D; Tan, WH; Tay, LL; Wang, X | 1 |
| Akiyama, Y; Fujita, K; Ishida, H; Kawara, K; Miwa, K; Saji, S; Sasaki, Y; Sunakawa, Y; Yamashita, K | 1 |
| Antonucci, A; Bruera, G; Cannita, K; Ficorella, C; Giuliante, F; Lanfiuti Baldi, P; Marchetti, P; Nuzzo, G; Ricevuto, E; Vicentini, R | 1 |
| Chan, KM; Chen, JS; Chiang, JM; Lee, CF; Lee, WC; Wang, JY; Yu, MC | 1 |
| Baba, E; Bando, H; Boku, N; Esaki, T; Fukunaga, M; Hyodo, I; Kato, S; Katsumata, K; Miyake, Y; Moriwaki, T; Ozeki, M; Satoh, T; Takashima, A; Yamashita, K; Yamazaki, K; Yoshida, S | 1 |
| Munakata, M; Sakata, Y | 1 |
| Kato, K | 1 |
| Decker, T; Fischer von Weikersthal, L; Giessen, C; Heinemann, V; Heintges, T; Jäger, E; Jung, A; Kirchner, T; Modest, DP; Neumann, J; Scheithauer, W; Stintzing, S; Stoll, C; Vehling-Kaiser, U | 1 |
| Boukovinas, I; Christophyllakis, Ch; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Kouroussis, Ch; Makrantonakis, P; Polyzos, A; Souglakos, J; Vamvakas, L; Xynogalos, S; Ziras, N | 1 |
| Capussotti, L; Ferrero, A; Langella, S; Lo Tesoriere, R; Russolillo, N; Vigano', L | 1 |
| Asseburg, C; Bravo Vergel, Y; Manca, A; Meade, A; Parmar, M; Sculpher, MJ; Seymour, MT; Stephens, R | 1 |
| Atreya, CE; Bergsland, EK; Ducker, GS; Feldman, ME; Shokat, KM; Warren, RS | 1 |
| Brunet, R; Evrard, S; Kauffmann, A; Laroche-Clary, A; Laurand-Quancard, A; Le Morvan, V; Robert, J; Smith, D | 1 |
| Abe, T; Ando, M; Kato, T; Nakashima, H; Shindo, J; Shiraki, A; Yamamoto, K; Yukita, Y | 1 |
| Chen, E; Feld, R; Knox, J; Krzyzanowska, MK; Liu, G; MacKay, H; Moore, MJ; Petronis, J; Renouf, DJ; Wang, L; Welch, S | 1 |
| Akashi, K; Baba, E; Esaki, T; Fujishima, H; Kusaba, H; Makiyama, A; Mitsugi, K; Nakano, S; Tanaka, R; Uchino, K | 1 |
| Benner, A; Dippold, W; Formentini, A; Kloor, M; Kornmann, M; Link, KH; Michel, S; Tikidzhieva, A; von Knebel Doeberitz, M | 1 |
| Assy, N; Basher, W; Chetver, L; Shnaider, J; Zidan, J | 1 |
| Hiyoshi, M; Hongo, K; Kaneko, M; Kawai, K; Kitayama, J; Murono, K; Nirei, T; Sasaki, K; Sunami, E; Tada, N; Takahashi, K; Tsuno, NH | 1 |
| Baek, SK; Cho, KS; Jeong, JH; Kim, SY; Yoon, HJ | 1 |
| da Costa Lima, AB; Macedo, LT; Sasse, AD | 1 |
| Harling, H; Kirkeby, LT; Mocellin, S; Petersen, SH; Wille-Jørgensen, P | 1 |
| Brodowicz, T; Giessen, C; Heinemann, V; Knittelfelder, R; Laubender, RP; Modest, DP; Reinacher-Schick, A; Schmiegel, W; Stintzing, S; Tannapfel, A; Vrbanec, D; Zielinski, CC | 1 |
| Colucci, G; Di Maio, M; Giuliani, F; Perrone, F | 1 |
| Conibear, J; Raouf, S; Tarver, K | 1 |
| Bennouna, J; Chatelut, E; Douillard, JY; El Hannani, C; Etienne-Grimaldi, MC; Faroux, R; Formento, JL; Francois, E; Francoual, M; Hennebelle, I; Jacob, JH; Milano, G | 1 |
| Akiyama, Y; Araki, K; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Nagashima, F; Saji, S; Sasaki, Y; Sunakawa, Y; Yamamoto, W; Yamashita, K | 1 |
| Martin, RC; Metzger, T; Schreeder, M; Scoggins, CR; Sharma, V; Tatum, C; Tomalty, D | 1 |
| Lee, KS; Nam, BH; Park, IH; Ro, J | 1 |
| Bleiberg, H; D'Haens, G; Deleu, I; Efira, A; Humblet, Y; Paesmans, M; Peeters, M; Rezaei Kalantari, H; Vandebroek, A; Vergauwe, P | 1 |
| Abbruzzese, A; Apollinari, S; Bestoso, E; Botta, C; Caraglia, M; Correale, P; Cusi, MG; Misso, G; Pastina, P; Sperlongano, P; Tagliaferri, P; Tassone, P | 1 |
| Ishibashi, N; Kibe, S; Murakami, N; Ogata, Y; Shirouzu, K; Takahashi, K; Takeuchi, M; Uchida, S; Yahara, T | 1 |
| Bufill, J; Burns, M; Cardenes, H; Chiorean, EG; Clark, R; Coleman, N; Curie, C; Hinkle, DT; LeBlanc, J; Loehrer, PJ; Robb, B; Sanghani, S; Schiel, MA; Tong, Y; Yu, M | 1 |
| Adam, R; Barroso, E; Capussotti, L; Elias, D; Figueras, J; Gigot, JF; Gruenberger, T; Herrera, J; Ijzermans, JN; Isoniemi, H; Laurent, C; Letoublon, C; Lucidi, V; Mirza, DF; Nuzzo, G; Pardo, F; Popescu, I; Poston, G; Sousa, FC; Viganò, L | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Cetin, B; Coskun, U; Isıkdogan, A; Kaplan, MA; Ozkan, M; Ozturk, SC | 1 |
| Fujita, K; Ishida, H; Kato, Y; Miwa, K; Saji, S; Sasaki, T; Sasaki, Y; Sunakawa, Y; Yamashita, K | 1 |
| Ernani, V; Hosein, PJ; Kawamura, C; Levi, JU; Loaiza-Bonilla, A; Macintyre, J; Maldonado, JC; Merchan, JR; Narayanan, G; Portelance, L; Ribeiro, A; Rocha-Lima, CM | 1 |
| Cakar, B; Karabulut, B; Karaca, B; Sezgin, C; Uslu, R; Varol, U | 1 |
| Barot, TC; Gulec, SA; Hall, M; Pennington, K; Schwartzentruber, D; Suthar, RR; Wheeler, J | 1 |
| Giessen, C; Heinemann, V; Jung, A; Kapaun, C; Kirchner, T; Laubender, RP; Modest, DP; Moosmann, N; Neumann, J; Stintzing, S; Wollenberg, A | 1 |
| Katzenstein, HM; Trobaugh-Lotrario, AD | 1 |
| Baek, JY; Chang, HJ; Hong, YS; Im, SA; Jung, KH; Kim, DY; Kim, JH; Kim, SY; Kim, TW; Shim, EK; Yeo, HY | 1 |
| Boku, N; Doyama, H; Fukutomi, A; Machida, N; Onozawa, Y; Taniguchi, H; Todaka, A; Tsuji, K; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Akay, OM; Bal, C; Gulbas, Z; Keskin, M; Kuş, E; Ustuner, Z | 1 |
| de Lima Lopes, G; Haaland, BA; Ku, GY | 1 |
| Choi, KC; Choi, KJ; Kim, SU; Yi, BR | 1 |
| Bafaloukos, D; Economopoulos, T; Eleftheraki, AG; Fountzilas, G; Kalogeras, KT; Klouvas, G; Koutras, A; Makatsoris, T; Nikitas, N; Papakostas, P; Papandreou, CN; Papaxoinis, G; Pectasides, D; Pentheroudakis, G; Samantas, E; Sgouros, J; Syrigos, KN; Timotheadou, E; Varthalitis, I; Xanthakis, I | 1 |
| Aigner, E; Block, NL; Buchholz, S; Datz, C; Hohla, F; Krishan, A; Perez, R; Rick, FG; Schally, AV; Seitz, S; Stadlmayr, A; Szalontay, L | 1 |
| Adenis, A; Adler, G; Aparicio, J; Barcelo, JR; Canon, JL; Cassinello, J; Castanon, C; Cunningham, D; D'Hondt, L; Fonseca, E; Garcia Giron, C; Hawkins, R; Hossfeld, DK; Kerger, J; Lofts, F; Lopez-Vivanco, G; Misset, JL; Mousseau, M; Nicolson, M; Rixe, O; Rodriguez, R; Roy, A; Schalhorn, A; Schoffski, P; Sörbye, H | 1 |
| Alvarez, PJ; Aranega, A; Boulaiz, H; Caba, O; Melguizo, C; Ortiz, R; Prados, J; Rama, AR; Rodríguez-Serrano, F | 1 |
| Akiyama, S; Andoh, H; Gamoh, M; Ishioka, C; Kato, S; Maeda, S; Mori, T; Murakawa, Y; Ohori, H; Sasaki, Y; Shimodaira, H; Suzuki, T; Takahashi, S; Yamaguchi, T; Yoshioka, T | 1 |
| Chargari, C; Deutsch, E; Huguet, F; Levy, A; Védrine, L | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, JS; Nam, BH; Yoon, SJ | 1 |
| Doornebal, J; Koopman, M; Lemmens, W; Punt, CJ; Teerenstra, S; Venderbosch, S | 1 |
| Bekaii-Saab, T; Blazer, M; Efries, D; Griffith, N; Juergens, K; Phillips, G; Reardon, J; Rose, J; Smith, Y; Weatherby, L | 1 |
| Berthet, C; Bigot, L; Bruno, A; Calvet, L; Dangles-Marie, V; Dartigues, P; De Thé, H; Demers, B; Dessen, P; Duchamp, O; Goéré, D; Gonin, P; Job, B; Julien, S; Lacroix, L; Landron, S; Lantuas, D; Lardier, G; Mariani, P; Merino-Trigo, A; Morgand, L; Nemati, F; Nunes, M; Pham, E; Pierré, A; Pocard, M; Prévost, G; Roman-Roman, S; Soliman, H; Vrignaud, P; Weiswald, LB | 1 |
| Sakata, Y; Satoh, T | 1 |
| Cai, F; Clerc, A; Dupertuis, YM; Granci, V; Lecumberri, E; Pichard, C | 1 |
| Arnold, D; Edelmann, T; Glockzin, G; Hildebrandt, B; Hollerbach, S; Illerhaus, G; Königsrainer, A; Richter, M; Schlitt, HJ; Schmoll, HJ; Stein, A; Wienke, A | 1 |
| Assadourian, S; Billemont, B; Cartot-Cotton, S; Khayat, D; Meric, JB; Rixe, O; Soussan-Lazard, K; Tejpar, S; Van Cutsem, E; Verslype, C | 1 |
| Arai, Y; Aramaki, T; Boku, N; Hamada, M; Inaba, Y; Kato, K; Morita, S; Muro, K; Ohtsu, A; Satake, M; Sato, Y; Shimada, Y; Takeuchi, Y; Yamada, Y | 1 |
| Carlsson, G; Holmberg, C; Pettersson, K; Sporrong, SK | 1 |
| Akyol, M; Bayoglu, IV; Can, A; Demir, L; Dirican, A; Erten, C; Kucukzeybek, Y; Medeni, M; Somali, I; Tarhan, MO | 1 |
| Brodowicz, T; Heinemann, V; Jung, A; Kirchner, T; Knittelfelder, R; Kurteva, G; Laubender, RP; Modest, DP; Neumann, J; Ocvirk, J; Papai, Z; Stintzing, S; Zielinski, CC | 1 |
| Fu, FF; Jiang, HP; Jiang, WQ; Li, YX; Teng, LS; Wang, HH; Wang, WB | 1 |
| Gao, F; Linehan, D; Lockhart, AC; Lubner, S; McWilliams, R; Menias, C; Peddi, PF; Picus, J; Sorscher, SM; Suresh, R; Tan, BR; Wang, J; Wang-Gillam, A | 1 |
| Berglund, Å; Byström, P; Glimelius, B; Johansson, B; Larsson, A; Nygren, P; Wernroth, L | 1 |
| Köhne, CH | 1 |
| Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V | 1 |
| Bekaii-Saab, TS; Bendell, JC; Cohn, AL; Dalal, D; Fish, S; Flick, ED; Grothey, A; Hurwitz, HI; Kozloff, M; Mun, Y; Roach, N; Tezcan, H | 1 |
| Asghar, U; Barbachano, Y; Chau, I; Constantinidou, A; Cunningham, D; Khan, A; Mudan, S; Rao, S; Shurmahi, F | 1 |
| Adua, D; Barucca, V; Colonna, M; Di Seri, M; Giannarelli, D; Longo, F; Mottolese, M; Romiti, A; Rossi, L; Ruco, L; Tomao, S; Veltri, E; Zoratto, F; Zullo, A | 1 |
| Alkis, N; Arpacı, E; Benekli, M; Berk, V; Bilici, A; Budakoglu, B; Buyukberber, S; Coskun, U; Dane, F; Demirci, U; Gumus, M; Inal, A; Isıkdogan, A; Kaya, AO; Ozkan, M; Yumuk, F | 1 |
| Allen, PJ; Bao, F; D'Angelica, MI; DeMatteo, RP; Fong, Y; Gönen, M; Jarnagin, WR; Kemeny, N; Kingham, TP; Park, JO; Shia, J; Wolf, PS | 1 |
| Block, NL; Buchholz, S; Datz, C; Hohla, F; Krishan, A; Rick, FG; Schally, AV; Seitz, S; Stadlmayr, A; Szalontay, L | 1 |
| Demolin, G; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N | 1 |
| Bosman, F; Cisar, L; Cunningham, D; d'Ario, G; Delorenzi, M; Fiocca, R; Klingbiel, D; Labianca, R; Nordlinger, B; Roth, AD; Tejpar, S; Van Cutsem, E; Yan, P | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Cetin, B; Coskun, U; Isikdogan, A; Kaplan, MA; Ozkan, M; Tufan, G | 1 |
| Curran, D; Folprecht, G; Griebsch, I; Hitre, E; Köhne, CH; Láng, I; Rougier, P; Sartorius, U; Van Cutsem, E | 1 |
| Albiol, M; Alsina, M; Codina-Barreras, A; Figueras, J; Guardeño, R; Hernandez-Yagüe, X; Lopez-Ben, S; Queralt, B; Soriano, J | 1 |
| Andoh, A; Shioya, M | 1 |
| Cuenod, CA; Dubreuil, O; Fabre, M; Kourie, HR; Landi, B; Markoutsaki, N; Palazzo, L; Rahmi, G; Rougier, P; Roussel, H; Taieb, J; Van der Stiegel, M | 1 |
| Douillard, JY; Peeters, M; Siena, S; Van Cutsem, E; Wiezorek, J; Williams, R; Zhang, K | 1 |
| Cho, EK; Chung, M; Hong, J; Kim, HS; Lee, JH; Lee, WK; Park, J; Park, SH; Park, YH; Shin, DB; Sym, SJ | 1 |
| Choi, KC; Hwang, KA; Kim, SU; Kim, YB; Yi, BR | 1 |
| Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ | 1 |
| Chang, YL; Cheng, AL; Liau, JY; Lin, LI; Lin, YL; Ou, DL; Tseng, LH; Yeh, KH; Yu, SC | 1 |
| Cubillo, A; De Vicente, E; García-García, E; Hernando-Requejo, O; Hidalgo, M; López, U; López-Ríos, F; Morelli, P; Muro, A; Prados, S; Quijano, Y; Rodriguez-Pascual, J; Rubio, C | 1 |
| Adenis, A; Bascoul-Mollevi, C; Bécouarn, Y; Bérille, J; Boige, V; Bouché, O; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Guimbaud, R; Raoul, JL; Ychou, M | 1 |
| Dvorák, J; Krajina, A; Malírová, E; Melichar, B; Nová, M; Ryska, A; Voboril, Z; Weiner, P | 1 |
| Benhaim, L; Boige, V; Bonnet, S; De Baere, T; Deschamps, F; Dromain, C; Ducreux, M; Dumont, F; Elias, D; Faron, M; Goéré, D; Lefèvre, JH; Malka, D | 1 |
| Jiao, SC; Liu, ZY; Shen, L; Wang, JW; Wang, Y; Xu, JM; Xu, N | 1 |
| Cinar, V; Erdik, B; Oyan, B; Ozturk, MA; Ozveren, O | 1 |
| Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S | 1 |
| de la Fouchardière, C; Derbel, O; Méeus, P; Orlandini, F; Penet, AS; Pérol, M; Péron, J; Stella, M | 1 |
| Bang, YJ; Choi, IS; Han, SW; Im, SA; Kang, EJ; Kim, JH; Kim, JS; Kim, JW; Kim, TY; Kim, YJ; Lee, JS; Lee, KW; Oh, DY | 1 |
| Cong, X; Gunturu, KS; Hochster, HS; Lacy, J; Stein, SM; Thumar, JR; Yao, X | 1 |
| Blough, D; Koepl, L; Mummy, D; Ramsey, S; Shankaran, V; Yim, YM; Yu, E | 1 |
| Baek, JY; Hong, YS; Kim, HJ; Kim, JC; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, JL; Lim, SB; Park, JH; Park, SJ; Yu, CS | 1 |
| Assadourian, S; Bloch, J; Cartot-Coton, S; Khayat, D; Soussan-Lazard, K; Spano, JP; Tejpar, S; Van Cutsem, E; Vandecaveye, V; Verslype, C | 1 |
| Fragoulis, EG; Korbakis, D; Scorilas, A | 1 |
| Conroy, T; Ducreux, M; Gavoille, C; Samalin, E; Ychou, M | 1 |
| Choi, EW; Cusack, JC; Donahue, JM; Fuchs, BC; Kasuya, H; Kawasaki, H; Kulu, Y; Kuruppu, DK; Tanabe, KK | 1 |
| Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M | 1 |
| Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA | 1 |
| Charpentier, M; Guo, L; Lu, W; Xiao, D; Yan, B; Yang, D | 1 |
| Bélanger, AS; Cecchin, E; Couture, F; Guillemette, C; Harvey, M; Innocenti, F; Jonker, D; Lévesque, E; Toffoli, G | 1 |
| Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M | 1 |
| Berlin, J; Chan, E; Ciombor, KK | 1 |
| Bauernhofer, T; Hubmann, E; Jilek, K; Keil, F; Leitner, G; Pichler, A; Pichler, M; Rabl, H; Tinchon, C; Uggowitzer, M | 1 |
| Aparicio, T; Bouché, O; Breysacher, G; Charneau, J; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Le Brun-Ly, V; Lecomte, T; Locher, C; Mitry, E; Ramdani, M; Seitz, JF; Stefani, L; Subtil, F; Teillet, L | 1 |
| Arnold, D; Dietrich, G; Freier, W; Geißler, M; Graeven, U; Hegewisch-Becker, S; Hinke, A; Kubicka, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schmoll, HJ; Tannapfel, A | 1 |
| Saif, MW; Skoura, E; Syrigos, KN | 1 |
| Fischer von Weikersthal, L; Giessen, C; Haas, M; Heinemann, V; Laubender, RP; Mansmann, UR; Modest, DP; Schalhorn, A; Stintzing, S | 1 |
| Einsele, H; Germer, CT; Hartlapp, I; Isbert, C; Kenn, W; Kunzmann, V; Müller, J; Scheurlen, M; Steger, U | 1 |
| Auby, D; Bouché, O; Ducreux, M; Etienne, PL; Michiels, S; Pénichoux, J; Pignon, JP; Rougier, P; Texereau, P | 1 |
| Gao, B; Gao, Z; Gavine, PR; Ji, J; Ji, Q; Kilgour, E; Liu, K; Shen, D; Su, X; Tang, L; Xie, L; Xu, Y; Yin, X; Zhang, J; Zhang, L; Zhang, X; Zhou, M | 1 |
| Choo, SP; Chuah, BYS; Cohn, AL; Cottrell, S; Dubey, S; Galimi, F; Hei, YJ; Kopp, MV; Loberg, R; Maurel, J; McCaffery, I; Mitchell, EP; Nowara, E; Pan, Y; Sakaeva, DD; Sastre, J; Suzuki, S; Tabernero, J | 1 |
| Koopman, M; Mol, L; Ottevanger, PB; Punt, CJ; van Gils, CW | 1 |
| Bellet, D; Bièche, I; Cottu, P; Dangles-Marie, V; Guinebretière, JM; Laurendeau, I; Marangoni, E; Massonnet, G; Nemati, F; Richon, S; Vacher, S; Validire, P; Weiswald, LB | 1 |
| El-Rayes, B; Gao, H; Landry, J; Shelton, JW; Shu, HK; Wang, L; Waxweiler, TV; Xu, Y | 1 |
| Hanna, N; Hayostek, C; Mitchell, E; Mohiuddin, M; Nichols, R; Paulus, R; Willett, C; Yalavarthi, S; Yuen, A | 1 |
| Alcindor, T; Moreau, LC; Rajan, R; Thirlwell, MP | 1 |
| Boxberger, F; Dörje, F; Harich, HD; Hohenberger, W; Koch, S; Neurath, MF; Siebler, J; Wein, A | 1 |
| Diasio, RB | 1 |
| Cassidy, J; Hochster, H | 1 |
| Bae, KS; Chang, HM; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG; Sym, SJ | 1 |
| Allen, TM; Anantha, M; Bally, MB; Dos Santos, N; Harasym, N; Hare, JI; Neijzen, RW; Waterhouse, DN; Webb, MS | 1 |
| Bruno, R; Claret, L; Gupta, M; Han, K; He, J; Joshi, A; Powell, B; Sarapa, N | 1 |
| Allen, JN; Blaszkowsky, LS; Clark, JW; Dias, LE; Faris, JE; Fernandez-del Castillo, C; Ferrone, CR; Guimaraes, AR; Hong, TS; Huynh, MA; Kwak, EL; Lillemoe, KD; McDermott, S; Murphy, JE; Ryan, DP; Sahani, DV; Szymonifka, J; Thayer, SP; Wargo, JA; Wo, JY; Zhu, AX | 1 |
| Gajdos, C; Jones, EL; Jones, TS; McManus, M; Shah, R | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; You, SX | 1 |
| Bekaii-Saab, T; Goldberg, RM | 1 |
| Chauffert, B; Ghiringhelli, F; Wiazzane, N | 1 |
| Graham, J; Lindsay, CR; Roxburgh, P | 1 |
| Huang, S; Park, JM; Sinicrope, FA; Tougeron, D | 1 |
| Aksu, G; Bilici, A; Cabuk, D; Gumus, M; Kaya, S; Oven Ustaalioglu, BB; Seker, M; Temiz, S; Uygun, K; Yildiz, R | 1 |
| Benstead, K; Brown, SR; Chambers, P; Chau, I; Dawson, L; Falk, S; Gwyther, S; Hill, M; Lowe, C; Maisey, N; Marshall, H; Maughan, T; Middleton, G; Napp, V; O'Callaghan, A; Oliver, A; Quirke, P; Richman, S; Seligmann, JF; Seymour, MT; Wadsley, J | 1 |
| Eng, C | 1 |
| de Gramont, A; Green, E; Haller, DG; McCleary, NJ; Meyerhardt, JA; O'Connell, M; Saltz, LB; Sargent, DJ; Twelves, CJ; Van Cutsem, E; Yothers, G | 1 |
| Cheng, H; Cream, LV; Drabick, JJ; El-Deiry, WS; Gallant, JN; Harouaka, R; Harvey, HA; Kumar, SM; Kunkel, M; Lamparella, NE; Matthew, EM; Robertson, GP; Truica, CI; Yang, Z; Zheng, S | 1 |
| Guan, W; Liu, B; Qian, X; Shen, J; Wang, H; Wei, J; Yu, L; Yue, G; Zou, Z | 1 |
| Biasco, G; Brandi, G; de Rosa, F; Derenzini, E; Di Girolamo, S; Ercolani, G; Falcone, A; Grazi, GL; Loupakis, F; Masi, G; Pantaleo, MA; Pietrabissa, A; Pinna, AD | 1 |
| Alvarez Suarez, S; Blanco Codeidido, M; García Alfonso, P; López Martín, P; Martin, M; Mondejar Solis, R; Muñoz Martin, A; Tapia Rico, G | 1 |
| Boers-Sonderen, MJ; Desar, IM; Koopman, M; Punt, CJ; van Herpen, CM | 1 |
| Bains, MS; Gerber, N; Goodman, KA; Ilson, DH; Janjigian, YY; Kelsen, DP; Rizk, N; Rusch, VW; Wu, AJ; Zhang, Z; Zheng, J | 1 |
| Alberts, SR; Blanke, CD; Cassidy, J; Cheung, WY; Kerr, DJ; Meyers, J; O'Connell, M; Sargent, DJ; Shi, Q; Van Cutsem, E; Yothers, G | 1 |
| Del Bene, F; Germani, M; Magni, P; Terranova, N | 1 |
| Brezault, C; Chaussade, S; Coriat, R; Dhooge, M; Dréanic, J; Goldwasser, F; Maillet, M; Mir, O | 2 |
| Ge, FJ; Lin, L; Liu, ZY; Sharma, MR; Wang, Y; Xu, JM | 1 |
| De Marchis, ML; Ferroni, P; Formica, V; Guadagni, F; La Farina, F; Laudisi, A; Ludovici, G; Palmirotta, R; Peeters, M; Rolfo, C; Roselli, M; Russo, A | 1 |
| Katayama, K; Nishino, T; Okitsu, H; Okitsu, N; Takahashi, Y; Tanaka, T | 1 |
| Fujiyama, Y; Kaneko, H; Kikuchi, M; Kinoshita, S; Nishizawa, T; Sakuno, T; Suzuki, H; Takahashi, M | 1 |
| Fujitani, K | 1 |
| Amagai, K; Boku, N; Denda, T; Fujita, Y; Hamamoto, Y; Kawai, H; Konishi, K; Mizusawa, J; Nakamura, K; Nishina, T; Nishisaki, H; Ohkawa, S; Ohtsu, A; Takashima, A; Tsuji, A; Tsuji, Y; Yamada, Y; Yamaguchi, K | 1 |
| Chen, H; Deng, X; Jin, J; Li, H; Peng, C; Shen, B; Zhan, Q; Zhang, X | 1 |
| Baek, SK; Kim, HJ; Kim, HS; Kim, SY; Kim, TY; Lee, KW; Nam, BH; Ryu, MH; Zang, DY | 1 |
| Bahary, N; Boone, BA; Gibson, MK; Krasinskas, AM; Lembersky, BC; Steve, J; Stoller, RG; Zeh, HJ; Zureikat, AH | 1 |
| Goi, T; Katayama, K; Koneri, K; Sawai, K; Yamaguchi, A | 1 |
| Bray, C; Celik, I; Chang, SC; Denne, J; Green, G; Harbison, C; Horak, C; Khambata-Ford, S; Van Cutsem, E; Zhao, L | 1 |
| Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Mattia, E; Dreussi, E; Polesel, J; Toffoli, G; Zagonel, V | 1 |
| Ando, H; Fujita, Y; Hamamoto, Y; Hazama, S; Hinoda, Y; Inoue, Y; Kanekiyo, S; Kato, T; Kobayashi, M; Mishima, H; Nagata, N; Nozawa, H; Oba, K; Oka, M; Okayama, N; Okuyama, Y; Sakamoto, J; Takahashi, K; Takemoto, H; Tsunedomi, R | 1 |
| Alvarez, E; Campos, B; Candamio, S; Casal, J; Gallardo, E; Grande, C; Mel, JR; París Bouzas, L; Quintero, G; Villanueva, MJ | 1 |
| Alameddine, R; Mukherji, D; Shamseddine, A; Temraz, S | 1 |
| Beeke, C; Bishnoi, S; Karapetis, CS; Maddern, G; Padbury, R; Padman, S; Price, TJ; Townsend, AR | 1 |
| Dasanu, CA; Joseph, R | 1 |
| Ames, MM; Erlichman, C; Goetz, MP; Goldberg, RM; Grothey, AA; Kuffel, MA; Mandrekar, SJ; McGovern, RM; McKean, HA; McWilliams, R; Reid, JM; Safgren, SL; Tan, AD | 1 |
| Cereda, V; di Bari, MG; Ferroni, P; Formica, V; Grenga, I; Guadagni, F; Raffaele, P; Roselli, M; Tesauro, M | 1 |
| Guren, T; Ikdahl, T; Kjersem, JB; Kure, EH; Lingjaerde, OC; Tveit, KM | 1 |
| Baba, H; Chika, N; Fukuchi, M; Hatano, S; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Matsuzawa, T; Mochiki, E; Okada, N; Tajima, Y; Yokoyama, M | 1 |
| Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA | 1 |
| Brutcher, E; Chen, Z; El-Rayes, BF; Hawk, N; Kauh, J; Kim, S; Kooby, DA; Landry, J; Mahaseth, H; Maithel, SK | 1 |
| Boku, N; Fukuda, H; Kato, K; Mizusawa, J; Nakamura, K; Ohtsu, A; Shimada, Y; Shirao, K; Takashima, A | 1 |
| Ikehata, M; Iwakawa, S; Ogawa, M; Tanaka, S; Ueda, K; Yamada, Y | 1 |
| Dong, S; Qi, B; Qu, H; Tang, N; Tong, X; Wang, L; Yu, B; Yu, M; Zhang, C; Zhang, N | 1 |
| Ba, Y; Bai, YX; Deng, T; Han, Y; Li, YH; Liu, XJ; Wang, Y; Xu, JM; Zhang, L | 1 |
| Albert-Mari, A; Jimenez-Torres, NV; Ruiz-Millo, O; Sendra-Garcia, A | 1 |
| Baek, JY; Chang, HJ; Kim, DY; Kim, MJ; Kim, SY; Kim, TH; Lee, SU; Oh, JH; Park, JW | 1 |
| Boku, N; Esaki, T; Fujitani, K; Hamamoto, Y; Hironaka, S; Hyodo, I; Morita, S; Moriwaki, T; Nagase, M; Nishina, T; Okamoto, I; Shimodaira, H; Sugimoto, N; Tokunaga, S; Tsuda, M; Tsumura, T; Ueda, S; Ura, T; Yamaguchi, K; Yasui, H | 1 |
| Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W | 1 |
| Giessen, C; Heinemann, V; Laubender, RP; Modest, DP; Quietzsch, D; Schalhorn, A; Schulz, C; Stintzing, S; Vehling-Kaiser, U; von Einem, JC; von Weikersthal, LF | 1 |
| Duffy, AG; Greten, TF | 1 |
| Ando, T; Fujinami, H; Horikawa, N; Hosokawa, A; Kajiura, S; Kobayashi, T; Mihara, H; Minemura, M; Nishikawa, J; Note, M; Ogawa, K; Sugiyama, T; Terada, M; Ueda, A; Yabushita, K; Yoshita, H | 1 |
| Lenz, HJ; Stintzing, S | 1 |
| Benson, AB; Bertagnolli, MM; Fuchs, CS; Goldberg, RM; Hantel, A; Imamura, Y; Liao, X; Mayer, RJ; McCleary, NJ; Meyerhardt, JA; Mowat, RB; Ng, K; Niedzwiecki, D; Ogino, S; Saltz, LB; Spiegelman, D; Whittom, R; Yamauchi, M | 1 |
| Bezan, A; Greil, R; Hauser-Kronberger, C; Hohla, F; Hopfinger, G; Rinnerthaler, G; Romeder, F; Stättner, S; Ulmer, H | 1 |
| Ferry, D; Fournier, M; Gebski, V; Gordon, S; Karapetis, CS; Price, TJ; Ransom, D; Simes, RJ; Tebbutt, N; Wilson, K; Yip, D | 1 |
| Besznyák, I; Bursics, A; Dede, K; Fekete, A; Kőszegi, G; Láng, I; Mersich, T; Mester, G; Pörneczi, B | 1 |
| Jiang, W; Li, Y; Liu, J; Ma, D; Yang, D | 1 |
| Borg, C; Cléau, D; Curtit, E; Demarchi, M; Dobi, E; Fratte, S; Guiu, B; Heyd, B; Jary, M; Kim, S; Lakkis, Z; Lamfichekh, N; Monnien, F; Nerich, V; Nguyen, T | 1 |
| Iwanaga, T; Iwasaki, Y; Karasawa, K; Kawasaki, K; Maeda, Y; Oohinata, R; Yajima, K; Yuu, K | 1 |
| Dasanu, CA; Nandy, N | 1 |
| Cho, YB; Chun, HK; Huh, JW; Kim, HC; Lee, WY; Park, YA; Yun, SH | 1 |
| Berthou, J; Bichard, D; Borg, C; Facy, O; Ghiringhelli, F; Heyd, B; Ladoire, S; Lakkis, Z; Limat, S; Lorgis, V; Nerich, V; Orry, D; Ortega-Deballon, P; Rat, P; Vincent, J | 1 |
| Aparicio, T; Breysacher, G; Chapet, S; Dousset, B; Faroux, R; Jouve, JL; Maillard, E; Martel-Lafay, I; Michel, P; Mornex, F; Nguyen, S; Pere-Verge, D; Pezet, D; Seitz, JF; Sobhani, I | 1 |
| Gervaz, P; Mentha, G; Morel, P; Naiken, SP; Roth, A; Rubbia-Brandt, L; Thomopoulos, T; Toso, C | 1 |
| Hwang, JH; Kim, DU; Kim, YT; Lee, MG; Lee, SH; Lee, SJ; Lee, YS; Ryu, JK; Woo, SM | 1 |
| Guo, Y; Shen, X; Shi, M; Yang, C; Yang, L; Zhang, J | 1 |
| Chang, SF; Hu, HM; Huang, CM; Huang, CW; Huang, ML; Huang, MY; Lu, CY; Tsai, HL; Wang, JY; Yu, FJ | 1 |
| Kim, JH; Kim, SE; Ku, KH; Moon, W; Park, MI; Park, SJ; Song, SE | 1 |
| Aster, RH; Curtis, BR; George, JN; Mirtsching, BC | 1 |
| Akashi, K; Ariyama, H; Baba, E; Ijichi, K; Komoda, M; Kubo, N; Kusaba, H; Tamura, S; Tsuchihashi, K; Uchino, K | 1 |
| Buonadonna, A; Caggiari, L; Cecchin, E; D' Andrea, M; De Re, V; De Zorzi, M; Innocenti, F; Racanelli, V; Talamini, R; Toffoli, G; Zagonel, V | 1 |
| Beau, J; Innominato, PF; Iurisci, I; Karaboue, A; Lévi, F; Madrid, JA; Moreau, T; Ortiz-Tudela, E; Rol, MA | 1 |
| Abrams, TA; Fuchs, CS; Meyer, G; Meyerhardt, JA; Moloney, J; Schrag, D | 1 |
| Endo, S; Hirai, S; Hirose, M; Hyodo, I; Saito, R; Suzuki, H; Ueno, T; Yamato, K | 1 |
| Andrade, AC; Barrios, CH; Chinen, RN; Correa, M; Coutinho, AK; del Giglio, A; Dutra, C; Forones, NM; Hoff, PM; Passos, VQ; Portella, Mdo S; Saragiotto, DF; van Eyll, B | 1 |
| Álvarez, R; Cubillo, A; de Vicente, E; García, E; Hernando, O; Hidalgo, M; López-Ríos, F; Perea, S; Plaza, C; Quijano, Y; Rodriguez-Pascual, J; Rubio, C; Sanchez, G | 1 |
| Gao, Y; Liu, M; Xiao, L | 1 |
| Bitzer, M; König, C; Malek, NP; Plentz, RR; Schempf, U; Sipos, B | 1 |
| Colussi, O; Landi, B; Lepère, C; Pernot, S; Portal, A; Rougier, P; Siauve, N; Taieb, J; Verrière, B; Zaanan, A | 1 |
| Altundag, K; Babacan, T; Balakan, O; Dag, MS; Dilli, I; Turkbeyler, IH | 1 |
| Christians, KK; Erickson, B; Evans, DB; George, B; Kelly, T; Mahmoud, A; Ritch, P; Thomas, JP; Tsai, S; Wang, H; Wiebe, L | 1 |
| Ando, Y; Fujii, T; Fujiwara, M; Hayashi, N; Kanda, M; Kobayashi, D; Kodera, Y; Koike, M; Mashita, N; Nakayama, G; Nomoto, S; Sugimoto, H; Tanaka, C; Uehara, K; Yamada, S | 1 |
| Bertaut, A; Ghiringhelli, F; Ladoire, S; Lorgis, V; Rambach, L; Vincent, J | 1 |
| Baba, H; Baba, Y; Etoh, K; Ishimoto, T; Iwagami, S; Iwatsuki, M; Miyamoto, Y; Murata, A; Sakamoto, Y; Shigaki, H; Sugihara, H; Watanabe, M; Yoshida, N | 1 |
| Glimelius, B; Gubanski, M; Lind, PA | 1 |
| Allen, PJ; Capanu, M; Cercek, A; Chou, JF; Correa-Gallego, C; DeMatteo, RP; DʼAngelica, MI; Fong, Y; Gewirtz, AN; Jarnagin, WR; Kemeny, N; Kingham, TP; Paty, PB | 1 |
| Boku, N; Fukase, K; Goto, M; Koizumi, W; Mizusawa, J; Nishina, T; Ohtsu, A; Takahari, D; Takashima, A; Tamura, T; Tsuji, A; Yamada, Y; Yamaguchi, K; Yamazaki, K; Yoshino, T | 1 |
| Chan, GL; Gao, J; Han, W; Qian, L; Wang, X; Wu, M; Yu, Y; Zhang, Y; Zhu, S | 1 |
| Bi, F; Cao, D; Chen, Y; Li, Q; Qiu, M | 1 |
| Bando, H; Fukunaga, M; Hazama, S; Iwamoto, S; Kato, T; Matsuda, C; Mishima, H; Miyake, Y; Oba, K; Sakamoto, J | 1 |
| Arai, T; Goto, A; Hamaguchi, T; Muro, K; Sasaki, Y; Shimada, Y; Shirao, K; Ura, T; Yamada, Y | 1 |
| Gillmore, R; Suarez Martinez-Falero, B | 1 |
| Cao, W; Cheng, C; Huo, BL; Wang, YH; Zhang, E | 1 |
| Chang, ZW; Dong, L; Han, ZF; Li, J; Lou, XP; Lu, P; Miao, JH | 1 |
| Bowers, M; Bridgewater, J; Butler, R; Cunningham, D; Dixon, E; Falk, S; Finch-Jones, M; Garden, OJ; Hickish, T; Hornbuckle, J; Iveson, T; Little, L; Maughan, T; O'Reilly, D; Peterson, M; Primrose, J; Pugh, S; Rees, M; Siriwardena, A; Stanton, L; Valle, J | 1 |
| Blaszkowsky, LS; Cashavelly, BJ; Kim, CY; Penson, RT; Riley, JP; Ryan, DP; Schapira, L; Wold, MC | 1 |
| Jensen, BV; Larsen, FO; Nielsen, DL; Palshof, JA; Pfeiffer, P | 1 |
| Doherty, GA; Lee, CS; Ryan, EJ | 1 |
| Abal, M; Barbazán, J; Candamio, S; Cano, A; Casares de Cal, Mde L; Díaz-López, A; Gómez-Tato, A; López-López, R; Muinelo-Romay, L; Vieito, M | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Alexander, HR; Culpepper, WJ; El-Kamary, SS; Jiang, Y; Lane, BF; Mindikoglu, AL; Reddy, SK; Reilly, C; Zhan, M | 1 |
| Arao, T; Hamaguchi, T; Hayashi, H; Hirashima, Y; Honma, Y; Horita, Y; Iwasa, S; Kato, K; Kimura, H; Matsumoto, K; Nakagawa, K; Nishio, K; Okita, NT; Shimada, Y; Takashima, A; Togashi, Y; Yamada, Y | 1 |
| Kræmer, PC; Ladekarl, M; Schmidt, HH | 1 |
| Inaba, T; Ishida, K; Kashiwaba, M; Kawagishi, R; Komatsu, H; Matsui, Y; Sugai, T; Uesugi, N; Wakabayashi, G | 1 |
| Chung, HY; Kang, BW; Kim, JG; Kwon, OK; Yu, W | 1 |
| Bertagnolli, MM; Dzieciatkowski, S; Emond, MJ; Foster, NR; Goldberg, RM; Grady, WM; Lao, VV; Luo, Y; Maizels, N; Monnat, RJ; Nam, E; Niedzwiecki, D; Renfro, LA; Saltz, LB; Shiovitz, S; Venook, A; Warren, RS | 1 |
| Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ | 1 |
| Bergamo, F; De Paoli, A; De Salvo, GL; Di Grazia, L; Esposito, G; Griguolo, G; Indraccolo, S; Lonardi, S; Mescoli, C; Nardin, M; Rugge, M; Zagonel, V; Zulato, E | 1 |
| Konno, F; Matsumoto, H; Mitsui, K; Namiki, K; Takahashi, T; Yoshida, R | 1 |
| Ema, A; Naito, M; Nakamura, T; Sato, T; Watanabe, M; Yamashita, K | 1 |
| Boku, N; Furuse, J; Ishido, K; Kasuga, A; Machida, N; Morizane, C; Nishina, T; Okusaka, T; Sudo, K; Takahashi, H; Tobimatsu, K; Yamaguchi, T | 1 |
| Bang, S; Chung, JB; Chung, MJ; Jo, JH; Park, JY; Park, SW; Song, SY | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, IV; Can, A; Coban, E; Demir, L; Dirican, A; Erten, C; Koyuncu, B; Kucukzeybek, Y; Somali, I; Tarhan, MO; Varol, U; Yildiz, Y | 1 |
| Hong, SM; Ihn, MH; Kang, SB; Kim, DW; Lee, SY; Oh, HK | 1 |
| Aoki, T; Fukayama, M; Hamada, T; Hasegawa, K; Isayama, H; Koike, K; Kokudo, N; Morikawa, T; Nakai, Y; Sakamoto, Y; Sasaki, T; Tanaka, M | 1 |
| Chaix, M; Ghiringhelli, F; Lorgis, V; Vincent, J | 1 |
| Bachet, JB; Blanc, JF; Carbonnel, F; Coriat, R; Cueff, A; De La Fouchardière, C; Francois, E; Gauthier, M; Lécaille, C; Malka, D; Manfredi, S; Marthey, L; Sa-Cunha, A; Solub, D; Taieb, J; Terrebonne, E; Thirot Bidault, A; Trouilloud, I | 1 |
| Ehninger, G; Folprecht, G; Hamann, S; Schütte, K; Stoehlmacher-Williams, J; Trarbach, T | 1 |
| Blackmon, SH; Correa, AM; Eng, C; Kee, B; Subbiah, IM; Swisher, SG; Vaporciyan, AA | 1 |
| Anantha, M; Bally, MB; Harasym, N; Manisali, I; Masin, D; Osooly, M; Ostlund, C; Santos, ND; Strutt, D; Sutherland, BW; Waterhouse, DN; Webb, MS; Wehbe, M | 1 |
| Chang, BW; Johung, KL; Saif, MW | 1 |
| Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H | 1 |
| Hirakawa, K; Ikeya, T; Maeda, K; Nagahara, H; Ohtani, H; Shibutani, M; Sugano, K | 1 |
| Melichar, B; Mohelnikova-Duchonova, B; Soucek, P | 1 |
| Liu, X; Xu, W | 1 |
| Bišof, V; Dedić Plavetić, N; Krpan, AM; Ozretić, D; Rakušić, Z; Simetić, L | 1 |
| Cereda, V; Cunningham, D; Ferroni, P; Formica, V; Guadagni, F; Luccchetti, J; Nardecchia, A; Roselli, M; Smyth, EC; Tesauro, M | 1 |
| Kasperczyk, S; Malinowska-Borowska, J; Nowak, P; Rogalska, A; Świętochowska, E; Słomian, G | 1 |
| Guo, B; Liu, J; Song, L; Wu, J; Zhao, DY | 1 |
| Tong, Y; Zheng, Y; Zhou, J | 1 |
| Akiyama, S; Arima, K; Chen, ZS; Furukawa, T; Horikuchi, F; Kamijo, Y; Kawahara, K; Minami, K; Nakagawa, M; Nishizawa, Y; Seki, N; Shinsato, Y; Tabata, S; Tachiwada, T; Takeda, Y; Tsujikawa, K; Yamamoto, M | 1 |
| Papadatos-Pastos, D; Rabbie, R; Ross, P; Sarker, D; Thillai, K | 1 |
| Elvin, P; Gallick, G; Jiang, ZQ; Kopetz, S; Maru, D; Morris, VK; Overman, MJ; Parikh, N | 1 |
| Bauer, S; Formentini, A; Galle, PR; Hoffman, A; Kittner, JM; Kornmann, M; Link, KH; Maderer, A; Moehler, M; Neumann, W; Rey, JW; Schad, A; Schwarz, M; Thomaidis, T; Trautmann, M; Weinmann, A | 1 |
| Goto, A; Hamamoto, Y; Morita, S; Nakajima, T; Nakayama, N; Nishina, T; Sakamoto, J; Shimada, K; Ura, T; Yamada, Y; Yamaguchi, T; Yamazaki, K | 1 |
| André, T; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Boucher, E; Etienne, PL; Gornet, JM; Guimbaud, R; Hammel, P; Louvet, C; Maillard, E; Nguyen, S; Rebischung, C; Ries, P; Rougier, P; Ychou, M | 1 |
| Boucher, E; Boudjema, K; Hénno, S; Le Prisé, E; Levi Sandri, GB; Meunier, B; Sulpice, L; Turner, K | 1 |
| Arnold, D; Boxberger, F; Herrenberger, J; Hinke, A; Hoeffkes, HG; Kutscheidt, A; Leutgeb, B; Petersen, V; Schroeder, J; Schulze, M; Seraphin, J; Stein, A; Valdix, AR | 1 |
| Bertagnolli, MM; Caracol, A; Emond, M; Foster, NR; Goldberg, RM; Grady, WB; Lao, VV; Maizels, N; Monnat, RJ; Niedzwiecki, D; Pavelitz, T; Rabinovitch, PS; Renfro, L; Saltz, LB; Welsch, P | 1 |
| Ba, Y; Chen, Y; Deng, T; He, Y; Li, W; Liu, R; Ren, L; Wang, X; Ying, G; Zhou, L; Zuo, D | 1 |
| Kirstein, MM; Kubicka, S; Lange, A; Manns, MP; Prenzler, A; Vogel, A | 1 |
| Goldberg, RM; Gray, E; Karrison, TG; Sargent, DJ; Sharma, MR | 1 |
| Cheng, L; Jia, J; Li, Q; Tu, L; Wang, X; Yan, D; Zheng, X | 1 |
| Bekaii-Saab, T; Blazer, M; Bloomston, M; Ellison, EC; Goldberg, RM; Muscarella, P; Phillips, G; Reardon, J; Schmidt, C; Williams, TM; Wu, C; Wuthrick, E | 1 |
| Brunner, S; Camenisch Gross, U; Cathomas, R; Freyholdt, T; Mey, U; von Moos, R | 1 |
| Bae, KS; Hong, YS; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG | 1 |
| Benson, AB; Chan, AT; Chan, JA; Fuchs, CS; Giovannucci, EL; Goldberg, RM; Hantel, A; Mayer, RJ; Meyerhardt, JA; Ng, K; Niedzwiecki, D; Ogino, S; Saltz, LB; Sato, K; Schaefer, PL; Venook, AP; Whittom, R | 1 |
| Chau, I; Cunningham, D; Khan, K; Moorcraft, SY; Peckitt, C; Rao, S; Watkins, D | 1 |
| Anne, PR; Erickson, BA; Haddock, M; Kachnic, LA; Lee, RJ; Meropol, NJ; Mitchell, EP; Moughan, J; Pollock, J; Rashid, A; Watson, JC; Willett, CG; Wong, SJ | 1 |
| Aparicio, T; Artru, P; Asnacios, A; Bonnetain, F; Dubreuil, O; Dupont-Gossard, AC; Fein, F; Gauthier, M; Landi, B; Lecomte, T; Lobry, C; Malka, D; Manet-Lacombe, S; Taïeb, J; Thirot-Bidault, A; Trouilloud, I; Zaanan, A | 1 |
| Arnold, D; Bhargava, P; Chevalier, S; Cunningham, D; Ferry, DR; Hoff, PM; Lakomỳ, R; Macarulla, T; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Schmoll, HJ; Ten Tije, AJ; Van Cutsem, E; Van Hazel, GA; Vishwanath, RL | 1 |
| Anantha, M; Bally, MB; Gill, N; Karim, T; Neijzen, R; Ng, SS; Strutt, D; Tai, IT; Wang, H; Waterhouse, D; Wong, MQ; Yapp, DT | 1 |
| Akinwande, O; Hayes, D; Martin, RC; Miller, A; O'Hara, R; Tomalty, D | 1 |
| Calkins, SM; Cinar, P; Kelley, RK; Venook, AP | 1 |
| Chen, Z; Guo, W; Li, J; Li, W; Liu, T; Shen, L; Xu, J; Zhang, W; Zhu, X | 1 |
| Cao, J; Ding, HH; Ji, ZY; Jiang, T; Jin, JH; Song, WF; Wang, JJ; Wang, LW; Wu, WD | 1 |
| Adam, R; Bridgewater, J; Chau, I; García Alfonso, P; Gruenberger, T; Hermann, F; Lasserre, S; Mudan, S; Rivoire, M; Waterkamp, D | 1 |
| Furuhata, T; Hayashi, T; Hirakawa, M; Hirata, K; Iyama, S; Kato, J; Kawano, Y; Kobune, M; Miyanishi, K; Mizuguchi, T; Murase, K; Ohnuma, H; Okagawa, Y; Okita, K; Osuga, T; Sato, T; Sato, Y; Takada, K; Takahashi, M; Takimoto, R | 1 |
| Beaty, K; Choe, JH; Eng, C; Fournier, KF; Mansfield, PF; Ohinata, A; Overman, MJ; Phillips, JK; Rafeeq, S; Royal, RE; Wolff, RA | 1 |
| Baroian, N; Buchner, P; Czejka, M; Dittrich, C; Sahmanovic, A; Schreiber, V | 1 |
| Allen, JN; Blaszkowsky, LS; Clark, JW; Deshpande, V; Faris, JE; Fernández-del Castillo, C; Ferrone, CR; Goyal, L; Hong, TS; Kwak, EL; Lillemoe, KD; Marchegiani, G; McDonnell, EI; Murphy, JE; Ryan, DP; Sabbatino, F; Santos, DD; Ting, DT; Warshaw, AL; Wo, JY; Zhu, AX | 1 |
| Erickson, BA; Evans, DB; Ritch, PS | 1 |
| Anchisi, S; Baertschi, D; Betticher, DC; Borner, M; Brauchli, P; Dietrich, D; Frueh, M; Herrmann, R; Hess, V; Koeberle, D; Kollar, A; Kueng, M; Matter, K; Moosmann, P; Popescu, RA; Roth, A; Saletti, P; Schacher, S; von Moos, R; Winterhalder, R | 1 |
| Nygren, P | 1 |
| Choi, DR; Choi, YK; Han, B; Kim, BC; Kim, HS; Kim, JB; Kim, JH; Kim, KY; Song, HH; Yoon, SN; Zang, DY | 1 |
| Aitini, E; Bajetta, E; Barni, S; Bertolini, A; Ciarlo, A; Di Bartolomeo, M; Dotti, KF; Iacovelli, R; Maggi, C; Perrone, F; Pietrantonio, F; Verusio, C | 1 |
| Dropkin, E; Strickler, JH; Strosberg, JR; Zhu, J | 1 |
| Ashcroft, L; Backen, A; Beech, J; Chau, I; Dive, C; Gollins, S; Hasan, J; Krebs, MG; Morris, K; Renehan, AG; Saunders, MP; Valle, JW | 1 |
| Herman, JM; Katz, MH; Marsh, Rde W; Talamonti, MS | 1 |
| Cho, JM; Go, SI; Jeon, KN; Kang, JH; Kang, MH; Kim, HG; Kim, MJ; Lee, A; Lee, GW; Lee, JH; Lee, US; Lee, WS | 1 |
| Bengrine, L; Ghiringhelli, F; Guion-Dusserre, JF; Lorgis, V; Vincent, J | 1 |
| André, T; Buyse, M; Delbaldo, C; Douillard, JY; Dupuis, O; Faroux, R; Guerin-Meyer, V; Jouhaud, A; Piedbois, P; Quinaux, E; Rougier, P; Ychou, M; Zawadi, A | 1 |
| Hoffmann, OI; Ilmberger, C; Jauch, KW; Joka, M; Magosch, S; Mayer, B | 1 |
| Nakagawa, F; Nukatsuka, M; Saito, H; Sakata, M; Takechi, T; Uchida, J | 1 |
| Aldrighetti, L; Cipriani, F; Ferrero, A; Langella, S; Ratti, F; Russolillo, N; Viganò, L | 1 |
| Kang, MH; Kim, JH; Kim, JW; Lee, HS; Lee, JS; Lee, KW; Moon, SU; Sung, JH | 1 |
| Hassan, AS; Naicker, M; Wan Ishak, WZ; Yusof, KH | 1 |
| Ise, Y; Kitagawa, C; Saka, H | 1 |
| Berk, V; Bozkurt, O; Duran, AO; Elmali, F; Inanc, M; Karaca, H; Ozaslan, E; Ozkan, M; Ucar, M | 1 |
| Gruenberger, B; Gruenberger, T; Singh, J; Starlinger, P; Stift, J; Stremitzer, S; Tamandl, D | 1 |
| Aitini, E; Barni, S; Borgonovo, K; Cabiddu, M; Coinu, A; Ghilardi, M; Lonati, V; Petrelli, F | 1 |
| Hu, XL; Li, BL; Sun, HG; Zhang, Y; Zhao, XH; Zhou, CY | 1 |
| Bencsikova, B; Bortlicek, Z; Dusek, L; Halamkova, J; Kiss, I; Melichar, B; Ostrizkova, L; Pavlik, T; Valik, D; Vyzula, R; Zdrazilova-Dubska, L | 1 |
| André, T; Ball, DE; Bapat, B; Kaye, JA; Smyth, EN | 1 |
| Bonetti, A; Giuliani, J; Piacentini, P | 1 |
| Addeo, A; Bini, R; Comelli, S; Leli, R; Savio, D; Vana, F; Vaudano, GP; Viora, T | 1 |
| Baba, H; Denda, T; Hata, T; Ina, K; Inukai, M; Iwamoto, S; Kato, T; Kunieda, K; Kurachi, K; Mishima, H; Morita, Y; Munemoto, Y; Nagata, N; Nakamura, M; Oba, K; Ooshiro, M; Sakamoto, J; Shimoyama, T; Takahashi, T; Tamagawa, H | 1 |
| Bateman, E; Keefe, D; Mayo, B; Stringer, A; Thorpe, D; Vanhoecke, B; Vanlancker, E | 1 |
| Ayez, N; Eggermont, AM; Grünhagen, DJ; Rothbarth, J; van der Stok, EP; van Meerten, E; Verhoef, C | 1 |
| Cline-Burkhardt, M; Cohn, A; Dakhil, S; Go, WY; Hecht, JR; Piperdi, B; Saleh, M; Tian, Y | 1 |
| Gao, SR; Li, LM; Wang, AR; Wang, GM; Xia, HP; Xu, HY | 1 |
| Dancour, A; David, EB; Domb, A; Eliakim, R; Gabai, RM; Galun, E; Golan, T; Goldes, Y; Goldin, E; Harari, G; Hen, N; Hubert, A; Khvalevsky, EZ; Kopleman, Y; Lahav, M; Raskin, S; Segal, A; Shemi, A | 1 |
| Goldstein, SR; Hierro, LC; O'Dwyer, PJ; Selvakumaran, M; Vasilevskaya, IA; Winkler, JD | 1 |
| Babel, I; Capello, M; Fleming, JB; Hanash, SM; Katz, MH; Lee, M; Maitra, A; Taguchi, A; Tian, W; Wang, H | 1 |
| Antoch, G; Graf, D; Häussinger, D; Knoefel, WT; Kröpil, P; Riemer, J; Schneitler, S | 1 |
| Ayadi, M; Bouygues, A; Chouaib, S; Ferrand, N; Larsen, AK; Muchardt, C; Ouaret, D; Sabbah, M; Thiery, JP | 1 |
| Kang, WK; Kim, ST; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Abramova, NA; Dvadnenko, KV; Kit, OI; Vladimirova, LY; Vodolazhskiy, DI | 1 |
| Butzke, B; Giessen-Jung, C; Heinemann, V; Oduncu, FS; Pfeufer, A; Rogowski, WH; Severin, F; Stollenwerk, B | 1 |
| Aparicio, T; Des Guetz, G; Landre, T; Mary, F; Nicolas, P; Taleb, C; Uzzan, B; Zelek, L | 1 |
| Bai, L; Han, C; Jiao, S; Li, J; Su, D; Wang, Y; Zhang, T | 1 |
| Matsusaka, S; Mizunuma, N; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M; Yamaguchi, T | 1 |
| Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M | 1 |
| Artru, P; Chalabreysse, P; Desramé, J; Lledo, G; Marsot, J; Mithieux, F; Pellerin, O; Pernot, S; Taieb, J; Watkin, E | 1 |
| Kapesa, L; Liu, W; Ma, J; Shen, H; Zeng, M; Zeng, S; Zhang, Y | 1 |
| Crocenzi, TS; Garcia-Monaco, RD; Kelly, LR; Laing, CJ; Martin, RC; Rilling, WS; Schreeder, M; Scoggins, CR; Sharma, VR; Strasberg, SM; Tatum, CM | 1 |
| Cheung, WY; Gill, S; Ho, MY; Kennecke, HF; Lim, HJ; Renouf, DJ | 1 |
| Hasegawa, Y; Nitta, H; Sasaki, A; Takahara, T; Umemura, A; Wakabayashi, G | 1 |
| Andréasson, H; Bjersand, K; Graf, W; Larsson, R; Mahteme, H; Nygren, P; Sundström Poromaa, I | 1 |
| Holcombe, RF; Planoutene, MV; Planoutis, KS; Planutis, AK | 1 |
| Chan, MT; Li, Z; Wu, WK; Yu, J; Yu, X | 1 |
| Dartigues, P | 1 |
| Goto, A; Ichikawa, Y; Iwasa, S; Kato, K; Matsumoto, H; Nagashima, K; Okita, NT; Shimada, Y; Yamada, Y; Yamaguchi, T; Yasui, H | 1 |
| Jiang, JL; Liu, Y; Ma, T; Xi, WQ; Yang, C; Ye, ZB; Zhang, J; Zhou, CF; Zhu, ZG | 1 |
| André, T; Bennouna, J; Borg, C; Bouché, O; Jary, M; Kim, S | 1 |
| Chang, GJ; Crane, CH; Das, P; Feig, BW; Krishnan, S; Minsky, BD; Rashid, A; Skibber, JM; Voong, KR; Wolff, RA; Yao, JC | 1 |
| Chung, KH; Jang, DK; Kim, YT; Lee, BS; Lee, SH; Ryu, JK | 1 |
| Bachet, JB; Blanc, JF; Coriat, R; Cunha, AS; Hentic, O; Innominato, P; Laurent, C; Marthey, L; Pietrasz, D; Raoul, JL; Regenet, N; Taieb, J; Terrebonne, E; Trouilloud, I; Turrini, O; Wagner, M | 1 |
| Chan, DL; Karapetis, CS; Pavlakis, N; Price, TJ; Segelov, E; Shapiro, J; Tebbutt, NC | 1 |
| Cheng, PC; Kuo, MY; Lai, JK; Liang, KH; Liao, MY; Lin, CW; Lu, RM; Wu, HC | 1 |
| Jabbar, AA; Zahir, MN | 1 |
| Ágoston, EI; Baranyai, Z; Bodoky, G; Bursics, A; Dede, K; Harsányi, L; Kulka, J; Szász, AM | 1 |
| Atanackovic, D; Bluemner, E; Bokemeyer, C; Brugger, W; Hapke, G; Hildebrandt, B; Illerhaus, G; Steffens, CC; Stein, A; Stöhlmacher, J; Stübs, P | 1 |
| Allegrini, G; Antoniotti, C; Boni, L; Carlomagno, C; Cazzaniga, M; Chiara, S; Cremolini, C; D'Amico, M; Falcone, A; Fontanini, G; Granetto, C; Lonardi, S; Loupakis, F; Lupi, C; Mezi, S; Ronzoni, M; Sensi, E; Tomasello, G; Tonini, G; Zaniboni, A | 1 |
| Ciuffreda, L; Fanchini, L; Mecca, C; Pinta, F; Ponzetti, A; Racca, P; Spadi, R; Zanini, M | 1 |
| Braren, R; Erkan, M; Esposito, I; Friess, H; Holzapfel, K; Kleeff, J; Kong, B; Michalski, CW; Nitsche, U; Schlitter, AM; Siveke, JT; Stöß, C; Wenzel, P | 1 |
| Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S | 1 |
| Basu, B; Calder, J; Corrie, P; Ghorani, E; Hewitt, C; Wong, HH | 1 |
| Leung, WW; Ng, SS; To, KK | 1 |
| Amagai, K; Boku, N; Gotoh, M; Hamamoto, Y; Kawai, H; Mizusawa, J; Nakamura, K; Nakayama, N; Nishina, T; Ohtsu, A; Shimada, Y; Shirao, K; Yamaguchi, K; Yasui, H | 1 |
| Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ | 1 |
| Aravantinos, G; Gazouli, M; Isaakidou, A; Karantanos, T; Pektasides, D; Sioziou, A; Theodoropoulos, GE | 1 |
| Aprile, G; Bonotto, M; Fasola, G; Fontanella, C; Giuliani, F; Lutrino, SE; Rihawi, K | 1 |
| Adhoute, X; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Breysacher, G; Charneau, J; Chone, L; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Khemissa, F; Lavau-Denes, S; Lecomte, T; Legoux, JL; Lepère, C; Locher, C; Maillard, E; Michel, P; Mitry, E; Phelip, JM; Provençal, J; Sobhani, I | 1 |
| Beltjens, F; Bengrine, L; Ghiringhelli, F; Ladoire, S; Vincent, J | 1 |
| Kim, SH; Ku, JL; Moon, HH | 1 |
| Ban, LY; Fang, FQ; Guo, HS; Liu, JW; Yu, PY; Zhang, J | 1 |
| Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Okumura, H; Tohyama, K; Tsuruta, A | 1 |
| Han, SW; Hong, YS; Hwang, IG; Jung, SH; Kang, HJ; Kang, WK; Kim, HS; Kim, ST; Kim, TW; Lee, J; Lee, JY; Lee, KH; Lim, HY; Lim, SH; Park, JO; Park, SH; Park, YS | 1 |
| Grapsa, D; Saif, MW; Syrigos, K | 1 |
| Ao, L; Cai, H; Chi, P; Guan, Q; Guo, Y; Guo, Z; Li, M; Li, X; Lu, X; Tong, M; Yan, H; Zheng, W | 1 |
| Bartnik, CM; Flowers, CR; Goldstein, DA; Neustadter, E; Zeichner, SB | 1 |
| Blay, J; Cutler, MJ; Hajducek, DM; Lowthers, EL; Richard, CL; Spagnuolo, PA | 1 |
| Adam, R; Afshar, M; Ajavon, Y; Boige, V; Bouchahda, M; Carvalho, C; Castaing, D; De Baere, T; Ducreux, M; Focan, C; Guimbaud, R; Hebbar, M; Innominato, P; Karaboué, A; Kunstlinger, F; Lepère, C; Lévi, FA; Rougier, P; Smith, D; Truant, S; Tumolo, S | 1 |
| Ahn, JB; Baik, SH; Hong, SP; Hur, H; Jung, I; Jung, M; Keum, KC; Kim, H; Kim, NK; Kim, TI; Koom, WS; Lim, JS; Min, BS; Park, YS; Roh, JK; Shin, SJ | 1 |
| Bayever, E; Belanger, B; Blanc, JF; Bodoky, G; Braiteh, F; Chen, LT; Chiu, CF; Cunningham, D; Dean, A; Dhindsa, N; Hubner, RA; Jameson, G; Lee, KH; Li, CP; Macarulla, T; Moyo, V; Schwartsmann, G; Shan, YS; Siveke, JT; Von Hoff, DD; Wang-Gillam, A | 1 |
| Ikeda, M; Ishida, K; Kume, K; Nishizuka, SS; Shimura, T; Takemoto, K; Young, L | 1 |
| Kuppusamy, G; Praveen, TK; Satish Kumar, MN; Tummala, S; Wadhwani, A | 1 |
| Almeida, PR; Assis-Júnior, EM; Brito, GA; Lima-Júnior, RC; Melo, AT; Pereira, VB; Ribeiro, RA; Wong, DV | 1 |
| Annaratone, L; Bonin, S; Bussolati, G; Capella, C; Chiaravalli, AM; Donada, M; Hoefler, G; Nardon, E; Pichler, M; Stanta, G | 1 |
| Fukushima, M; Nukatsuka, M; Shimamoto, Y; Takechi, T | 1 |
| Allen, PJ; D'Angelica, MI; DeMatteo, RP; Do, RK; Fong, Y; Gönen, M; Groot Koerkamp, B; Jarnagin, WR; Kemeny, NE; Kingham, TP; Klimstra, DS; Konstantinidis, IT | 1 |
| Kusumi, T; Manabe, M; Miyata, Y; Mizunuma, N; Morita, Y; Taniguchi, F; Touyama, T | 1 |
| Amitesh, R; Beeke, C; Karapetis, C; Lo, L; Maddern, G; Moore, J; Padbury, R; Price, TJ; Roder, D; Townsend, AR | 1 |
| Buc, E; Chatelut, E; De la Fouchardière, C; Mendoza, C; Mineur, L; Pezet, D; Phelip, JM; Quesada, JL; Rivoire, M; Roblin, X | 1 |
| Bagalà, C; Barone, C; Basso, M; Calegari, MA; Cassano, A; Cocomazzi, A; Indellicati, G; Larocca, LM; Martini, M; Orlandi, A; Zurlo, V | 1 |
| Auzolle, C; Bonnetain, F; Bouché, O; Brieau, B; Coriat, R; Ducreux, M; Goujon, G; Lecomte, T; Marthey, L; Pozet, A; Prieux, C; Rougier, P; Soibinet, P; Taieb, J; Tougeron, D; Zaanan, A | 1 |
| Akiyama, Y; Hasuike, Y; Higuchi, I; Ishikawa, A; Miyamoto, M; Okada, A; Tanigawa, T | 1 |
| André, T; Arbaud, C; Bachet, JB; Bennamoun, M; Bonnetain, F; Brusquant, D; Chibaudel, B; de Gramont, A; Dupuis, O; Garcia, ML; Hammel, P; Khalil, A; Larsen, AK; Louvet, C; Maindrault-Gœbel, F; Tournigand, C; Wang, YW; Yeh, CG | 1 |
| Huang, CW; Lin, YW; Lu, CY; Sung, YC; Tang, HC; Tsai, HL; Wang, JH; Wang, JY; Wu, CC; Yeh, YS | 1 |
| Adachi, N; Aoyama, H; Fujibayashi, Y; Furukawa, T; Saga, T; Wakizaka, H; Yoshii, Y; Zhang, MR | 1 |
| Allen, PJ; Boucher, TM; Capanu, M; Cercek, A; Chou, JF; D'Angelica, MI; DeMatteo, RP; Fong, YC; Jarnagin, WR; Kemeny, NE | 1 |
| Itoi, T; Kamisawa, T; Takaori, K; Wood, LD | 1 |
| Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N | 1 |
| Ahn, DH; Bekaii-Saab, T; Bupathi, M; Ciombor, KK; Goldstein, DA; Reardon, J; Stephens, JA; Wu, C | 1 |
| Fujiwara, Y; Kishi, K; Motoori, M; Ohue, M; Sakon, M; Sugimura, K; Takahashi, H; Yano, M | 1 |
| Boustani, AM; Cha, CH; Chang, B; Cong, X; Deng, Y; Hochster, HS; Indukala, D; James, ES; Kortmansky, JS; Lacy, J; Li, J; Patel, V; Salem, RR; Staugaard, C; Stein, SM | 1 |
| Bai, X; Gao, S; Li, G; Liang, T; Lou, J; Ma, T; Que, R; Shen, S; Su, R; Wei, Q; Yu, R; Yuan, Y | 1 |
| Abdullah, NM; Sharial, MM; Yusof, MM; Zaatar, A | 1 |
| Lim, K; Ur Rehman, SS; Wang-Gillam, A | 1 |
| He, MM; Jin, Y; Li, YH; Li, ZZ; Luo, HY; Pan, ZZ; Qiu, MZ; Ren, C; Ren, J; Shao, JY; Wang, DS; Wang, F; Wang, FH; Wang, ZQ; Xu, RH; Zhang, DS; Zhang, ZC; Zhao, Q | 1 |
| Belt, BA; Cusworth, BM; DeNardo, DG; Fields, RC; Fowler, KJ; Goedegebuure, SP; Hawkins, WG; Lim, KH; Linehan, DC; Lockhart, AC; Nieman, RK; Nywening, TM; Panni, RZ; Sanford, DE; Strasberg, SM; Suresh, R; Tan, BR; Toriola, AT; Wang-Gillam, A; Worley, LA; Yano, M | 1 |
| Chen, H; Li, Q; Tang, R; Wen, F; Wu, Y; Zhang, J; Zhang, P; Zhao, R; Zhou, J | 1 |
| Chong, DQ; Choo, SP; Chua, C; Imperial, M; Manalo, M; Ng, M; Tan, IB; Teo, P; Yong, G | 1 |
| Atherton, PJ; Grothey, A; Loprinzi, CL; Novotny, PJ; Sloan, JA; Thanarajasingam, G | 1 |
| Endlicher, E; Gelbmann, C; Klebl, F; Kullmann, F; Messmann, H; Rogler, G; Schnoy, E; Troppmann, M | 1 |
| Chai, CY; Chien, TM; Huang, CN; Lin, CH; Lu, YM | 1 |
| Cavaglione, G; Evesque, L; Follana, P; François, E; Gal, J; Reure, J; Saint, A | 1 |
| Artaç, M; Avcı, N; Çabuk, D; Coşkun, HŞ; Dane, F; Doruk, H; Faruk Aykan, N; Karaağaç, M; Karabulut, B; Karabulut, S; Korkmaz, L; Turhal, NS | 1 |
| Bardelli, A; Bonaldi, T; Cancelliere, C; Conte, A; Cuomo, A; Di Fiore, PP; Magni, E; Penna, G; Pozzi, C; Ravenda, PS; Rescigno, M; Sigismund, S; Silvola, A; Spadoni, I; Zampino, MG | 1 |
| Barile, R; Barone, C; Basso, M; Cassano, A; D'Argento, E; Martini, M; Rossi, S; Schinzari, G; Strippoli, A | 1 |
| Bennouna, J; Cabart, M; Campion, L; Douillard, JY; Dupuis, O; Frénel, JS; Hiret, S; Ramée, JF; Senellart, H | 1 |
| Allen, P; Beumer, BR; Chau, I; Conroy, T; El-Rayes, BF; Faris, JE; Hohla, F; Hong, TS; Hosein, PJ; Koerkamp, BG; Lacy, J; Marthey, L; Mellon, EA; Moorcraft, SY; Sadot, E; Shridhar, R; Suker, M; Taieb, J; van Eijck, CH; Wang-Gillam, A | 1 |
| Bosman, F; Brunner, N; Buhl, IK; Delorenzi, M; Gerster, S; Hansen, A; Jensen, PB; Jensen, T; Knudsen, S; Roth, A; Tejpar, S | 1 |
| Chang-Claude, J; Kap, EJ; Popanda, O | 1 |
| Hu, J; Tan, X | 1 |
| Grapsa, D; Passero, FC; Saif, MW; Syrigos, KN | 1 |
| Ahmad, SA; Bekaii-Saab, T; Cardin, D; Collisson, E; Conway, W; Frankel, W; Herman, JM; Hoffman, JP; Katz, MH; Kindler, H; LoConte, N; Lowy, AM; Marsh, Rde W; Martin, R; Philip, P; Schwartz, L; Shen, P; Shi, Q; Talamonti, M; Truty, M; Venook, AP | 1 |
| Havre, RF; Kalaitzakis, E; Meisner, S; Willemoe, GL | 1 |
| Ammari, S; Antoun, S; Bayar, MA; Chemama, S; Elias, D; Goéré, D; Lanoy, E; Raynard, B; Stoclin, A | 1 |
| Pan, Z; Peng, J | 1 |
| Hamaguchi, T; Honma, Y; Ikezawa, N; Iwasa, S; Kato, K; Nagashima, K; Okita, N; Shimada, Y; Shoji, H; Takashima, A; Yamada, Y; Yamaguchi, T | 1 |
| Besselink, MG; Mohammad, NH; Molenaar, IQ; Rombouts, SJ; van Rijssen, LB; van Santvoort, HC; Vogel, JA; Walma, MS; Wilmink, JW | 1 |
| Cohen, SJ; Dotan, E; Hall, MJ; Li, T; Vijayvergia, N; Wong, YN | 1 |
| Benson, AB; Burtness, BA; Cohen, SJ; Douglas, K; Enzinger, PC; Goldberg, RM; Ilson, DH; Mayer, RJ; Niedzwiecki, D; Venook, A; Villaflor, VM; Ye, X | 1 |
| Allorge, D; Barthelemy, C; Bonnabry, P; Décaudin, B; Humbert, L; Lebecque, M; Odou, P; Pinturaud, M; Richeval, C; Sidikou, O; Simon, N; Soichot, M; Vasseur, M | 1 |
| Bouchahda, M; Chatelut, E; Etienne-Grimaldi, MC; Focan, C; Innominato, P; Karaboué, A; Lévi, F; Milano, G; Paintaud, G | 1 |
| Lee, JR; Oh, PJ | 1 |
| Ellenrieder, V; König, A; Seufferlein, T | 1 |
| Hirano, A; Hiroshima, Y; Ishida, Y; Kasahara, K; Kawaguchi, D; Kikuchi, Y; Koda, K; Kosugi, C; Matsuo, K; Mori, M; Murakami, T; Shuto, K; Tanaka, K; Yamada, M; Yamazaki, K | 1 |
| Bajenova, O; Danilova, A; Koshkin, S; O'Brien, SJ; Petrov, N; Raskin, G; Tolkunova, E; Tomilin, A | 1 |
| Chllamma, MK; Cook, N; Dhani, NC; Dodd, A; Giby, K; Hedley, DW; Knox, JJ; Moore, MJ; Wang, L | 1 |
| Brutcher, E; Cassidy, RJ; Chen, Z; El-Rayes, BF; Hawk, N; Kooby, D; Landry, J; Maithel, SK; Sarmiento, JM; Shaib, WL; Zhang, C | 1 |
| Asakiewicz, C; Braiteh, F; Chaudhary, A; Denlinger, CS; Gao, L; Lee, JJ; Lin, Y; LoRusso, P; Nasroulah, F; Shepard, DR; Wang, D | 1 |
| Byrne, A; Dean, A; Hayden, I; Marinova, M | 1 |
| Bodoky, G; Ciuleanu, T; Clingan, P; Cohn, A; Garcia Alfonso, P; Garcia-Carbonero, R; Kim, TW; Lonardi, S; Nasroulah, F; Obermannová, R; Portnoy, D; Prausová, J; Tabernero, J; Van Cutsem, E; Yamazaki, K; Yang, L; Yoshino, T | 1 |
| Anderegg, MC; Haj Mohammad, N; Mali, RMA; Ngai, LL; Ter Veer, E; van Laarhoven, HWM; van Oijen, MGH; van Valkenhoef, G | 1 |
| Crea, F; Danesi, R; De Gregorio, V; Falcone, A; Fornaro, L; Graziano, F; Loupakis, F; Masi, G; Paolicchi, E; Ricci, V; Ronzoni, M; Vivaldi, C | 1 |
| Forsgård, RA; Frias, R; Holma, R; Korpela, R; Lindén, J; Österlund, P; Spillmann, T | 1 |
| Cunha, FQ; Leite, CA; Lima-Júnior, RC; Mota, JM; Ribeiro, RA; Souza, MH; Wanderley, CW; Wong, DV | 1 |
| Caparello, C; Falcone, A; Funel, N; Garajova, I; Giovannetti, E; Kazemier, G; Le Large, TY; Meijer, LL; Peters, GJ; Vasile, E | 1 |
| Blanc, JF; Carrato, A; Ciardiello, F; de Jong, FA; Ektare, V; Gill, S; Hubner, RA; Patel, DA; Vogel, A; Yang, Y | 1 |
| Caparello, C; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Petrini, I; Vasile, E; Vivaldi, C | 1 |
| Alcaide, J; Díez de Corcuera, I; Feliu, J; García García, T; Manzano, JL; Sastre, J; Valladares-Ayerbes, M; Vera, R | 1 |
| Bohle, W; Egger, J; Hann, A; Zoller, WG | 1 |
| Alcindor, T; Asmis, T; Bendell, J; Berry, S; Binder, P; Burkes, R; Chan, E; Chan, T; Gao, L; Gill, S; Jeyakumar, A; Kambhampati, SR; Kauh, J; Kudrik, F; Moore, M; Nasroulah, F; Ramdas, N; Rao, S; Rothenstein, J; Spratlin, J; Strevel, E; Tang, PA; Tang, S; Yang, L; Zbuk, K | 1 |
| Chen, HJ; Fang, S; Huang, ZH; Lin, XH; Yu, JL; Zou, ZW | 1 |
| Buyse, M; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Ozenne, B; Péron, J; Roche, L; Roy, P; Stanbury, T; Ychou, M | 1 |
| Andersen, CL; Lyskjær, I; Rasmussen, MH | 1 |
| Castillo, C; Collet-Benzaquen, D; Combemale, P; de la Fouchardière, A; Desseigne, F; Fattouh, K; Provensal, AM | 1 |
| Jia, J; Liu, C; Shen, L; Sun, Z; Wang, X; Zhang, X | 1 |
| Amano, R; Fukuoka, T; Hirakawa, K; Ikeya, T; Iseki, Y; Kimura, K; Maeda, K; Matsutani, S; Muguruma, K; Nagahara, H; Ohira, M; Shibutani, M; Tanaka, H; Toyokawa, T | 1 |
| Ding, Y; Li, DD; Li, JJ; Liu, W; Peng, RQ; Wen, XZ; Wu, XJ; Xie, B; Zhang, X; Zhang, XS; Zhu, SG | 1 |
| Aparicio, T; Auby, D; Bachet, JB; Bouché, O; Boulat, O; Breysacher, G; Cretin, J; Faroux, R; Gargot, D; Gasmi, M; Genet, D; Jouve, JL; Khemissa, F; Lecomte, T; Lepère, C; Locher, C; Maillard, E; Mitry, E; Ramdani, M; Seitz, JF; Sobhani, I; Stefani, L; Teillet, L | 1 |
| Chen, K; Gong, Y; Shen, Y; Zhang, Q; Zhou, T | 1 |
| Jin, DY; Lou, WH; Rong, YF; Wu, W; Xu, XF; Zhang, L | 1 |
| Ålgars, A; Carpen, O; Jokilehto, T; Kaare, M; Kytölä, S; Lintunen, M; Orpana, A; Österlund, P; Ristamäki, R; Ristimäki, A; Sundström, J; Vainionpää, R | 1 |
| Antunes, C; Bachet, JB; Cassinotto, C; Lucidarme, O; Pietrasz, D; Sa Cunha, A; Wagner, M; Zappa, M | 1 |
| Cheng, TL; Hu, HM; Huang, CW; Ma, CJ; Tsai, HL; Wang, JY; Wu, IC; Yeh, YS | 1 |
| Benahim, E; Boige, V; de Baere, T; Deschamps, F; Ducreux, M; Goéré, D; Malka, D; Tselikas, L | 1 |
| Adams, R; Brown, S; Cheadle, J; Elliott, F; Fisher, D; Maughan, T; Middleton, G; Quirke, P; Richman, SD; Seligmann, JF; Seymour, M; Smith, CG | 1 |
| Anderson, RG; Bischak, MM; Broskin, SA; Campbell, CA; Foltz, LE; Higby, KJ; Koper, JA; Nickle, AC; Resendes, KK | 1 |
| Gloor, B; Rau, T; Vinzens, S; Wochner, A; Zindel, J; Zweifel, M | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Ibrahim, T; Kattan, J; Kourie, HR | 1 |
| Ahrendt, SA; Bahary, N; Bartlett, DL; Choudry, HA; Dhir, M; Hogg, ME; Holtzman, MP; Pingpank, JF; Singhi, AD; Zeh, HJ; Zureikat, AH | 1 |
| Aroldi, F; Beretta, GD; Bertocchi, P; Meriggi, F; Prochilo, T; Zaniboni, A | 1 |
| Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Murono, K; Nakajima, J; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Tanaka, T; Watanabe, T; Yasuda, K | 1 |
| Bodoky, G; Harsanyi, L; Hegyi, P; Lakatos, G; Nehéz, L; Petranyi, A; Szűcs, A | 1 |
| Buonadonna, A; Cecchin, E; De Mattia, E; Giodini, L; Innocenti, F; Montico, M; Roncato, R; Solfrini, V; Toffoli, G | 1 |
| Hazama, S; Iida, M; Inoue, Y; Kanekiyo, S; Nagano, H; Sakamoto, K; Suzuki, N; Takeda, S; Tokuhisa, Y; Tokumitsu, Y; Tomochika, S; Tsunedomi, R; Ueno, T; Yoshino, S | 1 |
| Baretta, Z; Bonfill Cosp, X; Hallum, S; Martin-Richard, M; Mocellin, S; Roqué I Figuls, M; Solà, I | 1 |
| Byer, J; Chang, YD; Kim, DW; Kim, RD; Kothari, N; Mahipal, A | 1 |
| Loreni, G; Miele, V; Ramponi, S; Rastelli, M; Scevola, G; Sposato, S | 1 |
| Ando, M; Araida, T; Hamano, M; Hayashi, K; Hirai, E; Itabashi, M; Kameoka, S; Kawakami, K; Kuramochi, H; Nakajima, G; Okuyama, R; Yokomizo, H; Yoshimatsu, K | 1 |
| Assi, T; El Karak, F; El Rassy, E; Ghosn, M; Kattan, J | 1 |
| Amano, F; Kanai-Mori, A; Koike, A; Morishige, Y; Tamaki, R; Yanagihara, K | 1 |
| Bibeau, F; Del Rio, M; Emile, JF; Gongora, C; Martineau, P; Mollevi, C; Robert, J; Roger, P; Selves, J; Tubiana-Mathieu, N; Vie, N; Ychou, M | 1 |
| Dawson, DW; Donahue, TR; Hines, OJ; Muthusamy, VR; Reber, HA; Sugimoto, M | 1 |
| Cho, DH; Kim, CW; Kim, JC; Kim, MB; Kim, TW; Roh, SA; Yoon, YS | 1 |
| Ahn, S; Hwang, JH; Kim, HW; Kim, J; Kim, JW; Kim, YH; Lee, J; Lee, JC; Paik, KH | 1 |
| Blanc, JF; Botteman, MF; Chen, LT; Cubillo, A; de Jong, FA; Hubner, RA; Melisi, D; Pelzer, U; Siveke, JT; Solem, CT; Von Hoff, DD; Wan, Y; Wang-Gillam, A; Yang, Y | 1 |
| Beinse, G; Bonnetain, F; Borg, C; Bouché, O; Cleau, D; d'Engremont, C; de Mestier, L; Dupont-Gossart, AC; Fein, F; Heyd, B; Lakkis, Z; Louvet, C; Meurisse, A; Neuzillet, C; Rousseau, B; Tournigand, C; Vernerey, D; Vienot, A | 1 |
| Azuma, H; Hirano, H; Ibuki, N; Inamoto, T; Matsunaga, T; Nomi, H; Saito, K; Takahara, K; Takai, T; Tanda, N; Tsujino, T; Uchimoto, T; Yoshikawa, Y | 1 |
| Lamb, YN; Scott, LJ | 1 |
| Amlashi, FG; Blum Murphy, M; Bozkurt, M | 1 |
| Khorrami, S; Malekzadeh, R; Mowla, SJ; Rakhshani, N; Soleimani, M; Zavaran Hosseini, A | 1 |
| Bueno, R; Catalano, PJ; Enzinger, PC; Hong, TS; King, BL; Mamon, HJ; Martin, NE; Sanford, NN; Wo, JY | 1 |
| Antonios, A; Gharios, J; Tohme, C | 1 |
| Endo, I; Goto, A; Ichikawa, Y; Kobayashi, N; Shimamura, T; Tokuhisa, M | 1 |
| Guo, H; Han, K; Tang, H; Yan, Y; Zhang, J; Zhang, L; Zhang, X; Zhuang, K | 1 |
| Colville-Ebeling, B; Jensen, BV; Larsen, FO; Markussen, A; Nielsen, D; Riis, LB | 1 |
| Hashimoto, Y; Hirata, Y; Ishizaki, Y; Kitamura, S; Kuga, Y; Miwata, T; Mouri, T | 1 |
| Besselink, MG; Busch, OR; de Rooij, T; Dijkgraaf, MG; Martin, RC; Rombouts, SJ; Schoorlemmer, A; van Delden, OM; van Gulik, TM; van Hooft, JE; van Laarhoven, HW; van Lienden, KP; Vogel, JA; Wilmink, JW | 1 |
| Crispin, A; Fischer von Weikersthal, L; Giessen-Jung, C; Haas, M; Heinemann, V; Holch, JW; Jung, A; Kirchner, T; Kruger, S; Michl, M; Modest, DP; Neumann, J; Quietzsch, D; Schalhorn, A; Stahler, A; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Einem, J | 1 |
| Chang, GJ | 1 |
| Abdel-Rahman, WM; Al-Khayyal, NA; Aravind, SR; Nair, VA; Saber-Ayad, M | 1 |
| Andreou, A; Bahra, M; Beierle, AS; Duwe, G; Knitter, S; Lohneis, P; Öllinger, R; Pesthy, S; Pratschke, J; Raschzok, N; Sauer, IM; Schmelzle, M; Schmuck, RB; Sinn, M; Struecker, B | 1 |
| Antoniotti, C; Cascinu, S; Cremolini, C; Demurtas, L; Falcone, A; Gelsomino, F; Giampieri, R; Loretelli, C; Mandolesi, A; Masi, G; Meriggi, F; Pusceddu, V; Puzzoni, M; Scartozzi, M; Zaniboni, A; Ziranu, P | 1 |
| Collado, MC; Forsgård, RA; Frias, R; Korpela, K; Korpela, R; Marrachelli, VG; Monleon, D; Österlund, P; Spillmann, T | 1 |
| Drakopoulos, D; Gerolympou, M; Gkoura, S; Miaris, N; Res, H; Samantas, E; Sgouros, J; Spyropoulos, B | 1 |
| Huang, WF; Jiang, JH; Nie, J; Tan, DW; Wang, XF; Zhou, Y | 1 |
| Cinar, P; Ko, AH | 1 |
| Bilancia, D; Cascinu, S; Corsi, DC; Ferraú, F; Galli, F; Giordano, M; Iaffaioli, RV; Labianca, R; Leone, F; Lonardi, S; Marchetti, P; Nasti, G; Ronzoni, M; Rosati, G; Scartozzi, M; Zagonel, V; Zaniboni, A | 1 |
| Chionh, F; Lau, D; Price, T; Tebbutt, N; Yeung, Y | 1 |
| Adam, R; Boige, V; Bouchahda, M; Carvalho, C; Desterke, C; Ducreux, M; Focan, C; Guimbaud, R; Hebbar, M; Innominato, P; Karaboué, A; Lemoine, A; Lévi, F; Milano, G; Saffroy, R; Smith, D; Taieb, J | 1 |
| Carvalho, T; Ferreira, MG; Figueiredo, N; Fior, R; Gomes, A; Mendes, RV; Póvoa, V | 1 |
| Grothe, W; Ho, J; Moehler, M; Syn, NL; Tai, BC; Unverzagt, S; Wagner, AD; Yong, WP | 1 |
| Liauw, SL | 1 |
| Artioli, M; Braghiroli, MI; Braghiroli, OFM; Costa, FP; Fernandes, GDS; Girardi, DDM; Gumz, BP; Hoff, PM; Paterlini, ACCR; Teixeira, MC | 1 |
| Allen, JN; Berger, D; Blaszkowsky, LS; Clark, JW; Collura, C; Deshpande, V; Ferrone, CR; Lillemoe, KD; Miller, CL; Murphy, JE; Parikh, AR; Qadan, M; Ryan, DP; Smalley, R; Tanabe, KK; Taylor, MS; Worthington, S | 1 |
| Dunn, SP; Finegold, MJ; Furman, WL; Gao, Y; Katzenstein, HM; Krailo, MD; Langham, MR; Malogolowkin, M; McCarville, MB; McGahren, ED; Meyers, RL; O'Neill, AF; Ranganathan, S; Rodriguez-Galindo, C; Tiao, GM; Towbin, AJ; Weldon, CB; Xia, C | 1 |
| Chabot, JA; Hecht, EM; Kluger, MD; Rashid, MF; Rosario, VL; Schrope, BA; Steinman, JA | 1 |
| Gao, Z; Li, Z; Wang, P; Yan, J | 1 |
| Chalchal, H; Payette, E; Sarker, S | 1 |
| Li, XF; Liu, GF; Liu, L; Yu, SN; Zhang, SH | 1 |
| Azrumelashvili, T; Chikovani, T; Janikashvili, N; Kikodze, N; Mizandari, M; Paksashvili, N; Pantsulaia, I; Shanava, K | 1 |
| Berger, MD; Cao, S; Falcone, A; Heinemann, V; Lenz, HJ; Loupakis, F; Matsusaka, S; Miyamoto, Y; Ning, Y; Okazaki, S; Schirripa, M; Soni, S; Stintzing, S; Suenaga, M; Sunakawa, Y; Yang, D; Zhang, W | 1 |
| Barszcz, K; Bernas, T; Czarnecka, J; Kaminska, B; Kominek, A; Piwocka, K; Was, H | 1 |
| Abdel-Wahab, M; Berriochoa, CA; Khorana, A; Kumar, AMS; Leyrer, CM; Matthew Walsh, R | 1 |
| Arita, S; Baba, E; Esaki, T; Kajitani, T; Makiyama, A; Oda, H; Shimokawa, H; Shirakawa, T | 1 |
| Deshmukh, SP; Epstein, JD; Keith, SW; Kozak, GM; Lavu, H; Scott, BB; Winter, JM; Yeo, CJ | 1 |
| Allen, PJ; Balachandran, VP; Boucher, T; Capanu, M; Cercek, A; Chou, JF; D'Angelica, MI; DeMatteo, RP; Jarnagin, WR; Kemeny, NE; Kingham, TP; Pak, LM | 1 |
| Abdulla, A; Bagust, A; Beale, S; Boland, A; Fleeman, N; Kotas, E; McEntee, J; Palmer, D; Richardson, M; Stainthorpe, A | 1 |
| Becker, T; Bemelmans, M; Bruns, CJ; Denecke, T; Folprecht, G; Gebauer, B; Heinemann, V; Held, S; Lang, H; Modest, DP; Modest, HI; Neumann, UP; Pratschke, J; Rentsch, M; Ricard, I; Seehofer, D | 1 |
| Allen, JN; Blaszkowsky, LS; Cai, L; Castillo, CF; Clark, JW; Deshpande, V; Ferrone, CR; Hong, TS; Honselmann, KC; Lillemoe, KD; Michelakos, T; Murphy, JE; Nipp, RD; Parikh, A; Pergolini, I; Qadan, M; Ryan, DP; Warshaw, AL; Wo, JY | 1 |
| Corrie, PG; Doherty, GJ; Tempero, M | 1 |
| Ebadi, M; Field, CJ; Lehner, R; Mazurak, VC | 1 |
| Guisheng, L; Haixin, H; Li, H; Shaojun, C | 1 |
| Bruckner, HW; Gurell, D; Hirschfeld, A | 1 |
| Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, K; Kobayashi, Y; Komatsu, Y; Kotake, M; Miyamoto, Y; Morita, S; Nakamura, M; Ohori, H; Sato, A; Shimada, K; Shimodaira, H; Takahashi, S; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S | 1 |
| Blair, AB; Burkhart, RA; Cameron, JL; Gemenetzis, G; Groot, VP; He, J; Herman, JM; Hruban, RH; Javed, AA; Laheru, D; Makary, MA; Poling, J; Waters, KM; Weiss, MJ; Wolfgang, CL; Zheng, L | 1 |
| Eftekhar, E; Jaberi, H; Mansouri, A; Naghibalhossaini, F; Shefaghat, M; Tatar, M | 1 |
| Alesse, E; Bruera, G; Calvisi, G; Cannita, K; Cocciolone, V; Cortellini, A; Dal Mas, A; Ficorella, C; Mastroiaco, V; Ricevuto, E; Tessitore, A; Zazzeroni, F | 1 |
| Celestini, V; Cocco, T; De Rasmo, D; Fasano, C; Forte, G; Gadaleta, RM; Garattini, E; Grossi, V; Lepore Signorile, M; Longo, G; Moschetta, A; Peserico, A; Russo, L; Sanese, P; Scialpi, N; Signorile, A; Simone, C; Terao, M; Tezil, T; Villani, G | 1 |
| Artru, P; Bennouna, J; Ducreux, M; Lievre, A; Lledo, G | 1 |
| Bonucci, M; Fabbri, A; Ferrera, V; Fiorentini, C; Pastore, C | 1 |
| Carnaghi, C; Cimino, M; Darwish, SS; Del Fabbro, D; Donadon, M; Personeni, N; Procopio, F; Rimassa, L; Santoro, A; Torzilli, G; Vigano, L | 1 |
| Baumann, AB; D'Anastasi, M; Heinemann, V; Hesse, N; Hofmann, FO; Holch, JW; Modest, DP; Reiser, MF; Ricard, I; Sommer, WH; Stintzing, S | 1 |
| Alberts, SR; Hartgers, ML; Hassan, M; Jin, Z; Mahipal, A; Muppa, P; Nagorney, DM; Sanhueza, CT; Shubert, CR; Smyrk, TC; Truty, MJ | 1 |
| Denda, T; Fukunaga, M; Kanda, M; Kataoka, M; Kim, HM; Mishima, H; Munemoto, Y; Nagata, N; Oba, K; Sakamoto, J; Takano, N; Takemoto, H; Tokunaga, Y | 1 |
| Boeck, S; Caca, K; Ettrich, TJ; Fischer von Weikersthal, L; Freiberg-Richter, J; Fuchs, M; Haas, M; Heinemann, V; Held, S; Kanzler, S; Kruger, S; Kullmann, F; Kunzmann, V; Lerch, MM; Reinacher-Schick, A; Schenk, M; Siveke, JT; Westphalen, CB | 1 |
| Price, TJ | 1 |
| Kanemitsu, Y; Ochiai, H; Shida, D; Tanabe, T; Tsukamoto, S; Yoshida, T | 1 |
| Egger, J; Hann, A; Hermann, PC; Keller, F; Nosalski, E; Seufferlein, T | 1 |
| Draper, A | 1 |
| Geredeli, C; Yasar, N | 1 |
| Chen, H; Chen, Y; Gu, Y; Hoffman, RM; Li, Y; Wang, H; Wang, W; Wu, M; Xu, M; Yang, Z; Zhu, P | 1 |
| Bagust, A; Banks, L; Beale, S; Boland, A; Duarte, R; Greenhalgh, J; Kotas, E; Palmer, D; Richardson, M; Stainthorpe, A | 1 |
| Byrne, JD; DeSimone, JM; Jajja, MRN; Keeler, AW; Luft, JC; O'Neill, AT; Schorzman, AN; Yeh, JJ; Zamboni, WC | 1 |
| Chen, Y; Liu, J; Qi, F; Yan, Q; Zhang, G; Zheng, Z | 1 |
| Bugano, DDG; Maluf, FC; Rother, ET; Usón Junior, PLS | 1 |
| Chang, HM; Hong, SM; Hwang, DW; Hwang, I; Jeong, JH; Kang, J; Kim, KP; Kim, MH; Kim, SC; Lee, JH; Lee, SK; Lee, SS; Park, DH; Ryoo, BY; Seo, DW; Shin, SH; Song, KB; Song, TJ; Yoo, C | 1 |
| Kellett, C; Kim, CA; Lambert, P; Zhang, H | 1 |
| Elbadawy, M; Hazama, S; Kaneda, M; Nagano, H; Nakajima, M; Ohama, T; Sakurai, M; Sasaki, K; Sato, K; Suzuki, N; Takenouchi, H; Tsunedomi, R; Umata, K; Usui, T; Yamawaki, H | 1 |
| Ando, M; Kadowaki, S; Komori, A; Kondoh, C; Muro, K; Narita, Y; Taniguchi, H; Ura, T | 1 |
| Pacheco, MM; Powers, JM; Wickiser, JE | 1 |
| Bassi, C; Bonamini, D; Boninsegna, E; Manfredi, R; Marchegiani, G; Negrelli, R; Pozzi Mucelli, R; Salvia, R; Sureka, B; Todaro, V | 1 |
| Aparicio, T; Ghebriou, D; Guetz, GD; Landre, T; Maillard, E; Taleb, C; Zelek, L | 1 |
| Cervantes, A; Moreno Vera, S; Peeters, M; Taieb, J | 1 |
| Hosokawa, T; Ishikawa, T; Kanazawa, M; Kanbayashi, Y; Kawano, R; Nakajima, Y; Tabuchi, Y; Taguchi, T; Takayama, K; Yoshida, N; Yoshioka, T | 1 |
| Chen, J; Feng, J; Huang, L; Liu, B; Peng, P; Qiu, H; Xie, C; Yu, Q; Yuan, X; Zang, A; Zhang, T | 1 |
| Bahary, N; Dhir, M; Hamad, A; Hogg, ME; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Aparicio, T; Baconnier, M; Barbier, E; Bedenne, L; Bouché, O; El Hajbi, F; Etienne, PL; Faroux, R; Francois, E; Genet, D; Khemissa Akouz, F; Kirscher, S; Lavau-Denes, S; Lecomte, T; Locher, C; Oden-Gangloff, A; Paillaud, E; Retornaz, F; Rinaldi, Y; Taieb, J | 1 |
| Benson, AB; Blanke, CD; Chen, EY; Dragovich, T; Haller, DG; Lenz, HJ; Li, H; Lopez, CD; Mattek, N; Mori, M; Robles, C; Sanborn, RE | 1 |
| Akao, J; Otsuka, N; Shimizu, K; Tahara, J; Takayama, Y; Tokushige, K | 1 |
| Kopetz, S | 1 |
| Chouaib, S; Foucher, ED; Galon, J; Ghigo, C; Iovanna, J; Olive, D | 1 |
| Fan, Z; Liu, B; Lu, T; Tong, H | 1 |
| Bang, SM; Choi, IS; Choi, M; Kang, B; Kim, JH; Kim, JW; Kim, SH; Kim, YJ; Lee, JH; Lee, JO; Lee, JS; Lee, JY; Lee, KW; Suh, KJ | 1 |
| Chantrill, LA; Chin, VT; Nagrial, AM; Pokorny, AMJ; Yip, D | 1 |
| Bardeesy, N; Caravan, P; Erstad, DJ; Ferrone, CR; Fuchs, BC; Ghoshal, S; Graham-O'Regan, KA; Lanuti, M; Razavi, AA; Sojoodi, M; Tanabe, KK; Taylor, MS | 1 |
| Bekaii-Saab, TS; Cohn, AL; El-Rayes, BF; Fernando, NH; Goldberg, RM; Grogan, W; Horgan, AM; Ivanova, A; Kasbari, SS; Kim, RD; Leonard, G; McCaffrey, J; McDermott, R; Moore, DT; O'Neil, BH; O'Reilly, S; Olowokure, OO; Ryan, T; Sanoff, HK; Sherrill, GB; Yacoub, GH; Zamboni, W | 1 |
| Bosman, F; Brauchli, P; Delorenzi, M; Dietrich, D; Fiocca, R; Klingbiel, D; Piessevaux, H; Roth, AD; Tejpar, S; Yan, P | 1 |
| Covington, CM; Desai, AM; Glassman, DC; Harding, JJ; Ku, GY; Li, J; O'Reilly, EM; Palmaira, RL; Varghese, AM; Yu, KH | 1 |
| Deng, B; Jia, L; Li, X; Li, Y; Lou, Y; Tan, H; Yu, L | 1 |
| Canale, TD; Cheung, WY; Cho, H | 1 |
| Bell, TM; Couch, ME; Kays, JK; Kohli, MD; Koniaris, LG; O'Neill, BH; Shahda, S; Stanley, M; Zimmers, TA | 1 |
| Abrams, SL; Candido, S; Cervello, M; Cocco, L; Falasca, M; Lertpiriyapong, K; Libra, M; Lombardi, P; Martelli, AM; McCubrey, JA; Montalto, G; Murata, RM; Ratti, S; Rosalen, PL; Steelman, LS; Yang, LV | 1 |
| Aravantinos, G; Bafaloukos, D; Efstratiou, I; Fountzilas, G; Goudopoulou, A; Kalogera-Fountzila, A; Kalogeropoulou, L; Karavasilis, V; Kentepozidis, N; Koliou, GA; Kotoula, V; Koumakis, G; Laschos, K; Pectasides, D; Pentheroudakis, G; Petraki, C; Poulios, C; Samantas, E; Sgouros, J; Souglakos, I; Tikas, I; Voutsina, A; Vrettou, E; Zarkavelis, G | 1 |
| Abraham, I; Alberts, DS; Alsaid, N; Bootman, JL; Erstad, B; Gharaibeh, M; McBride, A; Slack, M | 1 |
| Chen, W; He, M; Liu, Q; Long, MM; Wang, H; Wang, J; Xu, SW; Yang, LH; Yang, RM; Zhan, M | 1 |
| Delpero, JR; Ewald, J; Gilabert, M; Marchese, U; Turrini, O | 1 |
| Chevalier, H; Neuzillet, C; Turpin, A | 1 |
| Bachet, JB; Cunha, AS; Michel, P; Portales, F; Schwarz, L; Tuech, JJ; Vernerey, D | 1 |
| Chen, CQ; Ding, HW; Li, DD; Ren, TS; Wang, J; Wu, Q; Zhao, CH; Zhao, QC | 1 |
| Fukuda, H; Fukutomi, A; Furuse, J; Ikeda, M; Ioka, T; Ishii, H; Katayama, H; Mizuno, N; Mizusawa, J; Okusaka, T; Ozaka, M; Ueno, H; Ueno, M | 1 |
| Beato, CAM; de Alencar Camara Vieira, FM; de Iracema Gomes Cubero, D; de Souza Victorino, APO; Julian, GS; Minowa, E; Novick, D | 1 |
| Besselink, MG; Boggi, U; Hackert, T; Klompmaker, S; Salvia, R; Weiss, M; Yamaue, H; Zeh, HJ | 1 |
| Berlin, J; Cardin, D; Das, S | 1 |
| Gbolahan, O; Hancock, BA; O'Neil, BH; Radovich, M; Sehdev, A; Shahda, S; Stanley, M; Wan, J; Wu, HH | 1 |
| Chi, Y; Jiang, ZC | 1 |
| Endo, M; Fujikawa, K; Fukai, Y; Hashishita, H; Sagawa, T; Tahatsu, K; Takada, S; Takahashi, Y | 1 |
| Barenboim, A; Brazowski, E; Geva, R; Goykhman, Y; Isakov, O; Klausner, JM; Lahat, G; Lubezky, N; Nachmany, I; Nakache, R; Rosen, G; Wolf, I | 1 |
| de Liguori Carino, N; McNamara, MG; O'Reilly, DA; Pihlak, R; Radhakrishna, G; Siriwardena, AK; Valle, JW | 1 |
| Aziz, M; Kao, CT; Kasi, A | 1 |
| Costa, FP; Faria, LDBB; Fernandes, GS; Girardi, DM; Hoff, PMG; Teixeira, MC | 1 |
| Assi, H; Charafeddine, M; Hammoud, MS; Makki, I; Mukherji, D; Nassif, S; Shamseddine, A; Temraz, S; Tfayli, A | 1 |
| Kim, S; Marshall, JL; Parisi, M; Patterson-Lomba, O; Signorovitch, JE; Ung, B; Xiang, CQ; Yang, H | 1 |
| Eskens, FALM; Groot Koerkamp, B; Nuyttens, JJ; Suker, M; van Eijck, CHJ | 1 |
| Bengrine, L; Collot, T; Fumet, JD; Ghiringhelli, F; Klopfenstein, Q; Vincent, J | 1 |
| Battaglin, F; Berger, MD; Cao, S; Cremolini, C; Falcone, A; Heinemann, V; Lenz, HJ; Lo, JH; Loupakis, F; Millstein, J; Naseem, M; Puccini, A; Soni, S; Stintzing, S; Tokunaga, R; Zhang, W | 1 |
| Bai, X; Gao, S; Li, G; Li, X; Liang, T; Lou, J; Ma, T; Que, R; Su, W; Wei, T; Zhang, Q; Zheng, L | 1 |
| Aparicio, T; Azzedine, A; Barbier, E; Bouche, O; Chapelle, N; Cohen, R; Dahan, L; Etienne, PL; Gornet, JM; Guimbaud, R; Hammel, P; Le Malicot, K; Lepage, C; Louvet, C; Mineur, L; Nguyen, S; Phelip, JM; Samalin, E; Sefrioui, D; Touchefeu, Y | 1 |
| Clifford, R; Gollins, S; Govindarajah, N; Parsons, JL; Vimalachandran, D; West, NP | 1 |
| Esna-Ashari, O; Fathi-Azarbayjani, A; Kheradmand, F; Malekinejad, H; Mohammadian, M; Rasmi, Y; Zeynali-Moghaddam, S | 1 |
| Aleba, A; Bachet, JB; Barbier, E; Breysacher, G; Brocard, F; Desauw, C; Di Fiore, F; Dupuis, OJM; Etienne, PL; Lagasse, JP; Lecomte, T; Lepage, C; Levache, CB; Lucidarme, O; Pernot, S; Raoul, JL; Taieb, J | 1 |
| Bang, SM; Choi, IS; Kim, JH; Kim, JW; Kim, SH; Kim, YJ; Lee, JH; Lee, JO; Lee, JS; Lee, JY; Lee, KW; Suh, KJ | 1 |
| Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Freiberg-Richter, J; Giessen-Jung, C; Graeven, U; Heinemann, V; Held, S; Jung, A; Kirchner, T; Modest, DP; Peuser, B; Peveling Genannt Reddemann, C; Schenk, M; Schuch, G; Schwaner, I; Stahler, A; Stintzing, S; Uhlig, J; Vehling-Kaiser, U | 1 |
| Caparello, C; Frampton, AE; Funel, N; Garajová, I; Giovannetti, E; Kazemier, G; Le Large, TYS; Meijer, LL; Vasile, E | 1 |
| Cao, D; Hou, S; Li, A; Li, M; Mou, Y | 1 |
| D'Haese, JG; Friess, H; Gloor, B; Hartmann, D; Kaufmann, B; Radenkovic, D; Stupakov, P | 1 |
| Egle, A; Greil, R; Jaud, B; Magnes, T; Melchardt, T; Ratzinger, L; Schlick, K; Weiss, L | 1 |
| Belanger, B; Blanc, JF; Bodoky, G; Braiteh, FS; Chen, LT; Chiu, CF; Cunningham, D; de Jong, FA; Dean, AP; Hubner, RA; Jameson, GS; Lee, KH; Li, CP; Macarulla, T; Mamlouk, K; Schwartsmann, G; Shan, YS; Siveke, JT; Wang-Gillam, A | 1 |
| Druzhkova, I; Ignatova, N; Kiselev, N; Prodanets, N; Shirmanova, M; Zagainov, V; Zagaynova, E; Zhukov, I | 1 |
| Adenis, A; Artru, P; Bennouna, J; Bertaut, A; Borel, C; Borg, C; Bouché, O; Conroy, T; Denis, MG; Deplanque, G; des Guetz, G; François, E; Ghiringhelli, F; Hebbar, M; Hiret, S; Seitz, JF; Stanbury, T | 1 |
| Barbolosi, D; Deyme, L; Gattacceca, F | 1 |
| Farhat, F; Kattan, J; Kourie, HR; Tabchi, S | 1 |
| Becker, C; Belanger, B; Blanc, JF; Chen, LT; Cubillo, A; de Jong, FA; Hubner, RA; Mamlouk, K; Melisi, D; Siveke, JT; Von Hoff, DD; Wang-Gillam, A; Yang, Y | 1 |
| Diaz, LA; Hellmann, MD; Hu, ZI; O'Reilly, EM; Shia, J; Stadler, ZK; Vyas, M; Wolchok, JD | 1 |
| Bai, X; Chen, Y; Gao, S; Guo, C; Huang, P; Li, G; Li, Q; Li, X; Liang, T; Lou, J; Ma, T; Que, R; Shen, Y; Wei, Q; Wei, S; Yu, R; Yuan, Y; Zhang, Q | 1 |
| Endo, I; Goto, A; Ichikawa, Y; Kobayashi, N; Kubota, K; Kurita, Y; Nakajima, A; Tokuhisa, M | 1 |
| Ge, K; Jia, C; Wang, Z; Wu, Q; Xu, X; Zheng, S | 1 |
| Almeida, PHRF; Andrade, EIG; Cherchiglia, ML; da Silva, WC; de Araujo, VE; de Assis Acurcio, F; Dos Santos, JBR; Godman, B; Kurdi, A; Lima, EMEA; Silva, MRRD | 1 |
| Boilève, A; De Lonlay, P; Ducreux, M; Hollebecque, A; Jozwiak, M; Leroy, F; Malka, D; Ottolenghi, C; Pontoizeau, C; Verret, B; Wicker, C | 1 |
| Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E | 1 |
| Bendell, J; Hochster, HS; Hurwitz, HI; Lee, JJ; Lenz, HJ; Nicholas, A; Palma, JF; Price, R; Reeves, JA; Scappaticci, F; Somer, B; Sommer, N; Tan, BR; Xiong, H | 1 |
| Gromski, MA; Hwang, JH; Kim, HW; Kim, J; Lee, J; Lee, JC | 1 |
| Ali, A; Choi, JG; Dowling, EC; Fernandez-Del Castillo, C; Ferrone, CR; Hong, TS; Hur, C; Kong, CY; Nipp, RD; Pandharipande, P; Ryan, DP; Schrag, D; Tramontano, A; Zhan, T | 1 |
| Jeong, S; Jeong, YA; Jo, MJ; Kim, BR; Kim, JL; Lee, DH; Na, YJ; Oh, SC; Park, SH | 1 |
| Bi, F; Chen, Y; Gou, H; Li, Q; Liu, J; Qiu, M; Wu, B; Zhang, J; Zhou, Y | 1 |
| Artru, P; Assenat, E; Bachet, JB; Ben Abdelghani, M; Biagi, JJ; Bouhier-Leporrier, K; Breysacher, G; Castan, F; Choné, L; Conroy, T; Cripps, C; Di Fiore, F; Faroux, R; Francois, E; Gourgou, S; Hammel, P; Hebbar, M; Jouffroy-Zeller, C; Juzyna, B; Kavan, P; Khemissa-Akouz, F; Lecomte, T; Legoux, JL; Malka, D; O'Callaghan, CJ; Raoul, JL; Rat, P; Sauvanet, A; Texereau, P; Volet, J; Wei, AC; Ychou, M | 1 |
| Barbier, E; Blanc, JF; Bourgeois, V; Desrame, J; Edeline, J; Malka, D; Manfredi, S; Michel, P; Neuzillet, C; Phelip, JM | 1 |
| Burt, A; Chen, EY; Donovan, J; Kampa-Schittenhelm, KM; Kearney, MR; Lopez, CD; Strother, J; Todd, K; Vaccaro, GM | 1 |
| Algül, H; Atzpodien, J; Berger, AW; Daum, S; Dickhut, A; Ettrich, TJ; Gallmeier, E; Geissler, M; König, A; Kornmann, M; Muche, R; Perkhofer, L; Prasnikar, N; Reinacher-Schick, A; Seufferlein, T; Tannapfel, A; Uhl, W; Wille, K; Wittel, U | 1 |
| Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O | 2 |
| Shi, S; Yu, X | 1 |
| Andalibi, H; Heinrich, B; Kafka, A; Klaus, A; Öhler, L; Schima, W; Vogl, UM; Vormittag, L; Winkler, T | 1 |
| Boige, V; Conroy, T; Ducreux, M; Hollebecque, A; Laurent-Puig, P; Malka, D; Seufferlein, T; Smolenschi, C; Van Laethem, JL | 1 |
| Fukutomi, A; Kamei, K; Kobayashi, M; Kobayashi, S; Matsumoto, I; Matsuoka, H; Mizuno, N; Omae, K; Ozaka, M; Suzuki, S; Todaka, A; Ueno, H; Uesugi, K | 1 |
| Bossevot-Desmaris, R; Bouchahda, M; Haydar, M; Innominato, P; Karaboué, A; Komarzynski, S; Lévi, F; Mocquery, M; Plessis, V; Ulusakarya, A | 1 |
| Belanger, B; Chen, LT; de Jong, FA; Hubner, RA; Mirakhur, B; Siveke, JT; Von Hoff, DD; Wang-Gillam, A | 1 |
| Romero, D | 1 |
| Soefje, SA | 1 |
| Albino, V; Fusco, R; Granata, V; Grimm, R; Izzo, F; Palaia, R; Petrillo, A; Piccirillo, M; Setola, SV | 1 |
| Aieta, M; Chiriacò, G; Conca, R; Multari, AG; Paganini, G; Petrioli, R; Rosellini, P; Roviello, G | 1 |
| Bonetti, A; Giuliani, J | 1 |
| Jiménez Gordo, AM; López Gómez, M | 1 |
| Allegrini, G; Antoniotti, C; Aprile, G; Bergamo, F; Boni, L; Borelli, B; Casagrande, M; Cremolini, C; Delfanti, S; Dell'Aquila, E; Di Donato, S; Falcone, A; Fontanini, G; Gemma, D; Granetto, C; Lonardi, S; Marmorino, F; Masi, G; Murgioni, S; Salvatore, L; Schirripa, M; Sensi, E; Tonini, G | 1 |
| Lima, CMSR | 1 |
| Bekaii-Saab, T | 2 |
| Yu, K | 1 |
| Behl, D; Chiorean, EG; Gaur, R; Guthrie, KA; Hingorani, SR; Hochster, HS; Kortmansky, JS; Lacy, J; McDonough, SL; Mehan, PT; Philip, PA; Ramanathan, RK; Seery, T; Shields, AF; Thumar, J | 1 |
| Blanc, JF; Chen, J; Chen, LT; de Jong, FA; Macarulla, T; Mirakhur, B; Siveke, JT; Wang-Gillam, A | 1 |
| Ananda, S; Cooray, P; Delahunty, R; Desai, J; Gibbs, P; Johns, J; Kosmider, S; Lee, B; Lee, M; Mckendrick, J; Tie, J; Tran, B; Wong, HL; Wong, R | 1 |
| Gallego, I; García, G; García-Alfonso, P; Lloansí, A; Muñoz, A; Ortega, L; Sandoval, C; Torres, G | 1 |
| Christy-Bittel, J; Ciardiello, F; Cuyle, PJ; Desai, J; Elez, E; Fakih, M; Gollerkeri, A; Grothey, A; Huijberts, S; Kopetz, S; Maharry, K; Montagut, C; Peeters, M; Sandor, V; Schellens, JHM; Tabernero, J; Van Cutsem, E; Wasan, H; Yaeger, R; Yoshino, T | 1 |
| Arnelo, U; Del Chiaro, M; Orsini, N; Persson, S; Rangelova, E; Segersvärd, R; Tanaka, K; Valente, R; Wefer, A | 1 |
| Kempenich, R; Kienle, GS; Lang-Avérous, G; Werthmann, PG | 1 |
| Furukawa, K; Kuboki, S; Ohtsuka, M; Takano, S; Takayashiki, T; Yoshitomi, H | 1 |
| Bendardaf, R; Pyrhönen, S; Sharif-Askari, FS; Sharif-Askari, NS; Syrjänen, K | 1 |
| Bang, S; Chung, MJ; Kim, SY; Lee, HS; Park, JY; Park, SW; Song, SY | 1 |
| Büchler, MW; Hackert, T; Heckler, M; Heger, U; Klaiber, U; Mihaljevic, AL; Sun, H; Tanaka, M | 1 |
| Chen, J; Hua, Z; Lu, B; Lu, C; Qu, C; Sun, Z; Tong, R; Zhang, J | 1 |
| Akaboshi, S; Baba, H; Hayashi, H; Ikuta, Y; Kamio, T; Masuda, T; Matumoto, K; Ogata, K; Ogawa, K; Ozaki, K; Takamori, H | 1 |
| Conroy, T; Ducreux, M | 1 |
| Blanc, JF; Buscail, E; Cassinotto, C; Chiche, L; Cossin, S; Dabernat, S; Dupin, C; Laurent, C; Marty, M; Pouypoudat, C; Smith, D; Terrebonne, E; Vendrely, V | 1 |
| Almohamad, W; Biondani, P; Chebib, A; Gumus, Y; Haydar, M; Karaboué, A; Krimi, S; Morère, JF; Teyar, N; Ulusakarya, A | 1 |
| Ambrož, M; Boušová, I; Lněničková, K; Matoušková, P; Skálová, L | 1 |
| Besselink, MG; Bruijnen, RCG; Busch, OR; de Hingh, IH; de Vries, J; Mohammad, NH; Molenaar, IQ; Nio, CY; van Delden, OM; van Laarhoven, HW; van Leeuwen, MS; van Lienden, KP; van Rijssen, LB; van Santvoort, HC; van Veldhuisen, E; Walma, MS; Wessels, FJ; Wilmink, JW; Yo, LS | 1 |
| Hirata, K; Hotta, Y; Imasato, M; Ishibashi, K; Iwamoto, S; Maeda, H; Makiyama, A; Mishima, H; Morita, S; Morita, Y; Munemoto, Y; Nagasaka, T; Nagata, N; Sakamoto, J; Takemoto, H; Tanaka, C; Toyofuku, A; Yoshida, Y | 1 |
| Asakuma, M; Gonen, M; Haeno, H; Hur, C; Inoue, Y; Kartoun, U; Kong, CY; Liu, LL; Michor, F; Nakamura, A; Shimizu, T; Stein, S; Tramontano, AC; Uchiyama, K; Yamamoto, KN | 1 |
| Auclin, E; Bachet, JB; Bruzzi, M; Cunha, AS; El-Hajjar, A; Gaujoux, S; Kourie, H; Louafi, S; Lourenco, N; Pietrasz, D; Sauvanet, A; Smith, D; Taieb, J; Touchefeu, Y; Trouilloud, I; Vaillant, JC | 1 |
| Bumberová, M; Dolinský, J; Janega, P; Jurišová, S; Kašperová, B; Macúch, J; Mego, M | 1 |
| Bertagnolli, MM; Blanke, CD; Goldberg, RM; Hochster, HS; Innocenti, F; Kabbarah, O; Lenz, HJ; Mayer, RJ; Niedzwiecki, D; Ou, FS; Qu, X; Tejpar, S; Venook, AP; Wirapati, P; Zemla, T | 1 |
| Addeo, P; Bachellier, P; Bahary, N; Bali, MA; Bekaii-Saab, T; Besselink, MG; Beumer, BR; Boone, BA; Buettner, S; Chau, I; Clarke, S; Dillhoff, M; El-Rayes, BF; Frakes, JM; Groot Koerkamp, B; Grose, D; Homs, MYV; Hosein, PJ; Jamieson, NB; Janssen, QP; Javed, AA; Katz, MHG; Khan, K; Kim, KP; Kim, SC; Kim, SS; Ko, AH; Lacy, J; Margonis, GA; McCarter, MD; McKay, CJ; Mellon, EA; Moorcraft, SY; Okada, KI; Paniccia, A; Parikh, PJ; Peters, NA; Rabl, H; Samra, J; Suker, M; Tinchon, C; van Eijck, CHJ; van Tienhoven, G; van Veldhuisen, E; Wang-Gillam, A; Weiss, MJ; Wilmink, JW; Yamaue, H | 1 |
| Burnett, A; Cloutier, AS; Dubé, P; Gervais, MK; Lecompte, MA; Sideris, L; Trabulsi, N; Trilling, B | 1 |
| Hirakata, A; Hosone, M; Kawashima, M; Makino, H; Matsushita, A; Nakamura, Y; Okusa, M; Takata, H; Tsujino, T; Ueda, J; Yokoyama, T; Yoshida, H | 1 |
| Choi, DW; Choi, SH; Han, IW; Han, S; Heo, JS; Park, DJ; Ryu, Y | 1 |
| Bai, L; Bi, F; Chen, Y; Cheng, Y; He, X; Hu, X; Li, J; Li, Y; Liu, W; Liu, Y; Luo, Y; Ouyang, X; Qin, S; Shi, Y; Sun, G; Sun, Y; Wang, L; Wang, Z; Xu, J; Yao, Q; Zhang, Y; Zheng, R | 1 |
| Allen, JN; Baglini, CV; Berger, DL; Blaszkowsky, LS; Boucher, Y; Clark, JW; Corcoran, RB; DeLaney, TF; Drapek, LC; Duda, DG; Faris, JE; Fernández-Del Castillo, C; Ferrone, CR; Goyal, L; Hong, TS; Jain, RK; Jiang, W; Kwak, EL; Lillemoe, KD; Ly, L; Murphy, JE; Nipp, RD; Parikh, AR; Qadan, M; Ryan, DP; Talele, N; Ting, DT; Weekes, CD; Wo, JY; Yeap, BY; Zhu, AX | 1 |
| Harada, H; Kugimoto, T; Kuroshima, T; Michi, Y; Mochizuki, Y; Oyama, J; Sakamoto, K | 1 |
| Argilés Martínez, G; Carmona-Bayonas, A; Castañón López, C; Fernández Montes, A; Gallego Plazas, J; García Paredes, B; Gutiérrez Abad, D; Jiménez Fonseca, P; Juez Martel, I; Llorente Ayala, B; López Doldán, MC; López Flores, M; López López, C; López Muñoz, AM; Martínez de Castro, E; Páez López, D; Sánchez Cánovas, M; Tobeña Puyal, M | 1 |
| Anderson, K; Bullock, A; Saade Lemus, P; Smith, M | 1 |
| Ishigame, T; Kenjo, A; Kimura, T; Kofunato, Y; Marubashi, S; Muto, M; Okada, R; Sato, N; Shimura, T; Suzushino, S; Tsukida, S | 1 |
| Das, M | 1 |
| Ahmed, S; Chalchal, H; Haider, K; Moser, M; Olson, C; Papneja, N; Shaw, J; Tan, K; Zaidi, A | 1 |
| Rahman, M; Washington, L | 1 |
| Assenat, E; Cassinotto, C; Kellil, T; Leon, P; Navarro, F; Panaro, F; Piardi, T; Rosso, E; Sega, V; Souche, R; Vendrell, J | 1 |
| Georgoulias, V; Hatzidaki, D; Katsaounis, P; Kentepozidis, N; Kotsakis, A; Kouroupakis, P; Matikas, A; Messaritakis, I; Nikolaidi, A; Pantazopoulos, N; Prinarakis, E; Souglakos, J; Tzovara, I | 1 |
| Aloia, TA; Fogelman, DR; Ho, L; Javadi, S; Katz, MHG; Kim, MP; Lee, JE; McAllister, F; Prakash, LR; Tzeng, CD; Varadhachary, G; Vauthey, JN; Vreeland, TJ | 1 |
| Byun, Y; Choi, YJ; Han, Y; Jang, JY; Kang, JS; Kim, H; Kim, SW; Kim, YT; Kwon, W; Lee, SH; Oh, DY; Ryu, JK | 1 |
| Block, C; Gorsuch, K; Gupta, D; Hill, D; Vashi, PG; Wan, L | 1 |
| Fu, DL; Jin, C; Warshaw, AL; Yang, F | 1 |
| Alonso, J; Bertran, J; Bigas, A; Borràs, E; Boulton, SJ; Colomer, C; Espinosa, L; González-Farré, M; Iglesias, M; Margalef, P; Martinez-Iniesta, M; Montagut, C; Pecharroman, I; Sabidó, E; Solé, L; Vert, A; Villanueva, A | 1 |
| Auriemma, A; Bassi, C; Binco, A; Bonamini, D; Casciani, F; Casetti, L; Ciprani, D; D'Onofrio, M; Esposito, A; Landoni, L; Maggino, L; Malleo, G; Marchegiani, G; Melisi, D; Merz, V; Nessi, C; Paiella, S; Salvia, R; Secchettin, E; Sereni, E; Simionato, F; Tuveri, M; Viviani, E; Zecchetto, C | 1 |
| Bang, JH; Bang, YJ; Eun Park, J; Hua Jin, M; Nam, AR; Oh, DY; Park, H | 1 |
| Kanno, M; Kichikawa, K; Koyama, F; Marugami, N; Masada, T; Nishiofuku, H; Otsuji, T; Sato, T; Sho, M; Tanaka, T; Tatsumoto, S | 1 |
| Büchler, MW; Hackert, T; Heger, U; Hinz, U; Klaiber, U; Liu, B; Michalski, CW; Sachsenmaier, M; Springfeld, C; Sun, H; Tanaka, M | 1 |
| Cai, Y; Chen, D; Chen, S; Deng, Y; Hu, H; Huang, M; Kang, L; Lan, P; Lin, F; Ling, J; Peng, J; Ren, D; Wang, H; Wang, J; Wang, L; Wu, X; Xiao, J; Zhang, J; Zhang, Y; Zheng, J; Zhou, Z | 1 |
| Bafaloukos, D; Bamia, C; Bombolaki, I; Chatzopoulos, K; Chrisafi, S; Efstratiou, I; Fountzilas, G; Kafiri, G; Koliou, GA; Kotoula, V; Kourea, HP; Makatsoris, T; Mauri, D; Mavroeidis, L; Papadopoulou, K; Papakostas, P; Papatsibas, G; Pectasides, D; Pentheroudakis, G; Petraki, K; Samantas, E | 1 |
| Castan, F; de Forges, H; Gallix, B; Gourgou, S; Nougaret, S; Rouanet, P; Vargas, HA | 1 |
| Cho, CS; Cuneo, KC; Griffith, KA; Kaza, R; Kim, E; Lawrence, TS; Nathan, H; Sahai, V; Shi, J; Sonnenday, CJ; Tran, NH; Zalupski, MM | 1 |
| Arango, MJ; Noonan, AM; Porter, K; Reardon, J; Tossey, JC; VanDeusen, JB | 1 |
| Fujiwara-Tani, R; Goto, K; Kawahara, I; Kishi, S; Kondo, M; Kuniyasu, H; Luo, Y; Mori, S; Mori, T; Nishiguchi, Y; Ohmori, H; Sasaki, T; Sho, M | 1 |
| Albino, V; Amore, A; Avallone, A; Belli, A; Botti, G; Capozzi, M; Casaretti, R; Cassata, A; Chiodini, P; D'Alterio, C; De Feo, G; De Stefano, A; Delrio, P; Di Marzo, M; Izzo, F; Napolitano, M; Nappi, A; Nasti, G; Normanno, N; Ottaiano, A; Pace, U; Palaia, R; Petrillo, A; Picone, C; Portella, L; Rachiglio, AM; Roma, C; Romano, C; Scala, S; Silvestro, L; Tafuto, S; Tamburini, M; Trotta, AM | 1 |
| Allain, EP; Buonadonna, A; Cecchin, E; Couture, F; D'Andrea, M; De Mattia, E; Guillemette, C; Jonker, D; Labriet, A; Lévesque, É; Rouleau, M; Simonyan, D; Toffoli, G; Villeneuve, L | 1 |
| Alistar, AT; Buyse, ME; Luther, S; Pardee, TS; Philip, PA; Rocha Lima, CM; Van Cutsem, E | 1 |
| Iyikesici, MS | 1 |
| Artemiyev, AI; Bashkov, AN; Bogoevich, Z; Kolyshev, IY; Kucherov, NN; Naydenov, EV; Shabalin, MV; Voskanyan, SE | 1 |
| Bonnet, E; Cattey-Javouhey, A; de La Fouchardière, C; Desseigne, F; Guibert, P; Lardy-Cléaud, A; Mastier, C; Rochefort, P; Sarabi, M | 1 |
| Aglietta, M; Brac, C; Buscaglia, P; Casadei-Gardini, A; Clerico, M; De Luca, E; Edeline, J; Falcone, A; Fornaro, L; Leone, F; Lièvre, A; Lombardi, P; Meurisse, A; Montagnani, F; Musettini, G; Neuzillet, C; Pasquini, G; Passardi, A; Satolli, MA; Spadi, R; Sperti, E; Vasile, E; Vernerey, D; Vienot, A; Vivaldi, C | 1 |
| Joseph, NE; Marsh, RW; Polish, A | 1 |
| Algül, H; Braren, R; Friess, H; Kaissis, G; Lohöfer, F; Muckenhuber, A; Rummeny, E; Schmid, R; Siveke, JT; Steiger, K; Weichert, W; Yen, HY; Ziegelmayer, S | 1 |
| Gaszynski, R; Gray, A; Merrett, N | 1 |
| Beerepoot, LV; Bloemendal, HJ; Boot, H; Chalabi, M; Clevers, H; Cuppen, E; Dijkstra, KK; Hoes, L; Kaing, S; Klein, M; McLean, CM; Ooft, SN; Prevoo, W; Schipper, L; Snaebjornsson, P; van de Haar, J; van der Velden, D; van Leerdam, M; van Werkhoven, E; Vis, DJ; Voest, EE; Weeber, F; Wessels, L | 1 |
| Artru, P; Béchade, D; Desrame, J; Hautefeuille, V; Le Roy, B; Locher, C; Lourenco, N; Pernot, S; Pointet, AL; Pozet, A; Soularue, E; Taieb, J; Tougeron, D; Trouilloud, I; Williet, N | 1 |
| Araida, T; Jibiki, N; Katagiri, S; Kuramochi, H; Nishino, T; Shimmura, H | 1 |
| Bruera, G; Carlei, F; Chiominto, A; Cosenza, P; Di Sibio, A; Giuliani, A; Mastropietro, S; Ricevuto, E; Romano, L; Schietroma, M | 1 |
| Cao, Y; Li, Q; Liu, Y; Zhang, Y; Zhou, J | 1 |
| Ahmad, S; Hasan, B; Hussain, I; Jain, AG; Jehanzeb, S; Khan, AK; Khetpal, N; Rahman, AU; Rashid, MU; Sarvepalli, D; Ullah, W | 1 |
| Alessandroni, P; Bergamo, F; Borelli, B; Catalano, V; Cremolini, C; Falcone, A; Giordani, P; Graziano, F; Intini, R; Lonardi, S; Mattioli, R; Negri, F; Rocchi, MBL; Rossini, D; Santini, D; Sarti, D; Stragliotto, S; Vincenzi, B; Zagonel, V | 1 |
| Chang, SC; Chao, Y; Chen, WS; Cheng, HH; Huang, SC; Jiang, JK; Lan, YT; Lin, CC; Lin, HH; Tai, CC; Teng, HW; Wang, HS; Yang, SH | 1 |
| Arora, SP; Cheetham, K; Coffey, M; Eng, KH; Fields, P; Fountzilas, C; Kalinski, P; Mahalingam, D; Moseley, JL; Nuovo, G; Raber, P; Wilkinson, GA; Zhang, B | 1 |
| Buonadonna, A; Cecchin, E; Couture, F; D'Andrea, M; De Mattia, E; Guillemette, C; Jonker, D; Labriet, A; Lévesque, É; Simonyan, D; Toffoli, G; Villeneuve, L | 1 |
| Bang, JH; Bang, YJ; Jin, MH; Nam, AR; Oh, DY; Park, H; Park, JE | 1 |
| Kim, HB; Lee, HJ; Lim, HJ; Park, JH; Park, SG | 1 |
| Agrawal, AK; Agrawal, S; Banach, J; Gamian, A; Makuch, S; Pielka, E; Pizon, M; Wietrzyk, J; Woźniak, M; Ziółkowski, P; Łuc, M | 1 |
| Arias, J; Beca, JM; Berry, SR; Biagi, JJ; Chan, KKW; Cheng, S; Coburn, N; Dai, WF; Earle, C; Gavura, S; Guo, H; Isaranuwatchai, W; Kennedy, ED; McLeod, R; Meyers, BM; Mittmann, N; Qiao, L; Redmond-Misner, R; Schwartz, D; Welch, S | 1 |
| Antista, M; Barault, L; Corallo, S; de Braud, F; Di Bartolomeo, M; Di Maio, M; Di Nicolantonio, F; Farina, G; Fucà, G; Gori, S; Guarini, V; Lobefaro, R; Lonardi, S; Longarini, R; Macagno, M; Martinetti, A; Milione, M; Morano, F; Mosconi, S; Murgioni, S; Pagani, F; Palermo, F; Perrone, F; Petrelli, F; Pietrantonio, F; Raimondi, A; Randon, G; Rimassa, L; Sartore-Bianchi, A; Tamborini, E; Tomasello, G | 1 |
| Igarashi, H; Imai, K; Ishigami, K; Koide, H; Mitsuhashi, K; Nakase, H; Nosho, K; Okita, K; Takemasa, I; Taniguchi, H | 1 |
| Allen, JN; Blaszkowsky, LS; Castillo, CF; Clark, JW; Ferrone, CR; Harrison, JM; Hong, TS; Horick, NK; Keane, FK; Lillemoe, KD; Qadan, M; Wo, JY | 1 |
| Bojko, A; Charzynska, A; Czarnecka-Herok, J; Dabrowski, M; Sikora, E | 1 |
| Bai, XL; Chen, W; Chen, YW; Fu, QH; Gao, SL; Guo, CX; Huang, DB; Li, X; Liang, TB; Ma, T; Que, RS; Su, W; Tang, TY; Zhang, Q; Zhang, XC | 1 |
| Asch, D; Beatty, GL; Domchek, SM; Nathanson, KL; O'Dwyer, PJ; Reiss, KA; Rosen, MA; Siegelman, ES; Wattenberg, MM; Yu, S | 1 |
| Bang, YJ; Belanger, B; Chen, JS; Chen, LT; Chiu, CF; Choi, HJ; Kim, JS; Lee, KH; Li, CP; Oh, DY; Park, JO; Rau, KM; Shan, YS; Shim, HJ | 1 |
| Attwood, K; Boland, PM; Fountzilas, C; Gosain, R; Iyer, R; Khushalani, N; Mukherjee, S; Tan, W | 1 |
| Bakkers, C; Bouamar, R; Brandt-Kerkhof, ARM; Burger, JWA; Constantinides, A; Creemers, GM; de Boer, NL; de Hingh, IHJT; de Man, FM; Deenen, MJ; Diepeveen, M; Koolen, SLW; Kranenburg, OW; Madsen, EVE; Mathijssen, RHJ; Rovers, KP; van Eerden, RAG; van Meerten, E; Verhoef, C | 1 |
| Chen, HR; El-Rayes, B; Farren, MR; Gong, J; Kooby, D; Krasinskas, A; Lesinski, GB; Liang, Y; Maithel, SK; Patel, P; Sarmiento, JM; Sayegh, L; Shaib, W; Ware, MB; Zaidi, M | 1 |
| Delpero, JR; Ewald, J; Garnier, J; Gilabert, M; Giovannini, M; Launay, S; Marchese, U; Medrano, J; Poizat, F; Turrini, O | 1 |
| Caffrey, TC; Clement, EJ; Cook, LM; Costanzo-Garvey, D; DiMaio, DJ; Fisher, KW; Grandgenett, PM; Grem, JL; Hollingsworth, MA; Krieger, KL; Lagundžin, D; Law, HC; Qiao, F; Wagner, ZS; Woods, NT; Yu, F | 1 |
| Abu Hilal, M; Alseidi, A; Balzano, G; Besselink, MG; Boggi, U; Butturini, G; Casadei, R; de Pastena, M; Dokmak, S; Edwin, B; Falconi, M; Keck, T; Korrel, M; Lof, S; Malleo, G; Tomazic, A; van Hilst, J; Wilmink, H; Zerbi, A | 1 |
| Belanger, B; Blanc, JF; Bodoky, G; Chen, LT; Cunningham, D; Dean, A; Lee, KH; Li, CP; Macarulla Mercadé, T; Siveke, JT; Wang-Gillam, A | 1 |
| Chang, TK; Chang, YT; Huang, CW; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yeh, YS | 1 |
| de Santibañes, E; de Santibañes, M; Mazza, O; Pekolj, J; Sanchez Clariá, R | 1 |
| Bapat, B; Brown, J; Candrilli, SD; García-Foncillas, J; Kaye, JA; Liepa, AM; Lorenzen, S; Madhwani, S | 1 |
| Cid, NG; Labandeira, CM; Manrique, MCA; Mata, JG; Montes, AF; Núñez, MÁ; Ron, DA; Vera, R | 1 |
| Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D | 1 |
| Belkouz, A; de Vos-Geelen, J; Eskens, FALM; Klümpen, HJ; Mathôt, RAA; Punt, CJA; van Gulik, TM; van Oijen, MGH; Wilmink, JW | 1 |
| Fogelman, DR; Hess, KR; Ho, L; Javle, MM; Mizrahi, JD; Overman, MJ; Pant, S; Raghav, KPS; Rogers, JE; Shroff, RT; Varadhachary, GR; Wolff, RA | 1 |
| Detlefsen, S; Kristensen, BW; Mortensen, MB; Nielsen, MFB; Pfeiffer, P; Schrøder, HD; Sørensen, MD; Wirenfeldt, M | 1 |
| André, T; Aparicio, T; Artru, P; Chautard, R; Cohen, R; Coriat, R; de la Fouchardiére, C; Des Guetz, G; Evrard, C; Ferru, A; Gentilhomme, L; Goujon, G; Hautefeuille, V; Henriques, J; Lecaille, C; Lecomte, T; Locher, C; Moulin, V; Sefrioui, D; Sueur, B; Taieb, J; Touchefeu, Y; Tougeron, D; Vernerey, D; Zaanan, A | 1 |
| Ahn, D; Barzi, A; Bekaii-Saab, T; Corvino, FA; Mamlouk, K; Miksad, R; Pulgar, S; Surinach, A; Torres, AZ; Valderrama, A; Wang, S | 1 |
| Dercle, L; Eggleton, P; Lu, L; Piessevaux, H; Qian, M; Schwartz, LH; Tejpar, S; Zhao, B | 1 |
| Batman, E; Cairns, DA; Cave, J; Chau, I; Craig, Z; Faluyi, O; Howard, H; Hubner, R; Lamarca, A; Mansoor, W; McNamara, MG; Meyer, T; Reed, N; Sarker, D; Sharma, R; Swain, J; Valle, JW; Wadsley, J; Wall, L | 1 |
| Deshpande, V; Fernandez-Del Castillo, C; Ferrone, CR; Hong, TS; Lillemoe, KD; Neyaz, A; Qadan, M; Rickelt, S; Shih, A; Shroff, S; Tabb, ES; Taylor, MS; Ting, DT; Wo, JY; Zhao, Q | 1 |
| Elssner, C; Gdynia, G; Goeppert, B; Hoffmeister, P; Ismail, L; Jäger, D; Jassowicz, A; Köhler, BC; Neukirch, L; Pató, A; Scherr, AL; Schmitt, N; Schulze-Bergkamen, H | 1 |
| Besselink, MG; Creemers, GJ; de Groot, JWB; de Vos-Geelen, J; Haj Mohammad, N; Homs, MYV; Latenstein, AEJ; Mackay, TM; Molenaar, IQ; Ten Tije, BJ; van der Geest, LGM; van Eijck, CHJ; van Laarhoven, HWM; Wilmink, JW | 1 |
| Allen, K; Alpert, L; Catenacci, DVT; Chase, L; de Wilton Marsh, R; Ferguson, MK; Gordon, B; Hart, J; Karrison, T; Kindler, HL; Kipping-Johnson, K; Liao, CY; Lomnicki, S; Markevicius, U; Maron, SB; Moore, K; Narula, S; Peterson, B; Polite, BN; Posner, MC; Prachand, VN; Racette, C; Rampurwala, MM; Roggin, KK; Setia, N; Siddiqui, UD; Turaga, K; Xiao, SY | 1 |
| Bozkurt Duman, B; Çil, T | 1 |
| Cai, X; Chen, Y; Fang, H; Fang, W; Li, H; Li, Q; Lin, X; Ma, D; Nie, Y; Peng, C; Shen, L; Wang, N; Wang, W; Xu, R; Zhao, Q; Zhu, B; Zhu, L | 1 |
| Fijnheer, R; Otten, JMMB | 1 |
| An, H; Heo, JS; Hong, CP; Hong, E; Kang, JM; Kim, SJ; Lee, S; Ooshima, A; Park, J; Park, JO; Park, S; Park, SH | 1 |
| Ajani, JA; Blum Murphy, M; Palmer, M; Rogers, JE; Trail, A; Xiao, L | 1 |
| Bøgsted, M; Detlefsen, S; Falkmer, UG; Fristrup, CW; Hansen, CP; Jensen, BV; Ladekarl, M; Larsen, JS; Mortensen, FV; Mortensen, MB; Pfeiffer, P; Poulsen, LØ; Rasmussen, LS; Sall, M; Skuladottir, H; Weber, B; Yilmaz, MK; Østerlind, K | 1 |
| He, C; Li, S; Lin, X; Wang, J; Zhang, Y | 1 |
| Kimura, M; Teramachi, H; Usami, E; Yoshimura, T | 1 |
| Delpero, JR; Ewald, J; Garnier, J; Gilabert, M; Giovannini, M; Marchese, U; Moureau-Zabotto, L; Poizat, F; Turrini, O | 1 |
| Bartlett, JMS; Biagi, J; Chadwick, D; Denroche, RE; Dodd, A; Fischer, SE; Gallinger, S; Grant, RC; Grünwald, BT; Hutchinson, S; Jang, GH; Khokha, R; Knox, JJ; Krzyzanowski, PM; Lam, B; Lungu, IM; Masoomian, M; Notta, F; O'Kane, GM; Peralta, M; Picardo, S; Ramotar, S; Vyas, F; Wang, Y; Wilson, JM; Zhang, A; Zogopoulos, G | 1 |
| Delpero, JR; Ewald, J; Garnier, J; Gilabert, M; Giovannini, M; Launay, S; Marchese, U; Moureau-Zabotto, L; Poizat, F; Turrini, O | 1 |
| Kubo, S; Tomita, N; Yamano, T | 1 |
| Bang, S; Chung, MJ; Jo, JH; Kang, H; Keum, J; Lee, HS; Park, JY; Park, SW; Song, SY | 1 |
| Doi, S; Fujiwara, H; Kawamura, T; Mikami, R; Nakamoto, Y; Noda, M; Okumoto, T; Tokunaga, Y; Tomita, N | 1 |
| Hoogeman, M; Loi, M; Magallon-Baro, A; Nuyttens, JJ; Suker, M; Van Eijck, C | 1 |
| Antico, G; Blauer-Petersen, C; Doleh, Y; Lal, LS; Pishvaian, M | 1 |
| Choi, YH; Jang, JY; Kim, SW; Kim, YT; Kwon, W; Lee, SH; Paik, WH; Ryu, JK; Shin, BS; You, MS | 1 |
| Fu, X; Mao, L; Qiu, YD; Tang, N; Xie, WQ | 1 |
| Chen, S; Feng, C; Guo, C; Hua, L; Huang, H; Li, G; Lin, Z; Mo, Q; Shen, Y; Wei, M; Xu, J | 1 |
| Aranda, E; Balbín, M; Bando, I; Bellosillo, B; Calle, SG; Díaz-Rubio, E; García-Alfonso, P; Llovet, P; Lopez, C; Martínez, A; Mediero, B; Moral, VM; Orden, V; Ortiz-Morales, MJ; Palanca, S; Peligros Gomez, MI; Quintero, G; Salud, A; Sastre, J; Viéitez, JM | 1 |
| Kimura, S; Kurioka, Y; Matsumoto, T; Matsuo, Y; Miura, K; Morishita, H; Okazaki, U; Takagi, S; Takatani, M; Tsuduki, T | 1 |
| Attard, JA; Chatzizacharias, NA; Faulkner, T; Isaac, J; Roberts, K | 1 |
| Endo, I; Kumamoto, T; Matsuyama, R; Murakami, T; Sawada, Y; Tsuchiya, N; Yabushita, Y | 1 |
| Barenboim, A; Ben-Haim, M; Brazowski, E; Geva, R; Golan, T; Goldes, Y; Goykhman, Y; Halpern, N; Klausner, JM; Lahat, G; Lubezky, N; Nachmany, I; Shacham-Shmueli, E; Wolf, I | 1 |
| Adam, R; Ballesta, A; Bouchahda, M; Chollet, P; Focan, C; Garufi, C; Giacchetti, S; Huang, Q; Innominato, PF; Karaboué, A; Lévi, FA | 1 |
| Cai, LH; Chen, JP; Fu, WH; Hao, HK; He, QL; Huang, CM; Jiang, LX; Li, E; Li, HL; Li, P; Li, SL; Li, Y; Li, YX; Li, Z; Lin, JP; Lin, JX; Lin, W; Tian, YT; Xie, JW; Xu, YC; Xu, ZK; Xue, FQ; Zhao, G; Zhao, YJ; Zheng, CH; Zhou, XJ; Zhou, YB; Zhu, ZG; Zou, BB | 1 |
| Alikhasi, A; Allahyari, A; Anjidani, N; Esfandbod, M; Ghadyani, M; Hajiqolami, A; Karbalaeian, M; Khosravi, A; Meskinimood, S; Mortazavizadeh, SM; Najafi, SN; Nekuee, A; Payandeh, M; Qarib, S; Rajaeinejad, M; Rezvani, A; Rezvani, H; Sadeghi, A; Salari, S; Shazad, B; Vahidfar, M | 1 |
| Chin, K; Kitagawa, Y; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Ota, Y; Shinozaki, E; Suenaga, M; Suzuki, T; Takahari, D; Wakatsuki, T; Yamaguchi, K | 1 |
| Choung, S; Fong, EJ; Foo, J; Gasho, J; Hashemi, N; Kim, S; Lau, R; Mumenthaler, SM; Spiller, E; Sun, RX; Ung, N | 1 |
| Abdelli, N; Barbe, C; Botsen, D; Bouché, O; Brasseur, M; Brugel, M; De Mestier, L; Deguelte, S; Desot, E; Grelet, S; Hautefeuille, V; Laurent-Badr, Q; Neuzillet, C; Pitta, A; Volet, J | 1 |
| Chen, H; Du, B; Hou, P; Jiang, T; Lai, J; Lin, M; Lin, X; Liu, Q; Wang, H; Wang, X; Yang, B; Zheng, J; Zhong, D | 1 |
| Dwarkasing, RS; Eskens, FALM; Groot Koerkamp, B; Homs, MYV; Nuyttens, JJ; Suker, M; van Eijck, CHJ | 1 |
| Bengrine-Lefevre, L; Ghiringhelli, F; Macaire, P; Paris, J; Schmitt, A; Vincent, J | 1 |
| Agrawal, S; Makuch, S; Winograd, K; Wiśniewski, J; Woźniak, M; Ziółkowski, P | 1 |
| Cai, Z; He, C; Li, S; Lin, X; Wang, J; Zhang, Y | 1 |
| Abushahin, L; Alexandra Diaz, D; Chen, W; Cloyd, JM; Dillhoff, M; Frankel, WL; Miller, ED; Noonan, A; Prabhakar, D; Williams, TM; Wolfe, AR; Yildiz, VO | 1 |
| Ahmed, S; Chalchal, H; Luo, Y; Moser, M; Shaw, J; Templeton, S; Wall, C; Zaidi, A | 1 |
| Bassi, C; Maggino, L; Malleo, G; Milella, M; Salvia, R | 1 |
| Du, GH; Wang, L; Wang, R; Wang, SM; Wei, GY | 1 |
| Abad, DG; Bockorny, B; Bohana-Kashtan, O; Borad, MJ; Borazanci, E; Chaney, M; Feliu, J; Geva, R; Golan, T; Hidalgo, M; Kadosh, S; Lustig, TM; Macarulla, T; Muñoz, A; Park, JO; Pedersen, KS; Peled, A; Ponz-Sarvise, M; Ramirez, RA; Semenisty, V; Shaw, SM; Sorani, E; Stemmer, SM; Vainstein Haras, A; Von Hoff, DD; Wolpin, BM | 1 |
| Acharya, A; Amin, M; Copsey, ML; Gao, F; Jin, RU; Lim, KH; Lockhart, AC; Morton, AE; Navo, KA; Park, H; Pedersen, KS; Rigden, C; Suresh, R; Tan, BR; Trikalinos, NA; Wang-Gillam, A | 1 |
| Artru, P; Bachet, JB; Benoist, S; Brouquet, A; Huguet, F; Karoui, M; Lefèvre, JH; Mariette, C; Sabbagh, C; Vernerey, D; Vicaut, E | 1 |
| Asaro, F; Fortuna, S; Garziera, M; Geremia, S; Scarabel, L; Toffoli, G | 1 |
| Abdul-Rahim, O; Khushman, M; Phung, T; Surinach, A | 1 |
| Almohamad, W; Biondani, P; Chebib, A; Ciacio, O; Gumus, Y; Haydar, M; Innominato, PF; Karaboué, A; Pittau, G; Ulusakarya, A | 1 |
| Allen, JN; Cai, L; Clark, JW; Deshpande, V; Fernández-Del Castillo, C; Ferrone, CR; Ferrone, S; Hong, TS; Kontos, F; Kurokawa, T; Lillemoe, KD; Michelakos, T; Neyaz, A; Qadan, M; Ryan, DP; Sabbatino, F; Taylor, MS; Ting, DT; Villani, V; Warshaw, AL; Weekes, CD; Wo, JY; Yamada, T | 1 |
| Artru, P; Dahan, L; De La Fouchardière, C; Guimbaud, R; Jouve, JL; Lepage, C; Montérymard, C; Pellerin, O; Pernot, S; Raoul, JL; Sefrioui, D; Smith, D; Taieb, J; Tougeron, D | 1 |
| Nowak-Sliwinska, P; Ramzy, GM; Rausch, M; Zoetemelk, M | 1 |
| Aprile, G; Brandi, G; Brieau, B; Casadei-Gardini, A; Dahan, L; Evesque, L; Filippi, R; Le Sourd, S; Lièvre, A; Lonardi, S; Meurisse, A; Neuzillet, C; Pointet, AL; Rousseau, B; Scartozzi, M; Silvestris, N; Tougeron, D; Vernerey, D; Vienot, A; Vivaldi, C | 1 |
| Baba, E; Boku, N; Denda, T; Esaki, T; Fujii, H; Goto, M; Hara, H; Hironaka, S; Hosokawa, A; Hyodo, I; Ishida, H; Kadowaki, S; Kishimoto, J; Koh, Y; Kuramochi, H; Makiyama, A; Matsumoto, S; Moriwaki, T; Muro, K; Nishina, T; Okuda, H; Otsu, S; Ozaki, Y; Sakai, D; Sakamoto, T; Sato, M; Satoh, T; Shimokawa, H; Shinozaki, K; Sugimoto, N; Tamagawa, H; Tamura, T; Taniguchi, H; Tokunaga, S; Tsuda, T; Tsuji, A; Tsushima, T; Yamazaki, K; Yasui, H | 1 |
| Bodea, R; Mercea, V; Nemes, A; Vidra, R | 1 |
| Ahn, DW; Choi, JH; Jeong, JB; Kang, J; Kim, YT; Lee, SH; Paik, WH; Ryu, JK | 1 |
| Ueno, M | 1 |
| Bachet, JB; Mas, L; Schwarz, L | 1 |
| Aprile, G; Belfiore, A; Boccaccino, A; Brich, S; Cattaneo, L; Centonze, G; Cillo, U; Corallo, S; Cremolini, C; De Braud, F; Falcone, A; Fassan, M; Fontanini, G; Germani, MM; Lonardi, S; Loupakis, F; Marmorino, F; Milione, M; Morano, F; Morelli, L; Moretto, R; Pietrantonio, F; Prisciandaro, M; Rossini, D; Urbani, L | 1 |
| Buchinger, D; Djanani, A; Prager, GW; Schmiderer, A; Taghizadeh, H; Unseld, M; Wilthoner, K | 1 |
| Frampton, JE | 1 |
| Kasi, A; Paluri, RK; Posey, JA; Young, C | 1 |
| Eberle, KC; Hollingsworth, MA; Mehla, K; Mundry, CS; Singh, PK | 1 |
| Bullock, A; Chiorean, EG; Oestreicher, N; Rowan, CG; Yeganegi, H | 1 |
| Alric, P; Carrier, G; Colombo, PE; Mourregot, A; Neron, M; Portales, F; Quenet, F; Rouanet, P | 1 |
| Anders, RA; Bever, KM; Durham, JN; Ferguson, AK; Fertig, EJ; Ho, WJ; Jaffee, EM; Ko, AH; Laheru, DA; Le, DT; Niu, N; Onners, B; Parkinson, RM; Sugar, EA; Thompson, ED; Wang-Gillam, A; Wilt, C; Wu, AA; Zheng, L | 1 |
| Abdel Moneim, R; Aldaly, M; Elsherbiny, M; Sakr, A; Shaaban, S | 1 |
| Arora, G; Axtell, AL; Bardeesy, N; Caravan, P; Chawla, A; Chen, YI; Deshpande, V; Erstad, DJ; Farrar, CT; Ferreira, DS; Ferrone, CR; Fuchs, BC; Ghoshal, S; Graham-O'Regan, KA; Humblet, V; Jones, C; Jordan, VC; Kontos, F; Lanuti, M; Li, S; Michelakos, T; Qadan, M; Rotile, NJ; Sojoodi, M; Tanabe, KK; Taylor, MS | 1 |
| Asaro, G; De Luca, A; Delfini, M; Guglielmi, G; Iavicoli, S; Sciubba, F; Spagnoli, M | 1 |
| Begg, SKS; Birnbaum, DJ; Castillo, CF; Clark, JW; Lillemoe, KD; Liss, AS; Mino-Kenudson, M; Schilling, O; Warshaw, AL; Wellner, UF | 1 |
| Bengrine, L; Fumet, JD; Ghiringhelli, F; Granconato, L; Hennequin, A; Palmier, R; Vincent, J | 1 |
| Anantharaman, A; Azarm, A; Cao, C; Lai, J; Moezardalan, K; Parikh, P | 1 |
| Bachet, JB; Bouhier Leporrier, K; Coriat, R; Gouttebel, MC; Gratet, A; Khemissa Akouz, F; Laharie, H; Le Malicot, K; Lepage, C; Louafi, S; Malka, D; Miglianico, L; Pointet, AL; Rinaldi, Y; Taieb, J; Terrebonne, E; Texereau, P; Thirot Bidault, A; Wahiba, B | 1 |
| Armenoult, L; Ayadi, M; Bigonnet, M; Blum, Y; Bournet, B; Brandone, N; Buscail, L; Canivet, C; Cros, J; de Reyniès, A; Duconseil, P; Dusetti, N; Elarouci, N; Garcia, S; Gayet, O; Gilabert, M; Giovannini, M; Grandval, P; Iovanna, J; Moutardier, V; Nicolle, R; Poizat, F; Roques, J; Rubis, M; Vanbrugghe, C | 1 |
| Fischer von Weikersthal, L; Fraccaroli, A; Haas, M; Heinemann, V; Heinrich, K; Held, S; Holch, JW; Jung, A; Kullmann, F; Modest, DP; Moehler, M; Scheithauer, W; Schulz, C; Stintzing, S; von Einem, JC | 1 |
| Moir, JAG; Severs, GR; Tingle, SJ; White, SA | 1 |
| Aldakkak, M; Barnes, CA; Christians, KK; Clarke, CN; Dua, K; Erickson, BA; Evans, DB; George, B; Hall, WA; Kamgar, M; Kulkarni, N; Ritch, PS; Tsai, S | 1 |
| Blakaj, A; Cecchini, M; Johnson, SB; Johung, KL; Kortmansky, JS; Lacy, J; Miccio, JA; Pahade, J; Salem, RR; Stein, S | 1 |
| Ahmad, S; Barrord, M; Choe, K; Esslinger, H; Kharofa, J; Latif, T; Olowokure, O; Patel, S; Poreddy, S; Smith, M; Sussman, J | 1 |
| Khan, GN; Patil, NR | 1 |
| Hines, OJ; Ye, L | 1 |
| Fogelman, D; Herman, J; Ikoma, N; Javle, M; Katz, MHG; Kim, M; Koay, EJ; Lee, JE; Overman, M; Pant, S; Perri, G; Prakash, L; Qiao, W; Tzeng, CW; Varadhachary, GR; Wolff, R | 1 |
| Ando, Y; Maeda, O; Shimokata, T | 1 |
| Joshi, SS; Kindler, HL; Sharma, MR | 1 |
| Du, J; Gu, J; Li, J | 1 |
| Bhutiani, N; Chen, Y; Li, Y; Martin, RCG; Pandit, H; Pulliam, ZR; Shi, X; Tan, M; Yu, Y; Zheng, Q | 1 |
| Chovanec, M; Janega, P; Macák, D; Makovník, M; Mardiak, J; Mego, M; Pazderová, N; Rejleková, K; Urbán, V | 1 |
| Ikeda, K; Kuwata, GO; Manome, Y | 1 |
| Ceyhan, GO; Damm, M; Kordes, M; Maggino, L; Moir, J; Rosendahl, J; Schorn, S; Weniger, M | 2 |
| Ahmad, SA; Beg, MS; Chiorean, EG; Duong, M; Gandhi, NS; Guthrie, KA; Hochster, HS; Lowy, AM; Philip, PA; Sohal, DPS; Wade, JL; Wang-Gillam, A | 1 |
| Al Thaalibi, M; McQuade, RM; Nurgali, K | 1 |
| Byun, JH; Kang, JH; Kim, HJ; Kim, JH; Kim, KP; Kim, SC; Lee, SS; Ryoo, BY; Yoo, C | 1 |
| Chen, JB; Chen, TL; Huang, CW; Huang, HY; Ke, TW; Lin, YW; Sung, YC; Tang, HC; Tsai, CS; Tsai, HL; Wang, HM; Wang, JH; Wang, JY; Wu, CC | 1 |
| Byun, Y; Chie, EK; Choi, YJ; Han, Y; Jang, JY; Kang, JS; Kim, H; Kim, HS; Kim, YT; Kwon, W; Lee, K; Lee, SH; Oh, DY; Paik, WH; Ryu, JK | 1 |
| Byun, JH; Hong, SM; Jang, JK; Kang, JH; Kim, HJ; Kim, JH; Kim, KP; Kim, SC; Lee, MG; Lee, SS; Seo, DW; Son, JH; Yoo, C | 1 |
| Camara, JC; Franco, F; Gutiérrez-Abad, D; Juez, I; León, A; López-Alfonso, A; Marrupe, D; Martín-Valadés, JI; Martínez-Amores, B; Pérez, M; Royuela, A; Ruiz-Casado, A | 1 |
| Besselink, MG; Busch, OR; de Jong, MC; Derksen, TC; Kazemier, G; Meijerink, MR; Puijk, RS; Ruarus, AH; Scheffer, HJ; Sorgedrager, NS; van Lienden, KP; van Veldhuisen, E; Vogel, JA; Vroomen, LG; Wilmink, JW | 1 |
| Ichikawa, H; Iwasa, Y; Iwashita, T; Mita, N; Shimizu, M; Shiraki, M; Uemura, S | 1 |
| Borg, C; Chevalier, H; Edeline, J; El Hajbi, F; Hammel, P; Lièvre, A; Meurisse, A; Neuzillet, C; Peugniez, C; Turpin, A; Vernerey, D; Vienot, A | 1 |
| Cha, HS; Hwang, JH; Kim, J; Kim, JW; Kim, MJ; Lee, JC; Lee, WJ; Park, P; Shin, DW; Woo, SM; Yang, SY | 1 |
| Hironaka, S; Hosokawa, A; Kusaba, H; Matsuda, C; Morita, S; Muro, K; Okamura, S; Shinozaki, K; Shirakawa, T; Tamura, T; Tsuda, M; Tsuda, T; Tsushima, T; Ueda, S; Yamashita, H; Yamazaki, K | 1 |
| Arnold, D; Collienne, M; Hauber, HP; Kuhns, M | 1 |
| Habib, JR; Wolfgang, CL | 1 |
| Abu Hilal, M; Alseidi, A; Balduzzi, A; Balzano, G; Bassi, C; Berrevoet, F; Besselink, MG; Bonds, M; Bossuyt, PM; Busch, OR; Butturini, G; Conlon, KC; Del Chiaro, M; Falconi, M; Frigerio, I; Fusai, GK; Gagnière, J; Griffin, O; Groot Koerkamp, B; Hackert, T; Halimi, A; Janssen, QP; Keck, T; Klaiber, U; Kleeff, J; Klompmaker, S; Labori, KJ; Lesurtel, M; Malleo, G; Marino, MV; Mortensen, MB; Nikov, A; Pandé, R; Pfeiffer, P; Pietrasz, D; Roberts, KJ; Sa Cunha, A; Salvia, R; Strobel, O; Tarvainen, T; van Laarhoven, HWM; van Roessel, S; van Veldhuisen, E; Wilmink, JW | 1 |
| Adler, W; Bechstein, WO; Boeck, S; Croner, RS; Fietkau, R; Ghadimi, M; Golcher, H; Grützmann, R; Hohenberger, WM; Imhoff, D; Jacobasch, L; Keilholz, L; Lubgan, D; Neumann, UP; Oettle, H; Pirkl, A; Reinacher-Schick, A; Rutzner, S; Semrau, S; Uhl, W; Wittel, UA | 1 |
| Abaei, A; Arnold, F; Barth, TFE; Beutel, AK; Gout, J; Kleger, A; Müller, M; Perkhofer, L; Rasche, V; Roger, E; Seufferlein, T | 1 |
| Baltatzis, M; De Liguori Carino, N; Rodriquenz, MG; Siriwardena, AK | 1 |
| Antico, G; Cole, A; Doleh, Y; Malangone-Monaco, E; Noxon, V; Pishvaian, MJ | 1 |
| Fukutomi, A; Hayashi, H; Horita, Y; Ishihara, S; Kamei, K; Kobayashi, N; Kobayashi, S; Mizuno, N; Okano, N; Omae, K; Ozaka, M; Sudo, K; Suzuki, S; Todaka, A; Uchiyama, T; Ueno, H; Uesugi, K; Yamaguchi, A | 1 |
| Cui, J; Qu, S; Wang, L; Zhang, X | 1 |
| Balachandran, VP; Boerner, T; Buisman, FE; D'Angelica, MI; Drebin, JA; Gonen, M; Jarnagin, WR; Kemeny, NE; Kingham, TP; Narayan, RR; Seier, K; Srouji, RM; Wei, A | 1 |
| Boldrini, L; Buwenge, M; Cellini, F; D'Aviero, A; Deodato, F; Dinapoli, N; Frascino, V; Macchia, G; Mattiucci, GC; Morganti, AG; Nardangeli, A; Valentini, V | 1 |
| Alhyari, L; Aljumaily, R; Assi, HA; Shikdar, S | 1 |
| Evans, S; Nagourney, AJ; Nagourney, RA; Sugarbaker, PH; Tran, PH | 1 |
| Besselink, MG; Bhairosingh, SS; Bonsing, BA; Busch, OR; de Muynck, LDAN; Fariňa-Sarasqueta, A; Franken, LC; Kuppen, PJK; Mieog, JSD; Sier, CFM; Swijnenburg, RJ; Vahrmeijer, AL; Verheij, J; Vuijk, FA; Wilmink, JW | 1 |
| Belli, A; Fusco, R; Granata, V; Izzo, F; Palaia, R; Petrillo, A | 1 |
| Du, GH; Wang, L; Wang, R; Wang, SM; Wang, Z; Wei, GY; Zhang, RP; Zhu, Y | 1 |
| Abdel-Rahman, O; Koski, S; Mulder, K | 1 |
| Abushahin, L; Belanger, B; Cockrum, P; Corvino, FA; Kim, GP; Surinach, A | 1 |
| Miao, Y; Pu, N; Thompson, E; Wolfgang, C; Yin, L; Yu, J | 1 |
| Chugh, P; Furukawa, M; Furuse, J; Ikeda, M; Ioka, T; Ishii, H; Kanai, M; Kawabe, K; Komatsu, Y; Nakamori, S; Okusaka, T; Ozaka, M; Sato, A; Shimizu, S; Sugimori, K; Tang, R; Ueno, M | 1 |
| Cui, H; Dai, G; Deng, G; Guan, J; Lou, C; Yuan, J; Zhang, W; Zhang, Y; Zhou, A; Zhou, J | 1 |
| Foster, L; Lamarca, A; Satyadas, T; Siriwardena, A; Valle, JW | 1 |
| Hui, F; Qi, X; Ren, T; Shen, Z; Wang, S; Xu, C; Zhang, Y; Zhao, Q | 1 |
| Burris, H; Chen, W; Eng, C; Esser, R; Lenz, HJ; Middleton, G; Nippgen, J; Scheithauer, W; Sobrero, A | 1 |
| Han, JK; Joo, I; Kim, JH; Lee, KB; Park, SJ | 1 |
| Al-Rajabi, R; Carroll, E; Diab, O; Kasi, A; Melancon, T; Rawlley, B | 1 |
| Chawla, SP; Higuchi, T; Hoffman, RM; Hu, K; Kawaguchi, K; Kiyuna, T; Miyake, K; Miyake, M; Oshiro, H; Razmjooei, S; Singh, SR; Wangsiricharoen, S; Zhang, Z | 1 |
| Bekaii-Saab, T; Belanger, B; Blanc, JF; Chen, LT; de Jong, FA; Macarulla, T; Mirakhur, B; Siveke, JT | 1 |
| Batra, SK; Bronich, TK; Lei, F; Ponnusamy, MP; Rachagani, S; Seshacharyulu, P; Talmon, GA; Xi, X | 1 |
| Eskens, FALM; Loi, M; Nuyttens, JJ; Suker, M; Teriaca, MA; van Eijck, CHJ | 1 |
| Ammori, JB; Bingmer, K; Hardacre, JM; Hue, JJ; Sugumar, K; Winter, JM | 1 |
| Bhargava, P; Choudhari, A; Goel, M; Gupta, S; Jadhav, P; Mandavkar, S; Ostwal, V; Parulekar, M; Patkar, S; Ramaswamy, A; Sharma, A; Srinivas, S | 1 |
| Besselink, MG; Blomjous, JG; Bollen, TL; Bosscha, K; Brada, LJ; Bruijnen, RC; Busch, OR; Creemers, GJ; Daams, F; de Hingh, IH; de Meijer, VE; de Vos-Geelen, J; de Vries, JJJ; Festen, S; Hermans, JJ; Jan de Groot, D; Kerver, ED; Liem, MS; Los, M; Meijerink, MR; Mekenkamp, LJ; Mohammad, NH; Molenaar, IQ; Nederend, J; Nio, CY; Patijn, GA; Patuleia, SIS; Polée, MB; Pruijt, JF; Renken, NS; Rombouts, SJ; Schouten, TJ; Stommel, MWJ; van Dam, R; van der Leij, C; van Leeuwen, MS; van Lienden, KP; van Santvoort, HC; Verweij, ME; Vulink, A; Walma, MS; Wessels, FJ; Willem de Groot, J; Wilmink, JW | 1 |
| Carneiro, BA; El-Deiry, WS; Marks, EI; Matera, R; Olszewski, AJ; Safran, H; Yakirevich, E | 1 |
| Karaca, M; Kayahan, N; Özet, A; Satış, H; Yapar, D | 1 |
| Burkhart, RA; Burns, WR; Cameron, JL; Delitto, D; Ding, D; He, J; Lafaro, KJ; Schmocker, RK; Wolfgang, CL; Wright, MJ | 1 |
| Catalano, O; Deshpande, V; Fernandez-Del Castillo, C; Ferrone, CR; Harrison, J; Hong, TS; Kontos, F; Lillemoe, KD; Michelakos, T; Qadan, M; Sekigami, Y; Wo, JY | 1 |
| Chen, B; Chen, M; Gu, X; Huang, C; Yu, W; Zeng, X | 1 |
| Huntington, SF; Lacy, J; O'Hara, M; Patel, KK; Stein, S | 1 |
| Bergeat, D; Boudjema, K; Delpero, JR; Ewald, J; Garnier, J; Marchese, U; Robin, F; Sulpice, L; Turrini, O | 1 |
| Borgonovo, K; Cabiddu, M; Ghidini, M; Ghilardi, M; Lonati, V; Nicoletti, M; Parati, MC; Petrelli, F; Ratti, M; Tomasello, G | 1 |
| Atias, D; Berger, R; Borgida, A; Cuggia, A; Denroche, RE; Dodd, A; Fischer, SE; Gallinger, S; Glick, Y; Golan, T; Grant, RC; Halperin, S; Holter, S; Jang, GH; Knox, JJ; Notta, F; O'Kane, GM; Park, JP; Raitses-Gurevich, M; Renouf, DJ; Schaeffer, DF; Stossel, C; Wang, Y; Williamson, L; Wilson, JM; Wong, HL; Zhang, A; Zogopoulos, G | 1 |
| Chen, Z; Diao, R; Li, H; Lv, Y; Yu, T; Zhou, J | 1 |
| Cepero, A; Martin-Guerrero, SM; Martin-Oliva, D; Melguizo, C; Munoz-Gamez, JA; Ortiz, R; Prados, J; Quinonero, F; Urbano, D | 1 |
| Bae, WK; Cheon, J; Choi, HJ; Chon, HJ; Hong, JY; Hwang, JE; Im, HS; Kang, B; Kang, JH; Kang, MJ; Kim, I; Kim, JH; Kim, JW; Lee, CK; Lim, SH; Park, HS; Park, JO; Yoo, C | 1 |
| von Figura, G; Wenzel, P | 1 |
| Ergözen, S; Gümüş, T | 1 |
| Ayukawa, H; Endo, S; Furuse, J; Furuta, T; Hirano, R; Kaneko, S; Kawai, K; Kobayashi, T; Minowa, Y; Nagashima, F; Naruge, D; Okano, N; Shibasaki, H; Yokokawa, A | 1 |
| Jaeger, M; Klassen, MD; Reinders, LMH; Schmidt, TC; Teutenberg, T; Tuerk, J; Vom Eyser, C | 1 |
| Al-Rajabi, R; Balducci, L; Banks, J; Brenner, W; Coveler, AL; Elquza, E; George, TJ; Hatoum, H; Hewitt, DB; Kennedy, E; Lavu, H; Leiby, B; Link, C; LoConte, N; Musher, B; Nissen, N; Rossi, G; Seng, J; Vaccaro, G; Vahanian, N; Yeo, CJ | 1 |
| Jahangiri, Y | 1 |
| Kang, J; Kim, SY; Kim, TW; Lee, JS; Morita, S; Muro, K; Park, YS; Sakamoto, J; Xu, RH | 1 |
| Carrato, A; Feliu, J; Garcia-Carbonero, R; Gómez-España, MA; Martín, AM; Maurel, J; Mercadé, TM; Montes, AF; Pazo-Cid, R; Vera, R | 1 |
| Addeo, P; Bachellier, P; Guerra, M | 1 |
| Bates, SE; Conroy, T; Fojo, T; Juzyna, B; Mutetwa, T; Nadkarni, G; Park, YA; Polak, P; Sigel, C; Sigel, K; Wisnivesky, JP; Ychou, M; Yeh, C; Zhou, M | 1 |
| Obonyo, D; Stricker, I; Tannapfel, A; Uslar, VN; Weyhe, D | 1 |
| Fu, X; He, J; Qiu, Y; Song, T; Tang, N; Xu, S | 1 |
| Besselink, MG; Bonsing, BA; Bos, H; Bosscha, KP; Coene, PPLO; de Hingh, IHJT; de Vos-Geelen, J; Groot Koerkamp, B; Homs, MYV; Janssen, QP; Karsten, TM; Liem, MSL; Loosveld, OJL; Patijn, GA; van Dam, JL; van der Kolk, MB; van Eijck, CHJ; van Santvoort, HC; van Tienhoven, G; Wilmink, JW; Zonderhuis, BM | 1 |
| Abdallah, R; Auclin, E; Bachet, JB; Coriat, R; Cunha, AS; de La Fouchardière, C; Fabiano, E; Forestier, J; Francois, E; Hautefeuille, V; Ksontini, F; Lecomte, T; Leroy, F; Marthey, L; Mas, L; Saint, A; Sarabi, M; Taieb, J; Tougeron, D; Vienot, A; Williet, N | 1 |
| Gui, Q; Li, D; Xu, C; Zhuge, Y | 1 |
| Karanicolas, PJ; Katz, MHG; Mavros, MN; Moris, D; O'Reilly, EM; Pawlik, TM | 1 |
| Kurasaka, C; Ogino, Y; Sato, A | 1 |
| Astaras, C; Borner, M; De Dosso, S; Fritsch, R; Meisel, A; Siebenhüner, AR; Szturz, P; Winder, T | 1 |
| Amini, A; Attiyeh, MA; Chung, V; Melstrom, LG | 1 |
| Bentrem, DJ; Vitello, DJ | 1 |
| Are, C; Pinninti, R; Rajappa, SJ | 1 |
| Evans, DB; Tsai, S; Ward, EP | 1 |
| Brown, ZJ; Cloyd, JM | 1 |
| Berger, AK; Bougatf, N; Busch, E; Hackert, T; Jäger, D; Springfeld, C; Werft, W | 1 |
| Fakih, M; Grothey, A; Tabernero, J | 1 |
| Bujko, K; Socha, J | 1 |
| Custodio, A; Feliu, J; Garcia-Cuesta, JA; Ghanem, I; Gutierrez-Sainz, L; Martinez-Perez, D; Villamayor, J; Viñal, D | 1 |
| Aoki, K; Hamano, T; Makishima, M; Oki, E; Sano, F; Yamanaka, T; Yamazaki, K; Yuki, S | 1 |
| Alig, S; Bararia, D; Boeck, S; Haas, M; Haebe, S; Heinemann, V; Kobold, S; Kruger, S; Metzger, P; Ormanns, S; Rataj, F; Sams, L; von Bergwelt-Baildon, M; Weigert, O; Werner, J; Westphalen, CB; Zhang, D | 1 |
| Cho, E; Kim, YJ; Park, CH | 1 |
| Basadonna, G; Canady, J; Cheng, X; Jones, O; Keidar, M; Ly, L; Murthy, SRK; Zhuang, T | 1 |
| Barbolosi, D; Deyme, L; Evrard, A; Gattacceca, F; Mbatchi, LC; Tubiana-Mathieu, N; Ychou, M | 1 |
| Fukuda, K; Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 1 |
| Barth, DA; Djanani, A; Gantschnigg, A; Gerger, A; Greil, R; Horvath, L; Moik, F; Pichler, M; Posch, F; Renneberg, F; Riedl, JM; Rossmann, CH; Schaberl-Moser, R; Schlick, K; Schwarzenbacher, E; Stöger, H; Stotz, M | 1 |
| Ashrafi-Zadeh, A; Chan, DL; Chua, TC; Clarke, S; Diakos, C; Gill, A; Hruby, G; Jamieson, NB; Kneebone, A; Maloney, S; Mittal, A; Nahm, CB; Pavlakis, N; Samra, JS; Wijetunga, AR | 1 |
| Cho, IR; Chun, JW; Huh, G; Kim, JS; Kim, YT; Lee, SH; Paik, WH; Park, N; Ryu, JK | 1 |
| Astras, G; Davakis, S; Dimitrokallis, N; Felekouras, E; Karamouzis, MV; Kountourakis, P; Moris, D; Oikonomou, D; Papalampros, A; Papamichael, D; Petrou, AS; Schizas, D | 1 |
| Afchain, P; Baudin, E; Desgrippes, R; Hadoux, J; Hautefeuille, V; Lepage, C; Lorgis, V; Monterymard, C; Scoazec, JY; Thuillier, F; Tougeron, D; Walter, T | 1 |
| de Gramont, A; Glimelius, B; Marshall, J; Stintzing, S; Yoshino, T | 1 |
| Chung, V; Fakih, M; Franko, J; Le, VH; Paz, BI; Singh, G | 1 |
| Chang, TK; Chen, PJ; Chen, YC; Cheng, TL; Chuang, KH; Huang, CW; Li, CC; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yin, TC | 1 |
| Amaro, CP; Falck, V; Ng, D; Shelemey, PT; Tam, VC | 1 |
| Bartolini, G; Bernardini, L; Casadei-Gardini, A; Cucchetti, A; Frassineti, GL; Massa, V; Passardi, A; Rapposelli, IG; Vivaldi, C | 1 |
| Han, JK; Joo, I; Kim, JH; Park, SJ | 1 |
| Besselink, MG; Bosscha, K; Brada, LJH; Bruijnen, RC; Busch, OR; Daamen, LA; de Hingh, IH; de Meijer, VE; de Vries, JJJ; Festen, S; Liem, MLS; Los, M; Mohammad, NH; Patijn, GA; Polée, MB; Quintus Molenaar, I; Stommel, MWJ; van Dam, RM; van Lienden, KP; van Roessel, S; van Santvoort, HC; Walma, MS; Wessels, FJ; Wilmink, HW; Yung Nio, C | 1 |
| Besselink, MG; de Wilde, RF; Groot Koerkamp, B; Homs, MYV; Janssen, QP; Kivits, IG; Nuyttens, JJME; Qi, H; van Dam, JL; van Eijck, CHJ; van Santvoort, HJ; van Tienhoven, G; Wei, AC; Wilmink, JW | 1 |
| Chen, P; Hong, J; Jin, J; Ng, DM; Xu, Y; Yang, T; Zhang, B; Zhou, F; Zhou, X | 1 |
| Arima, S; Fukahori, M; Hashimoto, S; Honda, T; Ide, Y; Ido, A; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Abad, DG; Alistar, A; Bockorny, B; Borazanci, E; Chaney, M; Feliu, J; Fernandez, MS; Geva, R; Gliko-Kabir, I; Guillén-Ponce, C; Hidalgo, M; Ickowicz, D; Kadosh, S; Macarulla, T; Muñoz, A; Oberstein, P; Peled, A; Ponz-Sarvise, M; Semenisty, V; Shemesh-Darvish, L; Sorani, E; Vainstein-Haras, A | 1 |
| Ay, C; Barth, DA; Djanani, A; Fandler-Höfler, S; Gantschnigg, A; Gary, T; Gerger, A; Greil, R; Gressenberger, P; Hatzl, S; Horvath, L; Jost, PJ; Moik, F; Pichler, M; Posch, F; Renneberg, F; Riedl, JM; Schlick, K; Schwarzenbacher, E; Stotz, M | 1 |
| Cui, J; Cui, X; Gong, W; Han, X; Lau, WY; Li, H; Li, M; Li, X; Liu, Y; Ren, T; Song, X; Wang, L; Wang, X; Wu, W; Wu, X; Zhu, Y; Zou, L | 1 |
| Hwang, JH; Kim, J; Kim, MA; Lee, JC; Shin, DW | 1 |
| Aparicio, T; Bachet, JB; Bignon, AL; Bouché, O; Dahan, L; Desrame, J; François, E; Le Malicot, K; Lecaille, C; Lepage, C; Malka, D; Petorin, C; Phelip, JM; Rebischung, C; Rinaldi, Y; Seitz, JF; Turpin, A; Williet, N | 1 |
| Chen, J; Hua, Q; Lin, Z; Pi, G; Wang, H; Yu, D; Zhang, D; Zhang, T; Zhao, L | 1 |
| Baba, H; Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kotake, M; Morita, S; Nakamura, M; Ohori, H; Sakashita, A; Sato, A; Shimada, K; Takahashi, M; Takahashi, S; Takashima, A; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S | 1 |
| Ata, FK; Yalcin, S | 1 |
| Besselink, MG; Bosscha, K; Brada, LJH; Bruijnen, RC; Busch, OR; Daamen, LA; de Hingh, IH; de Meijer, VE; de Vries, JJJ; Festen, S; Koerkamp, BG; Latifi, D; Liem, MSL; Magermans, LG; Molenaar, QI; Nio, YC; Patijn, GA; Polée, MB; Stommel, MWJ; van Dam, RM; van Eijck, C; van Lienden, KP; van Santvoort, HC; Walma, MS; Wessels, FJ; Wilmink, HJW | 1 |
| Baron, MK; Garrido-Laguna, I; Haaland, B; Moser, JC; Nevala-Plagemann, C; Wang, X | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Ido, A; Kawahira, M; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Ben Abdelghani, M; Caron, B; Duclos, B; Kurtz, JE; Nguimpi-Tambou, M; Noirclerc, M; Reimund, JM; Sondag, D | 1 |
| Batra, A; Cheung, WY; Tang, PA | 1 |
| Botta, GP; Fanta, P; Kato, S; Kurzrock, R; Lee, S; Okamura, R; Patel, H | 1 |
| Abraham, I; Alrawashdh, N; MacDonald, K; McBride, A | 1 |
| Boku, N; Kanemitsu, Y; Shida, D; Takashima, A; Tanabe, T; Tsukamoto, S; Yoshida, T | 1 |
| Abugomaa, A; Ayame, H; Elbadawy, M; Hayashi, K; Hayashi, SM; Hazama, S; Ishihara, Y; Kaneda, M; Nagano, H; Nakajima, M; Sasaki, K; Shibutani, M; Shinohara, Y; Suzuki, N; Takenouchi, H; Tsunedomi, R; Usui, T; Yamawaki, H | 1 |
| Agarwal, R; Grieb, BC | 1 |
| Aguirre, AJ; Perez, K; Singh, H; Wolpin, BM | 1 |
| Algül, H; Decker, T; Erickson, NT; Gesenhues, AB; Heinemann, V; Heintges, T; Höffkes, HG; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Lerch, MM; Link, H; Liu, L; Michl, M; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Stintzing, S; Theurich, S; von Weikersthal, LF | 1 |
| Carvalho, T; Castillo Martin, M; Costa, B; Couto, N; Fior, R; Rebelo de Almeida, C; Tavares Barroso, M | 1 |
| Chen, Z; Wang, M; Yang, L; Zhu, P | 1 |
| Chen, YW; Chen, ZL; Deng, YY; Pan, SY; Wang, MX; Yang, L; Zhu, PF | 1 |
| Azadmanesh, K; Fakhr, E; Teimoori-Toolabi, L; Zare, F | 1 |
| Callan, B; Callan, JF; Gao, J; Griffith, DM; Logan, KA; Love, M; McHale, AP; McKaig, T; Nesbitt, H; Taylor, M | 1 |
| Caputo, V; Cicero, G; De Luca, R; Ferrera, G; Mistretta, O; Paci, R; Rosati, G; Volpe, C | 1 |
| Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kumbrink, J; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schuster, V; Schwaner, I; Stahler, A; Stintzing, S | 1 |
| Beugniez, C; Bongiovanni, A; Duchêne, B; El Moghrabi, S; Escande, F; Hadj Bachir, E; Jonckheere, N; Jouy, N; Lagadec, C; Leteurtre, E; Paget, S; Pigny, P; Poiraud, C; Poulain, L; Renaud, F; Stoup, N; Tardivel, M; Truant, S; Van Seuningen, I; Vandepeutte, M; Vincent, A; Weiswald, LB | 1 |
| Chang, J; Doukas, M; Farshadi, EA; Koerkamp, BG; Pothof, J; Sampadi, B; Van 't Land, F; van der Sijde, F; van Eijck, CHJ; Vietsch, EE | 1 |
| Chie, EK; Jang, JY; Kang, JS; Kim, H; Kim, YT; Kwon, W; Lee, M; Lee, SH; Oh, DY; Ryu, JK | 1 |
| Catenacci, DVT | 1 |
| Caldwell, KE; Cullinan, DR; DeNardo, DG; Fields, RC; Gillanders, WE; Goedegebuure, SP; Hawkins, WG; Hogg, GD; James, CA; Liu, J; Mudd, JL; Peng, H; Takchi, R; Zuo, C | 1 |
| Au, T; Biskupiak, J; Kharat, AA; Nelson, R | 1 |
| Hwang, JH; Kim, J; Kim, JH; Lee, JC; Lee, YS | 1 |
| Akouz, FK; Barbier, E; Bourgeois, V; Coriat, R; Dahan, L; Desrame, J; Edeline, J; Ghiringhelli, F; Lecomte, T; Louafi, S; Ly, VL; Malka, D; Manfredi, S; Michel, P; Molin, Y; Neuzillet, C; Perrier, H; Phelip, JM; Soularue, E; Terrebonne, E | 1 |
| Besselink, MG; Bonsing, BA; Bosscha, K; de Groot, JWB; Groot Koerkamp, B; Haberkorn, BCM; Homs, MYV; Karsten, TM; Luelmo, SAC; Mekenkamp, LJM; Mustafa, DAM; van Bekkum, ML; van den Bosch, TPP; van der Sijde, F; van Eijck, CHJ; Vietsch, EE; Wilmink, JW | 1 |
| Delpero, JR; Ewald, J; Garnier, J; Magallon, C; Marchese, U; Palen, A; Turrini, O | 1 |
| Boku, N; Esaki, T; Izawa, N; Kawakami, K; Kawakami, T; Komoda, M; Makiyama, A; Masuishi, T; Mitani, S; Moriwaki, T; Nagashima, K; Nakajima, TE; Okuda, H; Tsuji, Y; Yamamoto, S; Yamamoto, Y; Yamazaki, K | 1 |
| Allen, PJ; Balachandran, VP; Cohen, NA; D'Angelica, MI; Drebin, JA; Goldman, DA; Gonen, M; Jarnagin, WR; Kingham, TP; McIntyre, CA; O'Reilly, EM; Sadot, E; Soares, KC; Varghese, AM; Wei, AC; Yu, KH | 1 |
| Hong, TH; Kim, H; Lee, MA; Park, SJ; Shin, K; Suh, JH | 1 |
| Bathe, O; Jacobs, R; Mazurak, VC; Monirujjaman, M; Nelson, R; Pant, A | 1 |
| Chao, Y; Lee, CY; Li, CP; Lin, LG; Yu, HY | 1 |
| Moskie, M; Schafthuizen, L; van 't Land, FR; van der Sijde, F; van Dijk, M; van Eijck, CHJ; van Laarhoven, HWM | 1 |
| Aoyama, T; Kazama, K; Numata, M; Oshima, T; Rino, Y; Sato, M; Sato, S; Shiozawa, M; Sugano, N; Tamagawa, H; Uchiyama, M; Yukawa, N | 1 |
| Arias, J; Beca, J; Biagi, JJ; Chan, KKW; Dai, WF; Earle, CC; Forbes, L; Gavura, S; Habbous, S; Raphael, MJ; Raskin, W; Tai, X | 1 |
| Bilić, I; Božina, N; Ganoci, L; Lešnjaković, L; Pleština, S; Šimičević, L; Trkulja, V | 1 |
| Bruns, C; Damanakis, AI; Deuß, B; Gebauer, F; Göser, T; Held, S; Kütting, F; Lutz, K; Popp, F; Quaas, A; Waldschmidt, D | 1 |
| Amato, F; Azevedo, SX; Begum, R; Biankin, AV; Braconi, C; Carotenuto, P; Chang, DK; Chau, I; Cunningham, D; Fassan, M; Guzzardo, V; Hahne, JC; Hallsworth, A; Hedayat, S; Jamieson, NB; Kirkin, V; Kouvelakis, K; Lampis, A; Lanese, A; Michalarea, V; Parisi, C; Previdi, MC; Rae, C; Raj, M; Rao, S; Sadanandam, A; Said-Huntingford, I; Scarpa, A; Sclafani, F; Starling, N; Upstill-Goddard, R; Valeri, N; Vicentini, C; Watkins, D; Workman, P; Wotherspoon, A; Young, K; Zito, D | 1 |
| Assenat, E; de la Fouchardière, C; Debourdeau, A; Desseigne, F; Fiess, C; Iltache, S; Mazard, T; Mollevi, C; Portales, F; Ychou, M | 1 |
| Cremolini, C; Esser, R; Falcone, A; Folprecht, G; Martinelli, E; Mazard, T; Modest, DP; Tsuji, A | 1 |
| Elango, S; Finkelmeier, F; Koch, C; Pession, U; Queck, A; Schmidt, J; Trebicka, J; Trojan, J; Waidmann, O; Walter, D | 1 |
| Ye, Y; Zheng, S | 1 |
| Asama, H; Hashimoto, M; Hikichi, T; Irie, H; Kato, T; Kobashi, R; Konno, N; Nakamura, J; Ohira, H; Okubo, Y; Sato, Y; Sugimoto, M; Suzuki, R; Takagi, T; Takasumi, M | 1 |
| Büchler, MW; Schneider, MA | 1 |
| Aranda, E; Díaz, IA; Élez, E; García-Alfonso, P; Gómez-España, MA; Graña, B; Grávalos, C; Losa, F; Martínez de Castro, E; Ortiz-Morales, MJ; Polo, E; Riesco, MDC; Rodriguez-Ariza, A; Ruiz-Casado, A; Safont, MJ; Salgado, M; Salud, A; Tabernero, J; Toledano-Fonseca, M; Valladares-Ayerbes, M | 1 |
| Cortesi, E; De Felice, F; Musio, D; Tombolini, V | 1 |
| Asama, H; Fukushima, T; Kawano, K; Kobayashi, S; Konno, N; Maeda, S; Morimoto, M; Nagashima, S; Oishi, R; Sano, Y; Tanaka, S; Tezuka, S; Ueno, M | 1 |
| Ito, Y; Kobuchi, S; Sakaeda, T; Sakai, S | 1 |
| Brandi, G; Ricci, AD; Rizzo, A | 1 |
| Yoo, C | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Iga, N; Ishizaki, M; Kawai, H; Miyauchi, S; Mizuno, D; Nishi, H; Suemori, K; Uno, F; Yamashita, K; Yoshida, R | 1 |
| Dawe, DE; Kim, CA; Lambert, P; McAndrew, EN; Rittberg, R; Zhang, H | 1 |
| Dai, WP; Jiao, XD; Li, XN; Liu, K; Qin, BD; Qin, WX; Sun, L; Wang, MM; Wang, Z; Ye, CY; Yuan, LY; Zang, YS | 1 |
| Artru, P; Auclin, E; Bechade, D; Ducoulombier, A; Edeline, J; Gilabert, M; Hautefeuille, V; Lièvre, A; Morin, C; Pernot, S; Sarabi, M; Taieb, J; Tougeron, D; Wasselin, J; Zaibet, S | 1 |
| Akazawa, M; Narimatsu, H; Sasahara, Y; Takumoto, Y | 1 |
| Bates, SE; Hur, C; Ingram, MA; Kastrinos, F; Kong, CY; Lauren, BN; Lim, F; Manji, GA; Park, J; Pumpalova, Y | 1 |
| Chen, K; Cheng, Y; Feng, GY; Shi, ZR | 1 |
| Alonso-Marañón, J; Cantero-Recasens, G; Espinosa, L; Garrido, M; Iglesias, M; Lobo-Jarne, T; Malhotra, V | 1 |
| Alexander, HR; Hochster, HS | 1 |
| Besselink, MG; Doppenberg, D; Groot Koerkamp, B; Janssen, QP; Jarnagin, WR; Katz, MHG; O' Reilly, EM; Paniccia, A; Prakash, LR; Tzeng, CD; van Dam, JL; van Eijck, CHJ; Wei, AC; Zureikat, AH | 1 |
| Cano-Cebrián, MJ; Dahlgren, D; Kullenberg, F; Lennernäs, H; Olander, T; Peters, K; Sjöblom, M | 1 |
| Abi Jaoude, J; Delahoussaye, AM; Feng, N; Fowlkes, N; Fujimoto, TN; Garcia Garcia, CJ; Gay, JP; Green, M; Marszalek, J; Molkentine, J; Taniguchi, CM | 1 |
| Chang, TK; Chen, PJ; Chen, YC; Huang, CW; Li, CC; Su, WC; Tsai, HL; Wang, JY; Yin, TC | 1 |
| Bai, LY; Chan, DC; Chen, JS; Chen, LT; Chen, YY; Cheng, FM; Chiang, NJ; Chiu, SC; Chiu, TJ; Chou, WC; Chuang, SC; Hsueh, SW; Li, CP; Peng, CM; Shan, YS; Su, YY; Yang, SH; Yen, CJ | 1 |
| Hong, JY; Jo, H; Kang, WK; Kim, H; Kim, ST; Lee, J; Lee, MS; Lee, YP; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Ebata, T; Fujii, T; Ishikawa, T; Kawashima, H; Kodera, Y; Maeda, O; Nagino, M; Ogawa, H; Ohno, E; Takami, H; Yamada, S; Yamaguchi, J; Yokoyama, Y | 1 |
| Inoue, Y; Ito, H; Mie, T; Oba, A; Ono, Y; Ozaka, M; Saiura, A; Sasahira, N; Sasaki, T; Sato, T; Takahashi, Y; Ushida, Y | 2 |
| Ando, M; Bando, H; Honda, K; Kadowaki, S; Kato, K; Masuishi, T; Matsubara, Y; Muro, K; Nakazawa, T; Narita, Y; Nozawa, K; Ogata, T; Tajika, M; Taniguchi, H | 1 |
| Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S | 1 |
| Bekaii-Saab, T; Dakhil, SR; Faggen, M; Fuchs, CS; Heying, EN; Lipsyc-Sharf, M; Meyerhardt, JA; Ng, K; Noble, S; Ou, FS; Rubinson, DA; Schrag, D; Schuetz, SR; Stella, PJ; Weckstein, DJ; Wender, DB; Yurgelun, MB; Zemla, TJ | 1 |
| Ahmad, U; Anthoney, A; Appleyard, J; Collinson, F; Damyanova, I; Dawood, M; Hubner, RA; Kamposioras, K; Lamarca, A; McNamara, MG; Papaxoinis, G; Pihlak, R; Razzaq, B; Valle, JW; Wright, F | 1 |
| Balachander, A; Biswas, SK; Chen, S; Choo, SP; Chowbay, B; Guo, YA; Lam, J; Lee, B; Lee, SS; Leong, WF; Lim, TKH; Ng, M; Ong, WS; Seet, A; Skanderup, AJ; Sutiman, N; Tai, D; Yeong, J | 1 |
| Innocenti, F; Milano, G; Minami, H | 1 |
| Abe, Y; Daiku, K; Higashi, S; Hirao, T; Ikezawa, K; Kai, Y; Kawamoto, Y; Maeda, S; Nakabori, T; Ohkawa, K; Takada, R; Uehara, H; Urabe, M; Yamai, T | 1 |
| Li, X; Lu, W; Tang, K; Wang, L | 1 |
| Batalini, F; Bullock, A; Bulushi, Y; Campoverde, LE | 1 |
| Aoki, Y; Han, Q; Hoffman, RM; Hozumi, C; Kubota, Y; Masaki, N; Tsunoda, T; Yamamoto, J | 1 |
| Gong, G; Hwang, DW; Hyung, J; Jeong, JH; Jin, H; Kim, K; Kim, SC; Lee, H; Lee, HJ; Lee, S; Lee, SS; Ryoo, BY; Song, TJ; Yoo, C | 1 |
| Hanazaki, K; Iguchi, M; Kitagawa, H; Kohsaki, T; Maeda, H; Munekage, M; Namikawa, T; Tanioka, N; Uchida, K; Uemura, S; Yamaguchi, S; Yamamoto, S | 1 |
| Amar-Farkash, S; Aran, D; Collisson, EA; Klein-Brill, A; Lawrence, G | 1 |
| Fukushima, T; Hamaguchi, T; Kobayashi, S; Morimoto, M; Nagashima, S; Oishi, R; Shin, M; Tezuka, S; Ueno, M; Yamachika, Y | 1 |
| Dai, H; Feng, W; Tang, C; Yao, L | 1 |
| Arciero, V; Arias, J; Beca, JM; Biagi, JJ; Chan, KKW; Dai, WF; Earle, CC; Gavura, S; Habbous, S; Isaranuwatchai, W; Luo, J; Mittmann, N; Parmar, A; Raphael, MJ; Tadrous, M | 1 |
| Dai, S; Jiang, C; Wu, Z; Zhou, L | 1 |
| Furuse, J; Ishii, H; Kobayashi, S; Ueno, M | 1 |
| Aihara, R; Araki, K; Hatanaka, T; Hosaka, H; Hoshino, T; Hosouchi, Y; Ijima, M; Ishida, F; Ishii, N; Kakizaki, S; Kobatake, T; Kurihara, E; Naganuma, A; Shirabe, K; Suzuki, Y; Tamura, Y; Uraoka, T; Yasuoka, H; Yoshida, S | 1 |
| Besselink, MG; Crane, CH; Doppenberg, D; Ellsworth, SG; Groot Koerkamp, B; Janssen, QP; Jarnagin, WR; Katz, MHG; O'Reilly, EM; Paniccia, A; Prakash, LR; Reyngold, M; Tzeng, CD; van Dam, JL; van Eijck, CHJ; Wei, AC; Zureikat, AH | 1 |
| Giuliani, J | 1 |
| Ahmad, S; Behr, S; Chuong, M; Collisson, E; Frankel, WL; Herman, JM; Katz, MHG; Leenstra, J; Marsh, R; Meyerhardt, JA; Meyers, J; O'Reilly, EM; Schwartz, L; Shi, Q; Vaccaro, G; Venook, A; Williams, TM; Wolpin, BM | 1 |
| Court, CM; D'Angelica, MI; Drebin, JA; Ecker, BL; Gonen, M; Janssen, QP; Jarnagin, WR; O'Reilly, EM; Tao, AJ; Wei, AC | 1 |
| Bian, J; Braithwaite, D; Chen, Z; George, TJ; Guo, J; Guo, Y; Kibbe, W; Prosperi, M; Wagner, L; Wang, F; Zhang, H | 1 |
| Gao, L; Liu, X; Ma, X; Ou, K; Wang, Q; Yang, L; Zhang, H | 1 |
| Hattori, N; Hayashi, M; Inokawa, Y; Kanda, M; Kodera, Y; Kurimoto, K; Nakayama, G; Otsu, T; Shimizu, D; Takami, H; Tanaka, C; Tanaka, H; Tanaka, N | 1 |
| Asagi, A; Hiasa, Y; Hino, K; Hyodo, I; Imamura, Y; Inoue, T; Kajiwara, T; Kanemitsu, K; Koizumi, M; Kokubu, M; Kumagi, T; Marui, K; Nadano, S; Nakasya, A; Nishide, N; Nishina, T; Numata, Y; Okujima, Y; Sakaguchi, C; Terao, T; Yoshimatsu, M | 1 |
| Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schwaner, I; Stahler, A; Stintzing, S | 1 |
| Ananda, S; Burge, M; Clarke, K; Gibbs, P; Jennens, R; Lee, B; Lipton, L; Michael, M; Nikfarjam, M; Pattison, S; Santucci, J; Shapiro, J; Tacey, M; Thomson, B; Wong, R; Zielinski, R | 1 |
| Antonuzzo, L; Avallone, A; Berardi, R; Bordonaro, R; Castellano, G; Chiarazzo, C; Ciardiello, D; Ciardiello, F; Damato, A; De Stefano, A; De Vita, F; Di Maio, M; Famiglietti, V; Gervaso, L; Giampieri, R; Latiano, TP; Lavacchi, D; Maiello, E; Maiorano, BA; Martinelli, E; Martini, G; Napolitano, S; Normanno, N; Oneda, E; Parisi, A; Parrella, P; Pinto, C; Rapisardi, S; Tamburini, E; Troiani, T; Zampino, MG; Zaniboni, A; Zichi, C | 1 |
| Barzi, A; McCombs, JS; Zheng, H | 1 |
| Artru, P; Assenat, E; Bauguion, L; Ben Abdelghani, M; Biagi, JJ; Bouché, O; Castan, F; Conroy, T; Evesque, L; Hammel, P; Lambert, A; Lecomte, T; Lopez, A; Mitry, E; Monard, L; Turpin, A; Wei, AC; Ychou, M | 1 |
| Gaddam, S; Gong, J; Gresham, G; Hendifar, A; Jacobs, JP; Kim, S; Lo, S; Moshayedi, N; Nissen, N; Osipov, A; Thomassian, S; Tighiouart, M; Yang, JC; Ye, JY | 1 |
| Afable, M; Gathirua-Mwangi, W; Khan, T; Wu, Y; Yang, T | 1 |
| Boige, V; Boilève, A; Cervantes, B; Ducreux, M; Hollebecque, A; Malka, D; Smolenschi, C; Valery, M | 1 |
| Besselink, MG; Debets, R; Dik, WA; Haberkorn, BCM; Homs, MYV; Janssen, QP; Koerkamp, BG; Luelmo, SAC; Mekenkamp, LJM; Mustafa, DAM; Oostvogels, AAM; Smits-Te Nijenhuis, MAW; van der Sijde, F; van Eijck, CHJ; Vietsch, EE; Wilmink, JW | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
| Buettner, GR; Carroll, RS; Cullen, JJ; Du, J; O'Leary, BR; Ruppenkamp, EK; Steers, GJ; Wagner, BA | 1 |
| Fedorinov, DS; Lyadov, VK; Sychev, DA | 1 |
| Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Mori, C; Okamoto, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T | 1 |
| Dong, LP; Liu, YM; Lu, WJ; Tang, KZ | 1 |
| Ikeda, M; Irisawa, A; Mitsunaga, S; Takahashi, H; Takeno, M; Watanabe, K | 1 |
| Dahlgren, D; Hellström, PM; Kullenberg, F; Lennernäs, H; Nygren, P; Peters, K; Rosenqvist, E; Sjöblom, M | 1 |
| Kulbacka, J; Michel, O; Płochocki, M; Rudno-Rudzińska, J | 1 |
| Nishimoto, A | 1 |
| Clevers, H; Fu, G; Guan, R; Hu, C; Hua, G; Li, X; Lv, T; Mu, P; Shen, L; Wan, J; Wang, Y; Xia, F; Xu, X; Yao, Y; Zhang, H; Zhang, L; Zhang, Z | 1 |
| García-Gil, S; Gutiérrez-Nicolás, F; Miarons, M; Riera, P | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Ido, A; Kawahira, M; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Tsuruta, N; Ueda, Y; Ureshino, N | 1 |
| Besselink, MG; Busch, OR; Haenen, SM; Post, HC; Roshani, S; Sarasqueta, AF; Tol, JAMG; van der Linden, MMD; van Steen, SCJ; Wilmink, JW; Wolkerstorfer, A | 1 |
| Chen, Y; Huang, P; Huang, X; Shi, G; Sun, Q; Yang, G; Zhou, Y | 1 |
| Hanuš, J; Kroupová, J; Štěpánek, F | 1 |
| Allen-Coyle, TJ; Clynes, M; Conlon, NT; Garner, W; Mager, DE; Niu, J; O'Sullivan, F; Roche, S; Straubinger, RM; Welsch, E | 1 |
| Dijk, FJ; Dorresteijn, B; Furber, MJW; Kranenburg, O; May, AM; Quirindongo, H; Raats, DAE; van Dijk, M; Wijler, LA | 1 |
| Boldig, K; Ganguly, A; Kadakia, M; Rohatgi, A | 1 |
| Jiang, W; Liu, Q; Yang, D; Yang, SB | 1 |
| Dasari, A; Deming, D; George, TJ; Kopetz, S; Lieu, CH; Lin, Y; Lucas, PC; Sahin, IH; Yothers, G | 1 |
| Hamamoto, Y; Hazama, S; Iida, M; Ioka, T; Kanesada, K; Matsui, H; Nagano, H; Ogihara, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tsunedomi, R; Yoshida, S | 1 |
| Bagby, SM; Cadogan, EB; Davis, SL; Diamond, JR; Durant, ST; Hartman, SJ; Hughes, GD; Leal, AD; Lieu, CH; Messersmith, WA; Pitts, TM; Schlaepfer, M; Simmons, DM; Tse, T; Yacob, BW | 1 |
| Betrian, S; Brac De La Perriere, C; Chaltiel, L; Delord, JP; Sarradin, V | 1 |
| Furuse, J; Furuya, M; Ikeda, M; Ioka, T; Okusaka, T; Teng, Z; Ueno, M | 1 |
| Cirillo, N; Huang, J; Hwang, AYM; Iskandar, M; Jia, Y; Kim, B; Mohammed, AI | 1 |
| Arora, P; Boyne, DJ; Brenner, DR; Cheung, WY; Gupta, A; Hernán, MA; Mackay, E; Wasiak, R | 1 |
| Chen, BS; Cheng, TC; Chiang, CH; Chiu, JH; Hsieh, CL; Luan, YZ; Ma, KS; Peng, CM | 1 |
| Dayyani, F; Johnson, A; Macarulla, T; Wainberg, ZA | 1 |
| de Koning, W; Groot Koerkamp, B; Homs, MYV; Moskie, M; Mustafa, DAM; van der Burg, SH; van der Sijde, F; van Eijck, CHJ; van Eijck, CWF | 1 |
| Fushiki, K; Hamauchi, S; Kawakami, T; Onozawa, Y; Oshima, K; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Hicks, JK | 1 |
| Brockmueller, A; Büsselberg, D; Kubatka, P; Mazurakova, A; Samuel, SM; Shakibaei, M | 1 |
| Dunichand-Hoedl, AR; Isesele, P; Mazurak, VC; Monirujjaman, M; Renani, LB | 1 |
| Hatefi, A; Li, G; Nikkhoi, SK | 1 |
| Arias, J; Beca, JM; Biagi, JJ; Chan, KKW; Coburn, N; Dai, WF; Earle, CC; Gavura, S; Habbous, S; Raphael, M; Saluja, R | 1 |
| Cockrum, P; Lamarre, N; O'Reilly, EM; Surinach, A; Wang, S; Yu, KH | 1 |
| Abou-Alfa, GK; Cheon, J; Hyung, J; Jeong, JH; Kang, BW; Kang, MJ; Kim, I; Kim, KP; Kim, KW; Lee, JS; Ryoo, BY; Ryu, H; Yoo, C | 1 |
| Boutin, R; Catalano, P; Dotan, E; Ioffe, D; Lenchik, L; Li, D; Marques, HS; O'Dwyer, PJ; Simon, MA; Wagner, LI; Wong, TZ; Yao, X; Zhen, DB | 1 |
| Gofir, A; Hutajulu, SH; Nugroho, DB; Yuwono, KA | 1 |
| André, T; Bodoky, G; Cremolini, C; Heinemann, V; Maughan, T; McDermott, R; Osterlund, P; Pfeiffer, P; Punt, CJA; Teske, AJ; Van Cutsem, E | 1 |
| Abe, S; Beck, Y; Chiyoda, T; Kimura, A; Kogure, R; Komagome, M; Maki, A; Ninomiya, R | 1 |
| Bohnenberger, H; Ghadimi, M; Kauffels, A; Nowack, H; Sperling, J; Spitzner, M; Sprenger, T | 1 |
| Assi, T; Cesne, AL; Ibrahim, R; Ibrahim, T; Khoury, R | 1 |
| Aldaz, A; Arbea, L; Chopitea, A; Martí-Cruchaga, P; Pardo, F; Ponz-Sarvise, M; Rodríguez-Rodríguez, J; Rotellar, F; Sala-Elarre, P; Subtil, JC; Urrizola, A; Vilalta-Lacarra, A; Zozaya, G | 1 |
| Cao, J; Ding, Y; Feng, X; Ji, D; Liu, L; Mao, C; Song, L; Song, W; Wu, Y; Xu, N; Zhang, J; Zhang, Y | 1 |
| Abe, S; Emoto, S; Ishihara, S; Kawai, K; Matsuzaki, H; Murono, K; Nagai, Y; Nozawa, H; Oba, K; Sasaki, K; Shinagawa, T; Sonoda, H; Yamamoto, Y; Yokoyama, Y; Yoshioka, Y | 1 |
| Antonuzzo, L; Barsotti, G; Bergamo, F; Casalino, S; De Toni, C; De Vita, F; Fasano, M; Giommoni, E; Giordano, G; Lonardi, S; Melisi, D; Merz, V; Milella, M; Noventa, S; Pinto, C; Pretta, A; Procaccio, L; Satolli, MA; Scartozzi, M; Spadi, R; Vaccaro, V; Zaniboni, A; Zecchetto, C; Zichi, C | 1 |
| Ardito, R; Arru, M; Garrone, O; Ghidini, M; Khakoo, S; Mini, E; Parisi, A; Petrelli, F; Russo, A; Tomasello, G | 1 |
| Bock, F; Cappel, ML; Frerker, B; Hildebrandt, G; Klautke, G; Kriesen, S; Manda, K | 1 |
| Chin, K; Fukuda, K; Fukuoka, S; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Shinozaki, E; Takahari, D; Wakatsuki, T; Yamaguchi, K; Yoshino, K | 1 |
| Chang, W; Fu, J; Lin, Q; Lv, Y; Tang, W; Wang, G; Xu, J; Xu, Y; Zhang, T; Zheng, X; Zhu, Z | 1 |
| Higashi, S; Hirao, T; Ikezawa, K; Kai, Y; Kawamoto, Y; Kimura, M; Kotani, M; Nakabori, T; Nozaki, K; Ohkawa, K; Seiki, Y; Takada, R; Takagi, M; Uehara, H; Urabe, M; Watsuji, K; Yagi, T; Yamai, T | 1 |
| Connors, DE; Curry, M; Dercle, L; Flynn, JR; Fojo, AT; Gönen, M; Moskowitz, CS; Schwartz, LH; Yang, H; Zhao, B | 1 |
| DeRemer, DL; Fabregas, JC; George, TJ; Hitchcock, K; Hughes, SJ; Kayaleh, O; Lee, JH; Nassour, I; Ramnaraign, B; Rogers, SC; Russell, K; Sahin, I; Singhal, R; Thomas, RM; Turk, A; Zlotecki, R | 1 |
| Guo, H; Guo, J; Huang, P; Huang, W; Huang, Z; Li, Y; Lin, C; Lin, J; Luo, B; Wang, L; Wei, M | 1 |
| Amin, M; Bansod, S; Boice, N; Brown, A; Grierson, PM; Lim, KH; Liu, J; Park, H; Pedersen, KS; Suresh, R; Tan, B; Trikalinos, NA; Wang-Gillam, A | 1 |
| Abbas, AE; Azzoli, CG; Cruz, A; El-Deiry, WS; George, A; Huntington, KE; Liguori, NR; Sevilla Uruchurtu, AS; Tummala, T; Zhang, L; Zhou, L | 1 |
| Ozawa, S | 1 |
460 review(s) available for fluorouracil and irinotecan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Research advances on anticancer activities of matrine and its derivatives: An updated overview.
Topics: Alkaloids; Antineoplastic Agents; Biomedical Research; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Matrines; Molecular Conformation; Neoplasms; Quinolizines; Sophora; Structure-Activity Relationship | 2019 |
Quinolone hybrids and their anti-cancer activities: An overview.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Quinolones; Structure-Activity Relationship | 2019 |
Recent advances in combretastatin A-4 codrugs for cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Drug Design; Humans; Neoplasms; Organophosphates; Stilbenes; Water | 2022 |
Acriflavine, an Acridine Derivative for Biomedical Application: Current State of the Art.
Topics: Acridines; Acriflavine; Anti-Bacterial Agents; COVID-19 Drug Treatment; Humans; Intercalating Agents; Neoplasms; SARS-CoV-2 | 2022 |
Role of chemotherapy for advanced colorectal cancer: new opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 1996 |
[Recent advance in chemotherapy for advanced colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Quinazolines; Remission Induction; Thiophenes; Thymidylate Synthase | 1996 |
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; DNA Topoisomerases, Type I; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Paclitaxel; Prodrugs; Taxoids; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan | 1995 |
[Chemotherapy for pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Irinotecan; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Taxoids | 1996 |
CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan | 1996 |
Chemotherapy for gastric cancer in Japan.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Stomach Neoplasms | 1997 |
Experimental chemotherapeutic agents for the treatment of colorectal carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drugs, Investigational; Enzyme Inhibitors; Female; Fluorouracil; Humans; Irinotecan; Male; Metalloendopeptidases; Platinum Compounds; Thymidylate Synthase; Topoisomerase I Inhibitors | 1997 |
[New anti-cancer drugs for gastrointestinal cancers].
Topics: Amino Acids; Antidotes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Fluorouracil; Gastrointestinal Neoplasms; Humans; Interferons; Irinotecan; Leucovorin; Paclitaxel; Taxoids | 1997 |
[Treatment of recurrent gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Doxorubicin; Drug Administration Schedule; Epirubicin; Etoposide; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Methotrexate; Mitomycin; Neoplastic Cells, Circulating; Peritoneal Neoplasms; Stomach Neoplasms | 1998 |
[Chemotherapy of gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Etoposide; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Methotrexate; Stomach Neoplasms | 1998 |
New drugs in the treatment of colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Topotecan; Trimetrexate; Uracil | 1998 |
[Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer].
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Enzyme Inhibitors; Fluorouracil; Hospitalization; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quality of Life; Quinazolines; Rectal Neoplasms; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors | 1998 |
Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; North America | 1998 |
European experience with irinotecan plus fluorouracil/folinic acid or mitomycin.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Therapy, Combination; Europe; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitomycins | 1998 |
Recommended guidelines for the treatment of chemotherapy-induced diarrhea.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Fluorouracil; Gastrointestinal Agents; Humans; Irinotecan; Octreotide; Practice Guidelines as Topic | 1998 |
Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Salvage Therapy | 1998 |
Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Cryosurgery; Embolization, Therapeutic; Fluorouracil; Hepatectomy; Humans; Infusions, Intra-Arterial; Injections, Intralesional; Irinotecan; Liver Neoplasms; Topoisomerase I Inhibitors; Treatment Failure; Trimetrexate | 1998 |
Chemotherapy for gastric carcinoma: new and old options.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Combinations; Enzyme Inhibitors; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 1998 |
[Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Hepatic Artery; Humans; Inactivation, Metabolic; Injections, Intra-Arterial; Injections, Intravenous; Irinotecan; Neoplasm Proteins; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Topoisomerase I Inhibitors | 1998 |
[Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Europe; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Palliative Care; Remission Induction; Salvage Therapy; Topoisomerase I Inhibitors; Treatment Outcome; United States | 1998 |
[Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
[Irinotecan in combination for colon cancer].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Europe; Fluorouracil; Irinotecan; Japan; Leucovorin; Mitomycin; Neoplasm Metastasis; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Topoisomerase I Inhibitors; Treatment Outcome; United States | 1998 |
[Gastrointestinal cancer and oral anticancer agents].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Drug Combinations; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 1999 |
Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Palliative Care; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors | 1999 |
Comparing irinotecan with best supportive care and infusional 5-fluorouracil: a critical evaluation of the results of two randomized phase III trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase III as Topic; Fluorouracil; Humans; Irinotecan; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors | 1999 |
Novel anticancer drugs in Japan.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Fluorouracil; Humans; Irinotecan; Japan; Neoplasms | 1999 |
Oxaliplatin: a new therapeutic option in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Drug Synergism; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 1999 |
Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Platinum; Quinazolines; Taxoids; Thiophenes; Topoisomerase I Inhibitors | 1999 |
Raltitrexed (Tomudex) in combination treatment for colorectal cancer: new perspectives.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 1999 |
Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Quinazolines; Thiophenes; Tumor Cells, Cultured | 1999 |
[New drugs in gastrointestinal oncology. Current status and future directions].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Taxoids; Tegafur; Thiophenes; Vinblastine; Vinorelbine | 1999 |
[Pharmacokinetic monitoring].
Topics: Antineoplastic Agents; Body Mass Index; Camptothecin; Colorectal Neoplasms; Drug Interactions; Drug Monitoring; Etoposide; Fluorouracil; Humans; Irinotecan; Liver; Paclitaxel; Topotecan | 2000 |
[New combination therapies for gastrointestinal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Docetaxel; Fluorouracil; Humans; Irinotecan; Leucovorin; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Analysis; Taxoids | 2000 |
[Adjuvant chemotherapy for colorectal carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2000 |
[State of the treatment for gastrointestinal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Doxorubicin; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Mitomycin; Stomach Neoplasms | 2000 |
[Colon carcinoma. Consensus of therapeutic strategies].
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Germany; Humans; Incidence; Irinotecan; Leucovorin; Lymphatic Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prodrugs | 2000 |
Progress in colorectal cancer chemotherapy: how far have we come, how far to go?
Topics: Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Immunotherapy; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes | 2000 |
Current treatment options for advanced colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2000 |
Combination chemotherapy and colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2000 |
[Outpatient treatment for gastrointestinal tract cancer in the Department of Surgery].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Lymphatic Metastasis; Quality of Life | 2000 |
[Latest progress on chemotherapy for advanced gastric cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2000 |
Pharmacogenetics: a tool for individualizing antineoplastic therapy.
Topics: Adenine; Antineoplastic Agents; Camptothecin; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Imides; Irinotecan; Isoquinolines; Mercaptopurine; Methyltransferases; Naphthalimides; Organophosphonates; Oxidoreductases; Pharmacogenetics; Phenotype | 2000 |
The role of irinotecan in colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Patient Selection; Topoisomerase I Inhibitors; Treatment Outcome | 1999 |
Novel oral chemotherapy agents.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasms; Tegafur; Temozolomide; Uracil | 2000 |
The changing face of chemotherapy in colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Thymidylate Synthase; Topoisomerase I Inhibitors | 2001 |
[Progress in chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxonic Acid; Pyridines; Tegafur | 2000 |
Gemcitabine: progress in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Matrix Metalloproteinase Inhibitors; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Determinants of prognosis and response to therapy in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxidoreductases; Polymorphism, Genetic; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase | 2001 |
Oxaliplatin: a new agent for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Approval; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome; United States; United States Food and Drug Administration | 2001 |
Developments in the treatment of gastric cancer in Europe.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Taxoids | 2000 |
Irinotecan in esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Paclitaxel; Topoisomerase I Inhibitors | 2000 |
Colorectal cancer: chemotherapy treatment overview.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome; Uracil | 2000 |
Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2000 |
Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2000 |
Irinotecan in preoperative combined-modality therapy for locally advanced rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Radiation Dosage; Rectal Neoplasms; Treatment Outcome | 2000 |
Second-line therapy in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2000 |
Novel combinations with oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes | 2000 |
Efficacy of oxaliplatin in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Treatment Outcome | 2000 |
Irinotecan in the treatment of colorectal cancer: clinical overview.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Analysis; Treatment Outcome | 2001 |
Adjuvant therapy of colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2001 |
Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Pyrimidines; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
[Home chemotherapy and/or outpatient chemotherapy for patient with advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Endpoint Determination; Fluorouracil; Home Infusion Therapy; Humans; Irinotecan; Quality of Life; Stomach Neoplasms | 2001 |
[New chemotherapies for colorectal cancer treatment].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2001 |
Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Methotrexate; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2001 |
Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2001 |
Irinotecan-induced dysarthria.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aphasia, Broca; Bone Neoplasms; Camptothecin; Dysarthria; Enzyme Inhibitors; Fatal Outcome; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Organoplatinum Compounds; Oxaliplatin; Premedication; Sigmoid Neoplasms | 2001 |
New adjuvant therapies for esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Digestive System Surgical Procedures; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2001 |
Optimizing the use of irinotecan in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Quality of Life; Retrospective Studies; Survival Analysis; Treatment Outcome | 2001 |
[Standard therapy of CPT-11 for colorectal cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin | 2001 |
[New therapeutic options in chemotherapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
[Chemotherapy of colorectal carcinoma].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Folic Acid; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Survival Analysis; Treatment Outcome | 2001 |
[The new chemotherapy of colorectal cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Postoperative Care; Prodrugs; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Time Factors | 2002 |
Gemcitabine-based combination treatment of pancreatic cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Patient Selection; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Prediction of the response of colorectal cancer to systemic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Survival Rate; Treatment Outcome | 2002 |
New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Forecasting; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Trimetrexate; Uracil | 2001 |
[Chemotherapy for the patients with esophageal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Paclitaxel | 2002 |
Capecitabine/irinotecan combination regimens in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan | 2002 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Respiratory Distress Syndrome; Taxoids; Treatment Outcome | 2002 |
Combined-modality therapy for rectal cancer using irinotecan.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Preoperative Care; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2002 |
Therapeutic advances in the management of metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Methotrexate; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2001 |
Chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2002 |
Targeting vascular endothelial growth factor in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease-Free Survival; Endothelial Growth Factors; Female; Fluorouracil; Humans; Indoles; Irinotecan; Leucovorin; Male; Neovascularization, Pathologic; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2002 |
The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2002 |
The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Design; Drug Synergism; Enzyme Induction; Epirubicin; Female; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Thymidine Phosphorylase; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
Recommendation for irinotecan, 5-fluorouracil, and leucovorin as first-line therapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2001 |
Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2001 |
Review of the role of CPT-11 in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2001 |
Advances in the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cancer Vaccines; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Uracil | 2001 |
[Gemcitabine-based combinations in inoperable pancreatic cancers].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Routes; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
Adjuvant therapy of colon cancer: a review.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Immunotherapy; Irinotecan; Leucovorin; Levamisole; Neoplasm Staging | 2002 |
Chemoradiation with novel agents for rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclooxygenase Inhibitors; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Rectal Neoplasms | 2002 |
Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Rate | 2002 |
Current status of capecitabine in the treatment of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Risk Factors; Stomatitis; Survival; Treatment Outcome | 2002 |
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Cancer pharmacogenomics: current and future applications.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Dihydrouracil Dehydrogenase (NADP); Disease Models, Animal; DNA Adducts; DNA Repair; Fluorouracil; Glucuronosyltransferase; Glutathione Transferase; Humans; Irinotecan; Mercaptopurine; Methyltransferases; Neoplasms; Organoplatinum Compounds; Oxidoreductases; Pharmacogenetics; Polymorphism, Genetic; Thymidylate Synthase | 2003 |
The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2003 |
[Economic assessment of adjuvant and palliative chemotherapy in colorectal cancer: a review].
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Levamisole; Palliative Care; Quality-Adjusted Life Years; Quinazolines; Thiophenes | 2003 |
Palliative treatment of patients with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Disease Progression; Enzyme Inhibitors; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Palliative Care; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Treatment Outcome; Uracil | 2003 |
[Chemotherapy for colorectal cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Time Factors | 2003 |
Irinotecan: promising activity in the treatment of malignant glioma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Glioma; Humans; Irinotecan; United States | 2003 |
Optimal use of the combination of irinotecan and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan | 2003 |
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Survival Rate; Treatment Outcome | 2003 |
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase 2; Deoxycytidine; Drug Administration Schedule; Enzyme Inhibitors; Flavonoids; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Isoenzymes; Leucovorin; Membrane Proteins; Organoplatinum Compounds; Oxaliplatin; Piperidines; Prostaglandin-Endoperoxide Synthases; Quinazolines; Thiophenes; Treatment Outcome | 2003 |
Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Recurrence, Local; Neoplasm Staging; Neovascularization, Pathologic; Predictive Value of Tests; Prognosis; Survival Analysis | 2003 |
Irinotecan in the treatment of gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2003 |
Current treatments and future perspectives in colorectal and gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Chemotherapy for advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Random Allocation; Treatment Outcome | 2003 |
[Recent advances in chemotherapy for digestive cancers with special references to gastric and colonic cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Docetaxel; Drug Administration Schedule; Drug Combinations; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2003 |
Tailoring chemotherapy in advanced colorectal cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA Helicases; DNA Repair; DNA-Binding Proteins; Endonucleases; ErbB Receptors; Fluorouracil; Glucuronosyltransferase; Glutathione Transferase; Humans; Irinotecan; Platinum Compounds; Proteins; Thymidylate Synthase; Transcription Factors; Xeroderma Pigmentosum Group D Protein | 2003 |
Colorectal cancer: integrating oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome | 2003 |
New perspectives in the management of pancreas cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Taxoids | 2003 |
Current and ongoing trials with irinotecan in the United States.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Pyrazoles; Sulfonamides | 2003 |
Alternative schedules with irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin | 2003 |
Induction therapy in patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2003 |
Review article: colorectal cancer chemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Floxuridine; Fluorouracil; Forecasting; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Quinazolines; Thiophenes | 2003 |
[Controversial issues in chemotherapy for inoperable gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2003 |
[Controversy of treatment for advanced colorectal cancer--intermedisine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pyridines; Tegafur | 2003 |
Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Treatment Outcome | 2003 |
Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; Reproducibility of Results | 2003 |
Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Analysis | 2003 |
[Polymorphism in colorectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genetic Predisposition to Disease; Humans; Irinotecan; Life Style; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Neoplasm Invasiveness; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Prodrugs; Prognosis; Risk Factors | 2003 |
[Chemotherapy for colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome; Uracil | 2003 |
[Application and problems in hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Interleukin-2; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy | 2003 |
[Home chemotherapy and outpatient treatment for metastatic colorectal cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fatal Outcome; Female; Fluorouracil; Home Care Services; Humans; Infusions, Intravenous; Irinotecan; Levamisole; Liver Neoplasms; Middle Aged; Quality of Life | 2003 |
[5-fluorouracil and leucovorin therapy for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; United States | 2003 |
[Irinotecan plus fluorouracil and leucovorin for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Prognosis; United States | 2003 |
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Pyridines; Tegafur; United States; Uracil | 2003 |
[Toxicities associated with chemotherapy in colorectal cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Nausea; Stomatitis; Thrombocytopenia; Vomiting | 2003 |
[Radiotherapy for locally relapsed rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Combined Modality Therapy; Fluorouracil; Humans; Intraoperative Period; Irinotecan; Neoplasm Recurrence, Local; Radiotherapy, High-Energy; Rectal Neoplasms | 2003 |
[Guidance and informed consent in colon cancer therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colorectal Neoplasms; Fluorouracil; Humans; Informed Consent; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Neoplasm Recurrence, Local | 2003 |
[The update on pancreatic cancer chemotherapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Infusions, Intra-Arterial; Irinotecan; Male; Mitomycin; Multicenter Studies as Topic; Pancreatic Neoplasms; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Time Factors | 2003 |
[Treatment of metastatic liver carcinoma: chemotherapy and immunotherapy].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms | 2003 |
Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Immunotherapy; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2003 |
Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cyclooxygenase Inhibitors; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Receptors, Growth Factor; Rectal Neoplasms | 2003 |
[Chemotherapy for colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Tegafur; Uracil | 2003 |
Overview of chemotherapy-induced diarrhea.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Fluorouracil; Humans; Irinotecan; Neoplasms; Nurse-Patient Relations; Nursing Assessment; Nursing Methodology Research; Octreotide; Oncology Nursing; Quality of Life | 2003 |
Development of new agents for the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2003 |
First-line treatment strategies to improve survival in patients with advanced colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2004 |
New developments in systemic chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2003 |
Focus on gastric cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cadherins; Camptothecin; Carcinogens; Docetaxel; Fluorouracil; Gerbillinae; Herpesvirus 4, Human; Humans; Irinotecan; Lymphatic Metastasis; Mice; Mice, Transgenic; Models, Animal; Mutation; Neoplasm Staging; Neoplasms, Experimental; Rats; Stomach Neoplasms; Taxoids | 2004 |
The role of new agents in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2004 |
Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Europe; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Survival Analysis; Survival Rate; United States | 2004 |
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2004 |
[Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2004 |
Systemic treatment of advanced colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Treatment Outcome | 2004 |
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Survival Rate; Treatment Outcome | 2004 |
Current approaches to first-line treatment of advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2004 |
Progress in the development of novel treatments for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2004 |
Current strategies in previously untreated advanced colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2004 |
[New therapy options in colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Treatment Outcome | 2004 |
Developments in combination chemotherapy for colorectal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2004 |
Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2004 |
Evidence-based update of chemotherapy options for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cyclooxygenase Inhibitors; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Receptors, Vascular Endothelial Growth Factor | 2004 |
[Advances in palliative and adjuvant chemotherapy of colon cancer].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Tegafur; Uracil | 2004 |
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Irinotecan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Role of DNA mismatch repair in apoptotic responses to therapeutic agents.
Topics: Alkylating Agents; Antineoplastic Agents; Apoptosis; Base Pair Mismatch; Camptothecin; Cisplatin; DNA Adducts; DNA Repair; Floxuridine; Fluorouracil; Guanine Nucleotides; HCT116 Cells; Humans; Irinotecan; Radiation, Ionizing; Thionucleotides | 2004 |
Current perspectives in the treatment of metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2004 |
Palliative chemotherapy for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Epirubicin; Fluorouracil; Humans; Irinotecan; Palliative Care; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Treatment Outcome | 2004 |
Intergroup trial fails to demonstrate a benefit with the addition of irinotecan to bolus 5-fluorouracil/leucovorin in stage III colon cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Rate | 2004 |
[CPT-11 combined chemotherapy for metastatic gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitomycin; Oxonic Acid; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
Which drug combination for colorectal cancer?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2004 |
[Colorectal cancer: current treatment options].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; DNA Mutational Analysis; Fluorouracil; Humans; Irinotecan; Mass Screening; Organoplatinum Compounds; Oxaliplatin; Risk; Survival Rate | 2004 |
[Recent results of irinotecan therapy in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Survival Analysis; Treatment Outcome | 2004 |
[Second-line chemotherapy for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Quality of Life; Survival Rate; Tegafur; Uracil | 2005 |
Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2004 |
Combined-modality therapy of rectal cancer with irinotecan-based regimens.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2004 |
Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Sensitivity and Specificity; Toxicogenetics | 2004 |
Systemic therapy for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Prodrugs; Pyridines | 2005 |
Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs | 2005 |
Adjuvant therapy of colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2005 |
Combined modality treatment for rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclooxygenase Inhibitors; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Transforming Growth Factor alpha | 2005 |
Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2005 |
Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genes, p53; Genes, ras; Genomic Instability; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Thymidylate Synthase | 2005 |
Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2005 |
[Chemotherapy of advanced stomach cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Stomach Neoplasms; Taxoids | 2004 |
Advances in colon cancer chemotheapy: nursing implications.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colonic Neoplasms; Community Health Nursing; Deoxycytidine; Drug Monitoring; Fluorouracil; Home Infusion Therapy; Humans; Irinotecan; Nurse's Role; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2005 |
[Colon cancer: molecular markers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; DNA Repair; DNA, Neoplasm; Feces; Fluorouracil; Genes, ras; Genes, Tumor Suppressor; Genetic Markers; Humans; Irinotecan; Microsatellite Repeats; Mutation; Oncogenes; Polymerase Chain Reaction; Prognosis; Prospective Studies; Sensitivity and Specificity; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Critical evaluation of current treatments in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Medical Oncology; Neoplasm Metastasis; Vascular Endothelial Growth Factors | 2005 |
The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; Quinazolines; Thiophenes; United Kingdom | 2005 |
New combinations in metastatic colorectal cancer: what are our expectations?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2005 |
Benefit-risk assessment of irinotecan in advanced colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index | 2005 |
Indications and effect on survival of standard chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prodrugs | 2005 |
New chemotherapeutic strategies in colorectal cancer.
Topics: Administration, Oral; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prodrugs | 2005 |
Irinotecan-based regimens in the adjuvant therapy of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2005 |
Perioperative adjunctive treatment in the management of operable gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Fluorouracil; Gastrectomy; Humans; Irinotecan; Leucovorin; Preoperative Care; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2005 |
Adjuvant therapy in colon cancer: which treatment in 2005?
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2005 |
Current therapies for advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2005 |
(Neo-)adjuvant treatments in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2005 |
Role of genomic markers in colorectal cancer treatment.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Irinotecan; Oncogenes; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests | 2005 |
[Chemotherapy of patients with colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Incidence; Irinotecan; Leucovorin; Neoplasm Staging; Netherlands; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis | 2005 |
Docetaxel in the management of advanced pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids; Thalidomide | 2005 |
Experience with docetaxel in the treatment of gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Stomach Neoplasms; Taxoids | 2005 |
Docetaxel in the treatment of esophageal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Irinotecan; Neoadjuvant Therapy; Taxoids | 2005 |
Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Colonic Neoplasms; Fluorouracil; Forecasting; Gene Expression Profiling; Genomics; Humans; Irinotecan; Loss of Heterozygosity; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2005 |
The treatment of colorectal carcinoma: standard chemotherapy and beyond.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Drug Delivery Systems; Fluorouracil; Humans; Immunotherapy; Irinotecan; Leucovorin; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2004 |
Systemic therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pemetrexed; Quinazolines | 2005 |
[Molecular biology in clinical cancer research: the example of digestive cancers].
Topics: Adenocarcinoma; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomedical Research; Camptothecin; Chromosomal Instability; Chromosomes, Human, 16-18; Chromosomes, Human, 21-22 and Y; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 8; Clinical Trials as Topic; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; DNA, Neoplasm; Fluorouracil; Forecasting; Genes, Tumor Suppressor; Genetic Markers; Humans; Immunohistochemistry; Irinotecan; Molecular Biology; Multivariate Analysis; Mutation; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenotype; Prognosis; Stomach Neoplasms | 2005 |
Advanced colorectal cancer: current treatment and nursing management with economic considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cause of Death; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Costs; Drug Hypersensitivity; Drug Industry; Female; Fluorouracil; Humans; Irinotecan; Male; Medical Assistance; Nausea; Neoplasm Staging; Nurse's Role; Oncology Nursing; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Patient Education as Topic; Treatment Outcome; United States; Vomiting | 2005 |
Metastatic colorectal cancer: is there one standard approach?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2005 |
Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Vitamin B Complex | 2005 |
[Drug therapy of patients with metastatic colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; Prognosis; Survival Rate | 2005 |
[SNPs associated with adverse effects].
Topics: Antineoplastic Agents; Camptothecin; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide | 2005 |
Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Pyrimidines; Treatment Outcome | 2005 |
Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Survival Analysis; Treatment Outcome | 2005 |
[Progression of adjuvant chemotherapy for colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2005 |
[Recent progress of chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Survival Rate | 2005 |
Adjuvant therapy for colon cancer 2005: new options in the twenty-first century.
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; History, 20th Century; History, 21st Century; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2006 |
Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2005 |
The role of bevacizumab as first-line therapy for colon cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic | 2005 |
Chemotherapy for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tegafur; Uracil; Vitamin B Complex | 2005 |
Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cryosurgery; Decision Trees; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prognosis; Risk Factors; Treatment Failure; Treatment Outcome | 2006 |
Chemotherapy for advanced pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Palliative Care; Pancreatic Neoplasms; Pemetrexed; Taxoids; Topoisomerase I Inhibitors | 2006 |
[The modern treatment of colorectal cancer. Present and future].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Immunologic Factors; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2006 |
Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; History, 20th Century; History, 21st Century; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Randomized Controlled Trials as Topic | 2006 |
Predicting the outcome of chemotherapy for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Treatment Outcome | 2006 |
Determinants of chemosensitivity in gastric cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dihydrouracil Dehydrogenase (NADP); DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Fluorouracil; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Glutathione S-Transferase pi; Humans; Irinotecan; Mutation; Organoplatinum Compounds; Polymorphism, Genetic; Stomach Neoplasms; Taxoids; Thymidylate Synthase; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2006 |
[Irinotecan for the treatment of metastatic colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Folic Acid; Humans; Irinotecan; Maximum Tolerated Dose; Multicenter Studies as Topic; Pharmacogenetics | 2006 |
Biological agents versus chemotherapy in the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Phthalazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2006 |
[Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Recurrence, Local; Oxonic Acid; Survival Rate; Tegafur | 2006 |
[Adjuvant treatment of colorectal cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Tegafur; Uracil | 2006 |
[S-1 as a single agent for colorectal cancer].
Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leukopenia; Neutropenia; Oxonic Acid; Survival Rate; Tegafur | 2006 |
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Rectal Neoplasms | 2007 |
[Present status and prospect of irinotecan application in adjuvant therapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Postoperative Care; Treatment Outcome | 2006 |
[Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cancer Vaccines; Carcinoma; Cetuximab; Colorectal Neoplasms; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Fluorouracil; Humans; Hungary; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2006 |
[Chemotherapy in advanced gastric cancer--to ensure timely and appropriate switch to subsequent treatment options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Methotrexate; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2007 |
[Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].
Topics: Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Survival Analysis | 2006 |
[Basic strategies on first- and second-line chemotherapy for advanced gastric cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Stomach Neoplasms; Survival Rate; Taxoids | 2007 |
[Up to date chemotherapy for colon cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Survival Rate | 2007 |
[Clinical development of chemotherapy for advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2007 |
[Standard chemotherapy for colonic neoplasms].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Tegafur; Uracil | 2007 |
Chemotherapy of advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 2007 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Sample Size; Survival Analysis | 2008 |
Adjuvant treatment of colon cancer: past, present and future.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Levamisole; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2007 |
[Adjuvant chemotherapy for colorectal cancer in Japan-current state and problem areas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Europe; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Staging; Oxonic Acid; Practice Guidelines as Topic; Rectal Neoplasms; Tegafur; United States; Uracil | 2007 |
Integration of novel agents into combined-modality treatment for rectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2007 |
Radiotherapy for localized rectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Radiotherapy Dosage; Radiotherapy, Conformal; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Rectal Neoplasms; Rectum; Survival Analysis; Treatment Outcome | 2007 |
Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Treatment Outcome | 2007 |
[Pre-operative chemotherapy for patients with hepatic metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Survival Analysis | 2007 |
[Bevacizumab (Avastin)].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Drug Administration Schedule; Drug Approval; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis | 2007 |
Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.
Topics: Adult; Antiemetics; Antineoplastic Agents, Phytogenic; Ataxia; Camptothecin; Capecitabine; Central Nervous System; Colorectal Neoplasms; Cytotoxins; Deoxycytidine; Dexamethasone; Dysarthria; Female; Fluorouracil; Granisetron; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Sarcoma, Small Cell; Serotonin Antagonists; Topoisomerase I Inhibitors | 2008 |
Combined-modality therapy for rectal cancer: future prospects.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
[Angiogenesis targeting in gastro-intestinal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms | 2007 |
Treatment of advanced colorectal cancer in the elderly.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colectomy; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Stents | 2007 |
[Palliative chemotherapy and radiotherapy for metastatic colorectal cancer].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quality of Life; Survival Rate | 2008 |
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2008 |
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Sulfonamides | 2008 |
Advances in neoadjuvant therapy for colorectal cancer with liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2008 |
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Confounding Factors, Epidemiologic; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Randomized Controlled Trials as Topic; Treatment Outcome | 2008 |
Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Vascular Endothelial Growth Factor A | 2007 |
Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biological Therapy; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Protein-Tyrosine Kinases; Signal Transduction; Vascular Endothelial Growth Factor A | 2007 |
[Antibody treatment in colorectal cancer--what the surgeon needs to know].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Panitumumab; Phthalazines; Pyridines; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A; Vitamin B Complex | 2008 |
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Treatment Outcome | 2008 |
Systemic treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Treatment Outcome | 2008 |
Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2008 |
Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Glutamates; Guanine; Humans; Irinotecan; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis; Randomized Controlled Trials as Topic; Risk Factors | 2008 |
[Current therapeutic options for liver metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Catheter Ablation; Colorectal Neoplasms; Combined Modality Therapy; Cryosurgery; Floxuridine; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Neoplasm Staging; Prognosis; Survival Rate; Time Factors | 2008 |
Neoadjuvant chemoradiation for rectal cancer: is more better?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Radiation; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2008 |
Colon cancer: update on adjuvant therapy.
Topics: Age Factors; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2008 |
Regional chemotherapy for liver-limited metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Mitomycin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2008 |
An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Combinations; ErbB Receptors; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids; Tegafur; Vascular Endothelial Growth Factor A | 2008 |
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Glass; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Microspheres; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Yttrium Radioisotopes | 2009 |
Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Fatty Liver; Floxuridine; Fluorouracil; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Irinotecan; Leucovorin; Liver; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Risk Factors | 2009 |
First-line therapeutic strategies in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Celecoxib; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Treatment Outcome; Vitamin B Complex | 2008 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colonic Neoplasms; Deoxycytidine; Digestive System Neoplasms; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Irinotecan; Microsatellite Repeats; Mutation; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2009 |
The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2008 |
The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Combined Modality Therapy; Europe; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Liver Neoplasms; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
[Colorectal cancers: prognostic and predictive factors of response to treatment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Chromosome Deletion; Chromosomes, Human, Pair 18; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Panitumumab; Prognosis | 2009 |
Second-line chemotherapy in advanced and metastatic CRC.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate | 2009 |
What's new in ... colorectal cancer. Meaningful progress in therapy options.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2009 |
A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Mismatch Repair; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prognosis; Treatment Outcome | 2009 |
Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Hemolytic-Uremic Syndrome; Humans; Irinotecan; Mitomycin; Prospective Studies; Purpura, Thrombotic Thrombocytopenic | 2010 |
Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypertension; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Proteins; Rectal Neoplasms; Retrospective Studies; Vascular Endothelial Growth Factor A | 2010 |
Genetic prognostic and predictive markers in colorectal cancer.
Topics: beta Catenin; Biomarkers, Tumor; Camptothecin; Capecitabine; Chromosomes, Human, Pair 18; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gene Expression Profiling; Genes, APC; Genes, p53; Genomic Instability; Humans; Irinotecan; Microsatellite Instability; Mutation; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2009 |
[Chemotherapy of elderly patients with colorectal cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Comorbidity; Cooperative Behavior; Decision Making; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Life Expectancy; Organoplatinum Compounds; Oxaliplatin; Patient Care Team | 2009 |
Evolving treatment of advanced colon cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colonic Neoplasms; Deoxycytidine; Disease Progression; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2009 |
A novel K-ras mutation in colorectal cancer. A case report and literature review.
Topics: Adenocarcinoma, Mucinous; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Tumor Suppressor Protein p53 | 2009 |
Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2009 |
Is there a role for second-line chemotherapy in advanced gastric cancer?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Platinum Compounds; Salvage Therapy; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors | 2009 |
Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2009 |
Chemotherapy, which drugs and when.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
[The development of the first line treatment of metastatic colorectal cancer (mCRC)].
Topics: Administration, Oral; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Precision Medicine; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2009 |
[Progress in chemotherapy for advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Fluorouracil; Gefitinib; Humans; Irinotecan; Methotrexate; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Quinazolines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Trastuzumab | 2009 |
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Rectal Neoplasms; Treatment Failure | 2010 |
Chemotherapy for advanced gastric cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Fluorouracil; Humans; Irinotecan; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids | 2010 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus | 2010 |
Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Oxaloacetates; Prodrugs; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Evolving pharmacotherapeutic strategies for small bowel adenocarcinoma.
Topics: Adenocarcinoma; Camptothecin; Clinical Trials as Topic; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan | 2010 |
Metastatic colorectal cancer: from improved survival to potential cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Catheter Ablation; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Medical Oncology; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 2010 |
Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimen for untreated metastatic advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Spheroids, Cellular; Survival Rate; Treatment Outcome | 2010 |
[Transition of chemotherapy for metastatic colorectal cancer and recent advances].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Survival Rate | 2010 |
[Recent developments of pharmacogenomics in the treatment of colorectal cancers].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Biotransformation; Camptothecin; Colorectal Neoplasms; Drug Delivery Systems; Drug Screening Assays, Antitumor; ErbB Receptors; Fluorouracil; Genotype; Glutathione Transferase; Humans; Irinotecan; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenotype; Signal Transduction | 2010 |
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2010 |
Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Vitamin B Complex | 2010 |
Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Risk Factors; Treatment Outcome | 2011 |
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP2D6; ErbB Receptors; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Pharmacogenetics; Tamoxifen | 2011 |
Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Capecitabine-based chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2011 |
Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Drug Approval; Europe; Fluorouracil; Humans; Irinotecan; Leucovorin; Mutation; Organoplatinum Compounds; United States; United States Food and Drug Administration | 2010 |
Update on capecitabine alone and in combination regimens in colorectal cancer patients.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Prodrugs; Radiotherapy, Adjuvant | 2010 |
Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2010 |
Adjuvant treatment of colon cancer: what is next?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds | 2011 |
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Logistic Models; Middle Aged; Multivariate Analysis; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Stomatitis; Survival Analysis; Treatment Outcome | 2011 |
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Research Design; Treatment Outcome | 2011 |
Common side effects and interactions of colorectal cancer therapeutic agents.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Complementary Therapies; Deoxycytidine; Drug Interactions; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab | 2011 |
[Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Forecasting; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Randomized Controlled Trials as Topic; Rectal Neoplasms; Time Factors; Treatment Outcome | 2011 |
[A case of sigmoid colon cancer with temporary dysarthria associated with irinotecan].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dysarthria; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Sigmoid Neoplasms | 2011 |
[Chemotherapy and rectal cancer].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2011 |
Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitomycin; Mutation; Organoplatinum Compounds; Oxaloacetates; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Vascular Endothelial Growth Factor A | 2012 |
Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fluorouracil; Humans; Irinotecan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Precision Medicine | 2011 |
Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2012 |
Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Genetic | 2012 |
[Chemotherapy for advanced colorectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin | 2011 |
[A case of irinotecan or panitumumab-induced interstitial pneumonia successfully treated by steroid pulse therapy].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Diseases, Interstitial; Male; Methylprednisolone; Middle Aged; Organoplatinum Compounds; Panitumumab; Tomography, X-Ray Computed | 2012 |
Second-line chemotherapy for advanced gastric cancer in Korea.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Republic of Korea; Stomach Neoplasms; Taxoids | 2012 |
Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Pyridines; Randomized Controlled Trials as Topic; Survival Analysis | 2012 |
Postoperative adjuvant chemotherapy in rectal cancer operated for cure.
Topics: Antineoplastic Agents; Biological Products; Camptothecin; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Postoperative Period; Randomized Controlled Trials as Topic; Rectal Neoplasms | 2012 |
Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Cisplatin; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Hepatoblastoma; Humans; Infant; Irinotecan; Liver Neoplasms; Male; Neoplasm Metastasis; Risk Factors; Survival Rate; Transplantation, Homologous | 2012 |
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2012 |
Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review).
Topics: Breast Neoplasms; Camptothecin; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Ganciclovir; Genes, Transgenic, Suicide; Genetic Engineering; Genetic Therapy; Humans; Irinotecan; Prodrugs; Stem Cells; Thymidine Kinase | 2012 |
S-1 for the treatment of gastrointestinal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Practice Guidelines as Topic; Tegafur | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Randomized Controlled Trials as Topic | 2012 |
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Codon; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Germany; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Mutation; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; ras Proteins; Treatment Outcome | 2012 |
Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Transcriptome; Vascular Endothelial Growth Factor A | 2012 |
Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Coronary Angiography; Diagnostic Errors; Docetaxel; Electric Countershock; Fatal Outcome; Fluorouracil; Gastrectomy; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Myocardial Infarction; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms; Takotsubo Cardiomyopathy; Taxoids; Ventricular Fibrillation | 2013 |
FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2013 |
The role of the FOLFIRINOX regimen for advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
Second-line therapy in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Drug Combinations; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2013 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes | 2003 |
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Prognosis; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Evidence-Based Medicine; Fluorouracil; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2013 |
Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase III as Topic; Docetaxel; Fluorouracil; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasm Staging; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids | 2013 |
Methods of overcoming treatment resistance in colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Rectum | 2014 |
Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Failure; Treatment Outcome; Young Adult | 2014 |
Immunological off-target effects of standard treatments in gastrointestinal cancers.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cytotoxicity, Immunologic; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Taxoids; Tumor Escape; Tumor Microenvironment | 2014 |
Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Rate; Treatment Outcome | 2014 |
[Advances in new chemotherapeutic drugs for preoperative chemoradiation of locally advanced rectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms | 2014 |
A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.
Topics: Alanine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Databases, Factual; ErbB Receptors; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; PubMed; Pyridines; Retreatment; Salvage Therapy; Treatment Failure; Triazines | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplasms; Diarrhea; Disease Models, Animal; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Inflammation; Intestinal Mucosa; Irinotecan; Mucositis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin | 2014 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Patient Selection; Stomach Neoplasms; Taxoids; Treatment Outcome | 2014 |
Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biotransformation; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenotype; Precision Medicine; Treatment Outcome | 2014 |
FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Vascular Endothelial Growth Factor A | 2014 |
Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Publication Bias | 2015 |
Pancreatic cancer and FOLFIRINOX: a new era and new questions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Patient Care Planning; Postoperative Care; Preoperative Care; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2015 |
Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Mammary Neoplasms, Experimental; Methotrexate; Mice; Mucositis; Rats | 2015 |
Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2015 |
MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; MicroRNAs; Organoplatinum Compounds; Oxaliplatin | 2015 |
[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Combined Modality Therapy; Cystadenofibroma; Diagnosis, Differential; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Leucovorin; Mesothelioma; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Oxaliplatin; Paclitaxel; Pemetrexed; Peritoneal Neoplasms | 2015 |
[Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2015 |
Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Rate; Treatment Outcome | 2015 |
Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fatal Outcome; Female; Fluorouracil; Humans; Irinotecan; Jaw Diseases; Middle Aged; Osteonecrosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tomography, X-Ray Computed | 2016 |
Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; DNA; Erlotinib Hydrochloride; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Maintenance Chemotherapy; Organoplatinum Compounds; Oxaliplatin; Quality of Life | 2016 |
Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2015 |
Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quality-Adjusted Life Years; Treatment Outcome; United States | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Fluorouracil; Gemcitabine; Genes, p16; Humans; Irinotecan; Leucovorin; Neoplasms, Cystic, Mucinous, and Serous; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Smad4 Protein; Tumor Suppressor Protein p53 | 2016 |
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Nausea; Neutropenia; Quality of Life; Randomized Controlled Trials as Topic | 2016 |
Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Nanoparticles; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2016 |
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate | 2016 |
Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; DNA Repair; DNA-Binding Proteins; Endonucleases; Fluorouracil; Genetic Markers; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pharmacogenomic Testing; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Xeroderma Pigmentosum Group D Protein | 2016 |
The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Prognosis | 2016 |
Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy; Radiotherapy, Adjuvant; Survival Rate | 2016 |
Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nanoparticles; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms | 2016 |
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Capecitabine; Cisplatin; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Methotrexate; Network Meta-Analysis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2016 |
Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cytokines; Fluorouracil; Humans; Intestinal Diseases; Irinotecan; Mucositis; Receptors, Cytokine | 2016 |
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Precision Medicine; Translational Research, Biomedical; Vascular Endothelial Growth Factor A | 2016 |
Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2016 |
Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Treatment Outcome | 2016 |
Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization; Colorectal Neoplasms; Drug Carriers; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2017 |
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2016 |
Second-line systemic therapy for metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Platinum Compounds; Ramucirumab; Stomach Neoplasms; Taxoids; Trastuzumab; Treatment Outcome | 2017 |
Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2017 |
Toxicity of chemotherapy regimens in advanced and metastatic pancreatic cancer therapy: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Network Meta-Analysis; Oxaliplatin; Pancreatic Neoplasms | 2018 |
Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Gentamicins; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Practice Guidelines as Topic; Treatment Outcome; United States | 2017 |
Oral versus intravenous fluoropyrimidines for colorectal cancer.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Floxuridine; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Palliative Care; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Tegafur; Uracil | 2017 |
Chemotherapy for advanced gastric cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Fluorouracil; Humans; Irinotecan; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids | 2017 |
Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Network Meta-Analysis; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2018 |
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Fluorouracil; Folic Acid; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms; Technology Assessment, Biomedical; Topoisomerase I Inhibitors | 2018 |
[Metastatic colorectal cancer: To stop or not to stop?]
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Maintenance Chemotherapy; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Withholding Treatment | 2018 |
Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review
.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kidney Failure, Chronic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Renal Dialysis; Taxoids | 2018 |
Updates in pancreatic cancer: Modest gains and hopeful targets.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Combinations; Drug Delivery Systems; Fluorouracil; Humans; Immunotherapy; Irinotecan; Leucovorin; Neoplastic Stem Cells; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms | 2019 |
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Models, Economic; Nanoparticles; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Technology Assessment, Biomedical | 2018 |
Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Survival Rate | 2018 |
Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2018 |
Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; Colonic Neoplasms; Docetaxel; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Immunotherapy; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrrolidines; Quality of Life; Taxoids; Thymine; Trifluridine; Uracil | 2018 |
Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hypoxia; Immunotherapy; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2018 |
The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fatigue; Fluorouracil; Humans; Irinotecan; Leucovorin; Nausea; Neutropenia; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2018 |
Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug Combinations; Fluorouracil; Humans; Immunotherapy; Irinotecan; Leucovorin; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic | 2018 |
Harnessing the Immune System in Pancreatic Cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Irinotecan; Leucovorin; Microsatellite Instability; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2018 |
Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Electroporation; Fluorouracil; Humans; Irinotecan; Leucovorin; Organometallic Compounds; Oxaliplatin; Pancreatic Ducts; Pancreatic Neoplasms; Radiotherapy | 2018 |
Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Fluorouracil; Humans; Immunotherapy; Irinotecan; Neoadjuvant Therapy; Oxaliplatin; Poly(ADP-ribose) Polymerase Inhibitors; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Rectal Neoplasms; Sorafenib | 2018 |
Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Tumor Burden | 2019 |
Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasms; Oxaliplatin; Tissue Distribution | 2019 |
Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2019 |
Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brazil; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Fees, Pharmaceutical; Fluorouracil; Humans; Hypertension; Incidence; Intestinal Perforation; Irinotecan; Oxaliplatin; Panitumumab; Reimbursement Mechanisms; Response Evaluation Criteria in Solid Tumors | 2018 |
Selecting chemotherapy for pancreatic cancer: Far away or so close?
Topics: Albumins; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Margins of Excision; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2019 |
Systemic treatment of pancreatic cancer revisited.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Irinotecan; Leucovorin; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2019 |
Managing the economic impact of advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost Control; Cost-Benefit Analysis; Deoxycytidine; Early Detection of Cancer; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Microsatellite Instability; Oxaliplatin; Pancreatic Neoplasms; Terminal Care | 2019 |
Nowadays pancreatic cancer prognosis.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Comorbidity; Deoxycytidine; Diabetes Mellitus; Diet; Drug Resistance, Neoplasm; Early Detection of Cancer; Fluorouracil; Gemcitabine; Genetic Predisposition to Disease; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Metastasis; Oxaliplatin; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Radiosurgery; Risk Factors; Spain | 2019 |
FOLFOXIRI plus biologics in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab | 2019 |
Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Preoperative Care; Prognosis; Survival Rate | 2019 |
Adjuvant treatment of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2019 |
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome | 2019 |
Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms | 2019 |
Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer.
Topics: Albumin-Bound Paclitaxel; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Treatment Outcome | 2019 |
[New progress in the treatment of locally advance pancreatic cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2019 |
Maintenance treatment in metastatic colorectal cancer: in search of the best strategy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Erlotinib Hydrochloride; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Maintenance Chemotherapy; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Withholding Treatment | 2020 |
Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2020 |
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; DNA Topoisomerases, Type I; Fluorouracil; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms; Topoisomerase I Inhibitors | 2020 |
Second-line treatment for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Topics: Adaptive Immunity; Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease Models, Animal; Disease-Free Survival; Fluorouracil; Humans; Immunity, Innate; Immunotherapy; Irinotecan; Leucovorin; Lymph Node Excision; Lymph Nodes; Mice; Mice, Transgenic; Neoadjuvant Therapy; Oxaliplatin; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Spleen; Splenectomy; T-Lymphocytes; Transplantation, Autologous; Tumor Escape; Tumor Microenvironment; United States | 2020 |
Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Mutation; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Progression-Free Survival; Survival Rate; Treatment Outcome; Tumor Microenvironment | 2020 |
Impact of chemotherapy-induced enteric nervous system toxicity on gastrointestinal mucositis.
Topics: Animals; Antineoplastic Agents; Cisplatin; Enteric Nervous System; Fluorouracil; Gastrointestinal Diseases; Humans; Inflammation; Irinotecan; Mucositis; Oxaliplatin; Vincristine | 2020 |
Contemporary management of pancreas cancer in older people.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Enhanced Recovery After Surgery; Fluorouracil; Gemcitabine; Geriatric Assessment; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2021 |
Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis.
Topics: Bevacizumab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Oxaliplatin | 2021 |
Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms | 2021 |
[Diagnostics and therapy of pancreatic carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2021 |
Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms | 2021 |
Treatment landscape of metastatic pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease Management; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Precision Medicine | 2021 |
A review of response in neoadjuvant therapy for exocrine pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms | 2021 |
Neoadjuvant therapy for pancreas cancer: Global perspective and optimal care pathways in low to middle-income countries.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Tertiary Care Centers | 2021 |
Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer-Medical college of Wisconsin perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase II as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Metastatic Acinar Cell Carcinoma of the Pancreas: A Retrospective Cohort Study on Systemic Chemotherapy and Review of the Literature.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
Topics: Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Mutation; Proto-Oncogene Proteins B-raf | 2021 |
Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Fluorouracil; Folic Acid; Humans; Irinotecan; Leucovorin; Oxaliplatin; Prognosis | 2021 |
Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies | 2021 |
The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Prognosis | 2021 |
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Publication Bias; Treatment Outcome | 2021 |
HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Neoplasm; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Lapatinib; Oxaliplatin; Oxonic Acid; Paclitaxel; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab | 2021 |
Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Ethnicity; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; DNA Damage; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; MicroRNAs; Neoadjuvant Therapy; Outcome Assessment, Health Care; Oxaliplatin; Pancreatic Neoplasms | 2021 |
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2022 |
Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Comparative Effectiveness Research; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Pyridines; Survival Rate; Tegafur; Treatment Outcome | 2022 |
Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2022 |
Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2022 |
Genotype-based chemotherapy for patients with gastrointestinal tumors: focus on oxaliplatin, irinotecan, and fluoropyrimidines.
Topics: Fluorouracil; Gastrointestinal Neoplasms; Genotype; Humans; Irinotecan; Oxaliplatin | 2022 |
Efficacy and safety of neoadjuvant Folfirinox and Gemcitabine plus Nab-Paclitaxel for borderline resectable and locally advanced pancreatic cancer: a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2022 |
Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Products; Capecitabine; Cisplatin; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitogen-Activated Protein Kinase Kinases; Oxaliplatin; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras) | 2022 |
Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin | 2022 |
The efficacy of irinotecan supplementation for colorectal cancer: A meta-analysis of randomized controlled studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dietary Supplements; Fluorouracil; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic | 2022 |
Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Humans; Irinotecan; Methotrexate; Mice; Mucositis; Rabbits; Rats; Reproducibility of Results; Stomatitis; Swine; Zebrafish | 2022 |
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms; Prospective Studies | 2023 |
Curcumin, calebin A and chemosensitization: How are they linked to colorectal cancer?
Topics: Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Curcumin; Cytostatic Agents; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Oxaliplatin | 2023 |
Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cerebral Infarction; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Stroke | 2023 |
Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; Fluorouracil; Humans; Irinotecan; Leucovorin; Network Meta-Analysis; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic | 2023 |
A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Radiation-Sensitizing Agents | 2023 |
688 trial(s) available for fluorouracil and irinotecan
| Article | Year |
|---|---|
Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Interactions; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 1994 |
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms | 1996 |
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Rectal Neoplasms; Remission Induction | 1997 |
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged | 1997 |
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quality of Life; Survival Rate | 1998 |
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Probability; Quality of Life; Survival Analysis; Treatment Failure | 1998 |
A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis | 1998 |
Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Remission Induction | 1999 |
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Vomiting | 1999 |
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Quality of Life; Treatment Outcome | 1999 |
A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Prospective Studies; Quality of Life; Survival Analysis; Topoisomerase I Inhibitors | 1999 |
Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Quality of Life; Survival Analysis; Topoisomerase I Inhibitors; Treatment Failure | 1999 |
Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis | 1999 |
[Irinotecan in the second-line therapy of metastatic colorectal carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Quality of Life; Time Factors | 1999 |
Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prognosis; Severity of Illness Index; Survival Rate; Treatment Outcome | 1999 |
Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
Topics: Adult; Aged; Animals; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Radioimmunotherapy | 1999 |
Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.
Topics: Administration, Oral; Administration, Topical; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Budesonide; Camptothecin; Diarrhea; Female; Fluorouracil; Glucocorticoids; Humans; Irinotecan; Loperamide; Male; Middle Aged; Treatment Failure | 1999 |
Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Recurrence; Survival Rate; Treatment Outcome | 1999 |
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 1999 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Rate | 2000 |
Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Administration Schedule; Female; Fluorouracil; France; Health Care Costs; Hospital Costs; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Salvage Therapy; Sensitivity and Specificity; Survival Analysis | 2000 |
Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Severity of Illness Index; Time Factors; Treatment Outcome | 2000 |
Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.
Topics: Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Length of Stay; Neoplasm Metastasis; Prospective Studies; Survival Analysis; Time Factors; Treatment Failure | 1999 |
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Topics: Adult; Aged; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Neutropenia; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Factors; Thiorphan | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mouth Mucosa; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Quality of Life; Stomatitis; Survival Analysis | 2000 |
5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 2000 |
Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2000 |
Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Quality of Life; Quinazolines; Thiophenes; Treatment Failure | 2000 |
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.
Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Hematologic Diseases; Humans; Infections; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Sensation Disorders; Treatment Outcome | 2000 |
Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Palliative Care; Prognosis; Prospective Studies; Severity of Illness Index; Survival Rate; Treatment Outcome | 2000 |
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2001 |
Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy | 2001 |
Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Quality of Life | 2001 |
Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Topics: Actuarial Analysis; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Salvage Therapy; Survival Analysis; Treatment Failure; Treatment Outcome | 2001 |
Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2001 |
Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis | 2001 |
Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Oxaliplatin | 2001 |
Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Survival Rate; Treatment Outcome | 2001 |
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2001 |
Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Remission Induction; Survival Analysis | 2002 |
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Quinazolines; Salvage Therapy; Secondary Prevention; Thiophenes; Treatment Outcome | 2002 |
Chronotherapy of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronotherapy; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Mice; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rats | 2002 |
Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Cost-Benefit Analysis; Drug Costs; Drug Resistance, Neoplasm; Female; Fluorouracil; Health Status; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome | 2002 |
Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Patient Compliance; Quality of Life; Survival Analysis | 2002 |
A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Survival Rate; Treatment Outcome | 2002 |
Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2002 |
Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Costs and Cost Analysis; England; Fluorouracil; Humans; Irinotecan; Leucovorin | 2002 |
Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Italy; Leucovorin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Quinazolines; Thiophenes; Treatment Outcome | 2002 |
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Folic Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms | 2002 |
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Survival Analysis; Treatment Outcome | 2002 |
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Survival; Treatment Outcome | 2002 |
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Neutropenia | 2002 |
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Survival Rate; Treatment Outcome; Vomiting | 2002 |
Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged | 2002 |
Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Failure | 2002 |
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Mouth Mucosa; Neoplasm Metastasis; Stomatitis; Treatment Outcome | 2002 |
Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Cryosurgery; Disease-Free Survival; Floxuridine; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Neoplasm Recurrence, Local; Prodrugs; Survival Analysis; Tomography, X-Ray Computed; Topoisomerase I Inhibitors; Treatment Outcome | 2001 |
Oxaliplatin combinations as first-line therapy in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Palliative Care; Probability; Pyridines; Survival Analysis; Treatment Outcome | 2002 |
N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Staging; Organoplatinum Compounds; Palliative Care; Pyridines; Survival Analysis | 2002 |
The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial.
Topics: Adult; Aged; Camptothecin; Canada; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Linear Models; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Probability; Prospective Studies; Quality of Life; Survival Analysis; Treatment Outcome | 2002 |
Irinotecan in 5-fluorouracil-refractory colorectal cancer.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2002 |
Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Probability; Survival Analysis; Survival Rate; Treatment Outcome | 2002 |
Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Risk Assessment; Survival Analysis; Treatment Outcome | 2002 |
Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Pyridines; Survival Analysis; Treatment Outcome | 2002 |
Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Salvage Therapy; Survival Analysis; Treatment Failure | 2002 |
Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Conformal; Rectal Neoplasms; Ultrasonics | 2003 |
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2003 |
A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Rectal Neoplasms | 2003 |
Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Cyclosporine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2003 |
Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with Fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Enzyme Inhibitors; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Palliative Care; Survival Analysis; Topoisomerase I Inhibitors; Treatment Failure | 2003 |
Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.
Topics: Adenoviridae; Adenovirus E1B Proteins; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Cytokines; Female; Fluorouracil; Genetic Therapy; Humans; Immunotherapy; Infusions, Intravenous; Interleukin-2; Irinotecan; Male; Middle Aged; Neoplasms; Pilot Projects; Tumor Suppressor Protein p53; Viral Vaccines; Virus Replication | 2003 |
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; United States | 2003 |
Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin | 2003 |
Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Hydroxyurea; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2003 |
Efficacy of chemoradiotherapy on pain relief in patients with intrapelvic recurrence of rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Pain; Pelvic Neoplasms; Radiotherapy Dosage; Rectal Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2003 |
A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2003 |
A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome | 2003 |
Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2003 |
Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Odds Ratio; Probability; Risk Assessment; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2003 |
Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged | 2003 |
5-fluorouracil as a protracted continuous infusion plus irinotecan (CPT-11) in patients with advanced colorectal cancer treated with fluoropyrimidine-based regimens as first line.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Treatment Outcome | 2003 |
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases | 2003 |
Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome | 2003 |
Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pilot Projects; Prospective Studies; Stomach Neoplasms | 2003 |
Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neutropenia | 2003 |
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Karnofsky Performance Status; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Rectal Neoplasms; Topoisomerase I Inhibitors | 2003 |
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2003 |
Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant | 2003 |
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2003 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2004 |
Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alopecia; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Spain; Treatment Outcome; Vomiting | 2003 |
A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Survival Rate; Treatment Outcome | 2003 |
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome | 2004 |
A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Spain; Survival Analysis; Treatment Outcome | 2003 |
Randomized trial comparing the addition of oxaliplatin or irinotecan to high-dose leucovorin and 5-Fluorouracil intravenous bolus every two weeks in metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group 0103.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Italy; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2003 |
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 2004 |
A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Survival Analysis | 2003 |
A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2004 |
FDA drug approval summaries: oxaliplatin.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Approval; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Random Allocation; Recurrence; United States; United States Food and Drug Administration | 2004 |
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Glucuronides; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Metastasis; Patient Selection; Quinazolines; Thiophenes; Vomiting | 2004 |
Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms | 2004 |
Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Treatment Outcome | 2004 |
Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Folic Acid; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2004 |
Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2004 |
Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2004 |
Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2004 |
Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Interactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Quality of Life; Survival Analysis | 2004 |
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Fluorouracil; Gene Expression Profiling; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Multivariate Analysis; Prognosis; Thymidylate Synthase; Treatment Outcome | 2004 |
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Humans; Infusion Pumps; Irinotecan; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 2004 |
Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome | 2004 |
The toxicity rates of two different regimens of irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Topoisomerase I Inhibitors | 2003 |
Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quality of Life | 2004 |
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Shock, Septic; Stomatitis; Survival Rate | 2004 |
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Quality of Life; Remission Induction; Treatment Outcome | 2004 |
First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Survival Rate | 2004 |
A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Stomatitis; Survival Analysis; Survival Rate | 2004 |
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate; Thiophenes; Thymidylate Synthase; Treatment Outcome | 2004 |
Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neutropenia; Prospective Studies; Safety; Time Factors | 2004 |
Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Prognosis; Survival Rate | 2004 |
Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome | 2004 |
Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2004 |
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Quinazolines; Treatment Outcome | 2004 |
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; France; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Survival Analysis; Survival Rate; Treatment Outcome | 2004 |
Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Interactions; Female; Floxuridine; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, fos; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Up-Regulation | 2004 |
Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome | 2004 |
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2004 |
Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: is this really a dangerous treatment?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Israel; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Time Factors; Treatment Outcome | 2004 |
Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Failure; Treatment Outcome | 2005 |
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quality of Life; Treatment Outcome | 2005 |
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2005 |
Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Rectal Neoplasms; Treatment Outcome | 2005 |
Concurrent RT with 5-FU/epirubicin and cisplatin or irinotecan for locally advanced upper GI adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Radiotherapy, Adjuvant; Treatment Outcome; Upper Gastrointestinal Tract | 2004 |
Irinotecan, epirubicin, and capecitabine in metastatic adenocarcinomas: preliminary results of a phase I study.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Irinotecan; Male; Treatment Outcome | 2004 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gene Frequency; Genotype; Germ-Line Mutation; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Linkage Disequilibrium; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Polymorphism, Genetic; Prognosis; Prospective Studies; Treatment Outcome; UDP-Glucuronosyltransferase 1A9 | 2005 |
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Placebos; Quality of Life; Safety; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2005 |
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Patient Selection; Prodrugs; Safety | 2005 |
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Treatment Failure | 2005 |
Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Time Factors; Treatment Outcome | 2005 |
Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Survival Analysis; Treatment Outcome | 2005 |
A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Female; Fluorouracil; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia | 2005 |
Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Rectal Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2005 |
Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dehydration; Diarrhea; Drug Interactions; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome | 2005 |
Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Fluorouracil; Glucose; Hemodilution; Humans; Hyperthermia, Induced; Hypoalbuminemia; Infusions, Parenteral; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Period; Prospective Studies; Red-Cell Aplasia, Pure; Treatment Outcome | 2005 |
Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Geriatric Assessment; Humans; Infusions, Intravenous; Irinotecan; Male; Neoplasm Invasiveness; Neoplasm Staging; Probability; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2005 |
Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Survival Analysis | 2005 |
A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Infusion Pumps; Irinotecan; Leucovorin; Male; Neoplasms; Neutropenia; Pharmacogenetics; Promoter Regions, Genetic; Thymidylate Synthase; Treatment Outcome | 2005 |
Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Remission Induction; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome | 2005 |
[Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2005 |
[Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronobiology Phenomena; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged | 2005 |
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged | 2005 |
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2005 |
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagogastric Junction; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Levoleucovorin; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
S-phase modulation by irinotecan: pilot studies in advanced solid tumors.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclin A; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Respiratory Tract Neoplasms; S Phase | 2005 |
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Korea; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Salvage Therapy; Survival Rate; Treatment Failure; Treatment Outcome | 2005 |
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Prodrugs; Rectal Neoplasms; Remission Induction; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2005 |
A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Glutamine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Survival Analysis | 2005 |
Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; CD3 Complex; CD4 Antigens; CD8 Antigens; Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Flow Cytometry; Fluorouracil; Granulocyte-Macrophage Colony-Stimulating Factor; HLA-A2 Antigen; Humans; Immunodominant Epitopes; Immunotherapy; Interferon-gamma; Interleukin-2; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Oligopeptides; Prospective Studies; T-Lymphocytes; Treatment Outcome | 2005 |
Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2005 |
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Cell Cycle Proteins; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; DNA Mutational Analysis; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins; Treatment Outcome; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2005 |
[Clinical evaluation of chemotherapy with irinotecan (CPT-11), l-leucovorin (l-LV), 5-fluorouracil (5-FU), and UFT for metastatic or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Rectal Neoplasms; Survival Rate; Tegafur; Uracil; Vomiting, Anticipatory | 2005 |
Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome; Weight Loss | 2005 |
Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Lactones; Middle Aged; Neoplasm Metastasis; Sulfones | 2005 |
Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Thymidylate Synthase | 2006 |
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Vomiting | 2005 |
Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Floxuridine; Fluorouracil; Humans; Irinotecan; Middle Aged; Models, Biological; Molecular Structure; Neoplasm Metastasis; Neoplasms; Prodrugs; Sesquiterpenes | 2005 |
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Failure | 2006 |
Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Probability; Prognosis; Risk Assessment; Statistics, Nonparametric; Survival Rate; Treatment Outcome | 2005 |
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis | 2006 |
A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p27; Disease-Free Survival; DNA, Neoplasm; Female; Fluorouracil; Gastrointestinal Diseases; Hepatectomy; Humans; Irinotecan; Life Tables; Liver Neoplasms; Male; Microsatellite Repeats; Middle Aged; Neoplasm Proteins; Neutropenia; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2005 |
Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dexamethasone; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2005 |
Irinotecan (CPT-11) combined with bolus 5-fluorouracil/leucovorin (Saltz regimen) as first-line chemotherapy of patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Survival Analysis | 2006 |
Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Time Factors; Treatment Outcome | 2005 |
Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dietary Supplements; Dose-Response Relationship, Drug; Female; Fluorouracil; Glutamates; Guanine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Time Factors; Treatment Outcome; Vitamins | 2005 |
Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Digestive System Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Saliva; Tissue Distribution | 2006 |
Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Treatment Outcome | 2006 |
Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Gene Expression Profiling; Humans; Immunohistochemistry; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; NF-kappa B; Prognosis; Taxoids; Treatment Outcome | 2006 |
Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2006 |
Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2006 |
Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Health Status; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Survival Analysis | 2005 |
Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms; Treatment Outcome | 2006 |
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Time Factors | 2006 |
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Indoles; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2006 |
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2006 |
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate | 2006 |
Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2006 |
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Drug Administration Schedule; Enteroendocrine Cells; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Failure; Treatment Outcome | 2006 |
FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrazoles; Sulfonamides; Treatment Outcome | 2006 |
[Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2006 |
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2006 |
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Prospective Studies; Treatment Outcome | 2006 |
A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Diarrhea; Drug Administration Schedule; Fecal Incontinence; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Irinotecan; Male; Middle Aged; Pancytopenia; Radiotherapy Dosage; Rectal Neoplasms | 2006 |
Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2006 |
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Netherlands; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2006 |
A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2006 |
Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2006 |
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Feasibility Studies; Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Logistic Models; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2006 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome | 2007 |
Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Radiotherapy Dosage; Rectal Neoplasms | 2006 |
Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Biomarkers; Body Composition; Camptothecin; Colorectal Neoplasms; Cytokines; Dietary Proteins; Dietary Supplements; Eicosapentaenoic Acid; Energy Intake; Female; Fluorouracil; Humans; Inflammation; Irinotecan; Leucovorin; Male; Malnutrition; Middle Aged; Nutritional Status; Nutritional Support; Phospholipids; Quality of Life; Treatment Outcome; Vitamin B Complex | 2007 |
Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis | 2007 |
A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2006 |
FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Paris; Prospective Studies; Time Factors; Treatment Outcome | 2007 |
Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Proliferation; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Feasibility Studies; Female; Fluorouracil; HT29 Cells; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Treatment Outcome | 2007 |
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Carboxylesterase; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2007 |
[Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate | 2006 |
Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Gastrointestinal Diseases; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Treatment Outcome | 2006 |
A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pelvic Neoplasms; Rectal Neoplasms; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2007 |
Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2007 |
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluorouracil; Glucuronates; Humans; Intestinal Mucosa; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Mucositis; Neoplasm Transplantation; Neoplasms, Experimental; Pyrazoles; Rats; Rats, Inbred F344; Sulfonamides | 2007 |
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms | 2007 |
Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgical; Camptothecin; Carcinoma; Female; Fluorouracil; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Complications; Prospective Studies; Survival Rate; Topoisomerase I Inhibitors; Vitamin B Complex | 2007 |
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Health Status; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Patient Compliance; Quality of Life; Salvage Therapy; Surveys and Questionnaires; Treatment Outcome | 2007 |
A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retreatment; Sample Size; Survival Rate; Treatment Failure | 2007 |
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis; Treatment Failure | 2008 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Sample Size; Survival Analysis | 2008 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Recurrence; Survival Analysis | 2007 |
A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Treatment Outcome | 2007 |
Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Patient Compliance | 2007 |
Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Panitumumab; Vitamin B Complex | 2007 |
Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Camptothecin; Female; Fluorouracil; Folic Acid; Humans; Irinotecan; Male; Middle Aged; Survival Analysis; Vitamin B Complex | 2007 |
Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Treatment Outcome | 2007 |
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2007 |
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis | 2007 |
TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Odds Ratio; Rectal Neoplasms; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2007 |
[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome | 2007 |
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Survival Rate; Treatment Outcome | 2007 |
Evaluation of adjuvant chemotherapy irinotecan + 5-fluorouracil + leucovorine in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Neoplasm Staging; Palliative Care; Prospective Studies; Survival Rate | 2007 |
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.
Topics: Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Retrospective Studies; Treatment Outcome | 2007 |
Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost of Illness; Fluorouracil; Greece; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2007 |
Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome | 2007 |
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2007 |
Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Capecitabine; Colorectal Neoplasms; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Irinotecan; Liver Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Risk Assessment; Survival Analysis; Treatment Outcome | 2007 |
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Lapatinib; Leucovorin; Male; Middle Aged; Neoplasms; Quinazolines; Tandem Mass Spectrometry | 2007 |
Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Treatment Outcome | 2007 |
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2008 |
Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2007 |
A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Safety | 2007 |
Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 2008 |
Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Rectal Neoplasms | 2007 |
FOLFIRI chemotherapy for metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival; Time Factors; Treatment Outcome | 2007 |
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Immunotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Vaccines, DNA | 2008 |
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Diarrhea; Double-Blind Method; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Pyrazoles; Shock, Septic; Sulfonamides; Survival Analysis | 2008 |
Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Thrombospondins; Vascular Endothelial Growth Factor A | 2007 |
Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2007 |
Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Quality of Life; Stomach Neoplasms; Surveys and Questionnaires; Treatment Outcome | 2008 |
Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Rate | 2008 |
Effect of preoperative chemotherapy on liver resection for colorectal liver metastases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Analysis | 2008 |
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with
Topics: Adult; Aged; Aminoquinolines; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organic Chemicals; Proliferating Cell Nuclear Antigen | 2008 |
Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2007 |
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Palliative Care; Survival Analysis | 2008 |
Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Stomach Neoplasms | 2007 |
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Sulfonamides | 2008 |
Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chronotherapy; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxaloacetates; Treatment Failure; Treatment Outcome | 2008 |
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Approval; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Survival Rate; United States; United States Food and Drug Administration | 2008 |
A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; gamma-Glutamyl Hydrolase; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Polymorphism, Single Nucleotide; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; Tandem Repeat Sequences; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Rectal Neoplasms; Survival Rate | 2008 |
Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Conformal; Rectal Neoplasms | 2008 |
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2009 |
Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Maximum Allowable Concentration; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2008 |
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Epirubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Topoisomerase II Inhibitors; Treatment Outcome | 2008 |
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Analysis | 2008 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2008 |
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Quality of Life; Stomach Neoplasms | 2008 |
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Fever; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin | 2008 |
A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Radiotherapy, Adjuvant; Rectal Neoplasms; Survival Analysis; Treatment Outcome | 2008 |
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2009 |
Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; T-Lymphocytes; Treatment Outcome; Viral Vaccines | 2008 |
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Spain; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Rectal Neoplasms; Remission Induction; Survival Rate; Vomiting; Young Adult | 2008 |
Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Patient Selection; Proportional Hazards Models; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2008 |
Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; DNA Adducts; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2009 |
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Prospective Studies; Quality of Life; Treatment Outcome | 2008 |
GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genotype; Glutathione S-Transferase pi; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Polymorphism, Genetic | 2008 |
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pain Measurement; Survival Analysis; Treatment Outcome | 2008 |
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms; Survival Analysis | 2009 |
[Phase I study of CPT-11 and continuous 5-FU / l-leucovorin combination therapy(modified AIO regimen)in patients with metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Tomography, X-Ray Computed | 2008 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines | 2009 |
Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Genotype; Haplotypes; Humans; Inactivation, Metabolic; Infusions, Intravenous; Irinotecan; Japan; Leucovorin; Linkage Disequilibrium; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Metastasis; Polymorphism, Single Nucleotide | 2008 |
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2008 |
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Quality of Life; Statistics, Nonparametric; Treatment Outcome | 2008 |
A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Carriers; Female; Fluorouracil; Humans; Hyaluronic Acid; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Survival Analysis; Treatment Outcome | 2009 |
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Placebos; Retrospective Studies; Survival Rate | 2009 |
Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Tegafur; Uracil | 2009 |
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Nausea; Proctitis; Rectal Neoplasms; Remission Induction; Vomiting | 2009 |
The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Predictive Value of Tests | 2009 |
DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gene Dosage; Humans; Irinotecan; Male; Middle Aged; Predictive Value of Tests; Prognosis | 2009 |
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Failure; Treatment Outcome | 2009 |
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Adenosquamous; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; DNA Methylation; DNA Mismatch Repair; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Incidence; Irinotecan; Male; Microsatellite Instability; Middle Aged; MutL Protein Homolog 1; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Prognosis; Promoter Regions, Genetic; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2009 |
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Simvastatin | 2009 |
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Recurrence; Risk Assessment | 2009 |
Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis; Tomography, X-Ray Computed | 2009 |
Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Rate; Tegafur; Tissue Distribution; Treatment Outcome | 2009 |
An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Digestive System Neoplasms; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Stomach Neoplasms; Taxoids; Treatment Outcome; Vitamin B Complex | 2010 |
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Digestive System Neoplasms; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Stomach Neoplasms; Time Factors; Treatment Outcome | 2009 |
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Microsatellite Instability; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Survival Analysis; Young Adult | 2009 |
FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Approval; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Treatment Outcome; United States; United States Food and Drug Administration | 2009 |
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Vomiting | 2009 |
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Pyrazoles; Sulfonamides; Survival Rate | 2009 |
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Neutropenia; Prospective Studies; Survival Analysis; Treatment Outcome | 2009 |
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Camptothecin; Drug Interactions; Female; Fluorouracil; Gastrointestinal Tract; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prodrugs | 2009 |
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2009 |
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging | 2009 |
A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Treatment Outcome | 2009 |
Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Capecitabine; Cell Cycle Proteins; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Endonucleases; Fluorouracil; Humans; Irinotecan; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; Transcription Factors; Tumor Suppressor Proteins | 2009 |
Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Time Factors | 2010 |
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Patient Compliance; Treatment Outcome | 2009 |
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Palliative Care; Quality of Life; Stomach Neoplasms; Young Adult | 2009 |
[Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Rate | 2009 |
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Stomach Neoplasms | 2010 |
[Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Radiotherapy, Adjuvant; Stomach Neoplasms | 2010 |
Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Australia; Brachytherapy; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Maximum Tolerated Dose; Microspheres; Middle Aged; Radiopharmaceuticals; Radiotherapy, Adjuvant; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome; Yttrium Isotopes | 2009 |
Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Colorectal Neoplasms; Complementarity Determining Regions; Female; Fluorouracil; Genes, T-Cell Receptor beta; Hematuria; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Proteinuria; Receptors, Antigen, T-Cell; T-Lymphocyte Subsets; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Microsatellite Instability; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Smad4 Protein; Telomerase; Tumor Suppressor Protein p53 | 2009 |
Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Rectal Neoplasms | 2009 |
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Survival Analysis; Treatment Outcome | 2010 |
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Rectal Neoplasms; Remission Induction; Salvage Therapy; Survival Rate; Vomiting; Young Adult | 2009 |
Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Tegafur | 2009 |
Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 2009 |
A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Gastrectomy; Gastrointestinal Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Peritoneal Neoplasms; Salvage Therapy; Stomach Neoplasms; Treatment Outcome | 2010 |
A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged | 2010 |
A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Deoxycytidine; Diarrhea; Fecal Incontinence; Female; Fluorouracil; Gangrene; Gastrointestinal Diseases; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Proctitis; Pyrazoles; Radiation Injuries; Radiation-Sensitizing Agents; Rectal Neoplasms; Sulfonamides | 2010 |
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Japan; Male; Middle Aged; Oxonic Acid; Proportional Hazards Models; Risk Assessment; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome; Young Adult | 2009 |
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Glutathione Transferase; Humans; Irinotecan; Leucovorin; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Predictive Value of Tests; Probability; Survival Analysis; Thymidylate Synthase; Time Factors; Treatment Outcome | 2009 |
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Microsatellite Instability; Mutation; MutL Protein Homolog 1; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Precision Medicine; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
Topics: Adult; Aged; Angiogenesis Inducing Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Cytokines; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 2010 |
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Italy; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Maximum Tolerated Dose; Middle Aged; Patient Selection; Phenotype; Polymorphism, Genetic; Risk Assessment; Time Factors; Treatment Outcome | 2010 |
A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Risk Assessment; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neutropenia; Retrospective Studies; Survival Rate; Thymidylate Synthase; Treatment Outcome | 2011 |
Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Recombinant Proteins; Stomach Neoplasms; Taxoids; Treatment Outcome | 2011 |
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Glutathione S-Transferase pi; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Survival Analysis | 2010 |
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyridazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Young Adult | 2010 |
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids; Treatment Outcome | 2010 |
Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Confidence Intervals; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Vitamin B Complex | 2010 |
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Treatment Outcome | 2010 |
Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Chronotherapy; ErbB Receptors; Female; Fluorouracil; Gene Amplification; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
[Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Endostatins; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Recombinant Proteins | 2010 |
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2010 |
Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2011 |
Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged | 2011 |
Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2010 |
Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Rectal Neoplasms; Time Factors; Treatment Outcome | 2010 |
Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a Phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Preoperative Period; Rectal Neoplasms; Remission Induction; Survival Rate | 2011 |
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
Topics: Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gene Frequency; Genotype; Germ-Line Mutation; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Patient Selection; Polymorphism, Genetic; Survival Analysis; Thymidylate Synthase; Treatment Outcome | 2010 |
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prodrugs; Tegafur | 2010 |
Treatment of colorectal cancer with and without bevacizumab: a phase III study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Hypertension; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2010 |
Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Proliferation; Cells, Cultured; Colorectal Neoplasms; Cytokines; Female; Fluorouracil; Greece; Humans; Irinotecan; Leucovorin; Lymphocyte Culture Test, Mixed; Male; Middle Aged; T-Lymphocytes; Time Factors; Treatment Outcome | 2012 |
Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Statistics as Topic; Stomach Neoplasms; Surveys and Questionnaires; Survival Analysis; Taxoids; Time Factors; Vitamin B Complex | 2010 |
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2012 |
Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Staging; Preoperative Care; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Radiotherapy Dosage; ras Proteins; Rectal Neoplasms; Remission Induction | 2011 |
KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Genes, ras; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Radiotherapy Dosage; Rectal Neoplasms; Remission Induction | 2011 |
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Piperidines; Protein Kinase Inhibitors; Treatment Outcome | 2010 |
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Research Design; Time Factors; Treatment Outcome | 2010 |
Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Japan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged | 2011 |
Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Young Adult | 2011 |
Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2010 |
An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Blood Chemical Analysis; Camptothecin; Disease Progression; Docetaxel; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Predictive Value of Tests; Prognosis; Taxoids; Upper Gastrointestinal Tract | 2010 |
FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; France; Humans; Infusions, Intravenous; Intra-Abdominal Fat; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Failure | 2012 |
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Levoleucovorin; Male; Middle Aged; Treatment Outcome | 2011 |
[Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer: an analysis of 21 cases].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2010 |
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2011 |
Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Prospective Studies; Survival Rate; Treatment Outcome; Tumor Burden | 2010 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Endostatins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Recombinant Proteins; Survival Rate; Taxoids; Treatment Outcome | 2010 |
[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Hypertension; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Rectal Neoplasms; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2010 |
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Tegafur; Treatment Failure | 2012 |
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cinnamates; Colorectal Neoplasms; Cyclohexanes; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epoxy Compounds; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Models, Statistical; Oxaloacetates; Republic of Korea; Sesquiterpenes; Survival Analysis; Treatment Failure | 2012 |
Normalization of T cell receptor repertoire diversity in patients with advanced colorectal cancer who responded to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Colorectal Neoplasms; Endostatins; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prognosis; Receptors, Antigen, T-Cell; Recombinant Proteins; Remission Induction | 2011 |
A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Greece; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Treatment Outcome; Young Adult | 2011 |
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Germany; Humans; Irinotecan; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Genetic Predisposition to Disease; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies; Severity of Illness Index; Topoisomerase I Inhibitors; Treatment Outcome | 2011 |
A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Japan; Male; Methotrexate; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Quality of Life; Severity of Illness Index; Survival Analysis | 2011 |
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuritis; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Remission Induction; Stomach Neoplasms; Young Adult | 2011 |
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Survival Rate; Thrombocytopenia | 2012 |
Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Linear Models; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Vitamin B Complex | 2011 |
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Research Design; Treatment Outcome | 2011 |
Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Young Adult | 2011 |
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Germany; Humans; Incidence; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Skin Diseases; Treatment Outcome | 2011 |
Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Retrospective Studies; Vitamin B Complex | 2012 |
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy Dosage; Rectal Neoplasms | 2012 |
Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia | 2012 |
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2012 |
Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Obesity; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
[Chemotherapy in patients with non-resectable colorectal cancer metastases to the liver: systemic or regional?].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Recurrence; Splenic Neoplasms; Treatment Outcome | 2011 |
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cell Count; Colorectal Neoplasms; Deoxycytidine; Endothelial Cells; Endothelium, Vascular; Female; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Proportional Hazards Models; Treatment Outcome; Tumor Burden | 2012 |
An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Real-Time Polymerase Chain Reaction; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2011 |
A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drugs, Chinese Herbal; Female; Fluorouracil; Half-Life; Humans; Irinotecan; Leucovorin; Male; Mice; Middle Aged; Phytotherapy | 2011 |
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Leucovorin; Male; Middle Aged; Models, Statistical; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Treatment Outcome | 2011 |
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Neoplasm Metastasis; Quality of Life | 2011 |
A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Transitional Cell; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms | 2013 |
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; France; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2011 |
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies; Survival Rate; Young Adult | 2011 |
The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Polymerase Chain Reaction; Premedication; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salvage Therapy; Skin Diseases; Survival Rate; Young Adult | 2011 |
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2011 |
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2012 |
Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Fluorouracil; Genotype; Humans; Irinotecan; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Radiation-Sensitizing Agents; Rectal Neoplasms; Treatment Outcome; Young Adult | 2011 |
[Pathological changes of rectal cancer after irinotecan, 5-fluorouracil or combined short-term radiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms; Treatment Outcome | 2011 |
Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms | 2011 |
Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Rectal Neoplasms; Remission Induction; Survival Rate | 2012 |
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins B-raf | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Peritoneal Neoplasms; Prospective Studies | 2012 |
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Metastasectomy; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2012 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Codon; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Germany; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome; Withholding Treatment | 2012 |
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Greece; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Treatment Outcome | 2012 |
A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Survival Rate; Treatment Outcome | 2012 |
Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome; Vitamin B Complex | 2012 |
Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Microsatellite Instability; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Prospective Studies; Treatment Outcome | 2012 |
First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2012 |
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies | 2012 |
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Epidermal Growth Factor; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Prospective Studies; Thymidylate Synthase | 2012 |
A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2012 |
Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Delivery Systems; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Prospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Taxoids; Treatment Outcome | 2013 |
A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2012 |
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Case-Control Studies; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Dendritic Cells; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Gemcitabine; Humans; Immunomodulation; Immunotherapy; Interleukin-2; Irinotecan; Killer Cells, Natural; Male; Middle Aged; Recombinant Proteins; T-Lymphocyte Subsets | 2012 |
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Thymidine Phosphorylase; Treatment Outcome | 2012 |
Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Chemoradiotherapy; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2013 |
Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Mutation; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Prognosis; Retrospective Studies; Signal Transduction; Skin; Treatment Outcome | 2013 |
KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Genes, ras; Humans; Irinotecan; Male; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Preoperative Care; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Radiotherapy Dosage; Rectal Neoplasms; Treatment Outcome | 2013 |
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Osteopontin; Treatment Outcome | 2012 |
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Taxoids | 2012 |
Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged | 2012 |
A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Isosorbide Dinitrate; Lung Neoplasms; Male; Middle Aged; Nitroglycerin; Treatment Outcome | 2012 |
Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Isoquinolines; Male; Middle Aged; Nausea; Ondansetron; Organoplatinum Compounds; Oxaliplatin; Palonosetron; Quinuclidines; Retrospective Studies; Treatment Outcome | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Randomized Controlled Trials as Topic | 2012 |
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Young Adult | 2013 |
Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Radiography, Interventional; Time Factors; Treatment Outcome | 2012 |
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2012 |
Evaluation of predictive markers for patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; C-Reactive Protein; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Evaluation Studies as Topic; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Linear Models; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prealbumin; Predictive Value of Tests; Prognosis; Receptors, Albumin; Sensitivity and Specificity; Serum Amyloid A Protein; Sweden; Tissue Inhibitor of Metalloproteinase-1; Tissue Polypeptide Antigen | 2012 |
Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Colorectal Neoplasms; Disease Progression; Drug Chronotherapy; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 2013 |
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 18; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Loss of Heterozygosity; Male; Microsatellite Instability; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Research Design; Smad4 Protein | 2012 |
Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; ras Proteins; Surveys and Questionnaires; Survival Analysis; Young Adult | 2013 |
Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Preoperative Care; Prognosis; Prospective Studies; Survival Rate | 2013 |
A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Stomach Neoplasms | 2013 |
Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Deoxycytidine; DNA Topoisomerases, Type I; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Phosphatidylinositol 3-Kinases; Pilot Projects; Precision Medicine; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Radiotherapy, Intensity-Modulated; ras Proteins; Rectal Neoplasms; Treatment Outcome | 2014 |
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quality of Life; Surveys and Questionnaires; Survival Rate | 2013 |
Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tissue Distribution | 2013 |
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Quality of Life; Time Factors; Treatment Outcome; Venous Thrombosis | 2013 |
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2013 |
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
Topics: 3' Untranslated Regions; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genetic Markers; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies; Severity of Illness Index | 2013 |
Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cognition Disorders; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Geriatric Assessment; Health Services for the Aged; Humans; Irinotecan; Logistic Models; Male; Multivariate Analysis; Neoplasm Metastasis; Prospective Studies; Treatment Outcome | 2013 |
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2013 |
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Genotype; Humans; Insulin-Like Growth Factor Binding Proteins; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG; Treatment Outcome | 2013 |
Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Netherlands; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Treatment Outcome | 2013 |
Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Camptothecin; Chemoradiotherapy; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Radiotherapy Dosage; Rectal Neoplasms; Survival Rate; Treatment Failure; Young Adult | 2013 |
A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Republic of Korea; Young Adult | 2013 |
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Glutamates; Guanine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis | 2013 |
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
Topics: Aged; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Panitumumab; Proportional Hazards Models; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Time Factors; Treatment Outcome; United Kingdom | 2013 |
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Prognosis; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Capecitabine, irinotecan (CAPIRI) and sunitinib in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Indoles; Irinotecan; Maximum Tolerated Dose; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Sex Factors; Survival Rate; Young Adult | 2013 |
Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cisplatin; Dihydrouracil Dehydrogenase (NADP); DNA-Binding Proteins; Drug Combinations; Endonucleases; Female; Fluorouracil; Gene Expression; Humans; Irinotecan; Male; Oxonic Acid; Prognosis; RNA, Messenger; Stomach Neoplasms; Survival; Tegafur; Thymidylate Synthase; Vascular Endothelial Growth Factor A | 2013 |
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Frequency; Genotype; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies; UDP-Glucuronosyltransferase 1A9 | 2013 |
Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Creatinine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Oxaloacetates | 2013 |
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2013 |
Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colon; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Rectum; Treatment Outcome | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome | 2014 |
Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Young Adult | 2013 |
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Paclitaxel; Platinum; Prospective Studies; Stomach Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Young Adult | 2014 |
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Microsatellite Instability; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Middle Aged; Treatment Outcome | 2013 |
Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Dose Fractionation, Radiation; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Postoperative Period; Preoperative Period; Stomach; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Delayed-Action Preparations; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Loperamide; Male; Middle Aged; Octreotide; Quality of Life; Severity of Illness Index; Young Adult | 2014 |
Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Clinical Decision-Making; Colorectal Neoplasms; Decision Trees; Disease-Free Survival; DNA Mutational Analysis; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinase; Precision Medicine; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Response Evaluation Criteria in Solid Tumors; Thymidine Phosphorylase; Thymidylate Synthase | 2016 |
The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin).
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Quality of Life; Stomach Neoplasms; Surveys and Questionnaires; Taxoids; Treatment Outcome | 2014 |
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Japan; Male; Neoplasm Metastasis; Prognosis; Risk Factors; Stomach Neoplasms | 2014 |
Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome; Tumor Burden | 2014 |
Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Treatment Outcome | 2014 |
Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prospective Studies; Recurrence; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2014 |
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Treatment Outcome | 2014 |
A phase I study of capecitabine combined with CPT-11 in metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Taxoids | 2014 |
CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; CpG Islands; Disease-Free Survival; DNA Methylation; DNA Mismatch Repair; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Phenotype; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2014 |
Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Diarrhea; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Rectal Neoplasms; Tegafur; Treatment Outcome | 2014 |
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2014 |
Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Maximum Tolerated Dose; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2014 |
A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Survival Rate; Tegafur | 2015 |
Association between chemotherapy and plasma adipokines in patients with colorectal cancer.
Topics: Adipokines; Adipose Tissue; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Prognosis; Prospective Studies; Survival; Treatment Outcome | 2014 |
A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Treatment Outcome; Young Adult | 2014 |
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; DNA-Binding Proteins; Female; Fluorouracil; Follow-Up Studies; Genetic Association Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; MRE11 Homologue Protein; Polymorphism, Single Nucleotide; Prognosis; Treatment Outcome; Young Adult | 2014 |
A phase I study of UGT1A1 *28/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRI.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Republic of Korea; Young Adult | 2015 |
Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiation-Sensitizing Agents; Radiotherapy Dosage; Rectal Neoplasms; Salvage Therapy; Survival Analysis | 2015 |
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Treatment Outcome | 2014 |
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2015 |
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Retreatment; Treatment Outcome | 2014 |
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2015 |
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2015 |
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2015 |
A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2015 |
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2015 |
Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate | 2015 |
Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Female; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Rectal Neoplasms; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2015 |
Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Necrosis; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Endostatins; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Recombinant Proteins; Survival Rate | 2015 |
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Survival Rate | 2015 |
SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salvage Therapy; Survival Rate | 2015 |
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients.
Topics: Absorbable Implants; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Implants; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; RNAi Therapeutics | 2015 |
Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Hypersensitivity; Endpoint Determination; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2015 |
Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Hepatic Artery; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome | 2015 |
S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2015 |
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Feasibility Studies; Female; Fluorouracil; Genes, ras; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Severity of Illness Index | 2015 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Intention to Treat Analysis; Irinotecan; Italy; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Time Factors; Treatment Outcome | 2015 |
Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Health Care Costs; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Quality of Life; Tegafur; Young Adult | 2015 |
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regime
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2016 |
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Hedgehog Proteins; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Treatment Outcome; Veratrum Alkaloids; Vomiting | 2016 |
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Multivariate Analysis; Proportional Hazards Models; Treatment Outcome | 2016 |
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Double-Blind Method; Drug Administration Schedule; Female; Fluorouracil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Republic of Korea; Simvastatin; Survival Analysis; Treatment Outcome | 2015 |
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2016 |
A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Chi-Square Distribution; Confidence Intervals; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Rectal Neoplasms; Tegafur | 2015 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2016 |
High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prognosis; Survival Rate | 2016 |
PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Quality of Life; Retreatment; Sucrose; Treatment Outcome | 2016 |
Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Outcome Assessment, Health Care; Polymorphism, Genetic; Promoter Regions, Genetic; Prospective Studies | 2016 |
Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Costs and Cost Analysis; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2016 |
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2016 |
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Macrophages; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Pyrrolidines; Receptors, CCR2 | 2016 |
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease Progression; Disease-Free Survival; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Rate; Time Factors; Treatment Failure | 2016 |
Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Chronotherapy; Europe; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2017 |
A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiation Injuries; Radiosurgery; Radiotherapy, Adjuvant; Treatment Outcome | 2016 |
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Ramucirumab | 2016 |
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Ramucirumab | 2016 |
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Geriatric Assessment; Humans; Irinotecan; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Neoplasm Metastasis; Prospective Studies; Quality of Life; Treatment Outcome | 2017 |
Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proto-Oncogene Proteins B-raf; Treatment Outcome | 2017 |
Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2017 |
EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; ErbB Receptors; Female; Florida; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Panitumumab; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2017 |
Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2017 |
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Nanoparticles; Pancreatic Neoplasms; Quality of Life; Retreatment; Survival Rate | 2017 |
Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retreatment; Treatment Outcome | 2017 |
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neuregulin-1; Organoplatinum Compounds; Oxaliplatin; Prognosis; Receptor, ErbB-2; Receptor, ErbB-3; Retrospective Studies | 2017 |
Treatment of Locally Advanced Rectal Cancer: Turning Good Rationale Into Good Evidence?
Topics: Antineoplastic Agents; Camptothecin; Chemoradiotherapy; Colectomy; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Care Management; Patient Selection; Rectal Neoplasms | 2017 |
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2017 |
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arylamine N-Acetyltransferase; ATP Binding Cassette Transporter, Subfamily B; Camptothecin; Catecholamine Plasma Membrane Transport Proteins; Cetuximab; Colorectal Neoplasms; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Glucuronosyltransferase; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Survival Rate; Treatment Outcome; Vitamin K Epoxide Reductases | 2017 |
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Follow-Up Studies; Genotype; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Leucovorin; Lymphatic Metastasis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; Population Groups; Prognosis; Protein Serine-Threonine Kinases; Survival Rate | 2017 |
Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxyuridine; Disease-Free Survival; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Rate; Treatment Outcome | 2018 |
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care | 2018 |
HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Tumor Microenvironment | 2018 |
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Progression-Free Survival; Tegafur; Young Adult | 2018 |
Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colon; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Nodes; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prospective Studies; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Male; Middle Aged; Oxaliplatin; Panitumumab; Progression-Free Survival; Prospective Studies; Treatment Failure | 2018 |
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Prospective Studies; Young Adult | 2018 |
Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Survival; Drug Combinations; Drug Costs; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Treatment Outcome | 2018 |
Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Stomach Neoplasms; Treatment Outcome | 2018 |
UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Frequency; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Survival Rate; Young Adult | 2018 |
FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2018 |
Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Survival Rate | 2018 |
A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Survival Rate; Young Adult | 2018 |
Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Phenylurea Compounds; Progression-Free Survival; Pyridines | 2018 |
Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Body Surface Area; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Glucuronosyltransferase; Humans; Incidence; Irinotecan; Leucovorin; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neutropenia; Neutrophils; Sex Factors; Treatment Outcome; Young Adult | 2018 |
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinotecan; Liposomes; Male; Middle Aged; Mutation; Nanoparticles; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Retrospective Studies | 2018 |
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drugs, Chinese Herbal; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Polymorphism, Genetic; Treatment Outcome; Vomiting; Young Adult | 2017 |
AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Oxaliplatin; Prognosis; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Rate; Young Adult | 2018 |
Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2018 |
Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Ki-67 Antigen; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tumor Suppressor Protein p53 | 2019 |
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate | 2019 |
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fatigue; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Oxaliplatin; Paresthesia; Progression-Free Survival; Rectal Neoplasms; Remission Induction; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Folic Acid; Humans; Irinotecan; Leucovorin; Male | 2019 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Middle Aged; Pancreatic Neoplasms; Polyethylene Glycols; Progression-Free Survival; Proportional Hazards Models | 2018 |
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Progression-Free Survival; Prospective Studies; Proto-Oncogene Proteins p21(ras); Time Factors | 2019 |
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Reported Outcome Measures; Progression-Free Survival; Quality of Life; Time Factors | 2019 |
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxaliplatin; Prognosis; Survival Rate; Young Adult | 2019 |
Tumor calcification as a prognostic factor in cetuximab plus chemotherapy-treated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate | 2019 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lung Diseases, Interstitial; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies | 2018 |
Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma; Cisplatin; Deoxycytidine; Drug Monitoring; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Neoplasm Invasiveness; Neoplasm Staging; Oxaliplatin | 2019 |
A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds | 2019 |
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Leucovorin; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Young Adult | 2018 |
FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Prognosis | 2019 |
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; Humans; Irinotecan; Karnofsky Performance Status; Leucovorin; Liposomes; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models | 2019 |
Diffusion kurtosis imaging and conventional diffusion weighted imaging to assess electrochemotherapy response in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Diffusion Tensor Imaging; Electrochemotherapy; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Sensitivity and Specificity; Statistics, Nonparametric; Thermal Conductivity; Treatment Outcome | 2019 |
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Ramucirumab; Stomach Neoplasms; Survival Rate | 2019 |
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2019 |
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Immunohistochemistry; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms; Survival Rate | 2019 |
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Pancreatic Neoplasms | 2019 |
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Folic Acid; Humans; Irinotecan; Male; Middle Aged; Mutation; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Sulfonamides; Survival Rate | 2019 |
Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Prognosis; Pyridines; Stomach Neoplasms; Survival Rate; Taxoids | 2019 |
Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Hydro-Lyases; Irinotecan; Male; Middle Aged; Panitumumab; Proto-Oncogene Proteins p21(ras) | 2019 |
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Predictive Value of Tests; Prognosis; Treatment Outcome | 2019 |
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxaliplatin; Proto-Oncogene Proteins p21(ras); Survival Analysis; Treatment Outcome | 2019 |
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Losartan; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2019 |
MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Rate | 2019 |
Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Cohort Studies; Colorectal Neoplasms; Drug Dosage Calculations; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Microspheres; Middle Aged; Prospective Studies; Survival Analysis | 2019 |
Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Preoperative Care; Prognosis; Prospective Studies; Rectal Neoplasms; Survival Rate; Young Adult | 2019 |
Early MRI predictors of disease-free survival in locally advanced rectal cancer from the GRECCAR 4 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Laparoscopy; Leucovorin; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Oxaliplatin; Precision Medicine; Prospective Studies; Rectal Neoplasms; Robotic Surgical Procedures; Tumor Burden; Young Adult | 2019 |
Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Radiotherapy, Intensity-Modulated | 2020 |
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Polymorphism, Genetic; Receptors, IgG; Treatment Outcome | 2019 |
A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Caprylates; Female; Fluorouracil; Follow-Up Studies; Humans; International Agencies; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Prospective Studies; Sulfides; Survival Rate | 2019 |
Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer.
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Oxaliplatin; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Salvage Therapy; Survival Rate | 2020 |
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Patient Safety; Treatment Outcome | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Proto-Oncogene Proteins p21(ras); Quality of Life; Survival Rate; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2020 |
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Endpoint Determination; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2020 |
Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Progression-Free Survival; Stomach Neoplasms; Sunitinib | 2020 |
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Genotyping Techniques; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Phenylurea Compounds; Precision Medicine; Prodrugs; Progression-Free Survival; Pyridines; Randomized Controlled Trials as Topic; Time Factors; Young Adult | 2019 |
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Progression; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; France; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate | 2020 |
Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Progression-Free Survival; Salvage Therapy | 2020 |
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Clinical Trials, Phase II as Topic; Docetaxel; Fluorouracil; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Quality of Life; Randomized Controlled Trials as Topic | 2020 |
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Positron-Emission Tomography; Stomach Neoplasms | 2020 |
Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nivolumab; Prognosis; Progression-Free Survival; Retrospective Studies; Stomach Neoplasms | 2020 |
Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Progression-Free Survival; Tegafur; Treatment Outcome | 2020 |
Daily dose to organs at risk predicts acute toxicity in pancreatic stereotactic radiotherapy.
Topics: Abdominal Pain; Acute Disease; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Data Analysis; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Nausea; Organs at Risk; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Radiation Dosage; Radiosurgery; Time Factors | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Bone Neoplasms; Camptothecin; Cell Count; Colorectal Neoplasms; DNA Mutational Analysis; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Microsatellite Instability; Middle Aged; Mutation; Neoplasm Staging; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Progression-Free Survival; Prospective Studies; Proto-Oncogene Proteins B-raf; ras Proteins; Risk Assessment; Young Adult | 2020 |
Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Prognosis; Sex Characteristics; Survival Rate | 2020 |
Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biosimilar Pharmaceuticals; Colorectal Neoplasms; Double-Blind Method; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Progression-Free Survival; Proportional Hazards Models | 2020 |
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Myeloid-Derived Suppressor Cells; Pancreatic Neoplasms; Peptides; Peritoneal Neoplasms; Receptors, CXCR4; Retroperitoneal Neoplasms; Survival Rate; T-Lymphocytes, Regulatory; Treatment Outcome | 2020 |
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Oxaliplatin; Peripheral Nervous System Diseases; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2020 |
NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Equivalence Trials as Topic; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaliplatin; Patient Compliance; Postoperative Complications; Preoperative Period; Proctectomy; Progression-Free Survival; Quality of Life; Randomized Controlled Trials as Topic; Rectal Neoplasms; Rectum | 2020 |
Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2020 |
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Oxaliplatin; Panitumumab; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); Time Factors | 2020 |
Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Health Care Costs; Hospitalization; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2020 |
A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ipilimumab; Irinotecan; Leucovorin; Macrophages; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms; Tumor Microenvironment | 2020 |
Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Oxaliplatin; Prognosis; Prospective Studies; Rectal Neoplasms; Survival Rate; Young Adult | 2020 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Drug Substitution; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome | 2020 |
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Hypercalciuria; Irinotecan; Leucovorin; Magnesium; Male; Nephrocalcinosis; Prognosis; Renal Tubular Transport, Inborn Errors; Retrospective Studies; Survival Rate | 2020 |
Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Electrochemotherapy; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Mice; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Perioperative Care; Prospective Studies; Treatment Outcome | 2020 |
Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Polymorphism, Genetic; Proto-Oncogene Proteins p21(ras) | 2020 |
Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Japan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Predictive Value of Tests; Prognosis; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Tomography, X-Ray Computed; Topoisomerase I Inhibitors; Treatment Outcome; Vitamin B Complex | 2020 |
R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Survival Analysis | 2021 |
nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2020 |
A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Tegafur | 2020 |
Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Proto-Oncogene Proteins p21(ras); Quality of Life; Retrospective Studies | 2021 |
Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis | 2021 |
A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Radiosurgery | 2021 |
Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer: A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Middle Aged; Quality of Life; Young Adult | 2021 |
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Standard of Care; Survival Analysis | 2022 |
Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Proton Pump Inhibitors | 2021 |
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled t
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Efficacy of Exercise Rehabilitation Program in Relieving Oxaliplatin Induced Peripheral Neurotoxicity.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Digestive System Neoplasms; Dose-Response Relationship, Drug; Exercise Therapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Peripheral Nervous System Diseases | 2021 |
Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Oxaliplatin; Topoisomerase I Inhibitors | 2021 |
FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Neuroendocrine; Etoposide; Female; Fluorouracil; Humans; Intestinal Neoplasms; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Oxaliplatin; Pancreatic Neoplasms; Platinum Compounds; Progression-Free Survival; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2021 |
A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Dietary Supplements; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Pilot Projects; Prospective Studies; Protective Agents; Silymarin; Treatment Outcome; Young Adult | 2021 |
Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Rate | 2021 |
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Nanoparticles; Pancreatic Neoplasms; Peptides | 2021 |
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms; Quality of Life | 2021 |
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxonic Acid; Proto-Oncogene Proteins B-raf; Quality of Life; Tegafur | 2021 |
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Prognosis; Prospective Studies; Retrospective Studies; Risk Factors; Survival Rate; Weight Loss | 2022 |
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf | 2021 |
Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Markov Chains; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; United States | 2021 |
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Progression-Free Survival; Time Factors | 2022 |
Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorouracil; Germany; Humans; Irinotecan; Leucovorin; Liposomes; Liver Neoplasms; Male; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Quality of Life | 2021 |
Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2021 |
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2022 |
Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Proto-Oncogene Proteins B-raf; Vemurafenib | 2022 |
Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neutropenia; Rectal Neoplasms; Retrospective Studies | 2023 |
Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan | 2022 |
A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Fluorouracil; Humans; Immunity; Irinotecan; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2022 |
Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Phenotype; Transcriptome; Tumor Microenvironment | 2022 |
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Prospective Studies | 2022 |
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI
Topics: Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic; Rectal Neoplasms | 2022 |
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatic Neoplasms | 2022 |
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Fluorouracil; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A | 2022 |
Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Circulating Tumor DNA; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies | 2022 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms | 2023 |
Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Middle Aged; Pancreatic Neoplasms | 2023 |
The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defin
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms; Prospective Studies; Quality of Life | 2023 |
Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Vascular Endothelial Growth Factor A | 2023 |
Preoperative chemoradiotherapy using tegafur/uracil, oral leucovorin, and irinotecan (TEGAFIRI) followed by oxaliplatin-based chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: the study protocol for a phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Rectal Neoplasms; Tegafur; Treatment Outcome | 2023 |
Modeling Tumor Growth Using Partly Conditional Survival Models: A Case Study in Colorectal Cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin | 2023 |
Single-arm, phase II study of intra-arterial chemotherapy plus total neoadjuvant therapy to optimise complete response in distal rectal cancer: a study protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Rectal Neoplasms | 2023 |
1232 other study(ies) available for fluorouracil and irinotecan
| Article | Year |
|---|---|
Synthesis and antitumor activity of the hexacyclic camptothecin derivatives.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Drug Stability; Enzyme Inhibitors; Humans; Mice; Sarcoma 180; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Design and synthesis of potent antitumor water-soluble phenyl N-mustard-benzenealkylamide conjugates via a bioisostere approach.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; In Situ Nick-End Labeling; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Nude; Mustard Compounds; Rats; Spectrometry, Mass, Electrospray Ionization | 2014 |
Amorfrutin C Induces Apoptosis and Inhibits Proliferation in Colon Cancer Cells through Targeting Mitochondria.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Caspases; Cell Cycle Checkpoints; Cell Proliferation; Colonic Neoplasms; Drug Screening Assays, Antitumor; Female; G1 Phase Cell Cycle Checkpoints; Glycyrrhiza; HT29 Cells; Humans; Inhibitory Concentration 50; Male; Membrane Potential, Mitochondrial; Mitochondria; Molecular Structure; Morocco; Peroxisome Proliferator-Activated Receptors; Plant Roots; Reactive Oxygen Species; Salicylates; Structure-Activity Relationship | 2016 |
Design, synthesis and biological evaluation of novel benzimidazole-2-substituted phenyl or pyridine propyl ketene derivatives as antitumour agents.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Ethylenes; HCT116 Cells; Hep G2 Cells; Humans; Ketones; MCF-7 Cells; Mice; Mice, Inbred BALB C; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship | 2016 |
Minor chemical modifications of the aminosteroid derivative RM-581 lead to major impact on its anticancer activity, metabolic stability and aqueous solubility.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Estranes; Humans; Liver; Molecular Structure; Solubility; Structure-Activity Relationship; Tumor Cells, Cultured; Water | 2020 |
Design, synthesis, and antitumor activity evaluation of steroidal oximes.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Oxidative Stress; Oximes; Steroids; Structure-Activity Relationship; Tumor Cells, Cultured | 2021 |
[Combination chemotherapy of BOF-A2, a new 5-FU derivative, with various anticancer agents against human cancer xenografts in nude mice].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Humans; Interferon-alpha; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitomycin; Neoplasm Transplantation; Transplantation, Heterologous | 1994 |
Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Codon; Colonic Neoplasms; Disease Progression; DNA, Neoplasm; Drug Resistance, Neoplasm; Exons; Female; Fluorouracil; Forecasting; Genes, ras; Guanine; Humans; Irinotecan; Male; Middle Aged; Mutation; Prognosis; Retreatment; Sequence Analysis, DNA; Survival Rate; Thymine; Treatment Failure | 1997 |
[Evaluation of a new anti-cancer drug regimen against uterine cervical cancer in nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Mitomycin; Neoplasm Transplantation; Paclitaxel; Uterine Cervical Neoplasms | 1997 |
[Efficacy of systemic chemotherapy in adenocarcinoma of the lung with pleuritis carcinomatosa].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pleural Effusion, Malignant; Pleurisy; Retrospective Studies; Survival Rate | 1997 |
Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Death; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorouracil; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Survival Analysis; Topoisomerase I Inhibitors | 1997 |
Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Enzyme Inhibitors; Fluorouracil; HT29 Cells; Humans; Irinotecan; S Phase; Thymidylate Synthase; Topoisomerase I Inhibitors | 1998 |
Irinotecan-induced immune thrombocytopenia.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Immunoglobulin G; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Thrombocytopenia | 1998 |
A risk-benefit assessment of irinotecan in solid tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Etoposide; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Risk Assessment | 1998 |
Irinotecan and 5-fluorouracil in colorectal cancer: time for a pause?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; DNA, Neoplasm; Drug Synergism; Fluorouracil; Humans; Irinotecan; Treatment Outcome | 1998 |
Colon cancer: new drug options improve on 5-FU.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1998 |
Irinotecan: toward clinical end points in drug development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Randomized Controlled Trials as Topic | 1998 |
US pivotal studies of irinotecan in colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; United States | 1998 |
Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Male; Outcome Assessment, Health Care; Palliative Care; Prostatic Neoplasms; Quality of Life; Research Design | 1998 |
[Effect of combination chemotherapy of low-dose CDDP. Continuous infusion of 5-FU, and intermittent CPT-11 administration for 2 advanced pancreatic cancer cases with liver metastasis].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms | 1998 |
Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Cell Survival; Deoxyuracil Nucleotides; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Humans; Intestinal Neoplasms; Irinotecan; Leucovorin; Thymidylate Synthase; Thymine Nucleotides; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1998 |
Improved survival in patients with advanced colorectal carcinoma failing 5-fluorouracil who received irinotecan hydrochloride and have high intratumor C-fos expression.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Irinotecan; Male; Middle Aged; Prognosis; Proto-Oncogene Proteins c-fos; Survival Analysis; Treatment Failure | 1998 |
Managing the side effects of chemotherapy for colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drugs, Investigational; Fluorouracil; Humans; Irinotecan; Patient Care Team; Quality of Life | 1998 |
High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; RNA, Messenger; Thymidine Phosphorylase; Thymidylate Synthase | 1998 |
Irinotecan may extend survival in people with metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 1998 |
Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Rhabdomyosarcoma; Transplantation, Heterologous | 1996 |
Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Screening Assays, Antitumor; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Tumor Cells, Cultured | 1998 |
4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Benzoates; Body Weight; Camptothecin; Carcinoma, Hepatocellular; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Molecular Structure; Neoplasm Invasiveness; Proto-Oncogene Proteins c-met; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; Specific Pathogen-Free Organisms; Survival Rate; Trimethylsilyl Compounds; Tumor Cells, Cultured | 1998 |
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Sesquiterpenes; Transplantation, Heterologous | 1999 |
[A case of advanced gastric cancer successfully treated by neoadjuvant chemotherapy with CPT-11, CDDP and 5-FU].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Fluorouracil; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Remission Induction; Stomach Neoplasms | 1999 |
Second line therapies move to the forefront in colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Fluorouracil; Hepatic Artery; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 1999 |
[Experimental study on intraperitoneal and intravenous administration of anti-tumor agents for liver metastasis].
Topics: Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; Fluorouracil; Infusions, Intravenous; Infusions, Parenteral; Irinotecan; Liver Neoplasms; Mice; Mice, Inbred BALB C; Tumor Cells, Cultured | 1999 |
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Rectal Neoplasms | 1999 |
Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Analysis; Treatment Outcome | 1999 |
Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Colonic Neoplasms; DNA Damage; DNA, Neoplasm; Fluorouracil; Humans; Irinotecan; Tumor Cells, Cultured | 1999 |
Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Stomach Neoplasms; Survival Rate | 1999 |
Inhibitory effect of combined administration with CPT-11 and 5-fluorouracil in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Carcinoma, Large Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Neoplasm Transplantation; Rats; Sarcoma, Yoshida; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1999 |
Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Combined Modality Therapy; DNA, Recombinant; DNA, Viral; Drug Resistance, Neoplasm; Fluorouracil; Gene Transfer Techniques; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Recent advances in colorectal chemotherapy: oral fluorinated pyrimidines, oxaliplatin and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2000 |
[Histoculture drug response assay on non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Tumor Cells, Cultured | 2000 |
[Weekly low-dose CPT-11 and HCFU for advanced colorectal cancer on an outpatient treatment basis].
Topics: Adenocarcinoma; Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Lymph Node Excision; Lymphatic Metastasis | 2000 |
Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Sigmoid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2000 |
Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Irinotecan; Kinetics; Maximum Tolerated Dose; Neoplasm Transplantation; Rats; Rats, Inbred F344; Time Factors | 2000 |
[A case of metastatic colon carcinoma in which a continuous intrahepatic artery-infusion of 5-FU leucovorin and cisplatin, and systemic chemotherapy with CPT-11 was very effective].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged | 2000 |
Moving beyond fluorouracil for colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia | 2000 |
[Weekly chemotherapy with alternating low-dose CPT-11 and low-dose FP against a far advanced pancreatic cancer--a case report].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Male; Pancreatic Neoplasms | 2000 |
Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Adhesion Molecules; Cytokines; Epithelial Cell Adhesion Molecule; Fluorouracil; Granulocyte-Macrophage Colony-Stimulating Factor; HT29 Cells; Humans; Interferons; Interleukins; Irinotecan; Lewis Blood Group Antigens; Macrophage Colony-Stimulating Factor; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Up-Regulation | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Analysis; Value of Life | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Quality of Life | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Data Interpretation, Statistical; Fluorouracil; Humans; Irinotecan; Leucovorin; Quality of Life | 2001 |
Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colonic Neoplasms; Drug Interactions; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Tumor Cells, Cultured | 2001 |
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bacterial Infections; Camptothecin; Cell Line; Cell Survival; Female; Fluorouracil; Glucagon-Like Peptide 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Intestines; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Peptides; Rats; Receptors, Glucagon; Survival Rate; Time Factors; Transfection; Tumor Cells, Cultured | 2001 |
North Central Cancer Treatment Group--Mayo Clinic trials in colon cancer.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole | 2001 |
A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged | 2001 |
The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin | 2001 |
Anticancer drugs as inducers of thermotolerance in yeast.
Topics: Antineoplastic Agents; Bleomycin; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Fluorouracil; Hot Temperature; Irinotecan; Methotrexate; Mitomycin; Saccharomyces | 2000 |
CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNA in mouse liver.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circadian Rhythm; Cytosol; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Fluorouracil; Immunohistochemistry; Irinotecan; Kinetics; Liver; Male; Mice; Mice, Inbred C57BL; Oxidoreductases; RNA, Messenger | 2001 |
[Chemotherapy of colorectal cancer--which therapy is justified for elderly patients?].
Topics: Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Geriatric Assessment; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant | 2001 |
[Irinotecan plus fluorouracil and folinic acid in metastatic colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2001 |
Researchers urge caution with standard regimen for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin | 2001 |
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Analysis | 2001 |
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis | 2001 |
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Fluorouracil; Gastrointestinal Diseases; Guidelines as Topic; Irinotecan; Leucovorin; Mortality; Randomized Controlled Trials as Topic; Risk Factors; Syndrome; Time Factors; Vascular Diseases | 2001 |
Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer.
Topics: Abdominal Pain; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Intestinal Obstruction; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Analysis; Tomography, X-Ray Computed | 2001 |
Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies.
Topics: Blotting, Northern; Blotting, Western; Camptothecin; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cisplatin; Cyclin A; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Fluorouracil; Folic Acid Antagonists; Gene Expression Regulation, Enzymologic; Humans; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Protein Serine-Threonine Kinases; Quinazolines; RNA, Messenger; Tetracycline; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 2001 |
[Sigmoid colon cancer with multiple liver metastasis (H3) effectively treated with CPT-11 and DSM (degradable starch microsphere) HAI therapy and intensive high dosage 5-FU HAI therapy--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Middle Aged; Sigmoid Neoplasms; Starch | 2001 |
[Four cases of multiple liver metastasis of colorectal cancer treated with hepatic resection after chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prognosis; Survival Rate | 2001 |
[Two cases of multiple liver metastases of colon cancer with systemic irinotecan and hepatic arterial injection of 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male | 2001 |
Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2001 |
Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspases; CD8-Positive T-Lymphocytes; Cell Survival; Chromium; Cisplatin; Colonic Neoplasms; Cytotoxicity, Immunologic; fas Receptor; Flow Cytometry; Fluorouracil; Humans; In Situ Nick-End Labeling; Intercellular Adhesion Molecule-1; Interferon-gamma; Irinotecan; Recombinant Proteins; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured | 2001 |
Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cisplatin; Colonic Neoplasms; Disease Models, Animal; Drug Synergism; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Signal Transduction; Sphingomyelins; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
Toxicity of irinotecan in patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin | 2001 |
Future treatment options with capecitabine in solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Forecasting; Humans; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Taxoids | 2002 |
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardiovascular Diseases; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Syndrome; Thrombosis | 2002 |
Recent development of anti-cancer drugs for treatment of GI malignancies in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pyridines; Tegafur | 2002 |
Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Patient Compliance; Retrospective Studies | 2002 |
Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Mutation; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
[A case of hepatic metastasis from rectal carcinoma successfully treated with pharmacokinetic modulating chemotherapy (PMC)-CPT-11 therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Hysterectomy; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Middle Aged; Neoplasm Invasiveness; Rectal Neoplasms; Sigmoid Neoplasms | 2002 |
[Initial results of randomized studies of metastatic colorectal carcinoma urge careful and controlled use of CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate | 2002 |
[A case of recurrent rectal cancer responding to weekly low-dose CPT-11/isovorin/5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Neoplasm Recurrence, Local; Rectal Neoplasms | 2002 |
Anaphylactic shock secondary to intravenous administration of folinic acid: a first report.
Topics: Aged; Aged, 80 and over; Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Treatment Outcome | 2002 |
[A case of advanced colon cancer with para-aortic lymph node metastasis responding greatly to treatment by adjuvant chemotherapy of low-dose CPT-11 on an outpatient basis].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis | 2002 |
New studies highlight benefit of Xeloda in new combination treatments for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrazoles; Sulfonamides | 2002 |
ERBITUX as a single agent and in combination in colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin | 2002 |
Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Cell Survival; Colonic Neoplasms; DNA, Neoplasm; Drug Interactions; Female; Fluorouracil; Glutamates; Guanine; HT29 Cells; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Transplantation, Heterologous | 2002 |
Another NICE mess.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Legislation, Drug; Organizational Policy; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; State Medicine; United Kingdom | 2002 |
Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Camptothecin; Cell Nucleus; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Glutathione; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Irinotecan; Isoenzymes; Lectins; Tumor Cells, Cultured | 2002 |
Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Colonic Neoplasms; Drug Synergism; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Membrane Glycoproteins; Mice; Mice, SCID; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2002 |
[A case of colon metastasis to the lung treated successfully with combined chemotherapy of CPT-11 and 5'-DFUR].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Combinations; Floxuridine; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Rectal Neoplasms; Tegafur; Uracil | 2002 |
25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2001 |
Capecitabine combinations in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2001 |
Irinotecan/5-fluorouracil/leucovorin in advanced colorectal cancer: Oncologic Drugs Advisory committee summary.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Retrospective Studies; Survival Analysis; United States; United States Food and Drug Administration | 2002 |
Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Product Surveillance, Postmarketing; Survival Analysis; United States; United States Food and Drug Administration | 2002 |
Lessons learned from the Saltz and Mayo Clinic regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Product Surveillance, Postmarketing; United States; United States Food and Drug Administration | 2002 |
[Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Tegafur; Uracil | 2002 |
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2002 |
Systemic chemotherapy for metastatic colorectal cancer: reasons to combine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome | 2002 |
Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Colonic Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Thymidylate Synthase; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2002 |
[A case of stage IV diffusely infiltrating colon cancer treated by surgical resection and chemoradiation therapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colectomy; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Sigmoid Neoplasms | 2002 |
[A case of gastric cancer associated with synchronous liver metastasis successfully treated with combination therapy of systemic and hepatic arterial infusion chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Stomach Neoplasms | 2002 |
Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Fluorouracil; Genetic Therapy; Humans; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Nude; Nuclear Proteins; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2003 |
Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Europe; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 2002 |
[Effectiveness of chemotherapy for outpatients with gastric or colorectal cancer].
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Outpatients; Oxonic Acid; Paclitaxel; Pyridines; Retrospective Studies; Stomach Neoplasms; Tegafur | 2002 |
Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Cisplatin; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Fluorouracil; Follow-Up Studies; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Leucovorin; Life Tables; Lymphokines; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Nitrates; Nitric Oxide; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Rectal Neoplasms; Survival Analysis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate | 2003 |
Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Retrospective Studies; Salvage Therapy; Time Factors | 2002 |
Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Camptothecin; Cell Division; Colorectal Neoplasms; Cyclin D1; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytoskeletal Proteins; Dinoprostone; Drug Synergism; Endothelial Growth Factors; Fluorouracil; Intercellular Signaling Peptides and Proteins; Interleukin-10; Interleukin-12; Irinotecan; Isoenzymes; Lactones; Liver Neoplasms, Experimental; Lymphokines; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Prostaglandin-Endoperoxide Synthases; Sulfones; Trans-Activators; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Hepatic artery infusion for liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer.
Topics: Antidiarrheals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drugs, Chinese Herbal; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leukopenia; Liver Neoplasms; Male; Middle Aged; Nausea; Rectal Neoplasms; Retrospective Studies; Survival Analysis; Thrombocytopenia; Vomiting, Anticipatory | 2003 |
Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Middle Aged; Nausea; Pilot Projects; Rectal Neoplasms; Salvage Therapy; Survival Analysis; Treatment Outcome; Vomiting, Anticipatory | 2003 |
Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, Adjuvant; Rectal Neoplasms; Time Factors | 2003 |
Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bacitracin; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Neomycin | 2003 |
[A case of irinotecan-resistant colon cancer responding to chronotherapy with oxaliplatin, 5-FU, l-LV].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Chronotherapy; Colonic Neoplasms; Drug Evaluation; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin | 2003 |
[A case of colon cancer with liver metastases and lymph node metastases successfully treated with surgery followed by CPT-11 and 5-FU chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged | 2003 |
Is liver disease an octreotide side effect?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Agents; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Octreotide | 2003 |
[Renal metastasis after curative resection of an epidermoid carcinoma of the esophagus].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Deglutition Disorders; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; Fluorouracil; Humans; Irinotecan; Kidney Neoplasms; Lymphatic Metastasis; Male; Neoplasm Staging; Prognosis; Tomography, X-Ray Computed | 2003 |
Chemotherapy with irinothecan, 5-fluorouracil and folinic acid in the first-line management of advanced colorectal carcinoma: retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2003 |
Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Remission Induction | 2003 |
Onycholysis associated with capecitabine in combination with irinotecan in two patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Nail Diseases; Nails | 2003 |
[A case of multiple lung metastases from colon cancer after sigmoidectomy treated effectively by chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colon, Sigmoid; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Postoperative Complications; Sigmoid Neoplasms; Tegafur; Uracil | 2003 |
[A case of effective weekly paclitaxel administration for metastatic gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Stomach Neoplasms | 2003 |
Advances in colon cancer.
Topics: Camptothecin; Colonic Neoplasms; Drug Combinations; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Pyridines; Treatment Outcome | 2003 |
Validation of the role of angiogenesis as a chemotherapeutic target.
Topics: Adaptation, Physiological; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Fluorouracil; Humans; Irinotecan; Leucovorin; Neovascularization, Pathologic; Randomized Controlled Trials as Topic; Survival Analysis; Wound Healing | 2003 |
Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Combined Modality Therapy; Endothelial Growth Factors; Fluorouracil; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Leucovorin; Lymphokines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Capecitabine in combination with irinotecan or oxaliplatin in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis | 2003 |
Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Vomiting | 2003 |
Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Flow Cytometry; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, MHC Class I; Humans; Irinotecan; Mice; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Up-Regulation | 2003 |
[A case of resected spinal metastasis following colectomy and hepatectomy for descending colon carcinoma].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Spinal Neoplasms | 2003 |
[A case of hepatic metastasis and local recurrence from rectal cancer responding to hepatic arterial infusion and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Combinations; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Rectal Neoplasms; Tegafur; Uracil | 2003 |
[A case of unresectable liver metastases from rectosigmoid colon cancer with survival for over 3 years after multidisciplinary treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Mitomycin; Rectal Neoplasms; Sigmoid Neoplasms | 2003 |
[A case of spinal infarction related to hepatic arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cecal Neoplasms; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infarction; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Spine | 2003 |
[Long-term survival after neck lymph node metastases from sigmoid colon cancer--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colon, Sigmoid; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Nodes; Lymphatic Metastasis; Neck; Sigmoid Neoplasms; Survivors; Tegafur; Uracil | 2003 |
[Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Krukenberg Tumor; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Ovarian Neoplasms; Ovariectomy; Stomach Neoplasms | 2003 |
Combined modality therapy in esophageal cancer: the Memorial experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Paclitaxel | 2003 |
[A case of advanced cancer with liver metastasis and paraaortic lymph node metastasis responding remarkably to combination chemotherapy of low-dose CDDP, 5-FU and CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Cisplatin; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Stomach Neoplasms | 2003 |
[A case of gastric carcinoma with multiple skin, bone, and bilateral ovary metastasis; effective treatment by chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Ovarian Neoplasms; Prognosis; Quality of Life; Skin Neoplasms; Stomach Neoplasms | 2003 |
Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Folic Acid; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Postoperative Complications; Retrospective Studies | 2003 |
Presentations from the Walter Reed Army Medical Center. Case 1: rectal carcinoma.
Topics: Adenocarcinoma, Mucinous; Adult; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoadjuvant Therapy; Patient Care Planning; Rectal Neoplasms; Rectum; Ultrasonography | 2003 |
Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Rectal Neoplasms; Survival Analysis | 2003 |
[Principles of postoperative therapy in rectal carcinoma].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Rectal Neoplasms; Time Factors | 2004 |
Chemoembolization of rat liver metastasis with irinotecan and quantification of tumor cell reduction.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Chemoembolization, Therapeutic; Colonic Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Irinotecan; Luminescent Measurements; Male; Microspheres; Rats; Rats, Inbred Strains | 2004 |
First-line hepatic infusion of pirarubicin in patients with isolated liver metastases: is it really promising?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Doxorubicin; Fluorouracil; Health Care Costs; Hepatic Artery; Humans; Immunosuppressive Agents; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Patient Selection; Treatment Outcome | 2004 |
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.
Topics: Antineoplastic Agents; Camptothecin; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Female; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Models, Biological; Ovarian Neoplasms; Paclitaxel | 2004 |
Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Irinotecan; Kinetics; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Reverse Transcriptase Polymerase Chain Reaction; Time Factors | 2004 |
Gilbert's syndrome and fluorouracil toxicity in colorectal cancer patients: which correlation?
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gilbert Disease; Humans; Irinotecan; Male; Middle Aged; Retrospective Studies | 2004 |
Response to chemotherapy (irinotecan plus 5-fluorouracil) in colorectal carcinoma can be predicted by tumour DNA content.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Ploidies; Predictive Value of Tests; Treatment Outcome | 2004 |
Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Genes, p53; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Tumor Suppressor Protein p53 | 2004 |
[A case report of colon cancer with liver and lung metastases responding to combination chemotherapy with l-LV, 5-fluorouracil and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Tumor Cells, Cultured | 2004 |
[A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Pleurisy; Quality of Life; Tegafur; Uracil | 2004 |
Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cytokines; Digestive System; Dose-Response Relationship, Drug; Female; Fluorouracil; Histocompatibility Antigens Class I; Intestinal Mucosa; Irinotecan; Jejunum; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Peptides; Time Factors | 2004 |
An immediate hemolytic reaction induced by repeated administration of oxaliplatin.
Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Antibody Specificity; Antigens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Grouping and Crossmatching; Blood Transfusion; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Disease Progression; Fatal Outcome; Female; Fluorouracil; Humans; Immunoglobulin G; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2004 |
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Endosonography; Esophageal Neoplasms; Esophagogastric Junction; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Preoperative Care; Prognosis; Remission Induction; Survival Rate | 2004 |
[A case of colon carcinoma with unresectable multiple liver metastases responding to various combined chemotherapies centering on hepatic arterial infusion therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Quality of Life | 2004 |
Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Treatment Outcome | 2004 |
[Management of chemotherapy induced diarrhea].
Topics: Antidiarrheals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Loperamide; Neoplasms; Octreotide; Patient Care Management; Practice Guidelines as Topic | 2004 |
Reactivation of hepatitis C virus after chemotherapy for colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colonic Neoplasms; Fluorouracil; Hepatitis C; Humans; Immunocompromised Host; Irinotecan; Leucovorin; Male; Recurrence | 2004 |
Irinotecan chemotherapy associated with transient dysarthria and aphasia.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aphasia; Camptothecin; Colonic Neoplasms; Dysarthria; Fluorouracil; Humans; Infusion Pumps; Irinotecan; Male | 2004 |
Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Drug Synergism; Floxuridine; Fluorouracil; Humans; Irinotecan; Nucleic Acids; Organoplatinum Compounds; Oxaliplatin; Uridine | 2004 |
The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines.
Topics: Base Sequence; Camptothecin; Cell Division; Cell Line, Tumor; Colorectal Neoplasms; Cyclin-Dependent Kinases; Etoposide; Flow Cytometry; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Oligonucleotides | 2004 |
Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2004 |
[Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2004 |
Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; NF-kappa B; Stomach Neoplasms | 2004 |
Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.
Topics: Administration, Oral; Anti-Bacterial Agents; Antidiarrheals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Loperamide; Neomycin | 2004 |
Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Leukopenia; Liver; Liver Neoplasms; Male; Middle Aged; Neutropenia; Retrospective Studies | 2004 |
Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Thymidylate Synthase; Topoisomerase I Inhibitors | 2004 |
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Colorectal Neoplasms; DNA Primers; Female; Fluorouracil; Genetic Vectors; Genotype; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Male; Middle Aged; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Polymerase Chain Reaction; Polymorphism, Genetic; Risk; Sequence Analysis, DNA | 2004 |
Treatment issues in pediatric gastric adenocarcinoma.
Topics: Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Catheter Ablation; Chemotherapy, Adjuvant; Child; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Gastrectomy; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Irinotecan; Liver Neoplasms; Lymph Node Excision; Neoplasm Recurrence, Local; Neoplastic Syndromes, Hereditary; Pancreatectomy; Prognosis; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Remission Induction; Reoperation; Splenectomy; Stomach Neoplasms; Taxoids | 2004 |
[A case of hepatic metastasis from colon cancer successfully treated with 5-FU, levofolinate (l-LV) and low-dose CPT-11].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Remission Induction | 2004 |
[A successfully resected case of colorectal cancer with multiple liver metastases treated with systemic chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colon, Sigmoid; Combined Modality Therapy; Drug Administration Schedule; Electrocoagulation; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Microwaves; Middle Aged; Sigmoid Neoplasms; Survivors | 2004 |
[Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis].
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Data Interpretation, Statistical; Fluorouracil; Gastrointestinal Neoplasms; Irinotecan; Male; Mitomycin; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Rats; Time Factors; Tumor Cells, Cultured | 2004 |
Roles of infusional high-dose 5-fluorouracil with leucovorin in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Taiwan | 2004 |
[A case of metastatic liver tumor from colorectal carcinoma--continued arterial infusion chemotherapy through a microcatheter located in replaced right hepatic artery].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheters, Indwelling; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male | 2004 |
[A case of 5-FU-resistant recurrent colon cancer treated with low-dose CPT-11/CDDP on an outpatient basis].
Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Male; Quality of Life | 2004 |
Bevacizumab in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Quality-Adjusted Life Years; Research Design | 2004 |
[Successful treatment of liver metastasis and extrahepatic metastasis with hepatic arterial infusion of CDDP, CPT-11, and 5-FU].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Rectal Neoplasms | 2004 |
[A case of disseminated tumor from cecal cancer with survival for over 5 years after twice surgical resection and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Cecal Neoplasms; Combined Modality Therapy; Floxuridine; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Seeding; Peritoneal Neoplasms; Reoperation | 2004 |
Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Camptothecin; Carboxylesterase; Cell Line, Tumor; Combined Modality Therapy; Cytosine Deaminase; Disease Models, Animal; Drug Delivery Systems; Female; Fluorouracil; Genetic Therapy; Genetic Vectors; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasms, Glandular and Epithelial; Promoter Regions, Genetic; Ribosomes; RNA, Messenger; Thymidylate Synthase; Time Factors; Transcription, Genetic | 2004 |
Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Contraindications; Enzyme Inhibitors; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Topoisomerase I Inhibitors | 2004 |
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Squamous Cell; Cell Differentiation; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hypoxia; Irinotecan; Magnetic Resonance Imaging; Mice; Mice, Nude; Microcirculation; Oxygen; Rats; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft.
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoembryonic Antigen; Carcinoma, Signet Ring Cell; Cell Proliferation; Colonic Neoplasms; Combined Modality Therapy; Complement System Proteins; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Survival Rate; Transplantation, Heterologous | 2005 |
Unfavourable expression of pharmacologic markers in mucinous colorectal cancer.
Topics: Adenocarcinoma, Mucinous; Aged; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Primers; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
Synergistic antitumor activity of capecitabine in combination with irinotecan.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Thiophenes | 2005 |
Importance of preclinical investigations of the integration of capecitabine into polychemotherapy regimens.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Thiophenes | 2005 |
Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Phenazines; Transplantation, Heterologous | 2005 |
Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Fluorouracil; HT29 Cells; Humans; Ibuprofen; Irinotecan; Lactones; Liver Neoplasms; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Sulfones; Survival Analysis; Xenograft Model Antitumor Assays | 2005 |
The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Caspases; Down-Regulation; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Fibroblasts; Fluorouracil; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Liver Neoplasms; Membrane Potentials; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Skin; Tumor Cells, Cultured; Vorinostat | 2005 |
Gastrointestinal Cancers--Second Annual Symposium. 27-29 January 2005, Hollywood, FL, USA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2005 |
Treatment of a Gilbert's syndrome patient with irinotecan, leucovorin and 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Gilbert Disease; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Mutation; Syndrome; Treatment Outcome | 2005 |
5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Heterozygote; Humans; Irinotecan; Mutation; Nausea; Sigmoid Neoplasms; Vomiting | 2005 |
Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle Proteins; Colorectal Neoplasms; Female; Fluorouracil; Humans; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Irinotecan; Liver Neoplasms; Male; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2005 |
Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronotherapy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Quality of Life | 2005 |
The irinotecan/5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Colonic Neoplasms; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Fluorouracil; HT29 Cells; Humans; Irinotecan; Superoxide Dismutase | 2005 |
Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2005 |
Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Oligonucleotide Array Sequence Analysis; Osteonectin; Transplantation, Heterologous | 2005 |
[Systemic therapy for colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Synergism; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fatty Liver; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prospective Studies; Risk Factors; Topoisomerase I Inhibitors | 2005 |
The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Thymidylate Synthase | 2005 |
[Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Fluorouracil; Humans; Irinotecan; Ki-67 Antigen; Male; Middle Aged; Prognosis; Thymidylate Synthase; Treatment Outcome | 2005 |
Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Caspase 3; Caspase Inhibitors; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cysteine Proteinase Inhibitors; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; HT29 Cells; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Protein Serine-Threonine Kinases; Quinazolines; rho-Associated Kinases; Thymidylate Synthase; Time Factors; Topoisomerase I Inhibitors | 2005 |
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2005 |
Cancer cell adaptation to chemotherapy.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Camptothecin; Cell Line, Tumor; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Neoplasms; Paclitaxel; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topotecan; Treatment Outcome; Up-Regulation | 2005 |
Chemotherapy for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2005 |
[Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Rectal Neoplasms | 2005 |
Capecitabine as third line therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Colonic Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prodrugs; Rectal Neoplasms; Retrospective Studies; Survival Rate | 2005 |
Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Camptothecin; Cell Proliferation; Colonic Neoplasms; Epidermal Growth Factor; Female; Fluorouracil; Galanin; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Leucovorin; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Octreotide; Organoplatinum Compounds; Oxaliplatin; Platelet Endothelial Cell Adhesion Molecule-1; Poly(ADP-ribose) Polymerases; Serotonin; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2005 |
Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; Survival Analysis; Thymidylate Synthase | 2005 |
Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chronotherapy; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
Adjuvant irinotecan regimens in combination with infusional 5-fluorouracil/leucovorin fail to improve outcomes in surgically resected colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Rate | 2005 |
[Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged | 2005 |
Regression of colorectal adenomas with intravenous cytotoxic chemotherapy in a patient with familial adenomatous polyposis.
Topics: Adenoma; Adenomatous Polyposis Coli; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Treatment Outcome | 2005 |
[A case of colon cancer with liver and lung metastases-efficacy of CPT-11/5-FU/l-LV (IFL) as part of ambulatory treatment].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Quality of Life; Sigmoid Neoplasms | 2005 |
Patient with angina secondary to capecitabine.
Topics: Adenocarcinoma; Angina Pectoris; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Sigmoid Neoplasms | 2005 |
Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboxylesterase; Chromatography, High Pressure Liquid; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Fluorouracil; Humans; Irinotecan; Kinetics; Leucovorin; Leukocytes, Mononuclear; Male; Middle Aged; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2005 |
Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; fas Receptor; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Quinazolines; RNA, Messenger; STAT1 Transcription Factor; Thiophenes; Tumor Suppressor Protein p53; Up-Regulation | 2005 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Irinotecan; Male; Mandibular Diseases; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Osteoradionecrosis; Paclitaxel; Prognosis; Radiotherapy Dosage; Treatment Failure; Treatment Outcome | 2006 |
[A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Lung Neoplasms; Middle Aged; Tegafur; Uracil | 2005 |
Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.
Topics: Analysis of Variance; Camptothecin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Length of Stay; Logistic Models; Lung; Male; Pneumonia; Postoperative Complications; Radiotherapy Dosage; Radiotherapy, Conformal; Respiratory Distress Syndrome; Retrospective Studies; Sex Factors; Statistics, Nonparametric | 2006 |
In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Cisplatin; Colorectal Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Leucovorin; Male; Middle Aged; Mitomycin; Taxoids | 2005 |
Non-invasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-Fluorouracil, CPT-11 and/or TRAIL.
Topics: Adolescent; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Cell Death; Cell Survival; Colon; Drug Combinations; Female; Fluorescence; Fluorouracil; Humans; Image Processing, Computer-Assisted; Irinotecan; Membrane Glycoproteins; Organ Culture Techniques; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2005 |
[A case of cecal cancer with multiple liver metastases responding to irinotecan (CPT-11)/cisplatin (CDDP) combination therapy for elevation of CA19-9 after complete response (CR) by l-leucovorin(LV)/5-fluorouracil(5-FU) therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cecal Neoplasms; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged | 2005 |
Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local | 2005 |
[Chemotherapy for liver metastasis of colorectal cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged | 2005 |
[A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Neoplasm Recurrence, Local | 2005 |
Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Health Services Accessibility; Humans; Irinotecan; Models, Theoretical; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2005 |
Novel two-step resection for lesions between the middle hepatic vein and vena cava which allows the middle hepatic vein to be preserved.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Follow-Up Studies; Hepatectomy; Hepatic Veins; Humans; Irinotecan; Leucovorin; Liver; Liver Neoplasms; Liver Regeneration; Male; Rectal Neoplasms; Vena Cava, Inferior | 2006 |
Unresectable hepatic colorectal metastases: need for new surgical strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2006 |
Irinotecan with bolus and infusional 5-flurouracil and folinic acid for patients with advanced or metastatic colorectal cancer previously treated with 5-flurouracil: a possible alternative to single-agent irinotecan in a 'real-life' setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies | 2005 |
Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; CpG Islands; Dendritic Cells; Disease Models, Animal; Female; Fluorouracil; Humans; Immunotherapy; Irinotecan; Mice; Mice, Inbred BALB C; Oligonucleotides | 2006 |
in vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Synergism; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins c-bcl-2 | 2006 |
[Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2006 |
Irinotecan/5-fluorouracil combination induces alterations in mitochondrial membrane potential and caspases on colon cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; HT29 Cells; Humans; Irinotecan; Membrane Potentials; Mitochondrial Membranes | 2005 |
[Adjuvant and palliative chemotherapy of colorectal cancer in Germany outside controlled trials].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Germany; Guideline Adherence; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Radiotherapy, Adjuvant; Survival Rate | 2006 |
[New chances in therapy of gastrointestinal tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Fluorouracil; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Randomized Controlled Trials as Topic | 2005 |
Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro.
Topics: Antigens, CD20; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; CD40 Antigens; Cell Survival; Clone Cells; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Etoposide; Female; Flow Cytometry; Fluorouracil; Humans; Integrin alpha1; Integrin alpha6; Irinotecan; Mitomycin; Uterine Cervical Neoplasms; X-Rays | 2006 |
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Fluorouracil; Gemcitabine; Gene Expression; GPI-Linked Proteins; Hepatocytes; Humans; Immunohistochemistry; Irinotecan; Membrane Glycoproteins; Organoplatinum Compounds; Oxaliplatin; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 10c; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor Decoy Receptors; Tumor Necrosis Factor-alpha | 2006 |
Individualizing chemotherapeutic treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bilirubin; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenetics; United States | 2006 |
Tumour regression and mesorectal lymph node changes after intensified neoadjuvant chemoradiation for carcinoma of the rectum.
Topics: Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; CD83 Antigen; Dendritic Cells; Deoxycytidine; Female; Fluorouracil; Humans; Immunoglobulins; Irinotecan; Lymph Nodes; Male; Membrane Glycoproteins; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms | 2006 |
[Outpatient based colorectal cancer treatment--the current status, challenges and future outlook].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Home Care Services, Hospital-Based; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Quality of Life | 2006 |
Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Bevacizumab; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Rectal Neoplasms; Thromboembolism; Tomography, X-Ray Computed | 2006 |
Turning point for colorectal cancer clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2006 |
Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glutathione Transferase; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length | 2006 |
Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Tumor Cells, Cultured | 2006 |
Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate | 2006 |
[Long-term repeatable chemotherapy for patients with advanced pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Remission Induction; Survival Rate; Tegafur | 2006 |
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Oligonucleotide Array Sequence Analysis; Poly A; RNA, Messenger | 2005 |
[Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study].
Topics: Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Quality of Life; Rectal Neoplasms | 2006 |
[A case of advanced gastric cancer with liver metastasis completely responding to CPT-11+low-dose 5-FU+CDDP chemotherapy].
Topics: Adenocarcinoma; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Cisplatin; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2006 |
Irinotecan cytotoxicity does not necessarily depend on the UGT1A1 polymorphism but on fluoropyrimidine: a molecular case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Genetic | 2006 |
[Case report of a liver metastasis from rectal cancer achieving complete response (CR) by a combination of intra-hepatic arterial infusion of irinotecan (CPT-11) with degradable starch microspheres (DSM) and weekly high-dose intra-hepatic arterial chemoth
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Mitomycin; Rectal Neoplasms; Starch | 2006 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Fibrosis; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2007 |
Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Drug Administration Schedule; Fatty Liver; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Retrospective Studies; Treatment Outcome | 2007 |
[A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colostomy; Drug Administration Schedule; Fluorouracil; Humans; Ileus; Irinotecan; Leucovorin; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Rectal Neoplasms | 2006 |
[What happened during these 12 years since CPT-11 was launched in Japan ?].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Drug Approval; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2006 |
5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Costs; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate | 2006 |
A case report--The marked response to gemcitabine combined with irinotecan and low-dose cisplatin chemotherapy for advanced gastric cancer with multiple liver metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Male; Remission Induction; Stomach Neoplasms; Treatment Outcome | 2006 |
[A case of successfully treated unresectable multiple liver metastases from colon cancer by hepatic arterial infusion chemotherapy and systemic chemotherapy].
Topics: Aged; Camptothecin; Carcinoma; Colectomy; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Remission Induction; Sigmoid Neoplasms | 2006 |
Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxa
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Pyrophosphatases; Thymidylate Synthase; X-ray Repair Cross Complementing Protein 1 | 2007 |
Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis.
Topics: Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Camptothecin; Cohort Studies; Colorectal Neoplasms; Databases, Factual; Disease Progression; Drug Resistance, Neoplasm; Drug Utilization; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; National Health Programs; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Practice Patterns, Physicians'; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Sex Distribution; Survival Analysis | 2007 |
Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Tumor Cells, Cultured | 2006 |
[Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Infusions, Intravenous; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neutropenia; Quality of Life; Rectal Neoplasms | 2007 |
Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Risk Assessment; Risk Factors | 2007 |
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Profiling; Humans; Irinotecan; Leucovorin; Male; Middle Aged | 2007 |
[Chemotherapy for elderly patients with colorectal cancer].
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Vomiting, Anticipatory | 2007 |
[A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Rectal Neoplasms; Retrospective Studies | 2007 |
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; CpG Islands; DNA Methylation; Female; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Massachusetts; Microsatellite Instability; Middle Aged; Quinazolines; Survival Rate | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Rectal Neoplasms; Vitamin B Complex | 2007 |
Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lewis X Antigen; Male; Middle Aged; Oligosaccharides; Orotate Phosphoribosyltransferase; Prognosis; Sialyl Lewis X Antigen; Survival Rate; Thymidine Phosphorylase; Thymidylate Synthase; Vitamin B Complex | 2007 |
Size matters. What can we learn from a small randomized trial?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Data Interpretation, Statistical; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2007 |
Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan; Leucovorin; Leukemia, Myeloid, Acute; Male; Prognosis; Recurrence; Remission Induction | 2007 |
Panitumumab in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Epidermal Growth Factor; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Panitumumab | 2007 |
Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Polymorphism, Genetic | 2007 |
Establishment and characterization of an IGSK-2 cell line derived from ascitic fluid of recurrent hCG and somatostatin secreted adenocarcinoma of the stomach.
Topics: Adenocarcinoma, Mucinous; Adult; Animals; Antigens, Tumor-Associated, Carbohydrate; Ascitic Fluid; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Cell Line, Tumor; Chorionic Gonadotropin; Cisplatin; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Somatostatin; Stomach Neoplasms | 2007 |
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Gene Expression Profiling; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies | 2008 |
Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2007 |
[Evaluation of combination chemotherapy with 5-FU, CDDP and CPT-11 for human gastric carcinoma transplanted into nude mice - comparative study of in vivo chemosensitivity test].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Stomach Neoplasms | 2007 |
[Long survival of a colon cancer case with multiple liver metastases cured by multidisciplinary therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxonic Acid; Sigmoid Neoplasms; Survivors; Tegafur | 2007 |
Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis.
Topics: Camptothecin; Cisplatin; Cytotoxins; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Melphalan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Peritoneal Neoplasms; Tumor Cells, Cultured | 2008 |
Chemotherapy-induced mucositis: focusing on diarrhea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Budesonide; Camptothecin; Dehydration; Diarrhea; Fluorouracil; Gastric Mucosa; Gastrointestinal Tract; Humans; Infusions, Intravenous; Intestinal Absorption; Intestinal Mucosa; Irinotecan; Leucovorin; Loperamide; Mice; Mucositis; Organoplatinum Compounds; Rats | 2007 |
In vitro simulation study of individualized chemotherapy in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2007 |
Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2007 |
[Therapeutic strategy for type 4 gastric cancer from the clinical oncologist standpoint].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Methotrexate; Middle Aged; Oxonic Acid; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
Extensive colonic ischemia following treatment with bevacizumab, fluouracil and CPT-11 in a young patient with advanced adenocarcinoma of the rectum.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colitis, Ischemic; Colonoscopy; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Rectal Neoplasms | 2007 |
Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Diarrhea; Fluorouracil; Granulomatosis with Polyangiitis; Hemorrhage; Humans; Irinotecan; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis | 2007 |
Capecitabine and irinotecan in advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Stomach Neoplasms; Treatment Outcome | 2007 |
A renewed call for equipoise.
Topics: Adenocarcinoma; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Ethics, Medical; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukemia; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Uncertainty | 2007 |
[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Rectal Neoplasms; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2007 |
Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Camptothecin; Colorectal Neoplasms; DNA Repair; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Metastasis; Nuclear Proteins; Treatment Outcome | 2007 |
Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in p53 mutant human colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Gene Expression; Gene Expression Profiling; Humans; Irinotecan; Leucovorin; Mutation; Oligonucleotide Array Sequence Analysis; Tumor Cells, Cultured; Up-Regulation | 2007 |
Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; Ileal Neoplasms; Irinotecan; Jejunal Neoplasms; Leucovorin; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2006 |
Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Adhesion; Cell Line, Tumor; Collagen Type II; Colonic Neoplasms; Female; Fibronectins; Floxuridine; Fluorouracil; Humans; Irinotecan; Laminin; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Nude; Models, Biological; Neoplasm Metastasis; Paclitaxel | 2007 |
Effect of betulinic acid on anticancer drug-resistant colon cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; bcl-2-Associated X Protein; bcl-Associated Death Protein; Betulinic Acid; Camptothecin; Caspases; Cell Death; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Humans; Irinotecan; Mitochondria; Multidrug Resistance-Associated Proteins; Organoplatinum Compounds; Oxaliplatin; Pentacyclic Triterpenes; Triterpenes | 2007 |
Therapy of colon carcinoma: an oncology perspective. Interview with Piotr M. Czaykowski by Paul C. Adams.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Carcinoma; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Quinazolines; Rectal Neoplasms; Thiophenes | 2007 |
Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Prospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2008 |
The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Caspase 7; Catechin; Cell Growth Processes; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Fluorouracil; Glioblastoma; Heat-Shock Proteins; Humans; Irinotecan; Molecular Chaperones; RNA, Small Interfering; Temozolomide; Transcription Factor CHOP; Transfection | 2007 |
Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Mismatch Repair; Europe; Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Male; Microsatellite Instability; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Staging; Nuclear Proteins; Thymidylate Synthase; Treatment Outcome | 2008 |
Pharmacodynamic study of the Saltz regimen for metastatic colorectal cancer in a hemodialyzed patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diabetes Mellitus, Type 1; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Renal Dialysis; Treatment Outcome | 2007 |
A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Body Surface Area; Body Weight; Camptothecin; Digestive System Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Models, Biological; Neoplasm Metastasis; Reproducibility of Results | 2007 |
[Systemic treatment of peritoneal metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Quality of Life | 2007 |
[A patient with recurrent rectal cancer in whom pulmonary metastasis disappeared by FOLFOX 4 therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Middle Aged; Organoplatinum Compounds; Rectal Neoplasms | 2007 |
[Long- term remission survival with a case of rectal carcinoid tumor with metastasis in the soft tissue effectively treated with the combination therapy of irinotecan/5-fluorouracil/levofolinate followed by resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoid Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Rectal Neoplasms; Rectum; Remission Induction; Soft Tissue Neoplasms; Time Factors; Treatment Outcome | 2007 |
Comparative cytotoxicity of C-1311 in colon cancer in vitro and in vivo using the hollow fiber assay.
Topics: Aminoacridines; Animals; Antineoplastic Agents; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Fluorouracil; HT29 Cells; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2007 |
[Two cases of stage IV gastric cancer who underwent total gastrectomy and achieved long-term survival by sequential chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Immunosuppressive Agents; Irinotecan; Male; Methotrexate; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2007 |
[A case report--combination chemotherapy with oral UFT and CPT-11, 5-FU, l-LV by hepatic arterial infusion for multiple hepatic metastasis from sigmoid colon cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Sigmoid Neoplasms; Tegafur; Uracil | 2007 |
Treatment of metastatic urachal carcinoma in an elderly woman.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Combined Modality Therapy; Cystectomy; Diagnosis, Differential; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Neoplasm Recurrence, Local; Pelvic Neoplasms; Radiotherapy, Adjuvant; Urachus; Urinary Bladder Neoplasms | 2008 |
Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fatal Outcome; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Tumor Lysis Syndrome | 2008 |
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis | 2008 |
Preoperative irinotecan/5-FU/leucovorin plus concurrent radiotherapy in rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Rectal Neoplasms; Survival Rate | 2008 |
Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Drug Synergism; Fluorouracil; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Polymers; Transplantation, Heterologous | 2008 |
[A case of multiple liver metastases from rectal cancer in poor performance status successfully treated with hepatic arterial infusion chemotherapy plus CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Rectal Neoplasms; Tomography, X-Ray Computed | 2007 |
Retrospective comparison of two different schedules of irinotecan, 5-fluorouracil and folinic acid in previously untreated patients with advanced colorectal carcinoma: a single institution experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Retrospective Studies; Survival Analysis | 2007 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic; Survival Rate | 2008 |
Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Failure; Treatment Outcome | 2008 |
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genetic Markers; Haplotypes; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Polymorphism, Genetic; Proportional Hazards Models; Prospective Studies; Salvage Therapy; Signal Transduction | 2008 |
Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?
Topics: Animals; Antineoplastic Agents; Camptothecin; Colon; Female; Fluorouracil; Immunohistochemistry; Interleukin-1; Interleukin-6; Intestinal Mucosa; Irinotecan; Jejunum; Methotrexate; Mouth Mucosa; Mucositis; NF-kappa B; Rats; Rats, Inbred Strains; Tumor Necrosis Factor-alpha | 2009 |
Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.
Topics: Amidohydrolases; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Drug Synergism; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Thymidylate Synthase | 2008 |
Chronic myeloid leukemia following the treatment of rectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Fusion Proteins, bcr-abl; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Leucovorin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Male; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Philadelphia Chromosome; Quinazolines; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Thiophenes | 2008 |
"Natural history" of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Drainage; Female; Fluorouracil; Humans; Hyperthermia, Induced; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Seeding; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Care; Retrospective Studies; Treatment Outcome | 2009 |
Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2008 |
Sequential vs combination colorectal cancer therapy sparks debate.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2008 |
Chemotherapy in elderly patients with colorectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Geriatric Assessment; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2008 |
Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dexamethasone; Female; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Time Factors; Treatment Outcome | 2008 |
Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Retrospective Studies | 2008 |
XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxaloacetates; Pilot Projects; Randomized Controlled Trials as Topic | 2007 |
[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Case-Control Studies; China; Colorectal Neoplasms; Diarrhea; Fluorouracil; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Young Adult | 2007 |
[A case of advanced gastric cancer with peritoneal metastasis successfully treated over 19 months with postoperative chemotherapy after non-curative surgery].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Methotrexate; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2008 |
Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2009 |
Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Treatment Outcome | 2008 |
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cytokines; Epithelium; Female; Fluorouracil; Gastrointestinal Tract; Gene Expression Regulation; Inflammation; Interleukin-1beta; Interleukin-6; Irinotecan; Methotrexate; NF-kappa B; Rats; Tumor Necrosis Factor-alpha | 2008 |
Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer.
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Camptothecin; Colorectal Neoplasms; Fluorouracil; HIV Infections; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 2008 |
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cecal Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colectomy; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organoplatinum Compounds; Quinazolines; Retroperitoneal Neoplasms; Sacrum; Thiophenes; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2008 |
Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-X Protein; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; ErbB Receptors; fas Receptor; Fluorouracil; Humans; Irinotecan; Myeloid Cell Leukemia Sequence 1 Protein; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand | 2008 |
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Pancreatic Neoplasms; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2008 |
Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Meta-Analysis as Topic; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur | 2008 |
Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biological Transport; Camptothecin; Cell Line, Tumor; Cell Survival; Cetuximab; Colorectal Neoplasms; Drug Interactions; Fluorodeoxyglucose F18; Fluorouracil; Glucose; Hexokinase; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Radiopharmaceuticals | 2008 |
[A case of sigmoid colon cancer with metastases of para-aortic lymph nodes treated with curative resection after irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2008 |
Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cations; Cisplatin; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interferon-beta; Irinotecan; Kidney Neoplasms; Liposomes; Mice; Mice, SCID; Paclitaxel; Thymidine Phosphorylase; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2008 |
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pleural Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Follow-Up Studies; Humans; Hypertension; Irinotecan; Italy; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Models, Statistical; Placebos; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome | 2008 |
Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Morbidity; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
[Is it possible to individualize prescription of medical treatment in colorectal cancer? The clinician point of view].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Prescriptions; ErbB Receptors; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2008 |
[The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Cyclin D1; Dihydrouracil Dehydrogenase (NADP); Epidermal Growth Factor; Fluorouracil; Glucuronosyltransferase; Glutathione Transferase; Humans; Irinotecan; Mutation; Organoplatinum Compounds; Polymorphism, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG; Thymidylate Synthase | 2008 |
Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Hypoxia; Doxorubicin; Fluorouracil; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Irinotecan; Liposomes; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Nanocapsules; Neoplasms, Experimental; Neovascularization, Pathologic; Tissue Distribution; Xenograft Model Antitumor Assays | 2008 |
[A case of metastatic lung and liver tumors from rectal cancer treated with oral UFT and CPT-11 by hepatic arterial infusion followed by FOLFOX and FOLFIRI].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed; Uracil | 2008 |
Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Immunosuppressive Agents; Infusions, Intravenous; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Prodrugs; Retrospective Studies; Survival Rate; Treatment Outcome; Vitamin B Complex | 2008 |
Race does not explain genetic heterogeneity in pharmacogenomic pathways.
Topics: Camptothecin; Cluster Analysis; Databases, Genetic; Fluorouracil; Genetic Heterogeneity; Humans; Insulin; Irinotecan; Metabolic Clearance Rate; Pharmacogenetics; Polymorphism, Single Nucleotide; Principal Component Analysis; Racial Groups | 2008 |
A dilemma in geriatric oncology: malignant bowel obstruction in an 81-year-old man.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Intestinal Obstruction; Irinotecan; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin | 2008 |
[The validity of full administration of 5-fluorouracil, irinotecan, and oxaliplatin to unresectable or recurrent colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2008 |
Chemotherapy for small-bowel Adenocarcinoma at a single institution.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Vitamin B Complex | 2009 |
In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA).
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Organoplatinum Compounds; Pyridines; Regression Analysis; Tumor Cells, Cultured | 2009 |
TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genotype; HSP90 Heat-Shock Proteins; HT29 Cells; Humans; Irinotecan; Male; Middle Aged; Mitochondria; Organoplatinum Compounds; Oxaliplatin; Peptide Fragments; Phenotype; RNA, Messenger; Transfection; Up-Regulation | 2009 |
Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colo
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Diarrhea; Dietary Supplements; Fatty Acids, Omega-3; Female; Fluorouracil; Glutamine; Immune Tolerance; Irinotecan; Leukocyte Count; Nutritional Status; Rats; Rats, Inbred F344; Treatment Failure; Xenograft Model Antitumor Assays | 2009 |
The CAIRO and FOCUS studies: which lesson is to be learned?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2009 |
Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Interactions; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Irinotecan | 2009 |
Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2009 |
Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2009 |
Experimental study of combination therapy with S-1 against pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Doxorubicin; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Inbred BALB C; Mitomycin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur; Xenograft Model Antitumor Assays | 2009 |
A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2009 |
Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Complications; Prospective Studies | 2009 |
Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Prodrugs; Tegafur | 2009 |
Treatment of gastric cancer cells with 5-fluorouracil/leucovorin and irinotecan induces distinct alterations in the mRNA expression of the apoptosis-related genes, including the novel gene BCL2L12.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Camptothecin; Cell Line, Tumor; Drug Therapy, Combination; Fluorouracil; Gene Expression; Humans; Irinotecan; Leucovorin; Muscle Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Stomach Neoplasms | 2009 |
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Irinotecan; Orotate Phosphoribosyltransferase; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2009 |
Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Drug Synergism; Esophageal Neoplasms; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Nude; Mice, SCID; Peritoneal Neoplasms; Plant Preparations; Prunus; Triterpenes; Xenograft Model Antitumor Assays | 2009 |
Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Palliative Care | 2009 |
Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Flow Cytometry; Fluorouracil; G1 Phase; G2 Phase; Humans; Irinotecan; Thymidylate Synthase; Tumor Cells, Cultured | 2009 |
Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum; Quinazolines; Treatment Outcome | 2009 |
Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Female; Fluorouracil; Glycolysis; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Proteins; Proteome; Pyruvate Kinase; Reproducibility of Results; Up-Regulation | 2009 |
Acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fanconi Syndrome; Female; Fluorouracil; Humans; Irinotecan | 2009 |
[Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Leucovorin; Male; Polymorphism, Genetic | 2009 |
[A case of hyperammonemia with encephalopathy related to FOLFIRI chemotherapy for advanced colon cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Consciousness Disorders; Fluorouracil; Humans; Hyperammonemia; Irinotecan; Leucovorin; Male; Middle Aged | 2009 |
A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cause of Death; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Monitoring; Fluorouracil; Humans; Irinotecan; Middle Aged; Multicenter Studies as Topic; Netherlands; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2010 |
Efficacy of 5-FU/LV plus CPT-11 as first-line adjuvant chemotherapy for stage IIIa colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging | 2009 |
Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Treatment Outcome; Vitamin B Complex | 2009 |
Radioembolization of liver metastases in patients with colorectal cancer: a nonsurgical treatment with combined modality potential.
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Maximum Tolerated Dose; Microspheres; Radiopharmaceuticals; Radiotherapy, Adjuvant; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome; Yttrium Isotopes | 2009 |
Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neutropenia; Odds Ratio; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line; Cell Proliferation; Colorectal Neoplasms; Drug Administration Schedule; Endothelial Cells; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Male; Mice; Microvessels; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Vascular Endothelial Growth Factor A | 2009 |
Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Injections, Intraperitoneal; Irinotecan; Leucovorin; Mice; Mice, Nude; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quinazolines; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Female; Fluorouracil; Interleukins; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Organoplatinum Compounds; Oxaliplatin; T-Lymphocytes | 2009 |
Colorectal cancer: Irinotecan therapy-following a trail of breadcrumbs?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Treatment Outcome | 2009 |
[Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Child; Colonic Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Rectal Neoplasms; Remission Induction; Young Adult | 2009 |
Long-term outcome of unresectable metastatic colorectal cancer: does "adjuvant" chemotherapy play a role after resection?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Pneumonectomy; Survival Rate; Treatment Outcome | 2009 |
Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Pilot Projects; Sirolimus; Treatment Outcome | 2009 |
Chemotherapy: Optimizing irinotecan regimens for colorectal cancer.
Topics: Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Gene Frequency; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Quality of Life; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Stomach Neoplasms | 2009 |
The impact of new treatment options for advanced colorectal cancer on routine care: results of a retrospective analysis of 206 consecutive patients treated in a community-based oncology group practice in Germany.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Germany; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Retrospective Studies; Survival Analysis; Vitamin B Complex | 2010 |
Treatment of gastric cancer in Asia: the missing link.
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Japan; Oxonic Acid; Patient Selection; Risk Assessment; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2009 |
Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma.
Topics: Acute Coronary Syndrome; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2009 |
[A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Fluorouracil; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasm Metastasis; Stomach Neoplasms; Tegafur; Uracil | 2009 |
[A case of interstitial pneumonitis induced by FOLFIRI+bevacizumab combination therapy for liver and lung metastasis of colon cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Sigmoid Neoplasms | 2009 |
Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Luminescent Measurements; Mice; Mice, Inbred BALB C; Mice, Nude; Random Allocation; Treatment Outcome; Vitamin B Complex | 2010 |
[A case report of metastatic liver tumor from rectosigmoid colon cancer demonstrating a pathological complete response with FOLFOX and FOLFIRI treatment].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Rectal Neoplasms; Sigmoid Neoplasms | 2009 |
[A curative resection with the combination of portal vein branch embolization and systemic chemotherapy in a patient with synchronous multiple and bilobar colorectal liver metastases].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Embolization, Therapeutic; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Portal Vein | 2009 |
[A case of advanced right colonic cancer successfully treated by surgery and post operative chemotherapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Postoperative Period; Tegafur | 2009 |
[A case of long-term survival of unresectable-advanced gastric cancer due to chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2009 |
En bloc resection for right colon cancer directly invading duodenum or pancreatic head.
Topics: Adult; Aged; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Duodenal Neoplasms; Duodenum; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2009 |
Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Recurrence; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Cholestasis, Intrahepatic; Combined Modality Therapy; Deoxycytidine; Duodenoscopy; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Hematoporphyrins; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Photochemotherapy; Photosensitizing Agents; Stents; Treatment Outcome | 2010 |
[Pulmonary embolism during palliative chemotherapy including cetuximab for metastatic colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Palliative Care; Pulmonary Embolism | 2010 |
[A case of advanced rectal cancer with liver and lung metastasis showing a complete response by neo-adjuvant FOLFOX4 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms | 2010 |
[Liver metastasis from sigmoid colon cancer showed a complete response to S-1 after recurrence with FOLFOX6 treatment].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Sigmoid Neoplasms; Tegafur | 2010 |
Usefulness of staging laparoscopy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2010 |
Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cetuximab; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Rate | 2010 |
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Male; Middle Aged; Neck Dissection; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Recombinant Proteins; Tongue Neoplasms | 2010 |
Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Duodenal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Ileal Neoplasms; Intestine, Small; Irinotecan; Jejunal Neoplasms; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2010 |
[A case of sigmoid colon cancer with lymphangitis carcinomatosa successfully treated with chemotherapies including molecular targeting drugs].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Lymphangitis; Male; Middle Aged; Organoplatinum Compounds; Sigmoid Neoplasms | 2010 |
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Line, Tumor; Cetuximab; Colonic Neoplasms; Deoxycytidine; Drug Synergism; ErbB Receptors; Fluorouracil; Gemcitabine; Genes, ras; Humans; Irinotecan; Killer Cells, Lymphokine-Activated; Mutation; Panitumumab; Up-Regulation | 2010 |
Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Indocyanine Green; Irinotecan; Leucovorin; Liver; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prospective Studies; Recovery of Function; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Strategic options on behalf of patients with metastatic colorectal cancer: mass tumor murder versus serial tumor killing.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2010 |
Glutathione modulators reverse the pro-tumour effect of growth factors enhancing WiDr cell response to chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Camptothecin; Cell Growth Processes; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Epidermal Growth Factor; Fluorouracil; Glutathione; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrrolidonecarboxylic Acid; Thiazolidines; Vascular Endothelial Growth Factor A | 2010 |
Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Genotype; Humans; Irinotecan; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Retrospective Studies; Treatment Outcome | 2011 |
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Glucuronosyltransferase; Health Surveys; Humans; Irinotecan; Mitomycin; Neutropenia; Organoplatinum Compounds; Pyridines; Risk Factors; State Medicine; United Kingdom | 2010 |
Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Colonic Neoplasms; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prodrugs; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2010 |
[mRNA quantification. The next challenge in routine diagnostics].
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Molecular Diagnostic Techniques; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; RNA, Messenger; Survival Rate; Thymidylate Synthase | 2010 |
Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Cohort Studies; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Genotype; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Retrospective Studies; Risk Factors; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taxoids | 2010 |
Dietary glycine protects from chemotherapy-induced hepatotoxicity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Dietary Supplements; Drug-Related Side Effects and Adverse Reactions; Fatty Liver; Female; Fluorouracil; Glycine; Immunohistochemistry; Irinotecan; Kupffer Cells; Leucovorin; Liver; Microcirculation; Neoadjuvant Therapy; Nitric Oxide Synthase Type II; Organoplatinum Compounds; Oxaliplatin; Phagocytosis; Rats; Rats, Sprague-Dawley; Transaminases | 2011 |
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2010 |
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genetic Association Studies; Glucuronosyltransferase; Heterozygote; Humans; Irinotecan; Japan; Leucovorin; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Prodrugs; Retrospective Studies; Survival Analysis; Topoisomerase I Inhibitors | 2011 |
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Research Design; Survival Rate; Tomography, X-Ray Computed | 2010 |
Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Focal Nodular Hyperplasia; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2011 |
Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Blood Cell Count; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Creatinine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Hemoglobins; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Patient Selection | 2010 |
Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colonic Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; HCT116 Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Mice; Mice, Nude; Models, Biological; Naphthalenes; Organoplatinum Compounds; Oxaliplatin; Xenograft Model Antitumor Assays | 2010 |
[Effects of irinotecan and 5-FU combination therapy in gastric cancer--is combination therapy synergic?].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Antagonism; Drug Synergism; Female; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Male; Middle Aged; Stomach Neoplasms | 2010 |
Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.
Topics: Camptothecin; Cell Line, Tumor; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Endocytosis; Floxuridine; Fluorodeoxyuridylate; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Irinotecan; MicroRNAs; National Cancer Institute (U.S.); Nucleosides; RNA, Messenger; Topoisomerase I Inhibitors; Topotecan; United States | 2010 |
Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; HCT116 Cells; Humans; Imidazoles; Immunohistochemistry; Irinotecan; Isoenzymes; Leucovorin; MAP Kinase Signaling System; Mice; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Xenograft Model Antitumor Assays | 2011 |
Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Germany; Health Status Indicators; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Peritoneal Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Pharmacogenetics; Polymorphism, Single Nucleotide; Predictive Value of Tests; Proportional Hazards Models; Radiography; Vascular Endothelial Growth Factor A | 2011 |
Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Female; Fluorouracil; Humans; Indocyanine Green; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Survival Rate; Treatment Outcome | 2011 |
[The efficacy of cetuximab for metastatic colorectal cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Rectal Neoplasms; Sigmoid Neoplasms | 2010 |
[A case of multiple lung and liver metastases from colon cancer treated with clinical benefit by hepatic arterial infusion chemotherapy plus cetuximab mono-therapy after standard chemotherapy failure].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Cetuximab; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Middle Aged; Organoplatinum Compounds; Sigmoid Neoplasms | 2010 |
[A long-term survival case of rectal cancer with Virchow's lymph node metastasis by multimodality therapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Rectal Neoplasms; Tegafur; Uracil | 2010 |
[A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy].
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aorta; Bevacizumab; Camptothecin; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Sigmoid Neoplasms; Tegafur; Uracil | 2010 |
[A case of unresectable multiple hepatic metastases from colorectal cancer successfully treated with IRIS (S-1, CPT-11) therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Oxonic Acid; Tegafur; Tumor Burden | 2010 |
[A long-term disease-free survival case of advanced rectal cancer with massive metastasis to the lateral pelvic and para-aortic lymph nodes].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Oxonic Acid; Pelvis; Rectal Neoplasms; Tegafur; Vitamin B Complex | 2010 |
Changing management and survival in patients with stage IV colorectal cancer.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Antineoplastic Agents; Australia; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Colostomy; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Proportional Hazards Models; Pyrimidines; Radiotherapy, Adjuvant; Survival Rate | 2011 |
Transcatheter arterial chemoembolization with docetaxel-loaded microspheres controls heavily pretreated unresectable liver metastases from colorectal cancer: a case study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Microspheres; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Taxoids | 2011 |
R1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Preoperative Period; Prognosis; Rectal Neoplasms; Retrospective Studies; Survival Rate; Time Factors | 2012 |
Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Confidence Intervals; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Epistaxis; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Hypertension; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Proteinuria; Retrospective Studies; Tegafur; Thrombosis; Treatment Outcome | 2011 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Capecitabine; Child; Child, Preschool; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infant; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer.
Topics: Antineoplastic Agents; Camptothecin; Cohort Studies; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Platinum Compounds; Retrospective Studies; Stomach Neoplasms; Taxoids | 2011 |
Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Feeding and Eating Disorders; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Three-drug combination regimen in pancreatic cancer treatment: are we there yet?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
APEX microarray panel for genotyping polymorphisms in cancer chemotherapy and estimation frequencies in a Slovak population.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Camptothecin; Drug Resistance, Neoplasm; Fluorouracil; Gene Frequency; Genetic Association Studies; Humans; Irinotecan; Linkage Disequilibrium; Methotrexate; Neoplasms; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Slovakia | 2011 |
Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Palliative Care; Prognosis; Radionuclide Imaging; Stomach Neoplasms; Treatment Outcome | 2011 |
Successful treatment of an intra-abdominal desmoid tumor with irinotecan, fluorouracil, and leucovorin plus bevacizumab in a patient with familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fibromatosis, Abdominal; Fibromatosis, Aggressive; Fluorouracil; Humans; Irinotecan; Leucovorin; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
In vitro cytotoxic effect of ethanol extract prepared from sporophyll of Undaria pinnatifida on human colorectal cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Survival; Colorectal Neoplasms; Culture Media; Ethanol; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Plant Extracts; Seaweed; Undaria; Xanthophylls | 2012 |
Tumor volume reduction rate after preoperative chemoradiotherapy as a prognostic factor in locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Preoperative Care; Rectal Neoplasms; Retrospective Studies; Tumor Burden | 2012 |
Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin | 2011 |
Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Italy; Leucovorin; Male; Middle Aged; Risk; Survival Analysis; Vitamin B Complex | 2011 |
Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms | 2011 |
Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; CDC2 Protein Kinase; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Inhibitor of Apoptosis Proteins; Irinotecan; Mice; Mice, Nude; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myb; Pyrimidines; Recombinant Proteins; RNA, Small Interfering; Thiazoles; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2011 |
A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Statistics as Topic | 2011 |
Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Research Design | 2011 |
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Death; Cell Nucleus; Cytoplasm; Deoxycytidine; Doxorubicin; Drug Synergism; Etoposide; Female; Fluorouracil; Gemcitabine; Genes, p53; Humans; Irinotecan; Liver Neoplasms; Mice; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinacrine; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Chemotherapy: Metastatic pancreatic cancer--is FOLFIRINOX the new standard?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Folic Acid Antagonists; Gene Expression; Glutamates; Guanine; Humans; Immunoblotting; Irinotecan; Lung Neoplasms; Pemetrexed; Phosphoribosylglycinamide Formyltransferase; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase; Vinblastine; Vinorelbine | 2011 |
Bevacizumab in combination with irinotecan, 5-fluorouracil and leucovorin given as first-line treatment of metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Treatment Outcome | 2011 |
[Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Quality of Life; Surveys and Questionnaires; Tegafur | 2011 |
Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Hyperthermia, Induced; Irinotecan; Male; Middle Aged; Neoplasm Seeding; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prospective Studies; Second-Look Surgery; Tumor Burden; Young Adult | 2011 |
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Medical Records; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Failure; Treatment Outcome | 2011 |
Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Comparative Effectiveness Research; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Retrospective Studies; SEER Program; Survival Analysis; Treatment Outcome; United States | 2011 |
Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Prognosis; Real-Time Polymerase Chain Reaction; Rectal Neoplasms; Statistics, Nonparametric; Transketolase; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Body Surface Area; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Precision Medicine | 2011 |
Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prospective Studies; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Effect of 5-fluorouracil treatment on SN-38 absorption from intestine in rats.
Topics: Animals; ATP-Binding Cassette Transporters; Base Sequence; Body Weight; Camptothecin; Cell Line; DNA Primers; Fluorouracil; Humans; Intestinal Absorption; Irinotecan; Male; Phosphorylation; Polymerase Chain Reaction; Proto-Oncogene Proteins c-jun; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger | 2011 |
Intraperitoneally administered irinotecan with 5-fluorouracil impair wound healing of colonic anastomoses in a rat model: an experimental study.
Topics: Anastomosis, Surgical; Anastomotic Leak; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Fluorouracil; Hydroxyproline; Irinotecan; Male; Neovascularization, Physiologic; Pressure; Rats; Rats, Wistar; Rupture; Tissue Adhesions; Wound Healing | 2011 |
Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost Savings; Cost-Benefit Analysis; ErbB Receptors; Fluorouracil; Genetic Testing; Germany; Humans; Irinotecan; Leucovorin; Markov Chains; Monte Carlo Method; Mutation; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; United States | 2012 |
FOLFIRINOX: a small step or a great leap forward?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Caco-2 Cells; Camptothecin; Case-Control Studies; Cell Line, Tumor; Colonic Neoplasms; DNA Methylation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Knockdown Techniques; HCT116 Cells; Humans; Irinotecan; Male; Membrane Proteins; Middle Aged; Organoplatinum Compounds; Oxaliplatin; RNA, Messenger | 2012 |
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Rate; Treatment Outcome | 2012 |
Novel activity of acriflavine against colorectal cancer tumor cells.
Topics: Acriflavine; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Female; Fluorouracil; High-Throughput Screening Assays; Humans; Irinotecan; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2011 |
[Irinotecan as second-line chemotherapy for 5-FU-resistant gastric cancer with disseminated intravascular coagulation: a case report].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Disseminated Intravascular Coagulation; Fatal Outcome; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Salvage Therapy; Stomach Neoplasms | 2011 |
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Female; Fluorouracil; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polycomb Repressive Complex 2; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Transcription Factors; Treatment Outcome | 2012 |
Chemotherapy between the first and second stages of a two-stage hepatectomy for colorectal liver metastases: should we routinely recommend it?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Premedication; Survival Rate | 2012 |
The effect of postoperative pelvic irradiation after complete resection of metastatic rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Postoperative Care; Radiotherapy, Adjuvant; Rectal Neoplasms; Retrospective Studies | 2012 |
Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Female; Fluorouracil; Health Care Costs; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quality-Adjusted Life Years; Survival Analysis | 2012 |
A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Ribonucleoproteins, Small Nuclear; RNA Interference; RNA, Small Interfering; Systems Biology | 2012 |
The central vein access port and catheter in outpatient chemotherapy for colorectal cancer: a retrospective study of 101 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization, Central Venous; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2012 |
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Blotting, Western; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Proto-Oncogene Proteins B-raf; Quinazolines; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Death, Sudden; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Male; Middle Aged | 2012 |
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Down-Regulation; Doxorubicin; Etoposide; Floxuridine; Fluorescent Antibody Technique; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomic Instability; Humans; Irinotecan; Metaphase; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; Protein Array Analysis; Reproducibility of Results; Tegafur; Tissue Array Analysis; Tumor Cells, Cultured; Up-Regulation; Uracil | 2012 |
Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer.
Topics: 3' Flanking Region; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Dosage; Genetic Association Studies; Glucuronosyltransferase; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Retrospective Studies; Survival Analysis | 2012 |
Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2011 |
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV stud
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2012 |
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2011 |
Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chi-Square Distribution; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Proportional Hazards Models; Retrospective Studies; Tomography, X-Ray Computed; Ultrasonography | 2012 |
The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Irinotecan; Markov Chains; Organoplatinum Compounds; Oxaliplatin; Prognosis; Quality-Adjusted Life Years; Risk Factors; State Medicine; Survival Analysis; United Kingdom | 2012 |
Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Indoles; Irinotecan; Mutation; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Purines; ras Proteins; TOR Serine-Threonine Kinases; Transcription Factors | 2012 |
Absence of transcriptomic signature of response to chemotherapy in metastatic colorectal carcinoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2012 |
SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIF1alpha.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Cell Division; Cell Hypoxia; Colorectal Neoplasms; Drug Resistance, Neoplasm; Flow Cytometry; Fluorouracil; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2012 |
Conventional chemotherapy of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2012 |
Dose-modified XELIRI chemotherapy for metastatic colorectal cancer--a retrospective study of 78 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Retrospective Studies | 2012 |
[A case of remnant liver metastases after resection of liver metastases from rectal cancer following treatment with 5-FU, L-OHP and CPT-11, with markedly effective treatment by cetuximab plus S-1].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Combined Modality Therapy; Drug Combinations; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Rectal Neoplasms; Recurrence; Salvage Therapy; Tegafur; Tomography, X-Ray Computed | 2012 |
Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Cetuximab; Colorectal Neoplasms; Contraindications; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Multivariate Analysis; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Tumor Burden | 2012 |
Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factors | 2012 |
Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasms; Neutropenia; Polypharmacy; Retrospective Studies | 2013 |
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2012 |
Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Databases, Factual; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retreatment; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Young Adult | 2012 |
Evaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Coagulation Disorders; Blood Coagulation Tests; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Thrombelastography | 2012 |
Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.
Topics: Animals; Antineoplastic Agents; Bombesin; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Gastrin-Releasing Peptide; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Male; Mice; Mice, Nude; Peptide Fragments; Receptors, Bombesin; Transplantation, Heterologous | 2012 |
Gef gene therapy enhances the therapeutic efficacy of cytotoxics in colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bacterial Toxins; Camptothecin; Cell Survival; Colonic Neoplasms; Combined Modality Therapy; Escherichia coli Proteins; Fluorouracil; Genetic Therapy; Humans; Irinotecan; Membrane Proteins; Organoplatinum Compounds; Oxaliplatin | 2012 |
FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2012 |
Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Netherlands; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Retrospective Studies; Treatment Outcome | 2012 |
Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.
Topics: Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptothecin; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Mice; Microsatellite Instability; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rats; Xenograft Model Antitumor Assays | 2012 |
Colon cancer cell chemosensitisation by fish oil emulsion involves apoptotic mitochondria pathway.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Combined Modality Therapy; Dietary Supplements; Drug Resistance, Neoplasm; Emulsions; Fatty Acids, Omega-3; Fish Oils; Fluorouracil; Food-Drug Interactions; Humans; Irinotecan; Membrane Potential, Mitochondrial; Mitochondria; Organoplatinum Compounds; Oxaliplatin; Triglycerides | 2013 |
Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Female; Fluorouracil; Hospitalization; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Office Visits; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Palliative Care; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Retrospective Studies; Scandinavian and Nordic Countries; Sweden | 2012 |
Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Turkey | 2012 |
Current stages of adjuvant treatment of colon cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Survival Analysis | 2012 |
Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Treatment Outcome; Young Adult | 2012 |
Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; DNA Mutational Analysis; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neutropenia; Platinum Compounds; Remission Induction; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids; Young Adult | 2012 |
Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Retrospective Studies; Risk Factors; Treatment Outcome | 2013 |
GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colonic Neoplasms; Fluorouracil; Growth Hormone-Releasing Hormone; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; S Phase Cell Cycle Checkpoints; Sermorelin; Transplantation, Heterologous | 2012 |
Bevacizumab-containing chemotherapy is safe in patients with unresectable metastatic colorectal cancer and a synchronous asymptomatic primary tumor.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Prognosis; Rectal Neoplasms; Retrospective Studies; Survival Rate; Young Adult | 2013 |
[Severe diarrhea].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Camptothecin; Diarrhea; Fluorouracil; Gastrointestinal Motility; Gout Suppressants; Humans; Immunosuppressive Agents; Irinotecan; Molecular Targeted Therapy | 2012 |
Double pancreatic and gastric adenocarcinomas: a rare association.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rare Diseases; Stomach Neoplasms; Tomography, X-Ray Computed | 2013 |
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
Topics: Alleles; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Codon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Frequency; Humans; Irinotecan; Leucovorin; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Panitumumab; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; ras Proteins; Retrospective Studies; Survival Analysis | 2013 |
Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP rrostate cancer cells.
Topics: Animals; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Coculture Techniques; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Engineering; Humans; Interferon-beta; Irinotecan; Male; Prodrugs; Prostatic Neoplasms; Rabbits; Stem Cells | 2012 |
KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA-Binding Proteins; Endonucleases; Fluorouracil; Humans; Irinotecan; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2012 |
Hepatic arterial infusion of irinotecan, 5-Fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate | 2012 |
Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; China; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Thymidylate Synthase; Treatment Outcome | 2012 |
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Survival Rate | 2013 |
Concomitant occurrence of pulmonary invasive aspergillosis and Pneumocystis pneumonia during FOLFIRINOX chemotherapy for pancreatic carcinoma.
Topics: Adenocarcinoma; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillus fumigatus; Camptothecin; Fluorouracil; Humans; Invasive Pulmonary Aspergillosis; Irinotecan; Male; Middle Aged; Neutropenia; Opportunistic Infections; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pneumocystis carinii; Pneumonia, Pneumocystis; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Signet Ring Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; SEER Program | 2013 |
Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retreatment; Young Adult | 2013 |
Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Cisplatin; Dopa Decarboxylase; Dose-Response Relationship, Drug; Etoposide; Fluorouracil; Gene Expression Regulation, Enzymologic; Humans; Irinotecan; Leucovorin; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms | 2013 |
Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis.
Topics: Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Herpesvirus 1, Human; Humans; Irinotecan; Methotrexate; NF-kappa B; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Transcriptional Activation; Tumor Necrosis Factor-alpha; Virus Replication | 2013 |
Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Line, Tumor; Doxorubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Hep G2 Cells; HT29 Cells; Humans; Irinotecan; Mice; Oxazoles; RNA Stability; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Irinotecan during pregnancy in metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cesarean Section; Colectomy; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Gestational Age; Humans; Infant, Newborn; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Treatment Failure | 2012 |
Aflibercept.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Placenta Growth Factor; Pregnancy Proteins; Protein Binding; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B | 2013 |
Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2013 |
Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Remission Induction; Treatment Outcome | 2013 |
Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic | 2013 |
FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Case-Control Studies; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Synergism; Female; Fluorouracil; Gene Amplification; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Piperazines; Pyrazoles; Receptor, Fibroblast Growth Factor, Type 2; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Taxoids; Treatment Outcome; Xenograft Model Antitumor Assays; Young Adult | 2013 |
A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Survival; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Mice, SCID; Microscopy, Confocal; Neoplasm Transplantation; Random Allocation; Real-Time Polymerase Chain Reaction; Spheroids, Cellular; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2013 |
In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Camptothecin; Chemoradiotherapy; Colorectal Neoplasms; Comet Assay; DNA Damage; Female; Fluorouracil; HCT116 Cells; Histones; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Poly(ADP-ribose) Polymerase Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Female; Fluorouracil; Germany; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Practice Guidelines as Topic; Prospective Studies; Vomiting; Young Adult | 2013 |
Selecting regimens in advanced colon cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2004 |
Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.
Topics: Animals; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Drug Combinations; Female; Fluorouracil; HT29 Cells; Humans; Irinotecan; Liposomes; Male; Mice; Tumor Burden | 2013 |
Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Longitudinal Studies; Male; Models, Biological; Randomized Controlled Trials as Topic; Regression Analysis; Treatment Outcome; Tumor Burden | 2013 |
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Massachusetts; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Multifocal anaplastic pancreatic carcinoma requiring neoadjuvant chemotherapy and total pancreatectomy: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2013 |
FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?
Topics: Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2013 |
How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins p21(ras) | 2013 |
MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Benzofurans; Camptothecin; Cell Death; Cell Nucleus; Cell Survival; Colonic Neoplasms; DNA Damage; DNA Mismatch Repair; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Fluorescent Antibody Technique; Fluorouracil; Gene Knockdown Techniques; HCT116 Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; MutL Protein Homolog 1; MutS Homolog 3 Protein; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Rad51 Recombinase | 2013 |
XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Will PICCOLO affect metastatic colorectal cancer therapy?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colectomy; Colorectal Neoplasms; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tegafur; Treatment Outcome | 2013 |
Predicting therapy response in live tumor cells isolated with the flexible micro spring array device.
Topics: Animals; Animals, Outbred Strains; Antineoplastic Agents; Camptothecin; Cell Separation; Cell Survival; Drug Screening Assays, Antitumor; Female; Fluorouracil; HCT116 Cells; High-Throughput Screening Assays; Humans; Irinotecan; Mice; Mice, SCID; Microfluidic Analytical Techniques; Neoplasm Transplantation; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prostheses and Implants; Treatment Outcome | 2013 |
Synergistic anticancer effects of polyphyllin I and evodiamine on freshly-removed human gastric tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Confidence Intervals; Diosgenin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Platinum; Quinazolines; RNA, Messenger; Stomach Neoplasms | 2013 |
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Metastasectomy; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Radiotherapy, Intensity-Modulated; Survival Rate; Tumor Burden | 2014 |
A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.
Topics: Algorithms; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kinetics; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Neoplasm Transplantation; Neoplasms, Experimental; Xenograft Model Antitumor Assays | 2013 |
Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies.
Topics: Aged; Albumins; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Glasgow Outcome Scale; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2013 |
Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Glucuronosyltransferase; Heterozygote; Humans; Irinotecan; Leucovorin; Male; Neutropenia; Polymorphism, Genetic; Severity of Illness Index; Treatment Outcome | 2013 |
TNF-α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Case-Control Studies; Female; Fluorouracil; Gastrointestinal Neoplasms; Genetic Predisposition to Disease; Haplotypes; Humans; Irinotecan; Male; Middle Aged; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Retrospective Studies; Risk; Tumor Necrosis Factor-alpha; Venous Thromboembolism | 2013 |
[Approximately four years of survival benefits for a case of gastric cancer postoperative carcinomatous peritonitis by combined modality therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Fatal Outcome; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Methotrexate; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms; Tegafur; Time Factors | 2013 |
[A case of metastatic colon cancer effectively treated by XELOX and IRIS].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Oxaloacetates; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2013 |
Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Survival; Drug Delivery Systems; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Leucovorin; Nanofibers; Nanotechnology; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Tumor Cells, Cultured | 2013 |
Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiosurgery; Retrospective Studies; Treatment Outcome | 2013 |
Partial response after transcatheter arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable colon cancer and hepatic metastasis: (case report).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Failure; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Remission Induction; Tomography, X-Ray Computed | 2013 |
Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Oligonucleotides; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genetic Variation; Genotype; Humans; Irinotecan; Leucovorin; Linkage Disequilibrium; Liver-Specific Organic Anion Transporter 1; Neoplasm Metastasis; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Treatment Outcome | 2013 |
Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2013 |
A curious case of oxaliplatin-induced neurotoxicity: recurrent, self-limiting dysarthria.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Dysarthria; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Recurrence; Time Factors | 2014 |
Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leukocyte Common Antigens; Male; Middle Aged; Neutrophils; Prognosis; Programmed Cell Death 1 Receptor; Prospective Studies; Toll-Like Receptor 4 | 2013 |
Oxaliplatin-based chemotherapy in patients aged 75 years or older with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Treatment Outcome | 2013 |
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Fatigue; Female; Filgrastim; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Treatment Outcome | 2013 |
Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Decitabine; DNA; DNA Modification Methylases; Drug Synergism; Epigenesis, Genetic; Fluorouracil; HCT116 Cells; Histone Deacetylase Inhibitors; HT29 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2014 |
Berberine enhances chemosensitivity to irinotecan in colon cancer via inhibition of NF‑κB.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Berberine; Camptothecin; Colonic Neoplasms; Down-Regulation; Doxorubicin; Fluorouracil; HCT116 Cells; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; NF-kappa B; RNA Interference; RNA, Small Interfering; Survivin; Transcription Factor RelA | 2014 |
Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Drug Costs; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Spain; Time Factors; Treatment Outcome | 2014 |
Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postoperative Period; Preoperative Period; Rectal Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome | 2013 |
Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, University; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Staging; Platinum; Prognosis; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2013 |
A small cog in a big wheel: PIK3CA mutations in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases | 2013 |
Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
Topics: Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Sex Characteristics; Treatment Outcome | 2014 |
Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Substitution; Fluorouracil; Heart Diseases; Humans; Irinotecan; Middle Aged; Quinazolines; Thiophenes | 2014 |
[Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Folic Acid; Hepatectomy; Hospitals, General; Humans; Irinotecan; Kaplan-Meier Estimate; Length of Stay; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Operative Time; Organoplatinum Compounds; Oxaliplatin; Surgery Department, Hospital; Treatment Outcome | 2013 |
[Efficacy and tolerance of maintenance therapy in patients with incurable advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2013 |
[Multidisciplinary therapy for 3 patients with lymph node recurrence after curative gastrectomy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Recurrence; Stomach Neoplasms | 2013 |
Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cholangitis; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Fatal Outcome; Fluorouracil; Gastrectomy; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pancreaticoduodenectomy; Sepsis | 2014 |
Prognostic factors associated with primary cancer in curatively resected stage IV colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed | 2014 |
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2014 |
Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Rectum | 2014 |
5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinote
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prognosis; Vitamin B Complex | 2014 |
FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer: a Korean single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Republic of Korea; Retrospective Studies; Survival Analysis | 2014 |
Irinotecan-induced immune thrombocytopenia.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Platelet Count; Thrombocytopenia | 2014 |
Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prednisolone; Prognosis; Radiography, Thoracic; Retrospective Studies | 2014 |
Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Gene Frequency; Genetic Variation; Genotype; HLA Antigens; HLA-B Antigens; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Receptors, KIR; Receptors, KIR3DL1; Treatment Outcome | 2014 |
The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circadian Rhythm; Fatigue; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Monitoring, Physiologic; Motor Activity; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Rest; Weight Loss | 2014 |
Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cancer Care Facilities; Cetuximab; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Databases, Factual; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Practice Patterns, Physicians'; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; United States | 2014 |
The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Caco-2 Cells; Camptothecin; Colonic Neoplasms; Drug Synergism; Female; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Random Allocation; Receptors, TNF-Related Apoptosis-Inducing Ligand; Sirtuin 1; Sirtuin 2; Sirtuins; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Colonoscopy; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Neoadjuvant Therapy; Positron-Emission Tomography | 2014 |
FOLFIRINOX as first-line treatment for unresectable acinar cell carcinoma of the pancreas: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Acinar Cell; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Treatment Failure | 2014 |
Cetuximab-induced esophageal ulcer: the first report in literature.
Topics: Abdomen, Acute; Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemoradiotherapy; Colostomy; Esophagitis; Esophagoscopy; Fluorouracil; Humans; Intestinal Obstruction; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Proctoscopy; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Rectal Neoplasms; Treatment Outcome; Ulcer; Vascular Endothelial Growth Factor A; Vomiting | 2014 |
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients.
Topics: Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Databases, Factual; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2014 |
Evaluation of the necessity of primary tumor resection for synchronous metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Digestive System Surgical Procedures; Female; Fluorouracil; Humans; Intestinal Obstruction; Intestinal Perforation; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Risk Factors | 2014 |
IL-1Ra selectively protects intestinal crypt epithelial cells, but not tumor cells, from chemotoxicity via p53-mediated upregulation of p21(WAF1) and p27(KIP1.).
Topics: Animals; Antimetabolites, Antineoplastic; Camptothecin; Cell Line; Cell Line, Tumor; Colon; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Epithelial Cells; Fluorouracil; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Irinotecan; Jejunum; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mucositis; Protective Agents; Recombinant Proteins; Tumor Suppressor Protein p53; Up-Regulation | 2014 |
Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Salvage Therapy; Survival Rate | 2014 |
A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genetic Predisposition to Disease; Humans; Irinotecan; Mutation; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Sepsis | 2014 |
A systemic analysis of S-1 regimens for treatment of patients with colon cancer.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2014 |
Caring for one of our own.
Topics: Camptothecin; Caregivers; Diphosphonates; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nurses; Organoplatinum Compounds; Oxaliplatin; Pain; Pain Management; Pancreatic Neoplasms; Patient-Centered Care; Physician-Patient Relations | 2014 |
A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2014 |
Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis.
Topics: Antineoplastic Agents; Camptothecin; Cohort Studies; Fatty Liver; Female; Fluorouracil; Humans; Irinotecan; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Probability; Retrospective Studies; Risk Factors | 2014 |
Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Survival Rate | 2014 |
Danish experiences with FOLFIRINOX as first-line therapy in patients with inoperable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Denmark; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Vitamin B Complex | 2014 |
The predictive and prognostic value of the Glasgow Prognostic Score in metastatic colorectal carcinoma patients receiving bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies | 2014 |
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Enzyme Activation; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Prognosis | 2014 |
[A case of advanced rectal cancer that showed complete response to the addition of XELOX+bevacizumab therapy to preoperative chemoradiotherapy with S-1/CPT-11].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Oxonic Acid; Rectal Neoplasms; Tegafur | 2014 |
Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Quinazolines; Republic of Korea; Retrospective Studies; Survivors; Treatment Outcome | 2014 |
Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphocytes; Male; Middle Aged; Neoplasm Staging; Neutrophils; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2014 |
Risk factors for bowel dysfunction after sphincter-preserving rectal cancer surgery: a prospective study using the Memorial Sloan Kettering Cancer Center bowel function instrument.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fecal Incontinence; Female; Fluorouracil; Humans; Ileostomy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Prospective Studies; Rectal Neoplasms; Risk Factors; Surveys and Questionnaires; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
A R0 resection case of initially unresectable metastatic pancreatic cancer downstaged by FOLFIRINOX therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2014 |
FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate | 2014 |
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2015 |
Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prospective Studies; Survival Rate | 2014 |
Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cholesterol; Colon; Diarrhea; Disease Models, Animal; Drug Therapy, Combination; Female; Fluorouracil; Intestine, Small; Irinotecan; Liposomes; Nanoparticles; Phosphatidylcholines; Rats, Sprague-Dawley | 2014 |
Locally advanced unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Pancreatic Neoplasms; Radiotherapy; Survival Analysis; Treatment Outcome | 2014 |
Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nutrition Assessment; Nutritional Status; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate | 2015 |
UGT1A1*28 polymorphisms: a potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Genetic; Topoisomerase I Inhibitors | 2014 |
Fatal outcome of posterior "reversible" encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fatal Outcome; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Neoplasm Staging; Posterior Leukoencephalopathy Syndrome | 2014 |
Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Inflammation; Irinotecan; Kaplan-Meier Estimate; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Retrospective Studies; ROC Curve | 2014 |
Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Deoxycytidine; Disease Progression; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2014 |
Gene signatures of drug resistance predict patient survival in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Survival Rate | 2015 |
Expression of ABCB6 is related to resistance to 5-FU, SN-38 and vincristine.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression; Humans; Irinotecan; KB Cells; Multidrug Resistance-Associated Proteins; Transfection; Vincristine | 2014 |
Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Focal Adhesion Kinase 1; Hepatectomy; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins pp60(c-src); Survival Analysis; Treatment Outcome | 2014 |
Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Treatment Outcome | 2014 |
Complete radiological response of an initially locally advanced unresectable pancreatic cancer to chemoradiotherapy using FOLFIRINOX regimen: report of a case.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2015 |
Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Germany; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Young Adult | 2015 |
Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Camptothecin; Case-Control Studies; Cell Proliferation; Cisplatin; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorescent Antibody Technique; Fluorouracil; Humans; Immunoenzyme Techniques; Irinotecan; Male; Matrix Metalloproteinase 7; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Syndecan-1; Tumor Cells, Cultured | 2014 |
Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Treatment Outcome; Tumor Burden | 2015 |
Knockdown of Merm1/Wbscr22 attenuates sensitivity of H460 non-small cell lung cancer cells to SN-38 and 5-FU without alteration to p53 expression levels.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Irinotecan; Lung Neoplasms; Methyltransferases; Reproducibility of Results; Tumor Suppressor Protein p53 | 2015 |
Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2015 |
Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA Mutational Analysis; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies | 2014 |
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Prospective Studies; Sex Factors; Treatment Outcome | 2015 |
FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Blood Vessels; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Colonic Neoplasms; Drug Delivery Systems; Fluorouracil; HT29 Cells; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Nanostructures; Regional Blood Flow; Xenograft Model Antitumor Assays | 2015 |
Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Carriers; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Liver; Liver Neoplasms; Male; Microspheres; Middle Aged | 2014 |
A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Capecitabine; Carboplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab | 2014 |
Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Bevacizumab; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Carcinoma, Signet Ring Cell; Cetuximab; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Grading; Organoplatinum Compounds; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Retrospective Studies; Survival Rate; Tumor Burden; Vascular Endothelial Growth Factor A | 2015 |
A simple method for comparing enzymatic capecitabine activation in various mono- and combination chemotherapies.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Carboxylesterase; Cytidine Deaminase; Deoxycytidine; Enzyme Activation; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2015 |
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Disease-Free Survival; Female; Fluorouracil; Humans; Imaging, Three-Dimensional; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Spiral Cone-Beam Computed Tomography; Treatment Outcome | 2015 |
Neoadjuvant therapy for localized pancreatic cancer: support is growing?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2015 |
Always look at the bright side of drugs?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors | 2015 |
Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis | 2015 |
Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Magnetic Resonance Imaging; Middle Aged; Pelvic Bones; Positron-Emission Tomography; Recurrence; Taxoids; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; France; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Impact of the spheroid model complexity on drug response.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cetuximab; Coculture Techniques; Everolimus; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Hydroxamic Acids; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Spheroids, Cellular; Stromal Cells; Trastuzumab; Treatment Outcome; Tumor Cells, Cultured; Tumor Microenvironment; Vorinostat | 2015 |
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Irinotecan; Male; Mice; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil; Xenograft Model Antitumor Assays | 2015 |
The Influence of Aging on Hepatic Regeneration and Early Outcome after Portal Vein Occlusion: A Case-Control Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biliary Tract Neoplasms; Camptothecin; Case-Control Studies; Chemotherapy, Adjuvant; Diabetes Complications; Embolization, Therapeutic; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Regeneration; Male; Middle Aged; Neoadjuvant Therapy; Organ Size; Organoplatinum Compounds; Oxaliplatin; Portal Vein; Preoperative Care; Radiography; Sex Factors; Young Adult | 2015 |
Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; G1 Phase Cell Cycle Checkpoints; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Protein Biosynthesis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines | 2016 |
Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Malaysia; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Postoperative Period; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2015 |
[Biomarkers for the prediction of adverse events].
Topics: Antineoplastic Agents; Biomarkers; Camptothecin; Fluorouracil; Humans; Irinotecan; Mercaptopurine; Tamoxifen | 2015 |
Analyses of multiple factors for determination of "selected patients" who should receive rechallenge treatment in metastatic colorectal cancer: a retrospective study from Turkey.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Prognosis; Retreatment; Retrospective Studies; Survival Rate; Turkey | 2015 |
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2015 |
Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; France; Gemcitabine; Health Resources; Hospice Care; Humans; Irinotecan; Leucovorin; Long-Term Care; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Patterns, Physicians'; Retreatment; Retrospective Studies; United Kingdom | 2015 |
Ampulla of Vater carcinoma in real-world clinical practice: a case series.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organ Sparing Treatments; Organoplatinum Compounds; Pancreaticoduodenectomy; Pylorus; Retrospective Studies; Treatment Outcome | 2015 |
Inferior mesenteric artery chemoembolization and chemotherapy for advanced rectal cancer: report of a clinical case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Mesenteric Artery, Inferior; Microspheres; Middle Aged; Organoplatinum Compounds; Rectal Neoplasms; Treatment Outcome; Tumor Burden | 2015 |
The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Digestive System Surgical Procedures; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Propensity Score; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2015 |
Clinical observation on recombinant human endostatin combined with chemotherapy for advanced gastrointestinal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Endostatins; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Recombinant Proteins; Survival Rate | 2015 |
Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Genes, Dominant; HT29 Cells; Humans; Immunohistochemistry; Irinotecan; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 8; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Transfection; Xenograft Model Antitumor Assays | 2015 |
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboxylesterase; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Male; Mass Spectrometry; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, RNA; Tissue Array Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Remission Induction; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors.
Topics: Antineoplastic Agents; Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Hyaluronan Receptors; Irinotecan; Neoplastic Stem Cells; Organoplatinum Compounds; Oxaliplatin; Protein Isoforms; Pyrimidinones; Reverse Transcriptase Polymerase Chain Reaction; Triazines; Wnt Signaling Pathway | 2015 |
Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Proportional Hazards Models; Prospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
[The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Incidence; Irinotecan; Leucovorin; Male; Middle Aged; Polymorphism, Genetic; Thrombocytopenia | 2015 |
The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Follow-Up Studies; Genotype; Germany; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Insurance, Health; Irinotecan; Leucovorin; Neoplasm Staging; Prognosis; Quality of Life; Quality-Adjusted Life Years; Survival Rate | 2016 |
[Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Treatment Outcome | 2015 |
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Duodenal Ulcer; Erlotinib Hydrochloride; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2016 |
Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Drug Carriers; Fluorouracil; Hepatic Artery; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Microspheres; Middle Aged; Organoplatinum Compounds; Prospective Studies; Remission Induction | 2015 |
Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Camptothecin; Colonic Neoplasms; Disease-Free Survival; DNA Mismatch Repair; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Male; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; Prognosis; Thymidylate Synthase; Treatment Outcome | 2015 |
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
Topics: Activities of Daily Living; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Camptothecin; Eligibility Determination; Female; Fluorouracil; Humans; Hyperbilirubinemia; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Renal Insufficiency; Retrospective Studies | 2017 |
Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2014 |
Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Proliferation; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Doxorubicin; Drug Screening Assays, Antitumor; Female; Fluorouracil; Follow-Up Studies; Humans; Hyperthermia, Induced; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Pseudomyxoma Peritonei; Tumor Cells, Cultured; Young Adult | 2015 |
SW480 colorectal cancer cells that naturally express Lgr5 are more sensitive to the most common chemotherapeutic agents than Lgr5-negative SW480 cells.
Topics: Antineoplastic Agents; Camptothecin; Cell Adhesion; Cell Count; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Neoplastic Stem Cells; Organoplatinum Compounds; Oxaliplatin; Receptors, G-Protein-Coupled; Transfection | 2015 |
Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biliary Tract Neoplasms; Camptothecin; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Polymorphism, Genetic; Retrospective Studies; Severity of Illness Index; Young Adult | 2015 |
Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Capecitabine; Carboplatin; Carcinoma, Neuroendocrine; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Diarrhea; Digestive System Surgical Procedures; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Pelvis; Radiation Injuries; Radiodermatitis; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Rectum; Retrospective Studies; Survival Rate; Tumor Burden | 2017 |
Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Drosophila Proteins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Nerve Tissue Proteins; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Survival Rate; Transcription Factors; Treatment Outcome | 2016 |
Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2015 |
An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Epithelial Cell Adhesion Molecule; Flow Cytometry; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Leucovorin; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Vitamin B Complex; Xenograft Model Antitumor Assays | 2015 |
Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cross-Sectional Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pakistan; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2015 |
[Occurrence, intratumoral heterogeneity, prognostic and predictive potential of microsatellite instability following surgical resection of primary colorectal carcinomas and corresponding liver metastases].
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA Mismatch Repair; Female; Fluorouracil; Genetic Markers; Humans; Irinotecan; Liver Neoplasms; Male; Microsatellite Instability; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Predictive Value of Tests; Prognosis; Survival Analysis | 2015 |
Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2015 |
Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2015 |
Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; ELAV-Like Protein 1; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Irinotecan; Male; MicroRNAs; Middle Aged; Neoplasm Proteins; RNA, Messenger | 2015 |
Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Glycoproteins; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Peptides; Polymorphism, Genetic; Prognosis; Survival Rate | 2015 |
Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colitis, Microscopic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2015 |
Correlation between the promoter methylation status of ATP-binding cassette sub-family G member 2 and drug sensitivity in colorectal cancer cell lines.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Promoter Regions, Genetic | 2016 |
Anti-cancer effects of 2-oxoquinoline derivatives on the HCT116 and LoVo human colon cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Colonic Neoplasms; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; HCT116 Cells; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Myeloid Cell Leukemia Sequence 1 Protein; p38 Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Quinolones | 2015 |
Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Gas Chromatography-Mass Spectrometry; Humans; Immunoassay; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate | 2015 |
Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Models, Genetic; Oligonucleotide Array Sequence Analysis; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Signal Transduction | 2015 |
Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26.
Topics: Animals; Camptothecin; Carcinogenesis; Cell Lineage; Cell Movement; Chemokine CXCL12; Colonic Neoplasms; Dipeptidyl Peptidase 4; Fluorouracil; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Hyaluronan Receptors; Irinotecan; Mice; Neoplasm Metastasis; Receptors, CXCR4; Xenograft Model Antitumor Assays | 2015 |
Systematic Protein Level Regulation via Degradation Machinery Induced by Genotoxic Drugs.
Topics: Apoptosis; Camptothecin; Cisplatin; DNA Damage; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Leupeptins; Mutagens; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Proteome | 2016 |
5-Fluorouracil enteric-coated nanoparticles for improved apoptotic activity and therapeutic index in treating colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Delayed-Action Preparations; Fluorouracil; Gastric Emptying; HCT116 Cells; Humans; Irinotecan; Male; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Organoplatinum Compounds; Oxaliplatin; Tissue Distribution | 2016 |
A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice.
Topics: Animals; Antineoplastic Agents; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Interleukin-6; Intestinal Mucosa; Irinotecan; Male; Mice; Mice, Inbred C57BL; Models, Animal; Mucositis; Peroxidase; Tumor Necrosis Factor-alpha | 2016 |
A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Codon; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Genes, erbB-1; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Proteins; Panitumumab; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Treatment Outcome | 2016 |
Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; ErbB Receptors; Female; Fluorouracil; gamma-Glutamyl Hydrolase; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peptide Synthases; Prognosis; RNA, Messenger; Tetrahydrofolate Dehydrogenase; Thymidine Phosphorylase | 2016 |
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Floxuridine; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Male; Middle Aged; Mitomycin; Retrospective Studies; Survival Rate | 2016 |
UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Body Fluids; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Prospective Studies; Risk Factors | 2016 |
BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?
Topics: Adult; Aged; Aged, 80 and over; Australia; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Genetic Testing; Humans; Irinotecan; Leucovorin; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proto-Oncogene Proteins B-raf; Treatment Outcome; Young Adult | 2016 |
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Metastasectomy; Microsatellite Instability; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Singapore | 2015 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Silicates; Singapore; Titanium | 2015 |
Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Cisplatin; Epirubicin; Female; Fluorouracil; France; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Middle Aged; Multivariate Analysis; Ovarian Neoplasms; Ovariectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2016 |
[Pre-Operative Treatment with Transcatheter Arterial Chemoembolization (TACE) and Hepatic Arterial Infusion (HAI) for Liver Metastasis from Gastric Cancer--A Case Report].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Combined Modality Therapy; Fluorouracil; Gastrectomy; Hepatectomy; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Stomach Neoplasms | 2015 |
Regorafenib as a potential adjuvant chemotherapy agent in disseminated small colon cancer: Drug selection outcome of a novel screening system using nanoimprinting 3-dimensional culture with HCT116-RFP cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Culture Techniques; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Screening Assays, Antitumor; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Luminescent Proteins; Mice; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Pyridines; Red Fluorescent Protein; Xenograft Model Antitumor Assays | 2016 |
Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dexamethasone; Disease-Free Survival; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Survival Rate; Young Adult | 2016 |
Usefulness of diagnostic laparoscopy with 5-aminolevulinic acid (ALA)-mediated photodynamic diagnosis for the detection of peritoneal micrometastasis in advanced gastric cancer after chemotherapy.
Topics: Adult; Aged; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diagnostic Imaging; Female; Fluorouracil; Humans; Irinotecan; Laparoscopy; Male; Middle Aged; Peritoneal Neoplasms; Photosensitizing Agents; Stomach Neoplasms | 2016 |
[Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Tertiary Care Centers; Treatment Outcome | 2016 |
Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Safety | 2016 |
Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Asian People; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2016 |
Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Clinical Trials as Topic; Cost-Benefit Analysis; Decision Support Techniques; Deoxycytidine; Drug Costs; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Analysis | 2016 |
Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies | 2016 |
Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Long Term Adverse Effects; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2016 |
Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Male; Middle Aged; Palliative Care; Retrospective Studies; Treatment Outcome | 2016 |
Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neoplasms, Second Primary; Urologic Neoplasms | 2016 |
Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome; Turkey | 2016 |
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calreticulin; Camptothecin; Cell Death; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Dendritic Cells; Disease Models, Animal; Endoplasmic Reticulum Stress; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Leucovorin; Mice; Panitumumab; Phagocytosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Sulfonamides; Unfolded Protein Response; Vemurafenib; X-Box Binding Protein 1 | 2016 |
ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2016 |
[KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; France; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis | 2016 |
Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data.
Topics: Camptothecin; Cell Line, Tumor; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cohort Studies; Colonic Neoplasms; Disease-Free Survival; Drug Evaluation, Preclinical; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Prognosis | 2016 |
Incompatibility between irinotecan and fluorouracil injections.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Incompatibility; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan | 2016 |
In brief: liposomal irinotecan (Onivyde) for pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Compounding; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Colonic perforation following endoscopic mucosal resection in a patient on bevacizumab treatment.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Diseases; Colonic Neoplasms; Colonic Polyps; Colonoscopy; Endoscopic Mucosal Resection; Female; Fluorouracil; Humans; Intestinal Perforation; Irinotecan; Leucovorin | 2016 |
Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.
Topics: Administration, Intravenous; Adult; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Camptothecin; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Operative Time; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Complications; Sarcopenia | 2016 |
[Research hotspot and progress of preoperative chemoradiotherapy for rectal cancer].
Topics: Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Rectal Neoplasms | 2016 |
Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Retrospective Studies | 2016 |
Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Comorbidity; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2016 |
Effectiveness of a Closed-System Transfer Device in Reducing Surface Contamination in a New Antineoplastic Drug-Compounding Unit: A Prospective, Controlled, Parallel Study.
Topics: Antineoplastic Agents; Camptothecin; Cyclophosphamide; Cytarabine; Deoxycytidine; Drug Compounding; Drug Contamination; Fluorouracil; Ganciclovir; Gemcitabine; Humans; Ifosfamide; Irinotecan; Methotrexate; Occupational Exposure; Prospective Studies | 2016 |
[Effect of Cancer Symptoms and Fatigue on Chemotherapy-related Cognitive Impairment and Depression in People with Gastrointestinal Cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Anxiety; Camptothecin; Cognitive Dysfunction; Depression; Drug Therapy, Combination; Fatigue; Female; Fluorouracil; Gastrointestinal Neoplasms; Hemoglobins; Humans; Irinotecan; Male; Memory; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Surveys and Questionnaires; Translating | 2016 |
Fractal Dimension of Tc-99m DTPA GSA Estimates Pathologic Liver Injury due to Chemotherapy in Liver Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemical and Drug Induced Liver Injury; Fatty Liver; Female; Fluorouracil; Fractals; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Radionuclide Imaging; Radiopharmaceuticals; Risk Factors; ROC Curve; Technetium Tc 99m Aggregated Albumin; Technetium Tc 99m Pentetate | 2016 |
Primary cultures of human colon cancer as a model to study cancer stem cells.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Mice; Neoplastic Stem Cells; Octamer Transcription Factor-3; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Substitution; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Sepsis; Treatment Outcome | 2016 |
Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Asian People; Camptothecin; Drug Interactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Ramucirumab | 2016 |
Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling.
Topics: Biomarkers, Tumor; Camptothecin; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Neoplasm Proteins; Neoplasms; Pathology, Molecular | 2016 |
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Topoisomerases, Type I; Female; Fluorouracil; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2016 |
Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague-Dawley rats.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Cholera Toxin; Colon; Contrast Media; Diarrhea; Fluorouracil; Gastrointestinal Diseases; Haptoglobins; Intestinal Mucosa; Iohexol; Irinotecan; Jejunum; Male; Organoplatinum Compounds; Oxaliplatin; Permeability; Protein Precursors; Rats; Rats, Sprague-Dawley | 2016 |
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Retreatment; Stomach Neoplasms; Survival Rate; Vomiting; White People | 2016 |
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Spain; Survival Rate | 2017 |
Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, Community; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prevalence; Retrospective Studies; Risk Factors; Survival Rate | 2016 |
Gap junction composed of connexin43 modulates 5‑fluorouracil, oxaliplatin and irinotecan resistance on colorectal cancers.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Connexin 43; Drug Resistance, Neoplasm; Fluorouracil; Gap Junctions; Gene Knockdown Techniques; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2016 |
Putting a brake on stress signaling: miR-625-3p as a biomarker for choice of therapy in colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; MicroRNAs; Organoplatinum Compounds; Oxaliplatin; RNA, Neoplasm; Signal Transduction; Stress, Physiological | 2016 |
Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 Cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Eruptions; Erlotinib Hydrochloride; Fluorouracil; Folliculitis; Humans; Irinotecan; Lung Neoplasms; Male | 2017 |
[Difference analysis of chemotherapy efficacy among different primary tumor sites in metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colon, Sigmoid; Colon, Transverse; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectum; Retrospective Studies | 2016 |
Prognostic Significance of MicroRNA-21 Expression in Patients with Unresectable Metastatic Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; MicroRNAs; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Real-Time Polymerase Chain Reaction | 2016 |
Late-stage inhibition of autophagy enhances calreticulin surface exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Protein-1 Homolog; Beclin-1; Calreticulin; Camptothecin; Cell Membrane; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Enzyme Inhibitors; Fluorouracil; HCT116 Cells; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Protein Transport; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases | 2016 |
SN38 increases IL-8 expression through the MAPK pathways in HCT8 cells.
Topics: Berberine; Camptothecin; Cell Line, Tumor; Cell Survival; Fluorouracil; Humans; Interleukin-8; Irinotecan; Janus Kinase 2; MAP Kinase Signaling System; Phosphorylation; Quinazolines; Up-Regulation | 2017 |
EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Follow-Up Studies; Gene Dosage; Genes, ras; High-Throughput Nucleotide Sequencing; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Panitumumab; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf | 2017 |
CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Immunosuppressive Agents; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vitamin B Complex | 2017 |
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Phenylurea Compounds; Pyridines; Retreatment; Treatment Outcome | 2017 |
5-Flurouracil disrupts nuclear export and nuclear pore permeability in a calcium dependent manner.
Topics: Active Transport, Cell Nucleus; Antimetabolites, Antineoplastic; Apoptosis; Calcium; Camptothecin; Caspases; Cell Nucleus; DNA Topoisomerases, Type I; Drug Interactions; Egtazic Acid; Fluorouracil; HeLa Cells; Humans; Irinotecan; Neoplasm Proteins; Nuclear Pore; Permeability; ran GTP-Binding Protein; Topotecan; Tumor Suppressor Protein p53 | 2017 |
Granulocyte Colony-stimulating Factor Producing Anaplastic Carcinoma of the Pancreas: Case Report and Review of the Literature.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Receptors, Granulocyte Colony-Stimulating Factor; Tomography Scanners, X-Ray Computed | 2017 |
Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Gastrointestinal Neoplasms; Genomics; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Pancreatectomy; Precision Medicine; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome | 2017 |
Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Survival Rate | 2017 |
Characterization of Conversion Chemotherapy for Secondary Surgical Resection in Colorectal Cancer Patients with Lung Metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies | 2017 |
Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Italy; Leucovorin; Male; Middle Aged; Neoplasm Staging; Patient Care Management; Pharmacogenomic Testing; Pharmacogenomic Variants; Retrospective Studies; Topoisomerase I Inhibitors | 2017 |
Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; CD3 Complex; CD56 Antigen; CD8 Antigens; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Inflammation; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2017 |
Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies | 2017 |
Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Treatment Failure; Treatment Outcome | 2017 |
Effects of 5-fluorouracil, adriamycin and irinotecan on HSC-39, a human scirrhous gastric cancer cell line.
Topics: Adenocarcinoma, Scirrhous; Apoptosis; Camptothecin; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Necrosis; Reactive Oxygen Species; Stomach Neoplasms | 2017 |
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Prognosis; Survival Rate; Transcriptome; Treatment Outcome | 2017 |
Preoperative Treatment With FOLFIRINOX and Successful Resection for a Patient With Mixed Acinar-Endocrine Carcinoma of the Pancreas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Acinar Cell; Carcinoma, Islet Cell; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Laparotomy; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Pancreaticoduodenectomy; Preoperative Period; Treatment Outcome | 2017 |
Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Reproducibility of Results; Sensitivity and Specificity | 2017 |
Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy-Induced Febrile Neutropenia; Dose-Response Relationship, Drug; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2017 |
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cancer Pain; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Health Status; Humans; Irinotecan; Jaundice; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Nomograms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies; Retreatment; Risk Factors; Smoking; Survival Rate | 2017 |
Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Colostomy; Fluorouracil; Humans; Irinotecan; Kidney Neoplasms; Kidney Pelvis; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Treatment Outcome; Ureterostomy; Urologic Neoplasms; Urothelium | 2017 |
MicroRNA-146a induces immune suppression and drug-resistant colorectal cancer cells.
Topics: Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; HEK293 Cells; HT29 Cells; Humans; Irinotecan; Lentivirus; Leukocytes, Mononuclear; MicroRNAs; T-Lymphocytes, Regulatory; Transfection | 2017 |
A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Patient Readmission; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Young Adult | 2017 |
Resectable pancreatic adenocarcinomas: will neoadjuvant FOLFIRINOX replace upfront surgery in the standard of care?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Recurrence, Local; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Standard of Care | 2017 |
Gastrin induces multidrug resistance via the degradation of p27Kip1 in the gastric carcinoma cell line SGC7901.
Topics: Aged; Camptothecin; Carcinoma; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Gastrins; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Phosphorylation; Proteolysis; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Stomach Neoplasms | 2017 |
Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Retrospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2017 |
[A Case of Effective Chemoradiotherapy Using mFOLFOX6 for Locally Advanced Rectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Rectal Neoplasms; Tegafur; Treatment Outcome | 2017 |
Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Electrochemotherapy; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2017 |
Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.
Topics: Animals; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Doxorubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Silencing; HCT116 Cells; HeLa Cells; Humans; Irinotecan; MCF-7 Cells; Mice, Knockout; Mutation; Neoplasm Invasiveness; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA Methylation; DNA Mutational Analysis; DNA, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gene Dosage; Genes, erbB-1; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Promoter Regions, Genetic; Proto-Oncogene Proteins B-raf; Retreatment; Retrospective Studies; Survival Rate | 2017 |
Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague-Dawley rats.
Topics: Animals; Antineoplastic Agents; Camptothecin; Feces; Fluorouracil; Gastrointestinal Diseases; Inflammation; Intestinal Mucosa; Irinotecan; Magnetic Resonance Spectroscopy; Male; Metabolome; Microbiota; Organoplatinum Compounds; Oxaliplatin; Permeability; Rats; Rats, Sprague-Dawley; RNA, Ribosomal, 16S; Severity of Illness Index | 2017 |
Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome | 2019 |
Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Mice; Mice, Inbred NOD; Mice, SCID; Organoplatinum Compounds; Oxaliplatin; Xenograft Model Antitumor Assays; Zebrafish | 2017 |
A Pancreatic Predicament.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiosurgery; Tomography, X-Ray Computed; Tumor Burden | 2017 |
Appendix 6: Cancer of the pancreas: MCBS eUpdate published online 20 June 2017 (www.esmo.org/Guidelines/Gastrointestinal-Cancers).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Medical Oncology; Nanostructures; Neoplasm Metastasis; Pancreatic Neoplasms | 2017 |
Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Retreatment; Retrospective Studies; Treatment Outcome | 2018 |
Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Margins of Excision; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prognosis; Treatment Outcome | 2017 |
Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Cisplatin; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Hepatoblastoma; Humans; Infant; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Pneumonectomy; Prognosis; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2017 |
Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Arteries; Celiac Artery; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Irinotecan; Leucovorin; Male; Mesenteric Artery, Superior; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Second Primary; Organometallic Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Radiosurgery; Radiotherapy, Intensity-Modulated; Survival Rate | 2018 |
Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Drug Carriers; Drug Delivery Systems; Fluorouracil; Humans; Hyaluronic Acid; Irinotecan; Lactic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Stomach Neoplasms | 2017 |
Impact of travel distance on access to treatment and survival in patients with metastatic colorectal cancer prescribed bevacizumab plus chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Health Services Accessibility; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Registries; Retrospective Studies; Saskatchewan; Survival Rate; Travel | 2017 |
Long-term survival in a patient with low-level inflammatory markers and liver metastasis, converted resectable by TACE.
Topics: Adenocarcinoma; Adult; Biomarkers; Camptothecin; Capecitabine; Chemoembolization, Therapeutic; Colectomy; Colonic Neoplasms; Fluorouracil; Hepatectomy; Humans; Inflammation Mediators; Irinotecan; Leucovorin; Liver Neoplasms; Male; Microspheres; Organoplatinum Compounds; Oxaliplatin; Remission Induction | 2017 |
Some chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features.
Topics: Antineoplastic Agents; Cellular Senescence; Colonic Neoplasms; Cyclin D1; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fluorouracil; HCT116 Cells; Humans; Hyaluronan Receptors; Irinotecan; Neoplastic Stem Cells; Oxaliplatin | 2018 |
Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Tumor Burden | 2017 |
Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Panitumumab; Retreatment; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Contraindications, Procedure; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Survival Rate; Tomography, X-Ray Computed | 2018 |
Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Chemotherapy diminishes lipid storage capacity of adipose tissue in a preclinical model of colon cancer.
Topics: Adipocytes; Adipose Tissue; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Size; Colonic Neoplasms; Disease Models, Animal; Fatty Acids; Fatty Acids, Monounsaturated; Fatty Acids, Omega-3; Female; Fluorouracil; Humans; Irinotecan; Lipogenesis; Mitochondria; Mitochondrial Proteins; Phospholipids; Proteome; Rats; Rats, Inbred F344; Triglycerides | 2017 |
Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboxylesterase; Colorectal Neoplasms; DNA Topoisomerases, Type I; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Prognosis; Progression-Free Survival; Topoisomerase I Inhibitors | 2018 |
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Docetaxel; Endometrial Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Retrospective Studies; Taxoids | 2018 |
Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Radiosurgery; Retrospective Studies; Survival Analysis | 2018 |
The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells.
Topics: Caco-2 Cells; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genotype; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Methylenetetrahydrofolate Reductase (NADPH2); Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Thymidylate Synthase | 2017 |
KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Nuclear Proteins; Oxaliplatin; Proto-Oncogene Proteins p21(ras); Transcription Factors; Treatment Outcome | 2018 |
Uncoupling FoxO3A mitochondrial and nuclear functions in cancer cells undergoing metabolic stress and chemotherapy.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cisplatin; CRISPR-Cas Systems; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; Forkhead Box Protein O3; Gene Editing; Gene Expression Regulation, Neoplastic; Genome, Mitochondrial; HEK293 Cells; Humans; Irinotecan; MAP Kinase Kinase Kinases; Metformin; Mice; Mice, Inbred C57BL; Mitochondria; NIH 3T3 Cells; Phosphorylation; Signal Transduction; Stress, Physiological | 2018 |
Integrated Cancer Treatment in the Course of Metastatic Pancreatic Cancer: Complete Resolution in 2 Cases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Humans; Hyperthermia, Induced; Integrative Oncology; Irinotecan; Leucovorin; Middle Aged; Mind-Body Therapies; Neoplasm Metastasis; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Phytotherapy; Remission Induction; Treatment Outcome | 2018 |
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Contraindications, Procedure; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Oxaliplatin; Response Evaluation Criteria in Solid Tumors; Risk Factors; Survival Rate; Tomography, X-Ray Computed; Tumor Burden | 2018 |
Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Margins of Excision; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreaticoduodenectomy; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Young Adult | 2018 |
Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancer.
Topics: Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin | 2018 |
Prognostic Impact of R0 Resection and Targeted Therapy for Colorectal Cancer with Synchronous Peritoneal Metastasis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Molecular Targeted Therapy; Oxaliplatin; Panitumumab; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Rectal Neoplasms; Survival Rate; Time Factors | 2018 |
FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; GTP Phosphohydrolases; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Mutation; Neoplasm Metastasis; Panitumumab; Prognosis; Proto-Oncogene Proteins p21(ras); Survival Rate | 2018 |
Ethanolic Extract of Traditional Chinese Medicine (TCM) Gamboge Inhibits Colon Cancer
Topics: Animals; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Ethanol; Fluorouracil; Garcinia; Humans; Immunohistochemistry; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Plant Extracts; Random Allocation; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2018 |
Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Drug Combinations; Drug Delivery Systems; Electrolytes; Fluorouracil; Humans; Iontophoresis; Irinotecan; Leucovorin; Mice; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Time Factors; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2018 |
Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies | 2018 |
Hedgehog Signals Mediate Anti-Cancer Drug Resistance in Three-Dimensional Primary Colorectal Cancer Organoid Culture.
Topics: Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; Hedgehog Proteins; Humans; Hyaluronan Receptors; Irinotecan; Neoplastic Stem Cells; Organoids; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins c-myc; Pyridines; Pyrimidines; trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride; Zinc Finger Protein GLI1 | 2018 |
Addition of Vincristine and Irinotecan to Standard Therapy in a Patient With Refractory High-risk Hepatoblastoma Achieving Long-term Relapse-free Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Hepatoblastoma; Humans; Irinotecan; Liver Neoplasms; Risk; Vincristine | 2019 |
Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organometallic Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2018 |
Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Camptothecin; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasms; Predictive Value of Tests; Quality of Life; Retrospective Studies; Salivation; Syndrome; Young Adult | 2018 |
Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2018 |
How should BRAF V600E-mutated colorectal cancer be treated?
Topics: Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Survival Analysis | 2018 |
Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Treatment Outcome | 2018 |
Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy.
Topics: Adenocarcinoma; Allografts; Animals; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Combinations; Fluorouracil; Humans; Irinotecan; Kinetics; Leucovorin; Male; Mice, Inbred C57BL; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Phenotype; Transplantation, Heterotopic | 2018 |
A population-based analysis of urban-rural disparities in advanced pancreatic cancer management and outcomes.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Healthcare Disparities; Humans; Irinotecan; Leucovorin; Male; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Rural Health; Rural Population; Urban Health; Urban Population | 2018 |
Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer.
Topics: Adipose Tissue; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Weights and Measures; Cachexia; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Phenotype; Prognosis; Retrospective Studies; Tomography, X-Ray Computed | 2018 |
Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals.
Topics: Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Glycogen Synthase Kinase 3; Humans; Irinotecan; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Signal Transduction | 2018 |
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Quality-Adjusted Life Years; United Kingdom | 2018 |
Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Oxaliplatin; Paclitaxel; Xenograft Model Antitumor Assays | 2018 |
Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Contraindications, Procedure; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Laparotomy; Leucovorin; Lymph Nodes; Male; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Survival Rate; Treatment Outcome; Withholding Treatment | 2019 |
[Maintenance strategies for advanced pancreatic cancer: Rationale and issues].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Maintenance Chemotherapy; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2018 |
Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Neoadjuvant Therapy; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2018 |
A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo.
Topics: A549 Cells; ADAM17 Protein; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; Fluorouracil; HeLa Cells; Hep G2 Cells; Humans; Irinotecan; MCF-7 Cells; Receptors, Notch; Signal Transduction | 2018 |
Treatment Patterns Among Patients with Metastatic and/or Unresectable Gastric Cancer in Brazil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brazil; Cisplatin; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Practice Patterns, Physicians'; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2019 |
Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer. How I do It.
Topics: Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Patient Selection; Postoperative Complications; Retrospective Studies; Survival Rate | 2018 |
Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; DNA Damage; DNA Repair; Female; Fluorouracil; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2018 |
[Data review and analysis of 22 cases of gastric cancer associated with pregnancy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cesarean Section; China; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis; Quinazolines; Stomach Neoplasms; Survival Rate; Thiophenes | 2018 |
Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Oxaliplatin; Prognosis; Skin Diseases; Survival Rate | 2018 |
Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Female; Fluorouracil; Humans; Intention to Treat Analysis; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organometallic Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Ducts; Pancreatic Neoplasms; Pancreaticoduodenectomy; Portal Vein; Postoperative Complications; Survival Rate | 2018 |
Pathological complete response in pancreatic adenocarcinoma with FOLFIRINOX.
Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diagnosis, Differential; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Tomography, X-Ray Computed; Weight Loss | 2018 |
Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Electronic Health Records; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Quality of Life; Retrospective Studies | 2019 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome; United States | 2018 |
FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Chemoradiotherapy; Cohort Studies; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2018 |
Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neuroendocrine Tumors; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Topics: 5'-Nucleotidase; Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; GPI-Linked Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Receptors, Purinergic P1; Survival Rate | 2019 |
Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Case-Control Studies; Circulating Tumor DNA; Female; Fluorouracil; High-Throughput Nucleotide Sequencing; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Sequence Analysis, DNA; Treatment Outcome; Tumor Burden | 2019 |
A molecular basis for the synergy between 17‑allylamino‑17‑demethoxy geldanamycin with Capecitabine and Irinotecan in human colorectal cancer cells through VEFG and MMP-9 gene expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Camptothecin; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gene Expression; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Irinotecan; Lactams, Macrocyclic; Matrix Metalloproteinase 9; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A | 2019 |
A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Databases, Factual; Disease-Free Survival; Female; Fluorides; Fluorouracil; Humans; Insurance, Health; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Oxaliplatin; Prognosis; Pyrimidines; Republic of Korea; Stomach Neoplasms; Taxoids | 2018 |
Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Down-Regulation; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Male; MicroRNAs; Middle Aged; Netherlands; Oxaliplatin; Pancreatic Neoplasms; Survival Rate | 2020 |
Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; BRCA2 Protein; Carcinoma, Acinar Cell; Drug Combinations; Fatal Outcome; Fluorouracil; Humans; Irinotecan; Laparotomy; Leucovorin; Male; Middle Aged; Mutation; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Phthalazines; Piperazines; Tomography, X-Ray Computed | 2018 |
Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2018 |
E-Cadherin in Colorectal Cancer: Relation to Chemosensitivity.
Topics: Adenocarcinoma; Antigens, CD; Antineoplastic Agents; Cadherins; Colonic Neoplasms; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Immunohistochemistry; Irinotecan; Oxaliplatin; Tumor Cells, Cultured | 2019 |
EARLY INCREASE of CA 19-9 in ADVANCED PANCREATIC CANCER RECEIVING FOLFIRINOX. Is it a sign of efficacy?.
Topics: Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms | 2016 |
Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Camptothecin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Fluorouracil; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Oxaliplatin; Pancreatic Neoplasms | 2018 |
Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Prospective Studies; Survival Rate; Treatment Outcome | 2019 |
Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Muscle, Skeletal; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia | 2019 |
5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Diseases; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Hyperammonemia; Irinotecan; Leucovorin; Neoplasms, Unknown Primary; Oxaliplatin; Prognosis; Retreatment | 2019 |
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Italy; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Liver Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Progression-Free Survival; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Treatment Failure | 2019 |
Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Republic of Korea; Survival Analysis; Treatment Outcome | 2018 |
Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Decision Support Techniques; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Models, Statistical; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate | 2019 |
Imatinib‑induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Stress; Endoribonucleases; Fluorouracil; Humans; Imatinib Mesylate; Irinotecan; JNK Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Stomach Neoplasms; Transcription Factor CHOP | 2019 |
Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Glucuronates; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Models, Biological; Neoplasm Metastasis; Organoplatinum Compounds | 2019 |
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Treatment Outcome | 2019 |
Home-Based e-Health Platform for Multidimensional Telemonitoring of Symptoms, Body Weight, Sleep, and Circadian Activity: Relevance for Chronomodulated Administration of Irinotecan, Fluorouracil-Leucovorin, and Oxaliplatin at Home-Results From a Pilot Stu
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Circadian Rhythm; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Patient Reported Outcome Measures; Patient-Centered Care; Pilot Projects; Sleep; Survival Analysis; Telemedicine; User-Computer Interface | 2018 |
FOLFIRINOX goes adjuvant.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Random Allocation; Survival Analysis; Treatment Outcome | 2019 |
FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2019 |
Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Topoisomerase Inhibitors | 2018 |
A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2018 |
New guideline-sanctioned and emerging interventions for pancreatic cancer.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Histone Acetyltransferases; Humans; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Pancreas; Pancreatic Neoplasms | 2018 |
Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Neoplasm Metastasis; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Topoisomerase Inhibitors | 2018 |
Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Databases, Factual; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Metastasectomy; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Panitumumab; Time Factors | 2020 |
Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Sweden | 2021 |
Long-term survival of a patient with advanced pancreatic cancer under adjunct treatment with
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Plant Extracts; Time Factors; Treatment Outcome; Viscum album | 2019 |
Cytoplasmic E-Cadherin Expression Is Associated With Higher Tumour Level of VEGFA, Lower Response Rate to Irinotecan-based Treatment and Poorer Prognosis in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Cell Membrane; Colorectal Neoplasms; Cytoplasm; Female; Finland; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2019 |
Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Muscle, Skeletal; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Treatment Outcome | 2019 |
CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Cohort Studies; Databases, Factual; Disease-Free Survival; Female; Fluorouracil; Germany; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Metastasectomy; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Oxaliplatin; Pancreatic Neoplasms; Patient Selection; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed | 2019 |
Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2019 |
FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Female; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Tertiary Care Centers; Treatment Outcome | 2019 |
Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Patient-Centered Care; Retrospective Studies; Survival Analysis | 2019 |
Antiproliferative Effects of Hop-derived Prenylflavonoids and Their Influence on the Efficacy of Oxaliplatine, 5-fluorouracil and Irinotecan in Human ColorectalC Cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Beer; Caco-2 Cells; Caspases; Cell Line, Tumor; Colorectal Neoplasms; Drug Combinations; Drug Interactions; Feeding Behavior; Flavanones; Flavonoids; Fluorouracil; Humans; Humulus; Irinotecan; Oxaliplatin; Plant Extracts; Propiophenones; Reactive Oxygen Species; Treatment Outcome; Xanthones | 2019 |
Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorouracil; Follow-Up Studies; Humans; Intraoperative Period; Irinotecan; Laparotomy; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Reproducibility of Results; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2019 |
Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Clinical Decision-Making; Computer Simulation; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Models, Biological; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Remission Induction; Tumor Burden | 2019 |
Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Preoperative Period; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome | 2019 |
Undifferentiated Carcinoma of the Pancreas - a Case Report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Fatal Outcome; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2018 |
Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Fluorouracil; Follow-Up Studies; Humans; Hyperthermia, Induced; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2019 |
Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Forecasting; Glucuronates; Humans; Irinotecan; Leucovorin; Leukopenia; Machine Learning; Male; Middle Aged; Models, Biological; Neutropenia; Oxaliplatin; Topoisomerase I Inhibitors | 2019 |
Conversion Surgery for Metastatic Pancreatic Mucinous Carcinoma Responsive to Systemic Chemotherapy with Modified FOLFIRINOX: A Case Report.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Nodes; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2019 |
Neoadjuvant therapy versus upfront surgery for borderline-resectable pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Selection Bias; Survival Analysis; Survival Rate; Treatment Outcome | 2020 |
Metastatic gastric adenocarcinoma of the tongue with initial symptoms of glossodynia.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gastric Mucosa; Glossalgia; Humans; Irinotecan; Leucovorin; Middle Aged; Oxaliplatin; Prognosis; Stomach Neoplasms | 2019 |
Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Data Analysis; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nomograms; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2019 |
Spontaneous regression of pancreatic cancer with liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lupus Erythematosus, Discoid; Middle Aged; Neoplasm Metastasis; Neoplasm Regression, Spontaneous; Oxaliplatin; Pancreatic Neoplasms | 2019 |
[FOLFIRINOX for Locally Advanced and Recurrent Pancreatic Cancer with UGT1A1 *6 and or UGT1A1*28 Polymorphisms-A Report of Two Cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Polymorphism, Genetic | 2019 |
Combined treatment for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Losartan; Neoplasm Staging; Oxaliplatin; Pancreatic Neoplasms | 2019 |
Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Community Health Planning; Deoxycytidine; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Saskatchewan | 2019 |
The seemingly innocuous presentation of metastatic pancreatic tail cancer: a case report.
Topics: Abdominal Pain; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Diabetes Mellitus; Diagnosis, Differential; Early Detection of Cancer; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Risk Factors | 2019 |
Microvascular invasion is a major prognostic factor after pancreatico-duodenectomy for adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Microvessels; Neovascularization, Pathologic; Oxaliplatin; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Retrospective Studies | 2019 |
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Failure | 2019 |
Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Factors; Sarcopenia; Survival Analysis | 2019 |
IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer.
Topics: Animals; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; Humans; I-kappa B Kinase; Irinotecan; MAP Kinase Signaling System; MCF-7 Cells; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Telomere; Xenograft Model Antitumor Assays | 2019 |
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Survival Analysis | 2019 |
Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Prospective Studies; Tumor Microenvironment | 2019 |
Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Predictive Value of Tests; Retrospective Studies; Survival Rate | 2020 |
Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
Topics: Aged; Alternative Splicing; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Prognosis; Prospective Studies; Protein Isoforms; Retrospective Studies; Survival Rate; Vascular Endothelial Growth Factor A | 2019 |
Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2019 |
Targeting claudin-4 enhances chemosensitivity of pancreatic ductal carcinomas.
Topics: Animals; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Claudin-4; Drug Synergism; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Male; Mice; Mice, Nude; Oxaliplatin; Pancreatic Neoplasms; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |
Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Germ Cells; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Prognosis; Ribosomal Proteins; Survival Rate; Tumor Cells, Cultured | 2019 |
Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Diet, Ketogenic; Female; Fluorouracil; Gemcitabine; Humans; Hyperbaric Oxygenation; Hyperthermia, Induced; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survivors | 2020 |
[Pure laparoscopic DP-CAR procedure with portal vein resection].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Fluorouracil; Humans; Irinotecan; Laparoscopy; Leucovorin; Middle Aged; Neoplasm Invasiveness; Oxaliplatin; Pancreatectomy; Pancreatic Fistula; Pancreatic Neoplasms; Portal Vein | 2019 |
FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Nomograms; Numerical Analysis, Computer-Assisted; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Pathologic Response to Primary Systemic Therapy With FOLFIRINOX in Patients With Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cause of Death; Chemotherapy, Adjuvant; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Hospitals, University; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pilot Projects; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Treatment Outcome | 2019 |
A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Keratins, Hair-Specific; Keratins, Type II; Leucovorin; Machine Learning; Male; Middle Aged; Neoplasm Proteins; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Sensitivity and Specificity; Survival Rate | 2019 |
Port-site metastasis of pancreatic adenocarcinoma following 'successful' completion of neoadjuvant chemoradiation using FOLFIRINOX.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Organoids; Oxaliplatin; Prospective Studies; Treatment Outcome | 2019 |
Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Treatment Failure | 2020 |
Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Carcinoma, Ductal, Breast; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; Genetic Testing; Germ Cells; Germ-Line Mutation; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymph Node Excision; Middle Aged; Mutation; Oxaliplatin; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2019 |
Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an exper
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Carcinoma, Neuroendocrine; Fluorouracil; Humans; Irinotecan; Male; Oxaliplatin; Rectal Neoplasms; Rectum; Synaptophysin; Thyroid Nuclear Factor 1; Treatment Outcome | 2019 |
Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Evolution; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Models, Theoretical; Multicenter Studies as Topic; Panitumumab; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2020 |
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies | 2020 |
Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Carboxylic Ester Hydrolases; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Germ-Line Mutation; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Metastasis; Polymorphism, Single Nucleotide | 2019 |
The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Prospective Studies; Transforming Growth Factor beta | 2020 |
Evaluation and Clinical Significance of Jagged-1-activated Notch Signaling by APEX1 in Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Colorectal Neoplasms; DNA-(Apurinic or Apyrimidinic Site) Lyase; Female; Fluorouracil; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Jagged-1 Protein; Male; Middle Aged; Oxaliplatin; Prognosis; Receptor, Notch1; Retrospective Studies; Survival Rate; Tumor Cells, Cultured | 2019 |
Insulin enhancement of the antitumor activity of chemotherapeutic agents in colorectal cancer is linked with downregulating PIK3CA and GRB2.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Caco-2 Cells; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Cyclophosphamide; Docetaxel; Down-Regulation; Drug Synergism; Female; Fluorouracil; GRB2 Adaptor Protein; Humans; Insulin; Irinotecan; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplastic Cells, Circulating; Oxaliplatin | 2019 |
Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Deoxycytidine; Emergency Service, Hospital; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hospitalization; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Propensity Score; Treatment Outcome | 2020 |
PRDM14 promotes malignant phenotype and correlates with poor prognosis in colorectal cancer.
Topics: Adenocarcinoma; Adenoma; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm Transplantation; Oxaliplatin; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Messenger; Transcription Factors; Tumor Burden | 2020 |
Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Female; Fluorouracil; Humans; Intraoperative Care; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Progression-Free Survival; Radiotherapy; Retrospective Studies | 2020 |
Diversity of the Senescence Phenotype of Cancer Cells Treated with Chemotherapeutic Agents.
Topics: Antineoplastic Agents; Cell Proliferation; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Fluorouracil; Humans; Irinotecan; Methotrexate; Neoplasms; Oxaliplatin; Paclitaxel; Phenotype; Tumor Cells, Cultured | 2019 |
The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cisplatin; Deoxycytidine; Fanconi Anemia Complementation Group N Protein; Female; Fluorouracil; Gemcitabine; Germ-Line Mutation; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Retrospective Studies | 2020 |
Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Peritoneal Neoplasms; Research Design | 2019 |
Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Female; Fluorouracil; Gene Expression; Humans; Irinotecan; Keratins; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Radiotherapy; Transcriptome; Tumor Microenvironment | 2020 |
Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Consensus; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Reference Standards; Survival Analysis; Treatment Outcome | 2020 |
The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Molecular Typing; Oxaliplatin; Pancreatic Neoplasms; Proteome; Proteomics; Survival Rate; Treatment Outcome | 2020 |
Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Internationality; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreas; Pancreatectomy; Pancreatic Fistula; Pancreatic Neoplasms; Postoperative Complications; Propensity Score; Retrospective Studies; Survival Analysis | 2020 |
Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Analgesics, Opioid; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease Progression; Docetaxel; Emergency Service, Hospital; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; France; Germany; Guideline Adherence; Hospice Care; Hospitalization; Humans; Irinotecan; Male; Middle Aged; Nutritional Support; Oxaliplatin; Palliative Care; Practice Guidelines as Topic; Practice Patterns, Physicians'; Receptor, ErbB-2; Retrospective Studies; Spain; Stomach Neoplasms; Treatment Failure; United Kingdom | 2020 |
Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Spatial and phenotypic characterization of pancreatic cancer-associated fibroblasts after neoadjuvant treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Phenotype | 2020 |
Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Mismatch Repair; DNA Repair Enzymes; Female; Fluorouracil; Humans; Irinotecan; Male; Microsatellite Instability; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Prognosis; Progression-Free Survival; Retrospective Studies; Survival Analysis; Young Adult | 2020 |
Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Outcome Assessment, Health Care; Pancreatic Neoplasms; Retrospective Studies; United States | 2020 |
Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Cetuximab; Cohort Studies; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Image Processing, Computer-Assisted; Irinotecan; Leucovorin; Liver Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Metastasis; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Signal Transduction; Tomography, X-Ray Computed; Transcriptome | 2020 |
Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Knockdown of Atg7 Induces Nuclear-LC3 Dependent Apoptosis and Augments Chemotherapy in Colorectal Cancer Cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 7; Beclin-1; Cell Survival; Cells, Cultured; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; HT29 Cells; Humans; Irinotecan; Microtubule-Associated Proteins | 2020 |
Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Medical Staff, Hospital; Middle Aged; Netherlands; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Regression Analysis; Young Adult | 2020 |
Steatohepatitis due to FOLFIRINOX regimen in adjuvant pancreas cancer treatment mimicking liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fatty Liver; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; China; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Medical Records; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Oxaliplatin; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2020 |
[Whether or not to use thromboprophylaxis in patients treated with chemotherapy for malignant disease].
Topics: Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoprevention; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Risk Adjustment; Risk Assessment; Venous Thromboembolism | 2019 |
Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Drug Synergism; Epithelial-Mesenchymal Transition; Fluorouracil; Gene Expression Regulation, Neoplastic; Irinotecan; Leucovorin; Liposomes; Mice, Inbred C57BL; Nanoparticles; Neoplasm Invasiveness; Pancreatic Neoplasms; Signal Transduction; Survival Analysis; Transcriptome; Transforming Growth Factor beta; Triazoles; Tumor Stem Cell Assay; Up-Regulation | 2020 |
Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Denmark; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Registries; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2020 |
Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: A propensity score matching analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Electroporation; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Propensity Score; Survival Analysis | 2020 |
Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Ramucirumab; Survival Rate | 2020 |
Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms | 2020 |
GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug Resistance, Neoplasm; Female; Fluorouracil; GATA6 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Prospective Studies; Response Evaluation Criteria in Solid Tumors; RNA-Seq | 2020 |
Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Outcome | 2020 |
A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; Female; Fluorouracil; Gemcitabine; Heterografts; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Jejunal Neoplasms; Leucovorin; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Treatment Failure; Trifluridine; Xenograft Model Antitumor Assays | 2020 |
Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Factor Analysis, Statistical; Febrile Neutropenia; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Republic of Korea; Retrospective Studies; Risk Factors; Survival Rate | 2020 |
Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis.
Topics: Aged; Aged, 80 and over; Albumins; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Duration of Therapy; Emergency Service, Hospital; Female; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Insurance, Health; Irinotecan; Leucovorin; Male; Medicare Part C; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; United States | 2020 |
Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2021 |
MUC1 promotes glycolysis through inhibiting BRCA1 expression in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Glucose; Glycolysis; Humans; Irinotecan; Lactic Acid; Leucovorin; Male; Mice, Nude; Mucin-1; Neoplasm Transplantation; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; China; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Polymorphism, Genetic; Precision Medicine; Progression-Free Survival; Retrospective Studies; Treatment Outcome | 2020 |
FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Substitution; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Salvage Therapy | 2020 |
Resection of Replaced Common Hepatic Artery in Locally Advanced Pancreatic Cancer: A Case Report and Analysis of Technical and Oncological Implications.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Female; Fluorouracil; Gastric Bypass; Hepatic Artery; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Pancreaticoduodenectomy; Splenic Artery; Vascular Grafting | 2020 |
Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Pyridines; Radiotherapy; Retrospective Studies; Tegafur; Time Factors | 2020 |
Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Mutation; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2020 |
Adjuvant chemotherapy for patients with gastric neuroendocrine carcinomas or mixed adenoneuroendocrine carcinomas.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Propensity Score; Stomach Neoplasms; Survival Analysis | 2020 |
Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Oxaliplatin; Peritoneal Neoplasms; Polyethylene Glycols; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Comparison of Cell and Organoid-Level Analysis of Patient-Derived 3D Organoids to Evaluate Tumor Cell Growth Dynamics and Drug Response.
Topics: Anthracyclines; Cell Proliferation; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Imaging, Three-Dimensional; Irinotecan; Microscopy, Confocal; Organoids; Staurosporine | 2020 |
Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diabetes Mellitus; Female; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Oxaliplatin; Pancreatic Neoplasms; Pancreatitis; Prognosis; Proportional Hazards Models; Retrospective Studies; Time-to-Treatment | 2020 |
Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Prospective Studies; Proto-Oncogene Proteins B-raf; Young Adult | 2020 |
The yield of chest computed tomography in patients with locally advanced pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Multiple Pulmonary Nodules; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Radiosurgery; Retrospective Studies; Tomography, X-Ray Computed | 2020 |
Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Oxaliplatin; Pancreatic Neoplasms; Recombinant Proteins | 2020 |
6-Shogaol enhances the anticancer effect of 5-fluorouracil, oxaliplatin, and irinotecan via increase of apoptosis and autophagy in colon cancer cells in hypoxic/aglycemic conditions.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Catechols; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Immunosuppressive Agents; Irinotecan; Oxaliplatin; Topoisomerase I Inhibitors | 2020 |
Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs radiofrequency ablation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Electroporation; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Propensity Score; Radiofrequency Ablation; Retrospective Studies; Tumor Burden | 2020 |
Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Linear Models; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Adjuvant; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tumor Burden | 2020 |
Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Saskatchewan; Survival Analysis; Treatment Outcome | 2021 |
Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Dihydrotanshinone attenuates chemotherapy-induced intestinal mucositis and alters fecal microbiota in mice.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Bacteria; Colon; Diglycerides; Disease Models, Animal; Feces; Fluorouracil; Furans; Gastrointestinal Microbiome; Interleukin-6; Intestinal Mucosa; Irinotecan; Male; Mice, Inbred C57BL; Mucositis; Phenanthrenes; Quinones; Triglycerides; Tumor Necrosis Factor-alpha | 2020 |
Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy.
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; HLA-G Antigens; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Models, Molecular; Protein Binding; Protein Conformation; Protein Isoforms; Solubility; Spectrometry, Fluorescence | 2020 |
Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2020 |
A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Disease-Free Survival; Female; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Response Evaluation Criteria in Solid Tumors; Retrospective Studies | 2020 |
Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Female; Fluorouracil; Genes, MHC Class I; Humans; Immunity; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Tumor Microenvironment | 2021 |
Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Drug Interactions; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Tumor Cells, Cultured | 2020 |
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Female; Fluorouracil; France; Humans; Irinotecan; Italy; Male; Middle Aged; Platinum; Prospective Studies; Pyrimidines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Challenges of pancreatic cancer chemotherapy in the COVID-19 era.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Capecitabine; Coronavirus Infections; COVID-19; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Pandemics; Pneumonia, Viral; Romania; SARS-CoV-2 | 2020 |
Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cholangiopancreatography, Endoscopic Retrograde; Cholestasis; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Prosthesis Failure; Retrospective Studies; Risk Factors; Sphincterotomy, Endoscopic; Stents; Time Factors; Treatment Outcome | 2020 |
[Nanoliposomal Irinotecan in Combination with Fluorouracil and Folinic Acid, As a New Option for Second-Line Treatment in Metastatic Pancreatic Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Europe; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Liposomes; Pancreatic Neoplasms; Quality of Life | 2020 |
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Time Factors; Treatment Outcome; Tumor Microenvironment | 2020 |
First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Carriers; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Nanoparticles; Retrospective Studies; Treatment Outcome | 2020 |
Distal Pancreatectomy with Celiac Axis Resection (Modified Appleby Procedure) and Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma After FOLFIRINOX Chemotherapy and Chemoradiation Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms | 2021 |
Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chemoradiotherapy, Adjuvant; Collagen; Disease-Free Survival; Female; Fibrosis; Fluorouracil; Follow-Up Studies; Heterocyclic Compounds; Humans; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Male; Mice; Middle Aged; Molecular Imaging; Molecular Probes; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organometallic Compounds; Oxaliplatin; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis; Xenograft Model Antitumor Assays | 2020 |
Efficacy of sodium hypochlorite in the degradation antineoplastic drugs by NMR spectroscopy.
Topics: Antineoplastic Agents; Azacitidine; Carcinogens; Cytarabine; Decontamination; Drug Interactions; Ethanol; Fluorouracil; Humans; Hypochlorous Acid; Irinotecan; Magnetic Resonance Spectroscopy; Occupational Exposure; Preliminary Data; Sodium Chloride; Sodium Hypochlorite; Time Factors | 2020 |
FOLFIRINOX
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Synchronous Primary Pancreatic Ductal Carcinoma and Colonic Adenocarcinoma Present in a Patient With History of Skin Squamous Cell Carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasms, Multiple Primary; Oxaliplatin; Pancreatic Neoplasms; Skin Neoplasms | 2020 |
Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Irinotecan; Leucovorin; Male; Mice; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Oxaliplatin; Pancreatic Neoplasms; Precision Medicine; Prognosis; Transcriptome; Young Adult | 2020 |
Calcium channel blockers in pancreatic cancer: increased overall survival in a retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Survival Rate; United Kingdom | 2020 |
Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxaliplatin; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Radiography; Retrospective Studies; Treatment Outcome | 2020 |
A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Middle Aged; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy; Retrospective Studies | 2020 |
Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Diagnostic Imaging; Dose Fractionation, Radiation; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Neoadjuvant Therapy; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreas; Pancreatic Neoplasms; Radiosurgery | 2020 |
Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms, Hereditary Nonpolyposis; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Should All Patients With Pancreatic Cancer Receive Chemotherapy Before Surgery?
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2020 |
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Radiography; Survival Rate; Treatment Outcome | 2020 |
5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Letter.
Topics: Albumins; Fluorouracil; Gastrointestinal Neoplasms; Genotype; Humans; Irinotecan; Leucovorin; Paclitaxel | 2020 |
5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Response.
Topics: Albumins; Fluorouracil; Gastrointestinal Neoplasms; Genotype; Humans; Irinotecan; Leucovorin; Paclitaxel | 2020 |
Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Checkpoint Kinase 2; Female; Fluorouracil; Genes, BRCA2; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Pedigree | 2020 |
Involvement of Corticotropin-releasing Hormone-related Peptides in Cellular Stress Caused by Anticancer Drugs in Colorectal Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Corticotropin-Releasing Hormone; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Receptors, Corticotropin-Releasing Hormone | 2020 |
Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Europe; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multiparametric Magnetic Resonance Imaging; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms | 2021 |
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2021 |
CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2021 |
Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison.
Topics: Ablation Techniques; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Electroporation; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Radiography, Interventional; Retrospective Studies; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Sarcopenia | 2021 |
FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Retrospective Studies | 2020 |
Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cross-Over Studies; Deoxycytidine; Febrile Neutropenia; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Progression-Free Survival; Registries; Republic of Korea; Survival Rate; Treatment Outcome | 2020 |
Severe Nonbacterial Thrombotic Endocarditis Resulting in Aortic Valve Insufficiency and Multiple Small Strokes in a Patient With Metastatic Pancreatic Cancer: Lessons for Optimal Management.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Aortic Valve Insufficiency; Diffusion Magnetic Resonance Imaging; Echocardiography, Transesophageal; Endocarditis; Fluorouracil; Humans; Irinotecan; Ischemic Stroke; Leucovorin; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Synopsis of the UK National Institute for Health and Care Excellence Guidelines on the Diagnosis and Management of Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Practice Guidelines as Topic; United Kingdom | 2020 |
Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2020 |
Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chromosomal Instability; DNA Damage; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Maintenance Chemotherapy; Mice; Mice, Nude; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Survival Analysis; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2020 |
Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Italy; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2020 |
The economic burden of metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost of Illness; Costs and Cost Analysis; Databases, Factual; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Health Care Costs; Health Resources; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Needs Assessment; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2020 |
FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Survival Analysis; Treatment Outcome | 2020 |
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Rate | 2021 |
Extrahepatic recurrence rates in patients receiving adjuvant hepatic artery infusion and systemic chemotherapy after complete resection of colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hepatic Artery; Humans; Incidence; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; United States | 2020 |
Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Radiation Dose Hypofractionation; Retrospective Studies; Survival Rate | 2021 |
Long-Term Survival With Nanoliposomal Irinotecan in Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Middle Aged; Nanoparticles; Pancreatic Neoplasms; Progression-Free Survival; Time Factors; Tomography, X-Ray Computed | 2020 |
Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Hyperthermic Intraperitoneal Chemotherapy; Irinotecan; Leucovorin; Mitomycin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Primary Cell Culture; Tumor Cells, Cultured | 2021 |
Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Intraoperative Care; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2020 |
Comments on "Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma".
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Animal; Electrochemotherapy; Electroporation; Fluorouracil; Humans; Irinotecan; Leucovorin; Mice; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Cryptotanshinone alleviates chemotherapy-induced colitis in mice with colon cancer via regulating fecal-bacteria-related lipid metabolism.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Bacteria; Colitis; Colon; Colonic Neoplasms; Feces; Fluorouracil; Gastrointestinal Microbiome; Irinotecan; Lipid Metabolism; Male; Mice, Inbred BALB C; Phenanthrenes; RNA, Ribosomal, 16S | 2021 |
Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Oxaliplatin | 2021 |
Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Longitudinal Studies; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2021 |
Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Circulating Tumor DNA; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liquid Biopsy; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Risk Assessment | 2021 |
FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Important CT and histopathological findings for recurrence and overall survival in patients with pancreatic ductal adenocarcinoma who underwent surgery after neoadjuvant FOLFIRINOX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tomography, X-Ray Computed | 2021 |
Dual deficiency of DPD and UGT1A1 in a case of colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Middle Aged; Mutation; Tomography, X-Ray Computed | 2020 |
A novel patient-derived orthotopic xenograft (PDOX) mouse model of highly-aggressive liver metastasis for identification of candidate effective drug-combinations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Body Weight; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms, Experimental; Mice, Nude; Phenylurea Compounds; Proof of Concept Study; Pyridines; Xenograft Model Antitumor Assays | 2020 |
Nanoscale platform for delivery of active IRINOX to combat pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Mice; Oxaliplatin; Pancreatic Neoplasms | 2021 |
Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2021 |
Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort.
Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2021 |
Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; DNA Repair; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Treatment Outcome | 2021 |
Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prospective Studies; Retrospective Studies | 2021 |
Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2021 |
Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Middle Aged; Mutation; Neoplasm Metastasis; Oxaliplatin; Postmenopause; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Survival Rate | 2021 |
Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Markov Chains; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; Quality-Adjusted Life Years; Sulfonamides | 2021 |
Pancreatectomy with Vascular Resection After Neoadjuvant FOLFIRINOX: Who Survives More Than a Year After Surgery?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Lactobacillus Kefiri LKF01 (Kefibios
Topics: Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Diarrhea; Endpoint Determination; Female; Fluorouracil; Humans; Irinotecan; Lactobacillus; Male; Probiotics; Prospective Studies; Treatment Outcome | 2021 |
Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group N Protein; Female; Fluorouracil; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Genomic Instability; Germ-Line Mutation; Homologous Recombination; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Recombinational DNA Repair; Sensitivity and Specificity; Survival Rate; Tumor Suppressor Protein p53; Whole Genome Sequencing | 2021 |
Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Irinotecan; Liver Neoplasms; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Xenograft Model Antitumor Assays | 2021 |
Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Republic of Korea; Retrospective Studies | 2021 |
Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer: A Letter to the Editor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diet, Ketogenic; Fluorouracil; Gemcitabine; Humans; Hyperbaric Oxygenation; Hyperthermia; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2021 |
Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboxylesterase; Cytochrome P-450 CYP3A; Fluorouracil; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Models, Biological; Oxaliplatin; Pancreatic Neoplasms; Polymorphism, Genetic | 2021 |
Quality control of cytostatic drug preparations-comparison of workflow and performance of Raman/UV and high-performance liquid chromatography coupled with diode array detection (HPLC-DAD).
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Cyclophosphamide; Cytostatic Agents; Deoxycytidine; Drug Compounding; Drug Stability; Drug Storage; Fluorouracil; Gemcitabine; Irinotecan; Quality Control; Spectrophotometry, Ultraviolet; Spectrum Analysis, Raman; Workflow | 2021 |
Comment: Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison.
Topics: Antineoplastic Combined Chemotherapy Protocols; Electroporation; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2021 |
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Humans; Irinotecan; Leucovorin; Medical Oncology; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Quality of Life; Societies, Medical; Spain | 2021 |
Distal pancreatectomy with en bloc celiac axis resection (DP-CAR) and arterial reconstruction: Techniques and outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Cohort Studies; Female; Fluorouracil; Hepatic Artery; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Plastic Surgery Procedures; Retrospective Studies; Treatment Outcome; Vascular Surgical Procedures | 2021 |
Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Veterans | 2021 |
Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Risk Assessment; Time Factors; Treatment Outcome | 2021 |
Zinc finger protein 91 accelerates tumour progression by activating β-catenin signalling in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Fluorouracil; Humans; Imidazoles; Irinotecan; Isoxazoles; Kaplan-Meier Estimate; Leucovorin; Mice; Mice, Nude; Oxaliplatin; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Transplantation, Heterologous; Ubiquitin-Protein Ligases; Wnt Signaling Pathway | 2021 |
Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Studies; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2021 |
Molecular Mechanisms and Tumor Biological Aspects of 5-Fluorouracil Resistance in HCT116 Human Colorectal Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Exome Sequencing; Floxuridine; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Platinum Compounds; Thymidylate Synthase | 2021 |
Are we already in the era of total neoadjuvant treatment for rectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms | 2021 |
Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Lymphocytes; Male; Middle Aged; Neutrophils; Oxaliplatin; Oxaloacetates; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Time Factors | 2021 |
Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Retrospective Studies | 2021 |
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Deoxycytidine; Female; Fluorouracil; Forkhead Transcription Factors; Gemcitabine; Hepatitis A Virus Cellular Receptor 2; Humans; Immune Checkpoint Proteins; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pilot Projects; Programmed Cell Death 1 Receptor; Progression-Free Survival; Prospective Studies; T-Lymphocytes, Regulatory | 2021 |
Endoscopic drainage for management of infected necrosis following EUS-TA in a patient with pancreatic cancer: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Pancreatic Ductal; Drainage; Endosonography; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Pancreatitis, Acute Necrotizing; Postoperative Complications; Stents; Treatment Outcome; Ultrasonography, Interventional | 2021 |
The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cholangiocarcinoma; Dose-Response Relationship, Drug; Drug Synergism; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Plasma Gases | 2021 |
Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Propensity Score; Retrospective Studies; Treatment Outcome | 2021 |
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Austria; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Progression-Free Survival; Propensity Score; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors | 2021 |
Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
Topics: Adenocarcinoma; Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Survival Rate; Tumor Burden | 2021 |
Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Propensity Score | 2021 |
Irreversible Electroporation (IRE) Combined With Chemotherapy Increases Survival in Locally Advanced Pancreatic Cancer (LAPC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Electroporation; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Laparotomy; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2021 |
Chemotherapy-induced early transient increase and surge of CA 19-9 level in patients with pancreatic Adenocarcinoma
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Metastatic pancreatic cancer with complete response to FOLFIRINOX treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Oxaliplatin; Pancreatic Neoplasms | 2021 |
Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Tomography, X-Ray Computed | 2021 |
Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nomograms; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2021 |
[Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil/leucovorin for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplasms; Consensus; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2021 |
Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nanoparticles; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Venous Thromboembolism | 2022 |
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Retrospective Studies | 2021 |
Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Muscle, Skeletal; Oxaliplatin; Pancreatic Neoplasms; Prognosis | 2021 |
The Cisplatin, 5-fluorouracil, Irinotecan, and Gemcitabine Treatment in Resistant 2D and 3D Model Triple Negative Breast Cancer Cell Line: ABCG2 Expression Data.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoplasm Proteins; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2022 |
Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only: Multicenter Propensity Score-matched Analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Netherlands; Oxaliplatin; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Propensity Score; Prospective Studies; Survival Rate | 2021 |
Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies | 2021 |
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Topics: Adult; Aged; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Nausea; Neoplasm Metastasis; Neutropenia; Outcome Assessment, Health Care; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Vomiting | 2021 |
Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome | 2021 |
SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Databases, Genetic; DNA Helicases; DNA-Binding Proteins; Female; Fluorouracil; Humans; Immune Checkpoint Inhibitors; Irinotecan; Leucovorin; Male; Microsatellite Instability; Middle Aged; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Retreatment; SMARCB1 Protein; Survival Rate; Transcription Factors | 2021 |
Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Drug Costs; Filgrastim; Fluorouracil; Health Services Accessibility; Humans; Irinotecan; Leucovorin; Middle Aged; Models, Economic; Oxaliplatin; Pancreatic Neoplasms; Polyethylene Glycols; SEER Program | 2021 |
Primary Tumor-Related Complications Among Patients With Unresectable Stage IV Colorectal Cancer in the Era of Targeted Therapy: A Competing Risk Regression Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Intestinal Obstruction; Intestinal Perforation; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Panitumumab; Regression Analysis; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate | 2021 |
Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Cycle; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Curcumin; Drug Synergism; Fluorouracil; Humans; Irinotecan; Male; Mice, SCID; Neoplastic Stem Cells; Organoids; Oxaliplatin | 2021 |
Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Oxaliplatin; Pancreatic Neoplasms | 2021 |
Establishment of Pancreatobiliary Cancer Zebrafish Avatars for Chemotherapy Screening.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zebrafish | 2021 |
Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer?
Topics: Age Factors; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies | 2022 |
Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review.
Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Fluorouracil; Humans; Immune Checkpoint Inhibitors; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms | 2022 |
LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Silencing; HCT116 Cells; Humans; Irinotecan; Lymphoid Enhancer-Binding Factor 1; Oxaliplatin; Wnt Signaling Pathway | 2021 |
A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Mice; Microbubbles; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome; Uridine | 2021 |
NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; COVID-19; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Oxaliplatin; Palonosetron; Pandemics; Prospective Studies; Pyridines; Vomiting | 2021 |
A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: First insight of the underlying mechanisms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoids; Oxaliplatin; Pancreatic Neoplasms | 2022 |
Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoids; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Pancreatic Neoplasms | 2023 |
Exploring New Approaches for Locally Advanced Gastroesophageal Adenocarcinomas: TNT, Irinotecan, and ctDNA.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Pancreatic Neoplasms; Pilot Projects; Rectal Neoplasms; Treatment Outcome; Trinitrotoluene | 2021 |
Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukocytes, Mononuclear; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms | 2021 |
Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Male; MicroRNAs; Middle Aged; Multivariate Analysis; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies | 2021 |
Intraoperative frozen section analysis of para-aortic lymph nodes after neoadjuvant FOLFIRINOX: will it soon become useless?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Frozen Sections; Humans; Irinotecan; Leucovorin; Lymph Nodes; Lymphatic Metastasis; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2022 |
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Progression-Free Survival; Pyrimidines; Retrospective Studies; Time Factors | 2021 |
Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Combined Modality Therapy; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2022 |
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Nanoconjugates; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies | 2021 |
Alterations in hepatic fatty acids reveal depletion of total polyunsaturated fatty acids following irinotecan plus 5-fluorouracil treatment in an animal model of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Models, Animal; Docosahexaenoic Acids; Fatty Acids, Omega-6; Fatty Liver; Female; Fluorouracil; Gene Expression; Irinotecan; Lipid Metabolism; Liver; Rats; Rats, Inbred F344; Signal Transduction; Topoisomerase I Inhibitors; Treatment Outcome; Triglycerides | 2021 |
Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Taiwan; Topoisomerase I Inhibitors | 2022 |
Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Quality of Life | 2022 |
Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2022 |
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Ontario; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2021 |
DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.
Topics: Adult; Antimetabolites; Bayes Theorem; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Genotype; Humans; Irinotecan; Neoplasms; Polymorphism, Single Nucleotide | 2022 |
Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2022 |
Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; DNA Mutational Analysis; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; High-Throughput Nucleotide Sequencing; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Programmed Cell Death 1 Receptor; Response Evaluation Criteria in Solid Tumors; Smad4 Protein; Tegafur; Tuberous Sclerosis Complex 2 Protein | 2021 |
Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.
Topics: Aged; Analgesics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Pregabalin; Retrospective Studies; Treatment Outcome | 2021 |
[Locally advanced pancreatic cancer after FOLFIRINOX: surgical resection enhances survival].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2022 |
Neoadjuvant Therapy for Rectal Cancer: Updates From the UNICANCER-PRODIGE 23 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms | 2022 |
Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Assessment of Drug-drug Interaction and Optimization in Capecitabine and Irinotecan Combination Regimen using a Physiologically Based Pharmacokinetic Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboxylesterase; Colorectal Neoplasms; Drug Interactions; Fluorouracil; Irinotecan; Rats | 2022 |
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer.
Topics: Biliary Tract Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin | 2022 |
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer - Author's reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Neoplasm Metastasis | 2022 |
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Nomograms; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Treatment Outcome | 2022 |
[A Case of Metastatic Pancreatic Ductal Adenocarcinoma Successfully Treated with Modified FOLFIRINOX and Concurrent Radiotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Oxaliplatin; Pancreatic Neoplasms | 2021 |
Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Nausea; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2022 |
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Correlation between Immunohistochemical Markers in Hepatocellular Carcinoma Cells and
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Oxaliplatin | 2022 |
Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Irinotecan; Kv Channel-Interacting Proteins; Mucin 5AC; Mucin-1; Mucins; Neoplasm Recurrence, Local; Repressor Proteins; Risk Factors | 2022 |
Bias and Pancreatic Cancer Reporting.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bias; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2022 |
FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Chemotherapeutics Combined with Luminal Irritants: Effects on Small-Intestinal Mannitol Permeability and Villus Length in Rats.
Topics: Animals; Doxycycline; Ethanol; Fluorouracil; Injections, Intraperitoneal; Intestinal Mucosa; Irinotecan; Irritants; Male; Mannitol; Mucositis; Organ Size; Permeability; Rats; Sodium Dodecyl Sulfate | 2022 |
Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Feasibility Studies; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Mice; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Comparison of
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Retrospective Studies | 2022 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Treatment Outcome | 2022 |
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Rectal Neoplasms | 2022 |
Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; Camptothecin; Diarrhea; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Nausea; Neutropenia; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Thrombocytopenia; Vomiting | 2022 |
ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Fluorouracil; Humans; Inflammation; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2022 |
5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Resu
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Response in
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Female; Fluorouracil; Germ-Line Mutation; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Tongue Neoplasms | 2022 |
Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carbon-Sulfur Lyases; Disease Models, Animal; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Methionine; Mice; Mice, Nude; Oxaliplatin; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2022 |
Successful conversion surgery after FOLFIRINOX therapy in a patient with advanced pancreatic acinar cell carcinoma with a solitary peritoneal dissemination: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Oxaliplatin; Pancreatic Neoplasms | 2022 |
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2022 |
A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Ontario; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Efficacy, Safety, and Impact on Patient Survival of PDL1/PD-1 Inhibitors versus FOLFIRINOX Regimens for Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Immune Checkpoint Inhibitors; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor | 2022 |
Management of elderly patients with unresectable pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis | 2022 |
Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Proto-Oncogene Proteins p21(ras); Retrospective Studies | 2022 |
Simulating Colorectal Cancer Trials Using Real-World Data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin | 2022 |
Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Retrospective Studies | 2022 |
Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Registries | 2022 |
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2022 |
Provider imaging practices and outcomes of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Oxaliplatin | 2022 |
Real-world overall survival of patients receiving cetuximab in later lines of treatment for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Rectal Neoplasms; Retrospective Studies | 2022 |
Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma.
Topics: Anal Canal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cetuximab; Epithelial Cells; Fluorouracil; Humans; Irinotecan; Retrospective Studies | 2023 |
Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemokine CCL4; Cytokines; Fluorouracil; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-18; Interleukin-7; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2022 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |
Pharmacological Ascorbate Enhances Chemotherapies in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Irinotecan; Leucovorin; Mice; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Incidence; Irinotecan; Leucovorin; Neutropenia; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Risk Factors | 2022 |
Evaluation and validation of chemotherapy-specific diarrhoea and histopathology in rats.
Topics: Animals; Antineoplastic Agents; Atrophy; Body Weight; Diarrhea; Doxorubicin; Fluorouracil; Idarubicin; Intestinal Mucosa; Irinotecan; Male; Methotrexate; Mucositis; Rats; Rats, Wistar | 2022 |
Predicting the chemosensitivity of pancreatic cancer cells as a personalized therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2022 |
Patient-derived tumor organoids predict responses to irinotecan-based neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
Topics: Chemoradiotherapy; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Neoplasms, Second Primary; Organoids; Rectal Neoplasms; Retrospective Studies | 2023 |
Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fluorouracil; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Painful lower limb nodules as first symptom of resectable pancreatic acinar cell cancer: a case report.
Topics: Acinar Cells; Aged; Carcinoma, Acinar Cell; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lipase; Lower Extremity; Oxaliplatin; Pancreatic Diseases; Pancreatic Neoplasms; Panniculitis | 2022 |
The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cisplatin; Fluorouracil; Humans; Immune Checkpoint Inhibitors; Irinotecan; Leucovorin; Liver Neoplasms; Treatment Outcome | 2022 |
Surprising efficacy twist of two established cytostatics revealed by a-la-carte 3D cell spheroid preparation protocol.
Topics: Adenocarcinoma; Cell Line, Tumor; Colonic Neoplasms; Cytostatic Agents; Fluorouracil; Humans; Irinotecan; Spheroids, Cellular; Tumor Microenvironment | 2022 |
FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2022 |
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Caspase 3; Cholecalciferol; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucine; Mice; Muscle, Skeletal; Nutritional Support; Oxaliplatin; Treatment Outcome | 2022 |
Managing life-threatening 5-fluorouracil cardiotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Camptothecin; Cardiotoxicity; Cardiotoxins; Colorectal Neoplasms; Coronary Vasospasm; Diltiazem; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Nitrates | 2022 |
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neutropenia; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Rectal Neoplasms | 2023 |
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; G2 Phase Cell Cycle Checkpoints; Humans; Irinotecan | 2022 |
5-fluorouracil with oxaliplatin and/or irinotecan for advanced sinonasal intestinal-type adenocarcinoma (ITAC).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2023 |
The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Center Real-World Study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms | 2022 |
A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2023 |
Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2023 |
Towards UGT1A1 guided irinotecan dosing.
Topics: Drug Interactions; Fluorouracil; Genotype; Humans; Irinotecan; Pharmacogenetics | 2023 |
Increased Expression of Hepatic Stearoyl-CoA Desaturase (SCD)-1 and Depletion of Eicosapentaenoic Acid (EPA) Content following Cytotoxic Cancer Therapy Are Reversed by Dietary Fish Oil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Fatty Liver; Female; Fish Oils; Fluorouracil; Interleukin-4; Irinotecan; Leptin; Liver; Neoplasms; Rats; Stearoyl-CoA Desaturase; Triglycerides | 2023 |
Stem cell-assisted enzyme/prodrug therapy makes drug-resistant ovarian cancer cells vulnerable to natural killer cells through upregulation of NKG2D ligands.
Topics: Female; Fluorouracil; Humans; Irinotecan; Neoplasm Recurrence, Local; NK Cell Lectin-Like Receptor Subfamily K; Ovarian Neoplasms; Prodrugs; Stem Cells; Up-Regulation | 2023 |
Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Ontario; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms | 2023 |
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer.
Topics: Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hand-Foot Syndrome; Humans; Immunologic Factors; Irinotecan | 2023 |
Predicting conversion surgery in patients with locally advanced pancreatic cancer after modified FOLFIRINOX treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Hepatic arterial infusion with nanoliposomal irinotecan leads to significant regression of tumor size of colorectal liver metastases in a CC531 rat model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Rats | 2023 |
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned?
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms | 2023 |
Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug Monitoring; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2023 |
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Continuity of Patient Care; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Pancreatic Neoplasms | 2023 |
Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Radiation-Sensitizing Agents; Treatment Outcome | 2023 |
Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Neoplasm Metastasis; Prognosis; Rectal Neoplasms; Retrospective Studies; Vascular Endothelial Growth Factor A | 2023 |
Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Mutation; Proto-Oncogene Proteins B-raf; Rectal Neoplasms; Vemurafenib | 2023 |
Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Levoleucovorin; Liposomes; Male; Pancreatic Neoplasms; Retrospective Studies | 2023 |
A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ergocalciferols; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Pilot Projects | 2023 |
Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer.
Topics: Carbolines; Fluorouracil; Humans; Irinotecan; Pancreatic Neoplasms | 2023 |
[Modulation of Expression of Drug Metabolizing Enzymes and Augmentation of Anti-cancer Drug Effects: Through Epigenetics and Three-dimensional Cancer Cell Culture Systems].
Topics: Antineoplastic Agents; Cell Culture Techniques; Colonic Neoplasms; Cytochrome P-450 CYP1A2; Decitabine; DNA; Epigenesis, Genetic; Fluorouracil; Humans; Irinotecan; Methyltransferases; Pharmaceutical Preparations | 2023 |